

CareNeeds PLUS (HMO SNP)

2019



PRESCRIPTION DRUG GUIDE

CarePlus Formulary
List of Covered Drugs

PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN.

This formulary was updated on 12/03/2019. For more recent information or other questions, please contact CarePlus Members Services, at **1-800-794-5907** or for TTY users, **711**. From October 1 - March 31, we are open 7 days a week; 8 a.m. to 8 p.m. From April 1 - September 30, we are open Monday - Friday, 8 a.m. to 8 p.m. You may always leave a voice mail message after-hours, Saturdays, Sundays, and holidays and we will return your call within 1 business day, or visit www.careplushealthplans.com.

CarePlus
HEALTH PLANS

Welcome to CarePlus!

Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take. When this drug list (formulary) refers to "we," "us", or "our," it means CarePlus. When it refers to "plan" or "our plan," it means CarePlus. This document includes a list of the drugs (formulary) for our plan which is current as of December 2019. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1 of each year, and from time to time during the year.

What is the CarePlus Medicare formulary?

A formulary is the entire list of covered drugs or medicines selected by CarePlus. The terms formulary and Drug List may be used interchangeably throughout communications regarding changes to your pharmacy benefits. CarePlus worked with a team of doctors and pharmacists to make a formulary that represents the prescription drugs we think you need for a quality treatment program. CarePlus will generally cover the drugs listed in the formulary as long as the drug is medically necessary, the prescription is filled at a CarePlus network pharmacy, and other plan rules are followed. For more information on how to fill your medicines, please review your Evidence of Coverage.

Can the formulary change?

Generally, if you are taking a drug on our 2019 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the 2019 coverage year except when a new, less expensive generic drug becomes available, when new information about the safety or effectiveness of a drug is released, or the drug is removed from the market. (See bullets below for more information on changes that affect members currently taking the drug.) Other types of formulary changes, such as removing a drug from our formulary will not affect members who are currently taking the drug. It will remain available at the same cost-sharing for those members taking it for the remainder of the coverage year. We feel it is important that you have continued access for the remainder of the coverage year to the formulary drugs that were available when you chose your plan, except for cases in which you can save additional money or we can ensure your safety. Below are changes to the drug list that will also affect members currently taking a drug:

- **New generic drugs.** We may immediately remove a brand name drug on our Drug List if we are replacing it with a new generic drug that will appear on the same or lower cost sharing tier and with the same or fewer restrictions. Also, when adding the new generic drug, we may decide to keep the brand name drug on our Drug List, but immediately move it to a different cost-sharing tier or add new restrictions. If you are currently taking that brand name drug, we may not tell you in advance before we make that change, but we will later provide you with information about the specific change(s) we have made.
 - If we make such a change, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. The notice we provide you will also include information on the steps you may take to request an exception, and you can also find information in the section below entitled "How do I request an exception to the Formulary?"
- **Drugs removed from the market.** If the Food and Drug Administration deems a drug on our formulary to be unsafe or the drug's manufacturer removes the drug from the market, we will immediately remove the drug from our formulary and provide notice to members who take the drug.
- **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may add a generic drug that is not new to market to replace a brand name drug currently on the formulary or add new restrictions to the brand name drug or move it to a different cost-sharing tier. Or we may make changes based on new clinical guidelines. If we remove drugs from our formulary, or add prior authorization, quantity limits and/or step therapy restrictions on a drug or move a drug to a higher cost-sharing tier, we must notify affected members of the change at least 30 days before the change becomes effective, or at the time the member requests a refill of the drug, at which time the member will receive a 30-day supply of the drug.

We'll notify members who are affected by the following changes to the formulary:

- When a drug is removed from the formulary
- When prior authorization, quantity limits, or step-therapy restrictions are added to a drug or made more restrictive
- When a drug is moved to a higher cost-sharing tier

What if you're affected by a Drug List change?

We'll notify you by mail at least 30 days before one of these changes happens or we will provide a 30-day refill of the affected medicine with notice of the change.

The enclosed formulary is current as of December 2019. We'll update the printed formularies each month and they'll be available on www.careplushealthplans.com.

To get updated information about the drugs covered by CarePlus, please visit www.careplushealthplans.com or call Member Services at **1-800-794-5907**; **TTY: 711**. From October 1 - March 31, we are open 7 days a week; 8 a.m. to 8 p.m. From April 1 - September 30, we are open Monday - Friday, 8 a.m. to 8 p.m. You may always leave a voice mail message after-hours, Saturdays, Sundays, and holidays and we will return your call within 1 business day.

How do I use the formulary?

There are two ways to find your drug in the formulary:

Medical condition

The formulary starts on page 10. We've put the drugs into groups depending on the type of medical conditions that they're used to treat. For example, drugs that treat a heart condition are listed under the category "Cardiovascular Agents." If you know what medical condition your drug is used for, look for the category name in the list that begins on page 10. Then look under the category name for your drug. The formulary also lists the Tier and Utilization Management Requirements for each drug (see page 5 for more information on Utilization Management Requirements).

Alphabetical listing

If you're not sure about your drug's group, you should look for your drug in the Index that begins on page 109. The Index is an alphabetical list of all of the drugs included in this document. Both brand-name drugs and generic drugs are listed. Look in the Index to search for your drug. Next to each drug, you'll see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of the drug in the first column of the list.

Prescription drugs are grouped into one of five tiers.

CarePlus covers both brand-name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand-name drug. Generally, generic drugs cost less than brand-name drugs.

- **Tier 1 - Preferred Generic:** Generic or brand drugs that are available at the lowest cost share for the plan
- **Tier 2 - Generic:** Generic or brand drugs that the plan offers at a higher cost to you than Tier 1 Preferred Generic drugs
- **Tier 3 - Preferred Brand:** Generic or brand drugs that the plan offers at a lower cost to you than Tier 4 Non-Preferred Drug drugs
- **Tier 4 - Non-Preferred Drug:** Generic or brand drugs that the plan offers at a higher cost to you than Tier 3 Preferred Brand drugs
- **Tier 5 - Specialty Tier:** Some injectables and other high-cost drugs

How much will I pay for covered drugs?

CarePlus pays part of the costs for your covered drugs and you pay part of the costs, too.

The amount of money you pay depends on:

- Which tier your drug is on
- Whether you fill your prescription at a network pharmacy
- Your current drug payment stage - please read your Evidence of Coverage (EOC) for more information

If you qualified for extra help with your drug costs, your costs may be different from those described above. Please refer to your Evidence of Coverage (EOC) or call Member Services to find out what your costs are.

Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These are called Utilization Management Requirements. These requirements and limits may include:

- **Prior Authorization (PA):** CarePlus requires you to get prior authorization for certain drugs to be covered under your plan. This means that you'll need to get approval from CarePlus before you fill your prescriptions. If you don't get approval, CarePlus may not cover the drug.
- **Quantity Limits (QL):** For some drugs, CarePlus limits the amount of the drug that is covered. CarePlus might limit how many refills you can get or how much of a drug you can get each time you fill your prescription. For example, if it's normally considered safe to take only one pill per day for a certain drug, we may limit coverage for your prescription to no more than one pill per day. Some drugs are limited to a 30-day supply regardless of tier placement.
- **Step Therapy (ST):** In some cases, CarePlus requires that you first try certain drugs to treat your medical condition before coverage is available for another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, CarePlus may not cover Drug B unless you try Drug A first. If Drug A does not work for you, CarePlus will then cover Drug B.
- **Part B versus Part D (B vs D):** Some drugs may be covered under Medicare Part B or Part D depending upon the circumstances. Information may need to be submitted to CarePlus that describes the use and the place where you receive and take the drug so a determination can be made.

For drugs that need prior authorization or step therapy, or drugs that fall outside of quantity limits, your health care provider can fax information about your condition and need for those drugs to CarePlus at **1-800-310-9071**. Representatives are available Monday - Friday, 8 a.m. - 8 p.m.

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 10.

You can ask CarePlus to make an exception to these restrictions or limits. See the section "**How do I request an exception to the formulary?**" on page 6 for information about how to request an exception.

Does healthcare reform impact my coverage?

Since 2011, Medicare has made changes to help with the cost of drugs while members are in the Prescription Drug Plan coverage gap, which is often called the "donut hole." The Centers for Medicare & Medicaid Services (CMS) work with the companies that make prescription drugs and health plans so you receive nearly 75 percent off the cost of many covered, brand-name drugs while you're in the coverage gap. Medicare members who receive the low-income subsidy ("Extra Help") or are covered by a qualified, commercial prescription plan through an employer won't get this discount.

What if my drug isn't on the formulary?

If your drug isn't included in this list of covered drugs, visit www.careplushealthplans.com to see if your plan covers your drug. You can also call Member Services and ask if your drug is covered.

If CarePlus doesn't cover your drug, you have two options:

- You can ask Member Services for a list of similar drugs that CarePlus covers. Show the list to your doctor and ask him or her to prescribe a similar drug that is covered by CarePlus.
- You can ask CarePlus to make an exception and cover your drug. See below for information about how to request an exception.

Talk to your health care provider to decide if you should switch to another drug that is covered or if you should request a formulary exception so that it can be considered for coverage.

How do I request an exception to the formulary?

You can ask CarePlus to make an exception to the coverage rules. There are several types of exceptions that you can ask to be made.

- **Formulary exception:** You can request that your drug be covered if it's not on the formulary.
- **Utilization restriction exception:** You can request coverage restrictions or limits not be applied to your drug. For example, if your drug has a quantity limit, you can ask for the limit not to be applied and to cover more doses of the drug.
- **Tier exception:** You can request a higher level of coverage for your drug. For example, if your drug is usually considered a non-preferred drug, you can request it to be covered as a preferred drug instead. This would lower how much money you must pay for your drug. Please remember a higher level of coverage cannot be requested for the drug if approval was granted to cover a drug that was not on the formulary.

Generally, CarePlus will only approve your request for an exception if the alternative drugs included on the plan's formulary, the lower cost-sharing drug, or other restrictions wouldn't be as effective in treating your health condition and/or would cause adverse medical effects.

You should contact us to ask for an initial coverage decision for a formulary, tier, or utilization restriction exception. When you ask for an exception, you should submit a statement from your health care provider that supports your request. This is called a supporting statement.

Generally, we must make the decision within 72 hours of receiving your health care provider's supporting statement. You can request a quicker, or expedited, exception if you or your health care provider thinks your health would seriously suffer if you wait as long as 72 hours for a decision. Once an expedited request is received, we must give you a decision no later than 24 hours after we get your health care provider's supporting statement.

Will my plan cover my drugs if they are not on the formulary?

You may take drugs that your plan doesn't cover. Or, you may talk to your provider about taking a different drug that your plan covers, but that drug might have a Utilization Management Requirement, such as a Prior Authorization or Step Therapy, that keeps you from getting the drug right away. In certain cases, we may cover as much as a 30-day supply of your drug during the first 90 days you're a member of the plan.

Here is what we'll do for each of your current Part D drugs that aren't on the formulary, or if you have limited ability to get your drugs:

- We'll temporarily cover a 30-day supply of your drug unless you have a prescription written for fewer days (in which case we will allow multiple fills to provide up to a total of 30 days of a drug) when you go to a pharmacy.
- There will be no coverage for the drugs after your first 30-day supply, even if you've been a member of the plan for less than 90 days, unless a formulary exception has been approved.

If you're a resident of a long-term care facility and you take Part D drugs that aren't on the formulary, we'll cover a 30-day supply unless you have a prescription written for fewer days (in which case we will allow multiple fills to provide up to a total of 30 days of a drug) during the first 90 days you're a member of our plan. We'll cover a

31-day emergency supply of your drug unless you have a prescription for fewer days (in which we will allow multiple fills to provide up to a total of 31 days of a drug) while you request a formulary exception if:

- You need a drug that's not on the formulary *or*
- You have limited ability to get your drugs *and*
- You're past the first 90 days of membership in the plan

Throughout the plan year, your treatment setting (the place where you receive and take your medicine) may change. These changes include:

- Members who are discharged from a hospital or skilled-nursing facility to a home setting
- Members who are admitted to a hospital or skilled-nursing facility from a home setting
- Members who transfer from one skilled-nursing facility to another and use a different pharmacy
- Members who end their skilled-nursing facility Medicare Part A stay (where payments include all pharmacy charges) and who now need to use their Part D plan benefit
- Members who give up Hospice Status and go back to standard Medicare Part A and B coverage
- Members discharged from chronic psychiatric hospitals with highly individualized drug regimens

For these changes in treatment settings, CarePlus will cover as much as a 30-day temporary supply of a Part D-covered drug when you fill your prescription at a pharmacy. If you change treatment settings multiple times within the same month, you may have to request an exception or prior authorization and receive approval for continued coverage of your drug. CarePlus will review requests for continuation of therapy on a case-by-case basis understanding when you're on a stabilized drug regimen that, if changed, is known to have risks.

Transition extension

CarePlus will consider on a case-by-case basis an extension of the transition period if your exception request or appeal hasn't been processed by the end of your initial transition period. We'll continue to provide necessary drugs to you if your transition period is extended.

A Transition Policy is available on CarePlus's website, www.careplushealthplans.com, in the same area where the Prescription Drug Guides are displayed.

For More Information

For more detailed information about your CarePlus prescription drug coverage, please read your Evidence of Coverage (EOC) and other plan materials.

If you have questions about CarePlus, please visit www.careplushealthplans.com or call Member Services at **1-800-794-5907**; **TTY: 711**. From October 1 - March 31, we are open 7 days a week; 8 a.m. to 8 p.m. From April 1 - September 30, we are open Monday - Friday, 8 a.m. to 8 p.m. You may always leave a voice mail message after-hours, Saturdays, Sundays, and holidays and we will return your call within 1 business day.

If you have general questions about Medicare prescription drug coverage, please call Medicare at **1-800-MEDICARE (1-800-633-4227)** 24 hours a day, seven days a week. TTY users should call **1-877-486-2048**. You can also visit www.medicare.gov.

CarePlus Formulary

The formulary that begins on the next page provides coverage information about the drugs covered by CarePlus. If you have trouble finding your drug in the list, turn to the Index that begins on page 109.

Your CarePlus plan has additional coverage of some drugs. These drugs aren't normally covered under Medicare Part D and aren't subject to the Medicare appeals process. These drugs are listed separately on page 107.

Your CarePlus plan has a contract with the Medicaid agency to provide additional coverage for certain prescription drugs that aren't normally covered in a Medicare prescription drug plan. These drugs are listed separately on page 108.

How to read your formulary

The first column of the chart lists categories of medical conditions in alphabetical order. The drug names are then listed in alphabetical order within each category. Brand-name drugs are CAPITALIZED and generic drugs are listed in lower-case italics. Next to the drug name you may see an indicator to tell you about additional coverage information for that drug. You might see the following indicators:

DL - Dispensing Limit; Drugs that may be limited to a 30 day supply

MO - Drugs that are typically available through mail-order. Please contact your mail-order pharmacy to make sure your drug is available.

The second column lists the tier of the drug. See page 4 for more details on the drug tiers in your plan.

The third column shows the Utilization Management Requirements for the drug. CarePlus may have special requirements for covering that drug. If the column is blank, then there are no utilization requirements for that drug. The supply for each drug is based on benefits and whether your health care provider prescribes a supply for 30, 60, or 90 days. The amount of any quantity limits will also be in this column (Example: "QL - 30 for 30 days" means you can only get 30 doses every 30 days). See page 5 for more information about these requirements.

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| Analgesics | | |
| acetamin-codein 300-30 mg/12.5; acetaminop-codeine 120-12 mg/5 DL | 3 | QL (2700 per 30 days) |
| acetaminophen-cod #2 tablet DL | 3 | QL (390 per 30 days) |
| acetaminophen-cod #3 tablet DL | 3 | QL (360 per 30 days) |
| acetaminophen-cod #4 tablet DL | 3 | QL (180 per 30 days) |
| BELBUCA 150 MCG, 300 MCG, 450 MCG, 600 MCG, 75 MCG, 750 MCG, 900 MCG BUCCAL FILM DL | 3 | QL (60 per 30 days) |
| butalb-acetaminoph-caff-codein DL | 4 | PA,QL (180 per 30 days) |
| butalb-caff-acetaminoph-codein DL | 4 | PA,QL (360 per 30 days) |
| butorphanol 1 mg/ml vial DL | 4 | QL (960 per 30 days) |
| butorphanol 10 mg/ml spray DL | 4 | QL (5 per 28 days) |
| butorphanol 2 mg/ml vial DL | 4 | QL (480 per 30 days) |
| CAPITAL WITH CODEINE SUSP DL | 4 | QL (2700 per 30 days) |
| celecoxib 100 mg, 200 mg, 400 mg, 50 mg capsule MO | 2 | QL (60 per 30 days) |
| diclofenac epolamine 1.3% ptch MO | 4 | PA,QL (60 per 30 days) |
| diclofenac sod ec 25 mg tab MO | 3 | |
| diclofenac sod ec 50 mg, 75 mg tab MO | 2 | |
| diclofenac sod er 100 mg tab MO | 2 | |
| diclofenac sodium 1% gel MO | 3 | |
| diclofenac-misoprost 50-0.2 tb; diclofenac-misoprost 75-0.2 tb MO | 4 | |
| EMBEDA ER 100-4 MG, 20-0.8 MG, 30-1.2 MG, 50-2 MG, 60-2.4 MG, 80-3.2 MG CAPSULE DL | 3 | QL (60 per 30 days) |
| endocet 10 mg-325 mg tablet; endocet 2.5 mg-325 mg tablet; endocet 5 mg-325 mg tablet; endocet 7.5 mg-325 mg tablet DL | 3 | QL (360 per 30 days) |
| etodolac 200 mg, 300 mg capsule MO | 3 | |
| etodolac 400 mg, 500 mg tablet MO | 3 | |
| etodolac er 400 mg, 500 mg, 600 mg tablet MO | 4 | |
| fentanyl 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 37.5 mcg/hour, 50 mcg/hr, 62.5 mcg/hour, 75 mcg/hr, 87.5 mcg/hour patch; fentanyl 37.5 mcg/hr patch; fentanyl 62.5 mcg/hr patch; fentanyl 87.5 mcg/hr patch DL | 4 | QL (20 per 30 days) |
| fentanyl cit otfc 1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg; fentanyl citrate otfc 1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg DL | 5 | PA,QL (120 per 30 days) |
| fentanyl 100 mcg/2 ml ampul DL | 4 | QL (720 per 30 days) |
| fentanyl 100 mcg/2 ml carpuct DL | 4 | QL (720 per 30 days) |
| FLECTOR 1.3 % TRANSDERMAL 12 HOUR PATCH MO | 4 | PA,QL (60 per 30 days) |
| flurbiprofen 100 mg, 50 mg tablet MO | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| hydrocodone-acetamin 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg; hydrocodone-acetamin 2.5-325; hydrocodone-acetamin 7.5-325 DL | 3 | QL (360 per 30 days) |
| hydrocodone-acetamin 10-325/15 DL | 3 | QL (2700 per 30 days) |
| hydrocodone-acetamin 7.5-325/15 DL | 3 | QL (5520 per 30 days) |
| hydrocodone-ibuprofen 10-200; hydrocodone-ibuprofen 10-200 mg, 5-200 mg DL | 4 | QL (150 per 30 days) |
| hydrocodone-ibuprofen 7.5-200 DL | 3 | QL (150 per 30 days) |
| hydromorphone 0.5 mg/0.5 ml, 1 mg/ml; hydromorphone 0.5 mg/0.5 ml, 1 mg/ml carpuct DL | 4 | QL (720 per 30 days) |
| hydromorphone 2 mg, 4 mg tablet DL | 3 | QL (360 per 30 days) |
| hydromorphone 2 mg/ml carpuct DL | 4 | QL (360 per 30 days) |
| hydromorphone 2 mg/ml vial DL | 4 | QL (360 per 30 days) |
| hydromorphone 4 mg/ml carpuct DL | 4 | QL (180 per 30 days) |
| hydromorphone 8 mg tablet DL | 3 | QL (240 per 30 days) |
| hydromorphone hcl 1 mg/ml amp DL | 4 | QL (720 per 30 days) |
| hydromorphone hcl 4 mg/ml amp DL | 4 | QL (180 per 30 days) |
| hydromorphone 1 mg/ml vial DL | 4 | QL (720 per 30 days) |
| hydromorphone 4 mg/ml vial DL | 4 | QL (180 per 30 days) |
| hydromorphone hcl 10 mg/ml vl DL | 4 | QL (144 per 30 days) |
| ibu 400 mg, 600 mg, 800 mg tablet MO | 1 | |
| ibuprofen 100 mg/5 ml susp MO | 2 | |
| ibuprofen 400 mg, 600 mg, 800 mg tablet MO | 1 | |
| indomethacin 25 mg, 50 mg, 75 mg capsule; indomethacin er 25 mg, 50 mg, 75 mg capsule MO | 4 | |
| ketoprofen 25 mg, 50 mg, 75 mg capsule MO | 3 | |
| ketorolac 10 mg tablet MO | 4 | QL (20 per 30 days) |
| meloxicam 15 mg tablet MO | 1 | QL (30 per 30 days) |
| meloxicam 7.5 mg tablet MO | 1 | QL (60 per 30 days) |
| methadone 10 mg/5 ml solution DL | 3 | QL (1800 per 30 days) |
| methadone 10 mg/ml oral conc DL | 3 | QL (360 per 30 days) |
| methadone 5 mg/5 ml solution DL | 3 | QL (3600 per 30 days) |
| methadone hcl 10 mg tablet DL | 3 | QL (240 per 30 days) |
| methadone hcl 10 mg/ml vial DL | 3 | QL (360 per 30 days) |
| methadone hcl 5 mg tablet DL | 3 | QL (480 per 30 days) |
| methadone intensol 10 mg/ml oral concentrate DL | 3 | QL (360 per 30 days) |
| morphine sulf 10 mg/5 ml soln DL | 3 | QL (2700 per 30 days) |
| morphine sulf 20 mg/5 ml soln DL | 3 | QL (1350 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| morphine sulf er 100 mg tablet DL | 3 | QL (180 per 30 days) |
| morphine sulf er 15 mg, 30 mg, 60 mg tablet DL | 3 | QL (120 per 30 days) |
| morphine sulf er 200 mg tablet DL | 3 | QL (90 per 30 days) |
| morphine sulfate 10 mg/ml vial DL | 4 | QL (360 per 30 days) |
| morphine sulfate ir 15 mg, 30 mg tab DL | 3 | QL (180 per 30 days) |
| morphine sulf 100 mg/5 ml conc DL | 3 | QL (540 per 30 days) |
| nabumetone 500 mg, 750 mg tablet MO | 2 | |
| naproxen 250 mg, 375 mg, 500 mg tablet MO | 1 | |
| naproxen dr 375 mg, 500 mg tablet MO | 2 | |
| naproxen sod cr 375 mg tablet MO | 4 | ST,QL (120 per 30 days) |
| naproxen sod cr 500 mg tablet MO | 4 | ST,QL (90 per 30 days) |
| naproxen sodium 275 mg, 550 mg tab MO | 4 | |
| NUCYNTA 100 MG, 50 MG, 75 MG TABLET DL | 4 | ST,QL (180 per 30 days) |
| oxaprozin 600 mg tablet MO | 4 | |
| oxycodon 10 mg/0.5 ml oral syr DL | 4 | QL (270 per 30 days) |
| oxycodone hcl 10 mg, 15 mg, 20 mg, 30 mg, 5 mg tablet DL | 3 | QL (360 per 30 days) |
| oxycodone hcl 100 mg/5 ml conc DL | 4 | QL (270 per 30 days) |
| oxycodone hcl 5 mg capsule DL | 4 | QL (360 per 30 days) |
| oxycodone hcl 5 mg/5 ml soln DL | 4 | QL (5400 per 30 days) |
| oxycodon-acetaminophen 2.5-325; oxycodon-acetaminophen 7.5-325; oxycodone-acetaminophen 10-325; oxycodone-acetaminophen 5-325 DL | 3 | QL (360 per 30 days) |
| oxycodone-aspirin 4.8355-325 DL | 4 | QL (360 per 30 days) |
| oxymorphone hcl 10 mg, 5 mg tablet DL | 4 | QL (360 per 30 days) |
| pentazocine-naloxone tablet DL | 4 | QL (360 per 30 days) |
| piroxicam 10 mg, 20 mg capsule MO | 3 | |
| primlev 10 mg-300 mg tablet; primlev 5 mg-300 mg tablet; primlev 7.5 mg-300 mg tablet DL | 5 | QL (390 per 30 days) |
| sulindac 150 mg, 200 mg tablet MO | 2 | |
| tramadol er 100 mg, 200 mg, 300 mg tablet; tramadol hcl er 100 mg, 200 mg, 300 mg tablet DL | 3 | QL (30 per 30 days) |
| tramadol hcl 50 mg tablet DL | 2 | QL (240 per 30 days) |
| tramadol-acetaminophn 37.5-325 DL | 3 | QL (240 per 30 days) |
| XTAMPZA ER 13.5 MG, 18 MG, 27 MG, 36 MG, 9 MG CAPSULE SPRINKLE DL | 3 | QL (60 per 30 days) |
| Anesthetics | | |
| bupivacaine 0.25% vial; bupivacaine 0.5% vial MO | 1 | |
| bupivacaine 0.25% vial; bupivacaine 0.5% ampul; bupivacaine 0.75% vial MO | 1 | |
| lidocaine 5% patch MO | 4 | PA,QL (90 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| lidocaine 5% in d7.5w ampul ^{MO} | 1 | |
| lidocaine hcl 2% jelly ^{MO} | 2 | |
| lidocaine hcl 2% jelly uro-jet ^{MO} | 2 | |
| lidocaine viscous 2 % mucosal solution ^{MO} | 2 | |
| lidocaine 0.5%-epi 1:200,000 ^{MO} | 2 | |
| lidocaine-prilocaine cream ^{MO} | 4 | |
| mepivacaine hcl 3% cartridge ^{MO} | 1 | |
| polocaine 1 % (10 mg/ml), 2 % injection solution ^{MO} | 1 | |
| polocaine-mpf 10 mg/ml (1 %), 15 mg/ml (1.5 %), 20 mg/ml (2 %) injection solution ^{MO} | 1 | |
| ropivacaine 0.2% 200 mg/100 ml; ropivacaine 0.5% 100 mg/20 ml; ropivacaine 0.75% 150 mg/20 ml; ropivacaine 1% 200 mg/20 ml vial ^{MO} | 4 | |
| Anti-Addiction/Substance Abuse Treatment Agents | | |
| acamprosate calc dr 333 mg tab ^{MO} | 4 | |
| buprenorphine 2 mg, 8 mg tablet sl ^{MO} | 3 | QL (90 per 30 days) |
| bupreno-nalox 2-0.5 mg, 4-1 mg, 8-2 mg sl film; buprenorp-nalox 2-0.5 mg, 4-1 mg, 8-2 mg sl film ^{MO} | 3 | QL (90 per 30 days) |
| buprenor-nalox 12-3 mg sl film ^{MO} | 3 | QL (60 per 30 days) |
| bupropion hcl sr 150 mg tablet ^{MO} | 3 | QL (90 per 30 days) |
| CHANTIX 0.5 MG, 1 MG TABLET ^{MO} | 4 | QL (56 per 28 days) |
| CHANTIX CONTINUING MONTH BOX 1 MG TABLET ^{MO} | 4 | QL (56 per 28 days) |
| CHANTIX STARTING MONTH BOX 0.5 MG (11)-1 MG (42) TABLETS IN DOSE PACK ^{MO} | 4 | QL (56 per 28 days) |
| disulfiram 250 mg, 500 mg tablet ^{MO} | 4 | |
| naloxone 0.4 mg/ml vial ^{MO} | 2 | |
| naloxone 0.4 mg/ml, 1 mg/ml carpject; naloxone 2 mg/2 ml syringe ^{MO} | 3 | |
| naltrexone 50 mg tablet ^{MO} | 2 | |
| NARCAN 4 MG/ACTUATION NASAL SPRAY ^{MO} | 3 | QL (2 per 30 days) |
| NICOTROL NS 10 MG/ML NASAL SPRAY ^{MO} | 4 | |
| VIVITROL 380 MG INTRAMUSCULAR SUSPENSION, EXTENDED RELEASE ^{DL} | 5 | QL (1 per 28 days) |
| ZUBSOLV 0.7 MG-0.18 MG SUBLINGUAL TABLET; ZUBSOLV 1.4 MG-0.36 MG SUBLINGUAL TABLET; ZUBSOLV 2.9 MG-0.71 MG SUBLINGUAL TABLET; ZUBSOLV 5.7 MG-1.4 MG SUBLINGUAL TABLET ^{MO} | 3 | QL (90 per 30 days) |
| ZUBSOLV 11.4 MG-2.9 MG SUBLINGUAL TABLET ^{MO} | 3 | QL (30 per 30 days) |
| ZUBSOLV 8.6 MG-2.1 MG SUBLINGUAL TABLET ^{MO} | 3 | QL (60 per 30 days) |
| Antibacterials | | |
| acetic acid 2% ear solution ^{MO} | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| amikacin sulf 1 gram/4 ml vial; amikacin sulf 1,000 mg/4 ml, 500 mg/2 ml vial MO | 4 | |
| amoxicillin 125 mg, 250 mg tab chew MO | 1 | |
| amoxicillin 125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, 400 mg/5 ml susp MO | 1 | |
| amoxicillin 250 mg, 500 mg capsule MO | 1 | |
| amoxicillin 500 mg, 875 mg tablet MO | 1 | |
| amox-clav 200-28.5 mg/5 ml, 250-62.5 mg/5 ml, 400-57 mg/5 ml, 600-42.9 mg/5 ml sus; amox-clav 200-28.5 mg/5 ml, 250-62.5 mg/5 ml, 400-57 mg/5 ml, 600-42.9 mg/5 ml susp MO | 2 | |
| amox-clav 250-125 mg, 500-125 mg, 875-125 mg tablet MO | 2 | |
| ampicillin 250 mg, 500 mg capsule MO | 1 | |
| ampicillin 1 gm add-vantage vl; ampicillin 1 gm vial; ampicillin 1 gram, 10 gram, 125 mg, 2 gram, 250 mg, 500 mg vial; ampicillin 10 gm vial; ampicillin 2 gm add-vantage vl; ampicillin 2 gm vial MO | 4 | |
| ampicillin-sulb 1.5 g add vial; ampicillin-sulbactam 1.5 gm vl; ampicillin-sulbactam 15 gm vl; ampicillin-sulbactam 3 gm vial MO | 4 | |
| AUGMENTIN 500 MG-125 MG TABLET; AUGMENTIN 875 MG-125 MG TABLET MO | 4 | PA |
| azithromycin 1 gm pwd packet MO | 3 | |
| azithromycin 100 mg/5 ml, 200 mg/5 ml susp MO | 3 | |
| azithromycin 250 mg, 500 mg tablet MO | 2 | |
| azithromycin 600 mg tablet MO | 2 | QL (16 per 60 days) |
| azithromycin i.v. 500 mg vial MO | 2 | |
| aztreonam 1 gm vial MO | 4 | |
| aztreonam 2 gm vial DL | 5 | |
| baciim 50,000 unit vial MO | 4 | |
| bacitracin 50,000 unit vial MO | 2 | |
| bacitracin 500 unit/gm ophth MO | 4 | |
| BESIVANCE 0.6 % EYE DROPS,SUSPENSION MO | 3 | |
| BETHKIS 300 MG/4 ML SOLUTION FOR NEBULIZATION DL | 5 | PA |
| BICILLIN C-R 1,200,000 UNIT/2 ML INTRAMUSCULAR SYRINGE; BICILLIN C-R 900,000 UNIT-300K UNIT/2 ML INTRAMUSCULAR SYRINGE MO | 4 | |
| BICILLIN L-A 1,200,000 UNIT/2 ML, 2,400,000 UNIT/4 ML, 600,000 UNIT/ML INTRAMUSCULAR SYRINGE MO | 4 | |
| cefaclor 250 mg, 500 mg capsule MO | 3 | |
| cefadroxil 250 mg/5 ml, 500 mg/5 ml susp MO | 3 | |
| cefadroxil 500 mg capsule MO | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| cefazolin 1 gm add-van vial; cefazolin 1 gm vial; cefazolin 1 gram, 10 gram, 500 mg vial; cefazolin 10 gm vial ^{MO} | 3 | |
| cefazolin 1 g/50 ml-dextrose; cefazolin 2 g/100 ml-dextrose; cefazolin 2 g/50 ml-dextrose ^{MO} | 3 | |
| cefdinir 125 mg/5 ml, 250 mg/5 ml susp ^{MO} | 3 | |
| cefdinir 300 mg capsule ^{MO} | 2 | |
| cefepime hcl 1 gm vial; cefepime hcl 1 gram, 2 gram vial ^{MO} | 4 | |
| cefepime-dextrose 1 gm/50 ml; cefepime-dextrose 2 gm/50 ml ^{MO} | 4 | |
| cefepime 1 gm injection; cefepime 2 gm injection ^{MO} | 4 | |
| cefixime 400 mg capsule ^{MO} | 4 | |
| cefotaxime sodium 1 gm vial; cefotaxime sodium 1 gram, 10 gram, 2 gram, 500 mg vial; cefotaxime sodium 10 gm vial; cefotaxime sodium 2 gm vial ^{MO} | 2 | |
| cefotetan 1 gm vial; cefotetan 10 gm vial; cefotetan 2 gm vial ^{MO} | 4 | |
| cefotetan-dextr 1 g duplex bag; cefotetan-dextr 2 g duplex bag ^{MO} | 4 | |
| cefoxitin 1 gm vial; cefoxitin 10 gm vial; cefoxitin 2 gm vial ^{MO} | 4 | |
| cefoxitin 1 gm piggyback bag; cefoxitin 2 gm piggyback bag ^{MO} | 4 | |
| cefpodoxime 100 mg, 200 mg tablet ^{MO} | 4 | |
| cefprozil 125 mg/5 ml, 250 mg/5 ml susp ^{MO} | 4 | |
| cefprozil 250 mg, 500 mg tablet ^{MO} | 3 | |
| ceftazidime 1 gm vial; ceftazidime 2 gm vial; ceftazidime 6 gm vial ^{MO} | 4 | |
| ceftazidime 1 gm piggyback; ceftazidime 2 gm piggyback ^{MO} | 4 | |
| ceftriaxone 1 gm add-vant vial; ceftriaxone 1 gm vial; ceftriaxone 1 gram, 10 gram, 2 gram, 250 mg, 500 mg vial; ceftriaxone 10 gm vial; ceftriaxone 2 gm add vial; ceftriaxone 2 gm vial ^{MO} | 3 | |
| ceftriaxone 1 gm-d5w bag; ceftriaxone 2 gm-d5w bag ^{MO} | 3 | |
| cefuroxime axetil 250 mg, 500 mg tab ^{MO} | 3 | |
| cefuroxime sod 1.5 gm vial; cefuroxime sod 1.5 gram, 7.5 gram, 750 mg vial; cefuroxime sod 7.5 gm vial ^{MO} | 3 | |
| cephalexin 125 mg/5 ml, 250 mg/5 ml susp ^{MO} | 2 | |
| cephalexin 250 mg, 500 mg capsule ^{MO} | 2 | |
| chloramphen na succ 1 gm vl ^{MO} | 3 | |
| CILOXAN 0.3 % EYE OINTMENT ^{MO} | 4 | |
| ciprofloxacin er 1,000 mg, 500 mg tab; ciprofloxacin er 1,000 mg, 500 mg tablet ^{MO} | 3 | |
| ciprofloxacin 0.2% otic soln ^{MO} | 4 | |
| ciprofloxacin 0.3% eye drop ^{MO} | 1 | |
| ciprofloxacin hcl 100 mg tab ^{MO} | 4 | |
| ciprofloxacin hcl 250 mg, 500 mg, 750 mg tab ^{MO} | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| <i>ciprofloxacin-d5w 200 mg/100 ml, 400 mg/200 ml</i> MO | 2 | |
| <i>ciprofloxacin 200 mg/20 ml, 400 mg/40 ml vl</i> MO | 2 | |
| <i>clarithromycin 125 mg/5 ml, 250 mg/5 ml sus</i> MO | 4 | |
| <i>clarithromycin 250 mg, 500 mg tablet</i> MO | 3 | |
| <i>clarithromycin er 500 mg tab</i> MO | 3 | |
| CLEOCIN 100 MG VAGINAL SUPPOSITORY MO | 4 | |
| CLINDAGEL 1 % TOPICAL GEL, ONCE DAILY DL | 5 | PA |
| <i>clindamycin hcl 150 mg, 300 mg, 75 mg capsule</i> MO | 2 | |
| <i>clindamycin 300 mg/50 ml, 600 mg/50 ml, 900 mg/50 ml-ns</i> MO | 4 | B vs D |
| <i>clindamycin-d5w 300 mg/50 ml, 600 mg/50 ml, 900 mg/50 ml</i> MO | 4 | |
| <i>clindamycin 75 mg/5 ml soln</i> MO | 4 | |
| <i>clindamycin pediatric 75 mg/5 ml oral solution</i> MO | 4 | |
| <i>clindamycin 1 %, 150 mg/ml, 300 mg/2 ml, 600 mg/4 ml, 900 mg/6 ml addvan; clindamycin ph 1% solution; clindamycin ph 900 mg/6 ml vl</i> MO | 3 | |
| <i>clindamycin 2% vaginal cream</i> MO | 4 | |
| <i>clindamycin ph 1% gel</i> MO | 4 | |
| <i>clindamycin phos 1% pledget</i> MO | 3 | |
| <i>clindamycin phosp 1% lotion</i> MO | 4 | |
| <i>clindamycin phosphate 1% gel</i> DL | 5 | PA |
| CLINDESSE 2 % VAGINAL CREAM, EXTENDED RELEASE MO | 4 | |
| <i>colistimethate 150 mg vial</i> MO | 4 | |
| <i>daptomycin 350 mg, 500 mg vial</i> DL | 5 | |
| <i>demeclocycline 150 mg, 300 mg tablet</i> MO | 4 | |
| <i>dicloxacillin 250 mg, 500 mg capsule</i> MO | 2 | |
| DIFICID 200 MG TABLET DL | 5 | QL (20 per 10 days) |
| <i>doripenem 250 mg, 500 mg vial</i> MO | 4 | |
| <i>doxy-100 100 mg intravenous solution</i> MO | 4 | |
| <i>doxycycline hyclate 100 mg vl</i> MO | 4 | |
| <i>doxycycline hyclate 100 mg, 20 mg tab</i> MO | 3 | |
| <i>doxycycline hyclate 100 mg, 50 mg cap</i> MO | 3 | |
| <i>doxycycline 25 mg/5 ml susp</i> MO | 4 | |
| <i>doxycycline mono 100 mg, 50 mg cap</i> MO | 2 | QL (60 per 30 days) |
| <i>doxycycline mono 100 mg, 50 mg, 75 mg tablet</i> MO | 3 | |
| <i>ertapenem 1 gram vial</i> DL | 5 | |
| <i>ery pads 2 % topical swab</i> MO | 3 | |
| ERYTHROCIN 500 MG INTRAVENOUS SOLUTION MO | 4 | |
| <i>erythromycin 0.5% eye ointment</i> MO | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| erythromycin dr 250 mg cap ^{MO} | 4 | |
| erythromycin 2% pledgets ^{MO} | 3 | |
| erythromycin 2% solution ^{MO} | 2 | |
| gatifloxacin 0.5% eye drops ^{MO} | 4 | QL (2.5 per 25 days) |
| gentak 0.3 % (3 mg/gram) eye ointment ^{MO} | 2 | |
| gentamicin 0.1% cream ^{MO} | 3 | |
| gentamicin 0.1% ointment ^{MO} | 3 | |
| gentamicin 20 mg/2 ml, 40 mg/ml vial; gentamicin 80 mg/2 ml vial ^{MO} | 2 | |
| gentamicin 3 mg/ml eye drop ^{MO} | 2 | |
| gentamicin 70 mg/ns 50 ml pb; gentamicin 90 mg/ns 100 ml pb; iso gentamicin 100 mg/100 ml, 100 mg/50 ml, 120 mg/100 ml, 60 mg/50 ml, 70 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml, 90 mg/100 ml; isoton gentamicin 100 mg/100 ml, 100 mg/50 ml, 120 mg/100 ml, 60 mg/50 ml, 70 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml, 90 mg/100 ml ^{MO} | 2 | |
| gentamicin ped 20 mg/2 ml vial ^{MO} | 2 | |
| gentamicin 10 mg/ml vial ^{MO} | 2 | |
| imipenem-cilastatin 250 mg, 500 mg vl ^{MO} | 4 | |
| INVANZ 1 GM ADD-VANTAGE VIAL; INVANZ 1 GRAM SOLUTION FOR INJECTION ^{DL} | 5 | |
| levofloxacin 25 mg/ml solution; levofloxacin 750 mg/30 ml vial ^{MO} | 4 | |
| levofloxacin 250 mg, 500 mg, 750 mg tablet ^{MO} | 2 | |
| levofloxacin 250 mg/50 ml, 500 mg/100 ml, 750 mg/150 ml-d5w ^{MO} | 4 | |
| lincomycin hcl 600 mg/2 ml vl ^{MO} | 4 | |
| linezolid 100 mg/5 ml susp ^{DL} | 5 | QL (1800 per 30 days) |
| linezolid 600 mg tablet ^{MO} | 4 | |
| linezolid 600 mg/300 ml-d5w ^{DL} | 5 | |
| linezolid 600mg/300ml-0.9%nacl ^{DL} | 5 | |
| mafenide acetate 50 gm powd pk ^{MO} | 4 | |
| meropenem iv 1 gm vial; meropenem iv 1 gram, 500 mg vial ^{MO} | 4 | |
| meropenem-0.9% nacl 1 gram/50; meropenem-0.9% nacl 500 mg/50 ^{MO} | 4 | |
| methenamine hipp 1 gm tablet ^{MO} | 4 | |
| metronidazole 0.75% cream ^{MO} | 4 | |
| metronidazole 0.75% lotion ^{MO} | 4 | |
| metronidazole 250 mg, 500 mg tablet ^{MO} | 2 | |
| metronidazole top 1% gel pump; metronidazole topical 0.75% gl; metronidazole topical 1% gel; metronidazole vaginal 0.75% gl ^{MO} | 4 | |
| metronidazole 500 mg/100 ml ^{MO} | 4 | |
| minocycline 100 mg, 50 mg, 75 mg capsule ^{MO} | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| MONUROL 3 GRAM ORAL PACKET MO | 4 | |
| moxifloxacin 0.5% eye drops MO | 3 | |
| moxifloxacin hcl 400 mg tablet MO | 4 | |
| mupirocin 2% ointment MO | 2 | |
| nafcillin 1 gm add-van vial; nafcillin 10 gm bulk vial; nafcillin 2 gm add-vant vial DL | 5 | |
| nafcillin 1 gm vial MO | 4 | |
| nafcillin 2 gm vial DL | 4 | |
| nafcillin 1 gm/ 50 ml inj; nafcillin 2 gm/ 100 ml inj DL | 5 | |
| neomycin 500 mg tablet MO | 3 | |
| neomy-polymyxin b 40 mg/ml amp MO | 3 | |
| nitrofurantoin 25 mg/5 ml susp MO | 4 | QL (2400 per 30 days) |
| nitrofurantoin mcr 100 mg, 50 mg cap MO | 4 | QL (90 per 365 days) |
| nitrofurantoin mono-mcr 100 mg MO | 4 | QL (90 per 365 days) |
| ofloxacin 0.3% ear drops MO | 4 | |
| ofloxacin 0.3% eye drops MO | 2 | |
| ofloxacin 300 mg, 400 mg tablet MO | 4 | |
| ORACEA 40 MG CAPSULE, IMMEDIATE - DELAY RELEASE MO | 4 | PA, QL (30 per 30 days) |
| ORBACTIV 400 MG INTRAVENOUS SOLUTION DL | 5 | QL (3 per 28 days) |
| oxacillin 1 gm add-vantage vl; oxacillin 1 gm vial; oxacillin 2 gm add-vantage vl; oxacillin 2 gm vial MO | 4 | |
| oxacillin 10 gm vial DL | 5 | |
| oxacillin 1 gm/ 50 ml inj; oxacillin 2 gm/ 50 ml inj MO | 4 | |
| paromomycin 250 mg capsule MO | 4 | |
| pen g k 1 million unit/50 ml DL | 5 | |
| pen g k 2 million unit/50 ml, 3 million unit/50 ml MO | 4 | |
| penicillin gk 20 million unit MO | 4 | |
| penicillin gk 5 million unit DL | 5 | |
| pen g 1.2 million unit/2 ml MO | 4 | |
| penicillin g 600,000 unit/1 ml DL | 5 | |
| penicillin g na 5 million unit DL | 5 | |
| penicillin vk 125 mg/5 ml, 250 mg/5 ml soln MO | 2 | |
| penicillin vk 250 mg, 500 mg tablet MO | 2 | |
| pfizerpen-g 20 million unit, 5 million unit solution for injection DL | 5 | |
| piperacil-tazobact 13.5 gm vl; piperacil-tazobact 13.5 gram, 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram; piperacil-tazobact 2.25 gm vl; piperacil-tazobact 3.375 gm vl; piperacil-tazobact 4.5 gm vial MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| <i>polymyxin b sulfate vial</i> MO | 3 | |
| PRIMSOL 50 MG/5 ML ORAL SOLUTION MO | 4 | |
| <i>silver sulfadiazine 1% cream</i> MO | 2 | |
| SIVEXTRO 200 MG INTRAVENOUS SOLUTION DL | 5 | QL (6 per 28 days) |
| SIVEXTRO 200 MG TABLET DL | 5 | QL (6 per 28 days) |
| SSD 1 % TOPICAL CREAM MO | 2 | |
| <i>streptomycin sulf 1 gm vial</i> DL | 5 | |
| <i>sulfacetamide 10% eye drops</i> MO | 2 | |
| <i>sulfacetamide 10% eye ointment</i> MO | 3 | |
| <i>sulfacetamide sod 10% top susp</i> MO | 4 | |
| <i>sulfadiazine 500 mg tablet</i> MO | 4 | |
| <i>sulfamethoxazole-tmp ds tablet; sulfamethoxazole-tmp ss tablet</i> MO | 1 | |
| <i>sulfamethoxazole-tmp iv vial</i> MO | 4 | |
| <i>sulfamethoxazole-tmp susp</i> MO | 4 | |
| SUPRAX 400 MG CAPSULE MO | 4 | |
| SYNERCID 500 MG INTRAVENOUS SOLUTION DL | 5 | |
| TEFLARO 400 MG, 600 MG INTRAVENOUS SOLUTION DL | 5 | |
| <i>tigecycline 50 mg vial</i> DL | 5 | |
| <i>tinidazole 250 mg, 500 mg tablet</i> MO | 3 | |
| <i>tobramycin 0.3% eye drop</i> MO | 2 | |
| <i>tobramycin 10 mg/ml, 40 mg/ml vial</i> MO | 2 | |
| TOBREX 0.3 % EYE OINTMENT MO | 4 | |
| <i>trimethoprim 100 mg tablet</i> MO | 2 | |
| <i>vancomycin 1 gm vial; vancomycin 1,000 mg, 1.25 gram, 1.5 gram, 10 gram, 250 mg, 5 gram, 500 mg, 750 mg vial; vancomycin hcl 1,000 mg, 1.25 gram, 1.5 gram, 10 gram, 250 mg, 5 gram, 500 mg, 750 mg vial; vancomycin hcl 10 gm vial; vancomycin hcl 5 gm vial</i> MO | 4 | |
| <i>vancomycin hcl 125 mg capsule</i> DL | 4 | QL (120 per 30 days) |
| <i>vancomycin hcl 250 mg capsule</i> DL | 5 | QL (240 per 30 days) |
| <i>vanco 1 gram/200 ml, 500 mg/100 ml, 750 mg/150 ml-0.9% nacl; vancomycin 1 g/200ml-0.9% nacl</i> MO | 4 | |
| <i>vancomycin 1 gram/200 ml, 750 mg/150 ml bag; vancomycin hcl 1g/200 ml bag</i> MO | 4 | |
| VIGAMOX 0.5 % EYE DROPS MO | 4 | PA |
| ZERBAXA 1.5 GRAM INTRAVENOUS SOLUTION DL | 5 | |
| Anticonvulsants | | |
| APTIOM 200 MG, 400 MG TABLET DL | 5 | PA,QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| APTIOM 600 MG, 800 MG TABLET DL | 5 | PA,QL (60 per 30 days) |
| BANZEL 200 MG TABLET DL | 5 | PA,QL (480 per 30 days) |
| BANZEL 40 MG/ML ORAL SUSPENSION DL | 5 | PA,QL (2760 per 30 days) |
| BANZEL 400 MG TABLET DL | 5 | PA,QL (240 per 30 days) |
| BRIVIACT 10 MG, 100 MG, 25 MG, 50 MG, 75 MG TABLET DL | 5 | PA,QL (60 per 30 days) |
| BRIVIACT 10 MG/ML ORAL SOLUTION DL | 5 | PA,QL (600 per 30 days) |
| BRIVIACT 50 MG/5 ML INTRAVENOUS SOLUTION MO | 4 | PA |
| BUTISOL SODIUM 30 MG TABLET MO | 4 | |
| <i>carbamazepine 100 mg tab chew</i> MO | 3 | |
| <i>carbamazepine 100 mg/5 ml susp</i> MO | 4 | |
| <i>carbamazepine 200 mg tablet</i> MO | 3 | |
| <i>carbamazepine er 100 mg, 200 mg, 300 mg cap</i> MO | 4 | |
| <i>carbamazepine er 100 mg, 400 mg tablet</i> MO | 4 | |
| <i>carbamazepine er 200 mg tablet</i> MO | 4 | QL (120 per 30 days) |
| CELONTIN 300 MG CAPSULE MO | 4 | |
| <i>clobazam 10 mg, 20 mg tablet</i> DL | 4 | PA,QL (60 per 30 days) |
| <i>clobazam 2.5 mg/ml suspension</i> DL | 4 | PA,QL (480 per 30 days) |
| DIASSTAT ACUDIAL 12.5 MG-15 MG-17.5 MG-20 MG RECTAL KIT DL | 4 | |
| <i>diazepam 10 mg rectal gel syst; diazepam 12.5-15-17.5-20 mg, 2.5 mg, 5-7.5-10 mg rectal gel sys; diazepam 20 mg rectal gel syst</i> DL | 4 | |
| <i>dilantin 30 mg capsule</i> MO | 4 | |
| <i>dilantin extended 100 mg capsule</i> MO | 4 | |
| DILANTIN INFATABS 50 MG CHEWABLE TABLET MO | 4 | |
| DILANTIN-125 125 MG/5 ML ORAL SUSPENSION MO | 4 | |
| <i>divalproex dr 125 mg cap sprnk</i> MO | 3 | |
| <i>divalproex sod dr 125 mg, 250 mg, 500 mg tab</i> MO | 2 | |
| <i>divalproex sod er 250 mg, 500 mg tab</i> MO | 4 | |
| EPIDIOLEX 100 MG/ML ORAL SOLUTION DL | 5 | PA |
| <i>epitol 200 mg tablet</i> MO | 3 | |
| EQUETRO 100 MG, 200 MG, 300 MG CAPSULE, EXTENDED RELEASE MO | 4 | |
| <i>ethosuximide 250 mg capsule</i> MO | 4 | |
| <i>ethosuximide 250 mg/5 ml soln</i> MO | 4 | |
| <i>felbamate 400 mg, 600 mg tablet</i> MO | 4 | |
| <i>felbamate 600 mg/5 ml susp</i> DL | 5 | |
| <i>fosphenytoin 100 mg pe/2 ml, 500 mg pe/10 ml; fosphenytoin 100 mg pe/2 ml, 500 mg pe/10 ml vl</i> MO | 3 | |
| FYCOMPA 0.5 MG/ML ORAL SUSPENSION DL | 5 | PA,QL (680 per 28 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| FYCOMPA 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| <i>gabapentin 100 mg, 300 mg, 400 mg capsule</i> MO | 2 | QL (270 per 30 days) |
| <i>gabapentin 250 mg/5 ml soln; gabapentin 250 mg/5 ml, 250 mg/5 ml (5 ml), 300 mg/6 ml (6 ml) soln; gabapentin 300 mg/6 ml soln</i> MO | 4 | QL (2250 per 30 days) |
| <i>gabapentin 600 mg, 800 mg tablet</i> MO | 2 | QL (180 per 30 days) |
| <i>lamotrigine 100 mg, 150 mg, 200 mg, 25 mg, 25 mg (35), 25 mg (42) -100 mg (7), 25 mg (84) -100 mg (14) tablet; lamotrigine tab start kit-blue; lamotrigine tab start kt-green; lamotrigine tab start kt-orang</i> MO | 2 | |
| <i>lamotrigine 25 mg, 5 mg disper tab; lamotrigine 25 mg, 5 mg disper tablet</i> MO | 2 | |
| <i>lamotrigine er 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg tablet</i> MO | 4 | |
| <i>lamotrigine odt 100 mg, 200 mg, 25 mg, 25 mg (21) -50 mg (7), 25 mg(14)-50 mg (14)-100 mg (7), 50 mg, 50 mg (42) -100 mg (14) tablet; lamotrigine odt kit (blue); lamotrigine odt kit (green); lamotrigine odt kit (orange)</i> MO | 4 | |
| <i>levetiracetam 1,000 mg, 250 mg, 500 mg, 750 mg tablet</i> MO | 2 | |
| <i>levetiracetam 100 mg/ml soln</i> MO | 2 | |
| <i>levetiracetam 500 mg/5 ml soln; levetiracetam 500 mg/5 ml, 500 mg/5 ml (5 ml) vial</i> MO | 4 | |
| <i>levetiracetam er 500 mg, 750 mg tablet</i> MO | 3 | |
| <i>levetiracetam-nacl 1,000mg/100; levetiracetam-nacl 1,500mg/100; levetiracetam-nacl 500 mg/100</i> MO | 2 | |
| NAYZILAM 5 MG/SPRAY (0.1 ML) NASAL SPRAY DL | 5 | QL (10 per 30 days) |
| ONFI 10 MG, 20 MG TABLET DL | 5 | PA,QL (60 per 30 days) |
| ONFI 2.5 MG/ML ORAL SUSPENSION DL | 5 | PA,QL (480 per 30 days) |
| <i>oxcarbazepine 150 mg, 300 mg, 600 mg tablet</i> MO | 3 | |
| <i>oxcarbazepine 300 mg/5 ml susp</i> MO | 4 | |
| PEGANONE 250 MG TABLET MO | 4 | |
| <i>phenobarbital 100 mg, 16.2 mg, 32.4 mg, 64.8 mg, 97.2 mg tablet</i> MO | 3 | QL (90 per 30 days) |
| <i>phenobarbital 15 mg, 60 mg tablet</i> MO | 3 | QL (120 per 30 days) |
| <i>phenobarbital 20 mg/5 ml elix</i> MO | 4 | QL (1500 per 30 days) |
| <i>phenobarbital 30 mg tablet</i> MO | 3 | QL (300 per 30 days) |
| PHENYTEK 200 MG, 300 MG CAPSULE MO | 4 | |
| <i>phenytoin 100 mg/4 ml, 125 mg/5 ml susp</i> MO | 2 | |
| <i>phenytoin 50 mg tablet chew</i> MO | 2 | |
| <i>phenytoin 50 mg/ml syringe</i> MO | 4 | |
| <i>phenytoin 50 mg/ml vial</i> MO | 4 | |
| <i>phenytoin sod ext 100 mg, 200 mg, 300 mg cap</i> MO | 2 | |
| <i>primidone 250 mg, 50 mg tablet</i> MO | 2 | |
| <i>roweepra 1,000 mg, 500 mg, 750 mg tablet</i> MO | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| <i>roweepra xr 500 mg, 750 mg tablet, extended release</i> ^{MO} | 3 | |
| SABRIL 500 MG TABLET ^{DL} | 5 | PA,QL (180 per 30 days) |
| SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION ^{MO} | 4 | ST,QL (90 per 30 days) |
| SPRITAM 250 MG TABLET FOR ORAL SUSPENSION ^{MO} | 4 | ST,QL (360 per 30 days) |
| SPRITAM 500 MG TABLET FOR ORAL SUSPENSION ^{MO} | 4 | ST,QL (180 per 30 days) |
| SPRITAM 750 MG TABLET FOR ORAL SUSPENSION ^{MO} | 4 | ST,QL (120 per 30 days) |
| <i>subvenite 100 mg, 150 mg, 200 mg, 25 mg tablet</i> ^{MO} | 2 | |
| <i>subvenite starter (blue) kit 25 mg (35) tablets in a dose pack</i> ^{MO} | 2 | |
| <i>subvenite starter (green) kit 25 mg (84)-100 mg (14) tablet, dose pack</i> ^{MO} | 2 | |
| <i>subvenite starter (orange) kit 25 mg (42)-100 mg (7) tablet, dose pack</i> ^{MO} | 2 | |
| SYMPAZAN 10 MG, 20 MG, 5 MG ORAL FILM ^{DL} | 5 | PA,QL (60 per 30 days) |
| TEGRETOL XR 100 MG, 400 MG TABLET, EXTENDED RELEASE ^{MO} | 4 | |
| TEGRETOL XR 200 MG TABLET, EXTENDED RELEASE ^{MO} | 4 | QL (120 per 30 days) |
| <i>tiagabine hcl 12 mg, 16 mg, 2 mg, 4 mg tablet</i> ^{MO} | 4 | |
| <i>topiramate 100 mg, 200 mg, 50 mg tablet</i> ^{MO} | 2 | QL (120 per 30 days) |
| <i>topiramate 15 mg, 25 mg sprinkle cap</i> ^{MO} | 2 | |
| <i>topiramate 25 mg tablet</i> ^{MO} | 2 | QL (90 per 30 days) |
| <i>valproate sod 500 mg/5 ml v1</i> ^{MO} | 2 | |
| <i>valproic acid 250 mg capsule</i> ^{MO} | 2 | |
| <i>valproic acid 250 mg/5 ml soln; valproic acid 250 mg/5 ml, 250 mg/5 ml (5 ml), 500 mg/10 ml (10 ml) soln; valproic acid 500 mg/10 ml sol</i> ^{MO} | 2 | |
| <i>vigabatrin 500 mg powder packet</i> ^{DL} | 5 | PA,QL (180 per 30 days) |
| <i>vigabatrin 500 mg tablet</i> ^{DL} | 5 | PA,QL (180 per 30 days) |
| <i>vigadrone 500 mg oral powder packet</i> ^{DL} | 5 | PA,QL (180 per 30 days) |
| VIMPAT 10 MG/ML ORAL SOLUTION ^{MO} | 4 | QL (1395 per 30 days) |
| VIMPAT 100 MG, 150 MG, 200 MG, 50 MG TABLET ^{MO} | 4 | |
| VIMPAT 200 MG/20 ML INTRAVENOUS SOLUTION ^{MO} | 4 | |
| <i>zonisamide 100 mg, 25 mg, 50 mg capsule</i> ^{MO} | 2 | |
| Antidementia Agents | | |
| <i>donepezil hcl 10 mg tablet</i> ^{MO} | 1 | QL (60 per 30 days) |
| <i>donepezil hcl 10 mg, 5 mg tablet; donepezil hcl odt 10 mg, 5 mg tablet</i> ^{MO} | 1 | QL (30 per 30 days) |
| <i>galantamine 4 mg/ml oral soln</i> ^{MO} | 4 | QL (200 per 30 days) |
| <i>galantamine er 16 mg, 24 mg, 8 mg capsule</i> ^{MO} | 4 | QL (30 per 30 days) |
| <i>galantamine hbr 12 mg, 4 mg, 8 mg tablet</i> ^{MO} | 4 | QL (60 per 30 days) |
| <i>memantine 5-10 mg titration pk</i> ^{MO} | 2 | PA,QL (98 per 30 days) |
| <i>memantine hcl 10 mg, 5 mg tablet</i> ^{MO} | 2 | PA,QL (60 per 30 days) |
| <i>memantine hcl 2 mg/ml solution</i> ^{MO} | 4 | PA,QL (360 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| <i>memantine hcl er 14 mg, 21 mg, 28 mg, 7 mg capsule</i> ^{MO} | 3 | PA,QL (30 per 30 days) |
| NAMZARIC 14 MG-10 MG CAPSULE SPRINKLE,EXTENDED RELEASE; NAMZARIC 21 MG-10 MG CAPSULE SPRINKLE,EXTENDED RELEASE; NAMZARIC 28 MG-10 MG CAPSULE SPRINKLE,EXTENDED RELEASE; NAMZARIC 7 MG-10 MG CAPSULE SPRINKLE,EXTENDED RELEASE ^{MO} | 3 | QL (30 per 30 days) |
| NAMZARIC 7/14/21/28 MG-10 MG CAPSULE,SPRINKLE,EXTEND RELEASE,DOSE PACK ^{MO} | 3 | QL (28 per 28 days) |
| <i>rivastigmine 13.3 mg/24hr ptch; rivastigmine 4.6 mg/24hr patch; rivastigmine 9.5 mg/24hr patch</i> ^{MO} | 4 | QL (30 per 30 days) |
| <i>rivastigmine 1.5 mg, 3 mg capsule</i> ^{MO} | 4 | QL (90 per 30 days) |
| <i>rivastigmine 4.5 mg, 6 mg capsule</i> ^{MO} | 4 | QL (60 per 30 days) |
| ANTIDEPRESSANTS | | |
| <i>amitriptyline hcl 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg tab</i> ^{MO} | 3 | PA |
| <i>amoxapine 100 mg, 150 mg, 25 mg, 50 mg tablet</i> ^{MO} | 4 | PA |
| <i>bupropion hcl 100 mg, 75 mg tablet</i> ^{MO} | 3 | QL (180 per 30 days) |
| <i>bupropion hcl sr 100 mg tablet</i> ^{MO} | 3 | QL (120 per 30 days) |
| <i>bupropion hcl sr 150 mg tablet</i> ^{MO} | 3 | QL (90 per 30 days) |
| <i>bupropion hcl sr 200 mg tablet</i> ^{MO} | 3 | QL (60 per 30 days) |
| <i>bupropion hcl xl 150 mg tablet</i> ^{MO} | 3 | QL (90 per 30 days) |
| <i>bupropion hcl xl 300 mg tablet</i> ^{MO} | 3 | QL (60 per 30 days) |
| <i>citalopram hbr 10 mg, 40 mg tablet</i> ^{MO} | 1 | QL (30 per 30 days) |
| <i>citalopram hbr 10 mg/5 ml soln</i> ^{MO} | 3 | |
| <i>citalopram hbr 20 mg tablet</i> ^{MO} | 1 | QL (60 per 30 days) |
| <i>clomipramine 25 mg, 50 mg, 75 mg capsule</i> ^{MO} | 4 | PA |
| <i>desipramine 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg tablet</i> ^{MO} | 4 | PA |
| <i>desvenlafaxine suc er 100 mg, 25 mg, 50 mg; desvenlafaxine suc er 100 mg, 25 mg, 50 mg tb</i> ^{MO} | 3 | QL (30 per 30 days) |
| <i>duloxetine hcl dr 20 mg, 30 mg, 40 mg, 60 mg cap</i> ^{MO} | 2 | QL (60 per 30 days) |
| EMSAM 12 MG/24 HR, 6 MG/24 HR, 9 MG/24 HR TRANSDERMAL 24 HOUR PATCH ^{DL} | 5 | QL (30 per 30 days) |
| <i>escitalopram 10 mg tablet</i> ^{MO} | 1 | QL (45 per 30 days) |
| <i>escitalopram 20 mg, 5 mg tablet</i> ^{MO} | 1 | QL (30 per 30 days) |
| <i>escitalopram oxalate 5 mg/5 ml</i> ^{MO} | 4 | QL (600 per 30 days) |
| FETZIMA 120 MG, 20 MG, 40 MG, 80 MG CAPSULE,EXTENDED RELEASE ^{MO} | 4 | PA,QL (30 per 30 days) |
| FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE,24 HR,DOSE PACK ^{MO} | 4 | PA,QL (28 per 28 days) |
| <i>fluoxetine 20 mg/5 ml solution</i> ^{MO} | 2 | |
| <i>fluoxetine dr 90 mg capsule</i> ^{MO} | 4 | QL (4 per 28 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| fluoxetine hcl 10 mg, 40 mg capsule ^{MO} | 1 | QL (60 per 30 days) |
| fluoxetine hcl 20 mg capsule ^{MO} | 1 | QL (120 per 30 days) |
| fluvoxamine maleate 100 mg, 25 mg, 50 mg tab ^{MO} | 2 | QL (90 per 30 days) |
| imipramine hcl 10 mg, 25 mg, 50 mg tablet ^{MO} | 3 | PA |
| imipramine pamoate 100 mg, 125 mg, 150 mg, 75 mg cap ^{MO} | 4 | PA |
| maprotiline 25 mg, 50 mg, 75 mg tablet ^{MO} | 4 | |
| MARPLAN 10 MG TABLET ^{MO} | 4 | |
| mirtazapine 15 mg, 30 mg, 45 mg odt ^{MO} | 4 | QL (30 per 30 days) |
| mirtazapine 15 mg, 30 mg, 45 mg tablet ^{MO} | 2 | QL (30 per 30 days) |
| mirtazapine 7.5 mg tablet ^{MO} | 2 | |
| nefazodone hcl 100 mg, 150 mg, 200 mg, 250 mg, 50 mg tablet ^{MO} | 4 | |
| nortriptyline 10 mg/5 ml soln ^{MO} | 4 | PA |
| nortriptyline hcl 10 mg, 25 mg, 50 mg, 75 mg cap ^{MO} | 4 | PA |
| olanzapine-fluoxetine 12-25 mg, 12-50 mg, 3-25 mg, 6-25 mg, 6-50 mg ^{MO} | 4 | QL (30 per 30 days) |
| paroxetine er 12.5 mg, 37.5 mg tablet ^{MO} | 4 | PA,QL (60 per 30 days) |
| paroxetine er 25 mg tablet ^{MO} | 4 | PA,QL (90 per 30 days) |
| paroxetine hcl 10 mg, 20 mg tablet ^{MO} | 3 | PA,QL (30 per 30 days) |
| paroxetine hcl 30 mg, 40 mg tablet ^{MO} | 3 | PA,QL (60 per 30 days) |
| PAXIL 10 MG/5 ML ORAL SUSPENSION ^{MO} | 4 | PA |
| perphen-amitrip 2 mg-10 mg tab; perphen-amitrip 2 mg-25 mg tab; perphen-amitrip 4 mg-10 mg tab; perphen-amitrip 4 mg-25 mg tab; perphen-amitrip 4 mg-50 mg tab ^{MO} | 4 | PA |
| phenelzine sulfate 15 mg tab ^{MO} | 3 | |
| PRISTIQ 100 MG, 25 MG, 50 MG TABLET,EXTENDED RELEASE ^{MO} | 4 | PA,QL (30 per 30 days) |
| protriptyline hcl 10 mg, 5 mg tablet ^{MO} | 4 | PA |
| sertraline 20 mg/ml oral conc ^{MO} | 3 | |
| sertraline hcl 100 mg tablet ^{MO} | 1 | QL (60 per 30 days) |
| sertraline hcl 25 mg, 50 mg tablet ^{MO} | 1 | QL (90 per 30 days) |
| tranylcypromine sulf 10 mg tab ^{MO} | 4 | |
| trazodone 100 mg, 150 mg, 50 mg tablet ^{MO} | 1 | |
| trazodone 300 mg tablet ^{MO} | 3 | |
| trimipramine maleate 100 mg, 25 mg, 50 mg cap; trimipramine maleate 100 mg, 25 mg, 50 mg cp ^{MO} | 4 | PA |
| TRINTELLIX 10 MG, 20 MG, 5 MG TABLET ^{MO} | 4 | ST,QL (30 per 30 days) |
| venlafaxine hcl 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg tablet ^{MO} | 2 | |
| venlafaxine hcl er 150 mg cap ^{MO} | 2 | QL (60 per 30 days) |
| venlafaxine hcl er 37.5 mg cap ^{MO} | 2 | QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| venlafaxine hcl er 75 mg cap ^{MO} | 2 | QL (90 per 30 days) |
| VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK; VIIBRYD 10 MG, 10 MG (7)- 20 MG (23), 20 MG, 40 MG TABLET ^{MO} | 4 | PA,QL (30 per 30 days) |
| ZULRESSO 5 MG/ML INTRAVENOUS SOLUTION ^{DL} | 5 | PA,QL (100 per 365 days) |
| Antiemetics | | |
| aprepitant 125 mg, 40 mg capsule ^{MO} | 4 | B vs D,QL (2 per 28 days) |
| aprepitant 125-80-80 mg pack ^{MO} | 4 | B vs D,QL (6 per 28 days) |
| aprepitant 80 mg capsule ^{MO} | 4 | B vs D,QL (4 per 28 days) |
| compro 25 mg rectal suppository ^{MO} | 4 | |
| dronabinol 10 mg, 2.5 mg, 5 mg capsule ^{MO} | 4 | B vs D,QL (120 per 30 days) |
| droperidol 2.5 mg/ml vial ^{MO} | 3 | |
| granisetron hcl 0.1 mg/ml vial; granisetron hcl 1 mg/ml vial ^{MO} | 4 | |
| granisetron hcl 1 mg tablet ^{MO} | 3 | B vs D,QL (28 per 28 days) |
| granisetron hcl 1 mg/ml vial ^{MO} | 4 | |
| granisetron hcl 4 mg/4 ml vial ^{MO} | 4 | QL (4 per 28 days) |
| meclizine 12.5 mg, 25 mg tablet ^{MO} | 4 | |
| metoclopramide 10 mg, 5 mg tablet ^{MO} | 1 | |
| metoclopramide 10 mg/2 ml syr ^{MO} | 2 | |
| metoclopramide 10 mg/2 ml vial; metoclopramide 5 mg/5 ml, 5 mg/ml soln ^{MO} | 2 | |
| ondansetron odt 4 mg, 8 mg tablet ^{MO} | 2 | B vs D,QL (90 per 30 days) |
| ondansetron 4 mg/5 ml solution ^{MO} | 4 | B vs D,QL (450 per 30 days) |
| ondansetron 40 mg/20 ml vial ^{MO} | 2 | |
| ondansetron hcl 24 mg tablet ^{MO} | 2 | B vs D,QL (30 per 30 days) |
| ondansetron hcl 4 mg, 8 mg tablet ^{MO} | 2 | B vs D,QL (90 per 30 days) |
| ondansetron hcl 4 mg/2 ml syr ^{MO} | 2 | |
| ondansetron hcl 4 mg/2 ml vial ^{MO} | 2 | |
| prochlorperazine 25 mg supp ^{MO} | 4 | |
| prochlorperazine 10 mg/2 ml vl ^{MO} | 4 | |
| prochlorperazine 10 mg, 5 mg tab; prochlorperazine 10 mg, 5 mg tablet ^{MO} | 1 | B vs D |
| promethazine 12.5 mg, 25 mg, 50 mg tablet ^{MO} | 4 | PA |
| SANCUSO 3.1 MG/24 HOUR TRANSDERMAL PATCH ^{MO} | 4 | QL (4 per 30 days) |
| scopolamine 1 mg/3 day patch ^{MO} | 4 | QL (10 per 30 days) |
| trimethobenzamide 300 mg cap ^{MO} | 4 | B vs D |
| Antifungals | | |
| ABELCET 5 MG/ML INTRAVENOUS SUSPENSION ^{DL} | 5 | B vs D |
| AMBISOME 50 MG INTRAVENOUS SUSPENSION ^{DL} | 5 | B vs D |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| <i>amphotericin b 50 mg vial</i> ^{MO} | 4 | B vs D |
| <i>caspofungin acetate 50 mg, 70 mg vial</i> ^{DL} | 5 | |
| <i>ciclodan 0.77 % topical cream</i> ^{MO} | 2 | |
| <i>ciclodan 8 % topical solution</i> ^{MO} | 2 | |
| <i>ciclopirox 0.77% cream</i> ^{MO} | 2 | |
| <i>ciclopirox 0.77% gel</i> ^{MO} | 4 | |
| <i>ciclopirox 0.77% topical susp</i> ^{MO} | 3 | |
| <i>ciclopirox 8% solution</i> ^{MO} | 3 | |
| <i>clotrimazole 1% cream</i> ^{MO} | 2 | |
| <i>clotrimazole 1% solution</i> ^{MO} | 3 | |
| <i>clotrimazole 10 mg troche</i> ^{MO} | 2 | |
| <i>clotrimazole-betamethasone crm</i> ^{MO} | 3 | |
| <i>clotrimazole-betamethasone lot</i> ^{MO} | 4 | |
| CRESEMBA 186 MG CAPSULE ^{DL} | 5 | PA |
| CRESEMBA 372 MG INTRAVENOUS SOLUTION ^{DL} | 5 | PA |
| <i>econazole nitrate 1% cream</i> ^{MO} | 4 | |
| ERAXIS(WATER DILUENT) 100 MG, 50 MG INTRAVENOUS SOLUTION ^{DL} | 5 | |
| <i>fluconazole 10 mg/ml, 40 mg/ml susp</i> ^{MO} | 3 | |
| <i>fluconazole 100 mg, 150 mg, 200 mg, 50 mg tablet</i> ^{MO} | 2 | |
| <i>fluconazole-dext 200 mg/100 ml, 400 mg/200 ml</i> ^{MO} | 2 | |
| <i>fluconazole-nacl 100 mg/50 ml, 200 mg/100 ml, 400 mg/200 ml</i> ^{MO} | 2 | |
| <i>flucytosine 250 mg, 500 mg capsule</i> ^{DL} | 5 | |
| <i>griseofulvin 125 mg/5 ml susp</i> ^{MO} | 4 | |
| <i>griseofulvin ultra 125 mg, 250 mg tab</i> ^{MO} | 4 | |
| <i>gynazole-1 2 % vaginal cream</i> ^{MO} | 4 | |
| <i>itraconazole 100 mg capsule</i> ^{MO} | 4 | QL (120 per 30 days) |
| <i>ketoconazole 2% cream</i> ^{MO} | 2 | |
| <i>ketoconazole 2% shampoo</i> ^{MO} | 2 | |
| <i>miconazole-3 200 mg vaginal suppository</i> ^{MO} | 3 | |
| MYCAMINE 100 MG, 50 MG INTRAVENOUS SOLUTION ^{DL} | 5 | |
| <i>naftifine hcl 1% cream; naftifine hcl 2% cream</i> ^{MO} | 4 | ST |
| NATACYN 5 % EYE DROPS,SUSPENSION ^{MO} | 4 | |
| NOXAFIL 100 MG TABLET,DELAYED RELEASE ^{DL} | 5 | PA,QL (93 per 30 days) |
| NOXAFIL 200 MG/5 ML (40 MG/ML) ORAL SUSPENSION ^{DL} | 5 | PA,QL (840 per 28 days) |
| NOXAFIL 300 MG/16.7 ML INTRAVENOUS SOLUTION ^{DL} | 5 | PA |
| <i>nyamyc 100,000 unit/gram topical powder</i> ^{MO} | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| <i>nystatin 100,000 unit/gm cream</i> ^{MO} | 2 | |
| <i>nystatin 100,000 unit/gm oint</i> ^{MO} | 2 | |
| <i>nystatin 100,000 unit/gm powd</i> ^{MO} | 2 | |
| <i>nystatin 100,000 unit/ml susp</i> ^{MO} | 2 | |
| <i>nystatin 500,000 unit oral tab</i> ^{MO} | 3 | |
| <i>nystatin-triamcinolone cream</i> ^{MO} | 4 | |
| <i>nystatin-triamcinolone ointm</i> ^{MO} | 4 | |
| <i>nystop 100,000 unit/gram topical powder</i> ^{MO} | 2 | |
| <i>posaconazole 200 mg/5 ml susp</i> ^{DL} | 5 | PA,QL (840 per 28 days) |
| <i>posaconazole dr 100 mg tablet</i> ^{DL} | 5 | PA,QL (93 per 30 days) |
| <i>terbinafine hcl 250 mg tablet</i> ^{MO} | 2 | QL (90 per 365 days) |
| <i>terconazole 0.4% cream; terconazole 0.8% cream</i> ^{MO} | 2 | |
| <i>terconazole 80 mg suppository</i> ^{MO} | 4 | |
| <i>voriconazole 200 mg vial</i> ^{DL} | 5 | PA |
| <i>voriconazole 200 mg, 50 mg tablet</i> ^{DL} | 5 | PA,QL (120 per 30 days) |
| <i>voriconazole 40 mg/ml susp</i> ^{DL} | 5 | PA,QL (400 per 30 days) |
| Antigout Agents | | |
| <i>allopurinol 100 mg, 300 mg tablet</i> ^{MO} | 1 | |
| <i>allopurinol sodium 500 mg vial</i> ^{MO} | 4 | |
| COLCRYS 0.6 MG TABLET ^{MO} | 3 | QL (120 per 30 days) |
| <i>febuxostat 40 mg, 80 mg tablet</i> ^{MO} | 3 | ST,QL (30 per 30 days) |
| <i>probenecid 500 mg tablet</i> ^{MO} | 3 | |
| <i>probenecid-colchicine tablet</i> ^{MO} | 3 | |
| ULORIC 40 MG, 80 MG TABLET ^{MO} | 3 | ST,QL (30 per 30 days) |
| Antimigraine Agents | | |
| AIMOVI AUTOINJECTOR 140 MG/ML SUBCUTANEOUS AUTO-INJECTOR ^{MO} | 4 | PA,QL (1 per 30 days) |
| AIMOVI AUTOINJECTOR 70 MG/ML SUBCUTANEOUS AUTO-INJECTOR ^{MO} | 4 | PA,QL (2 per 30 days) |
| AIMOVI 140 MG DOSE-2 AUTOINJ ^{MO} | 4 | PA,QL (2 per 30 days) |
| <i>almotriptan malate 12.5 mg, 6.25 mg tab</i> ^{MO} | 4 | ST,QL (9 per 30 days) |
| <i>dihydroergotamine 1 mg/ml amp</i> ^{DL} | 5 | |
| <i>dihydroergotamine 4 mg/ml spry</i> ^{DL} | 5 | QL (8 per 30 days) |
| EMGALITY PEN 120 MG/ML SUBCUTANEOUS PEN INJECTOR ^{MO} | 4 | PA,QL (2 per 30 days) |
| EMGALITY 120 MG/ML SUBCUTANEOUS SYRINGE ^{MO} | 4 | PA,QL (2 per 30 days) |
| ERGOMAR 2 MG SUBLINGUAL TABLET ^{DL} | 5 | |
| <i>ergotamine-caffeine 1-100mg tb</i> ^{MO} | 4 | |
| <i>frovatriptan succ 2.5 mg tab</i> ^{MO} | 4 | ST,QL (12 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| <i>migergot 2 mg-100 mg rectal suppository</i> ^{DL} | 5 | QL (20 per 28 days) |
| <i>naratriptan hcl 1 mg, 2.5 mg tablet</i> ^{MO} | 3 | QL (9 per 30 days) |
| RELPAK 20 MG, 40 MG TABLET ^{MO} | 4 | ST,QL (9 per 30 days) |
| <i>rizatriptan 10 mg, 5 mg odt</i> ^{MO} | 3 | QL (12 per 30 days) |
| <i>rizatriptan 10 mg, 5 mg tablet</i> ^{MO} | 2 | QL (12 per 30 days) |
| <i>sumatriptan 4 mg/0.5 ml, 6 mg/0.5 ml cart; sumatriptan 4 mg/0.5 ml, 6 mg/0.5 ml refill</i> ^{MO} | 4 | QL (6 per 30 days) |
| <i>sumatriptan 4 mg/0.5 ml, 6 mg/0.5 ml inject</i> ^{MO} | 4 | QL (6 per 30 days) |
| <i>sumatriptan 6 mg/0.5 ml syrng</i> ^{MO} | 4 | QL (6 per 30 days) |
| <i>sumatriptan 6 mg/0.5 ml vial</i> ^{MO} | 4 | QL (6 per 30 days) |
| <i>sumatriptan succ 100 mg, 25 mg, 50 mg tablet</i> ^{MO} | 2 | QL (9 per 30 days) |
| Antimyasthenic Agents | | |
| <i>guanidine hcl 125 mg tablet</i> ^{MO} | 3 | |
| <i>pyridostigmine br 30 mg, 60 mg tablet</i> ^{MO} | 3 | |
| REGONOL 5 MG/ML INJECTION SOLUTION ^{MO} | 4 | |
| Antimycobacterials | | |
| CAPASTAT 1 GRAM SOLUTION FOR INJECTION ^{MO} | 4 | |
| <i>cycloserine 250 mg capsule</i> ^{DL} | 5 | |
| <i>dapsone 100 mg, 25 mg tablet</i> ^{MO} | 3 | |
| <i>ethambutol hcl 100 mg, 400 mg tablet</i> ^{MO} | 4 | |
| <i>isoniazid 100 mg, 300 mg tablet</i> ^{MO} | 1 | |
| <i>isoniazid 100 mg/ml vial</i> ^{MO} | 1 | |
| <i>isoniazid 50 mg/5 ml solution</i> ^{MO} | 4 | |
| PASER 4 GRAM GRANULES DELAYED-RELEASE PACKET ^{MO} | 4 | |
| PRIFTIN 150 MG TABLET ^{MO} | 4 | |
| <i>pyrazinamide 500 mg tablet</i> ^{MO} | 4 | |
| <i>rifabutin 150 mg capsule</i> ^{MO} | 4 | |
| <i>rifampin 150 mg, 300 mg capsule</i> ^{MO} | 3 | |
| <i>rifampin iv 600 mg vial</i> ^{DL} | 5 | |
| RIFATER 50 MG-120 MG-300 MG TABLET ^{MO} | 4 | |
| SIRTURO 100 MG TABLET ^{DL} | 5 | PA,QL (68 per 28 days) |
| TRECTOR 250 MG TABLET ^{MO} | 4 | |
| Antineoplastics | | |
| <i>abiraterone acetate 250 mg tab</i> ^{DL} | 5 | PA,QL (120 per 30 days) |
| ABRAXANE 100 MG INTRAVENOUS SUSPENSION ^{DL} | 5 | PA |
| <i>adriamycin 10 mg, 10 mg/5 ml, 2 mg/ml, 20 mg/10 ml, 50 mg/25 ml intravenous solution</i> ^{MO} | 4 | B vs D |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| ADRIAMYCIN 50 MG INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AFINITOR 10 MG, 2.5 MG, 5 MG, 7.5 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| AFINITOR DISPERZ 2 MG, 3 MG, 5 MG TABLET FOR ORAL SUSPENSION DL | 5 | PA |
| ALECENSA 150 MG CAPSULE DL | 5 | PA,QL (240 per 30 days) |
| ALIMTA 100 MG, 500 MG INTRAVENOUS SOLUTION DL | 5 | PA |
| ALIQOPA 60 MG INTRAVENOUS SOLUTION DL | 5 | PA,QL (3 per 28 days) |
| ALUNBRIG 180 MG, 90 MG, 90 MG (7)- 180 MG (23) TABLET; ALUNBRIG 90 MG (7)-180 MG (23) TABLETS IN A DOSE PACK DL | 5 | PA,QL (30 per 30 days) |
| ALUNBRIG 30 MG TABLET DL | 5 | PA,QL (180 per 30 days) |
| <i>amifostine 500 mg vial</i> DL | 5 | B vs D |
| <i>anastrozole 1 mg tablet</i> MO | 1 | QL (30 per 30 days) |
| ARRANON 250 MG/50 ML INTRAVENOUS SOLUTION DL | 5 | |
| <i>arsenic trioxide 10 mg/10ml vl; arsenic trioxide 12 mg/6 ml vl</i> DL | 5 | PA |
| ARZERRA 1,000 MG/50 ML, 100 MG/5 ML INTRAVENOUS SOLUTION DL | 5 | PA,QL (400 per 28 days) |
| AVASTIN 25 MG/ML INTRAVENOUS SOLUTION DL | 5 | PA |
| BALVERSA 3 MG TABLET DL | 5 | PA,QL (90 per 30 days) |
| BALVERSA 4 MG TABLET DL | 5 | PA,QL (60 per 30 days) |
| BALVERSA 5 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| BAVENCIO 20 MG/ML INTRAVENOUS SOLUTION DL | 5 | PA |
| BELEODAQ 500 MG INTRAVENOUS SOLUTION DL | 5 | PA |
| BENDEKA 25 MG/ML INTRAVENOUS SOLUTION DL | 5 | PA |
| BESPONSA 0.9 MG(0.25 MG/ML INITIAL CONCENTRATION) INTRAVENOUS SOLUTION DL | 5 | PA |
| <i>bexarotene 75 mg capsule</i> DL | 5 | PA,QL (300 per 30 days) |
| <i>bicalutamide 50 mg tablet</i> MO | 3 | QL (30 per 30 days) |
| BICNU 100 MG INTRAVENOUS SOLUTION MO | 4 | B vs D |
| <i>bleomycin sulfate 15 unit, 30 unit vial</i> MO | 3 | B vs D |
| <i>bortezomib 3.5 mg vial</i> DL | 5 | PA |
| BOSULIF 100 MG TABLET DL | 5 | PA,QL (120 per 30 days) |
| BOSULIF 400 MG, 500 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| BRAFTOVI 50 MG CAPSULE DL | 5 | PA,QL (120 per 30 days) |
| BRAFTOVI 75 MG CAPSULE DL | 5 | PA,QL (180 per 30 days) |
| <i>busulfan 60 mg/10 ml vial</i> MO | 4 | B vs D |
| BUSULFEX 60 MG/10 ML INTRAVENOUS SOLUTION MO | 4 | B vs D |
| CABOMETYX 20 MG, 40 MG, 60 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| CALQUENCE 100 MG CAPSULE DL | 5 | PA,QL (60 per 30 days) |
| CAPRELSA 100 MG TABLET DL | 5 | PA,QL (60 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| CAPRELSA 300 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| carboplatin 50 mg/5 ml vial MO | 3 | B vs D |
| carmustine 100 mg vial MO | 4 | B vs D |
| cisplatin 100 mg/100 ml vial MO | 4 | B vs D |
| cladribine 10 mg/10 ml vial DL | 5 | B vs D |
| clofarabine 20 mg/20 ml vial DL | 5 | B vs D |
| CLOLAR 20 MG/20 ML INTRAVENOUS SOLUTION DL | 5 | B vs D |
| COMETRIQ 100 MG/DAY (80 MG X 1-20 MG X 1) CAPSULES DL | 5 | PA,QL (56 per 28 days) |
| COMETRIQ 140 MG/DAY (80 MG X 1-20 MG X 3) CAPSULES DL | 5 | PA,QL (112 per 28 days) |
| COMETRIQ 60 MG/DAY (20 MG X 3/DAY) CAPSULES DL | 5 | PA,QL (84 per 28 days) |
| COPIKTRA 15 MG, 25 MG CAPSULE DL | 5 | PA,QL (56 per 28 days) |
| COSMEGEN 0.5 MG INTRAVENOUS SOLUTION DL | 5 | B vs D |
| COTELLIC 20 MG TABLET DL | 5 | PA,QL (63 per 28 days) |
| cyclophosphamide 1 gm vial; cyclophosphamide 1 gram, 2 gram, 500 mg vial; cyclophosphamide 2 gm vial MO | 4 | B vs D |
| cyclophosphamide 25 mg, 50 mg capsule MO | 4 | B vs D |
| CYRAMZA 10 MG/ML INTRAVENOUS SOLUTION DL | 5 | PA,QL (200 per 28 days) |
| cytarabine 20 mg/ml vial MO | 1 | B vs D |
| cytarabine 100 mg/5 ml (20 mg/ml), 2 gram/20 ml (100 mg/ml), 20 mg/ml vial; cytarabine 100 mg/5 ml vial; cytarabine 2 g/20 ml vial MO | 1 | B vs D |
| dacarbazine 100 mg, 200 mg vial MO | 4 | B vs D |
| dactinomycin 0.5 mg vial DL | 5 | B vs D |
| DARZALEX 20 MG/ML INTRAVENOUS SOLUTION DL | 5 | PA,QL (400 per 30 days) |
| daunorubicin 20 mg/4 ml vial MO | 1 | B vs D |
| DAURISMO 100 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| DAURISMO 25 MG TABLET DL | 5 | PA,QL (60 per 30 days) |
| decitabine 50 mg vial DL | 5 | PA |
| dexrazoxane 250 mg, 500 mg vial MO | 4 | B vs D |
| DOCEFREZ 20 MG INTRAVENOUS SOLUTION MO | 4 | B vs D |
| DOCEFREZ 80 MG INTRAVENOUS SOLUTION DL | 5 | B vs D |
| docetaxel 160 mg/16 ml vial; docetaxel 160 mg/8 ml vial; docetaxel 20 mg/2 ml vial; docetaxel 20 mg/ml vial; docetaxel 200 mg/10 ml vial; docetaxel 80 mg/4 ml vial; docetaxel 80 mg/8 ml vial MO | 4 | B vs D |
| doxorubicin 10 mg, 10 mg/5 ml, 2 mg/ml, 20 mg/10 ml, 50 mg, 50 mg/25 ml vial; doxorubicin 150 mg/75 ml vial MO | 4 | B vs D |
| doxorubicin liposome 20mg/10ml DL | 5 | PA |
| DROXIA 200 MG, 300 MG, 400 MG CAPSULE MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| ELITEK 1.5 MG, 7.5 MG INTRAVENOUS SOLUTION DL | 5 | PA |
| EMCYT 140 MG CAPSULE DL | 5 | |
| EMPLICITI 300 MG, 400 MG INTRAVENOUS SOLUTION DL | 5 | PA |
| epirubicin 200 mg/100 ml, 50 mg, 50 mg/25 ml vial; epirubicin hcl 200 mg/100 ml, 50 mg, 50 mg/25 ml vial MO | 4 | B vs D |
| ERBITUX 100 MG/50 ML, 200 MG/100 ML INTRAVENOUS SOLUTION DL | 5 | PA |
| ERIVEDGE 150 MG CAPSULE DL | 5 | PA,QL (28 per 28 days) |
| ERLEADA 60 MG TABLET DL | 5 | PA,QL (120 per 30 days) |
| erlotinib hcl 100 mg, 150 mg tablet DL | 5 | PA,QL (30 per 30 days) |
| erlotinib hcl 25 mg tablet DL | 5 | PA,QL (90 per 30 days) |
| ERWINAZE 10,000 UNIT SOLUTION FOR INJECTION DL | 5 | PA,QL (60 per 28 days) |
| ETOPOPHOS 100 MG INTRAVENOUS SOLUTION MO | 4 | B vs D |
| etoposide 100 mg/5 ml vial MO | 3 | B vs D |
| EVOMELA 50 MG INTRAVENOUS SOLUTION DL | 5 | PA |
| exemestane 25 mg tablet MO | 4 | QL (60 per 30 days) |
| FARESTON 60 MG TABLET DL | 5 | QL (30 per 30 days) |
| FARYDAK 10 MG, 15 MG, 20 MG CAPSULE DL | 5 | PA,QL (6 per 21 days) |
| FASLODEX 250 MG/5 ML INTRAMUSCULAR SYRINGE DL | 5 | PA,QL (30 per 30 days) |
| floxuridine 500 mg vial MO | 1 | B vs D |
| fludarabine 50 mg, 50 mg/2 ml vial MO | 4 | B vs D |
| fluorouracil 1 gram/20 ml, 2.5 gram/50 ml, 5 gram/100 ml, 500 mg/10 ml vial; fluorouracil 1,000 mg/20 ml vl; fluorouracil 2,500 mg/50 ml vl; fluorouracil 5,000 mg/100 ml MO | 4 | B vs D |
| flutamide 125 mg capsule MO | 4 | |
| FOLOTYN 20 MG/ML (1 ML), 40 MG/2 ML (20 MG/ML) INTRAVENOUS SOLUTION DL | 5 | PA |
| fulvestrant 250 mg/5 ml syring DL | 5 | PA,QL (30 per 30 days) |
| GAZYVA 1,000 MG/40 ML INTRAVENOUS SOLUTION DL | 5 | PA,QL (120 per 28 days) |
| gemcitabine 1 gram/26.3 ml vl; gemcitabine 2 gram/52.6 ml vl; gemcitabine 200 mg/5.26 ml vl; gemcitabine hcl 1 gram, 1 gram/26.3 ml (38 mg/ml), 2 gram, 2 gram/52.6 ml (38 mg/ml), 200 mg, 200 mg/5.26 ml (38 mg/ml) vial MO | 4 | B vs D |
| GILOTRIF 20 MG, 30 MG, 40 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| GLEOSTINE 10 MG, 40 MG, 5 MG CAPSULE MO | 4 | PA |
| GLEOSTINE 100 MG CAPSULE DL | 5 | PA |
| HALAVEN 1 MG/2 ML (0.5 MG/ML) INTRAVENOUS SOLUTION DL | 5 | PA |
| HERCEPTIN 150 MG, 440 MG INTRAVENOUS SOLUTION; HERCEPTIN 150 MG, 440 MG VIAL DL | 5 | PA |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| HERCEPTIN HYLECTA 600 MG-10,000 UNIT/5 ML SUBCUTANEOUS SOLUTION DL | 5 | PA,QL (5 per 21 days) |
| HEXALEN 50 MG CAPSULE DL | 5 | |
| <i>hydroxyurea 500 mg capsule</i> MO | 2 | |
| IBRANCE 100 MG, 125 MG, 75 MG CAPSULE DL | 5 | PA,QL (21 per 28 days) |
| ICLUSIG 15 MG TABLET DL | 5 | PA,QL (60 per 30 days) |
| ICLUSIG 45 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| <i>idarubicin hcl 20 mg/20 ml vl</i> DL | 5 | B vs D |
| IDHIFA 100 MG, 50 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| <i>ifosfamide 1 gm vial; ifosfamide 1 gm/20 ml vial; ifosfamide 3 gm vial; ifosfamide 3 gm/60 ml vial</i> MO | 3 | B vs D |
| <i>imatinib mesylate 100 mg tab</i> DL | 5 | PA,QL (180 per 30 days) |
| <i>imatinib mesylate 400 mg tab</i> DL | 5 | PA,QL (60 per 30 days) |
| IMBRUVICA 140 MG CAPSULE DL | 5 | PA,QL (90 per 30 days) |
| IMBRUVICA 420 MG, 560 MG TABLET DL | 5 | PA,QL (28 per 28 days) |
| IMBRUVICA 70 MG CAPSULE DL | 5 | PA,QL (28 per 28 days) |
| IMFINZI 50 MG/ML INTRAVENOUS SOLUTION DL | 5 | PA |
| IMLYGIC 10EXP6 (1 MILLION) PFU/ML SUSPENSION FOR INJECTION DL | 5 | PA,QL (4 per 365 days) |
| IMLYGIC 10EXP8 (100 MILLION) PFU/ML SUSPENSION FOR INJECTION DL | 5 | PA,QL (8 per 28 days) |
| INLYTA 1 MG TABLET DL | 5 | PA,QL (180 per 30 days) |
| INLYTA 5 MG TABLET DL | 5 | PA,QL (60 per 30 days) |
| INREBIC 100 MG CAPSULE DL | 5 | PA,QL (120 per 30 days) |
| IRESSA 250 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| <i>irinotecan hcl 100 mg/5 ml, 40 mg/2 ml, 500 mg/25 ml vial; irinotecan hcl 100 mg/5 ml, 40 mg/2 ml, 500 mg/25 ml vl</i> MO | 4 | B vs D |
| ISTODAX 10 MG/2 ML INTRAVENOUS SOLUTION DL | 5 | PA |
| IXEMPRA 15 MG, 45 MG INTRAVENOUS SOLUTION DL | 5 | PA |
| JAKAFI 10 MG, 15 MG, 20 MG, 25 MG, 5 MG TABLET DL | 5 | PA,QL (60 per 30 days) |
| JEVTANA 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION DL | 5 | PA |
| KADCYLA 100 MG, 160 MG INTRAVENOUS SOLUTION DL | 5 | PA |
| KANJINTI 150 MG, 420 MG INTRAVENOUS SOLUTION DL | 5 | PA |
| KEYTRUDA 25 MG/ML INTRAVENOUS SOLUTION DL | 5 | PA |
| KISQALI 200 MG/DAY (200 MG X 1) TABLET DL | 5 | PA,QL (21 per 28 days) |
| KISQALI 400 MG/DAY (200 MG X 2) TABLET DL | 5 | PA,QL (42 per 28 days) |
| KISQALI 600 MG/DAY (200 MG X 3) TABLET DL | 5 | PA,QL (63 per 28 days) |
| KISQALI FEMARA CO-PACK 200 MG/DAY(200 MG X 1)-2.5 MG TABLET DL | 5 | PA,QL (49 per 28 days) |
| KISQALI FEMARA CO-PACK 400 MG/DAY(200 MG X 2)-2.5 MG TABLET DL | 5 | PA,QL (70 per 28 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| KISQALI FEMARA CO-PACK 600 MG/DAY(200 MG X 3)-2.5 MG TABLET DL | 5 | PA,QL (91 per 28 days) |
| KYPROLIS 10 MG, 30 MG, 60 MG INTRAVENOUS SOLUTION DL | 5 | PA |
| LARTRUVO 190 MG/19 ML VIAL DL | 5 | PA |
| LENVIMA 10 MG/DAY (10 MG X 1), 4 MG CAPSULE DL | 5 | PA,QL (30 per 30 days) |
| LENVIMA 12 MG/DAY (4 MG X 3), 18 MG/DAY (10 MG X 1-4 MG X2), 24 MG/DAY(10 MG X 2-4 MG X 1) CAPSULE; LENVIMA 18 MG/DAY (10 MG X 1 AND 4 MG X 2) CAPSULE; LENVIMA 24 MG PER DAY (10 MG X 2 AND 4 MG X 1) CAPSULE DL | 5 | PA,QL (90 per 30 days) |
| LENVIMA 14 MG/DAY(10 MG X 1-4 MG X 1), 20 MG/DAY (10 MG X 2), 8 MG/DAY (4 MG X 2) CAPSULE DL | 5 | PA,QL (60 per 30 days) |
| <i>letrozole 2.5 mg tablet</i> MO | 2 | QL (30 per 30 days) |
| <i>leucovorin cal 500 mg/50 ml vial; leucovorin calcium 10 mg/ml, 100 mg, 200 mg, 350 mg, 50 mg, 500 mg vial; leucovorin calcium 10 mg/ml, 100 mg, 200 mg, 350 mg, 50 mg, 500 mg vial</i> MO | 2 | B vs D |
| <i>leucovorin calcium 10 mg, 15 mg, 25 mg, 5 mg tab</i> MO | 2 | |
| LEUKERAN 2 MG TABLET DL | 5 | |
| <i>levoleucovorin 10 mg/ml, 175 mg vial; levoleucovorin 175 mg/17.5 ml</i> DL | 5 | PA |
| <i>levoleucovorin 50 mg vial</i> MO | 4 | PA |
| LEVULAN 20 % TOPICAL SOLUTION MO | 4 | |
| LIBTAYO 50 MG/ML INTRAVENOUS SOLUTION DL | 5 | PA,QL (7 per 21 days) |
| <i>lipodox 2 mg/ml intravenous suspension</i> DL | 5 | PA |
| <i>lipodox 50 2 mg/ml intravenous suspension</i> DL | 5 | PA |
| LONSURF 15 MG-6.14 MG TABLET DL | 5 | PA,QL (100 per 30 days) |
| LONSURF 20 MG-8.19 MG TABLET DL | 5 | PA,QL (80 per 30 days) |
| LORBRENA 100 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| LORBRENA 25 MG TABLET DL | 5 | PA,QL (90 per 30 days) |
| LUMOXITI 1 MG INTRAVENOUS SOLUTION DL | 5 | PA |
| LYNPARZA 100 MG, 150 MG TABLET DL | 5 | PA,QL (120 per 30 days) |
| LYNPARZA 50 MG CAPSULE DL | 5 | PA,QL (448 per 28 days) |
| MARQIBO 5 MG/31 ML (0.16 MG/ML) (FINAL CONC.) INTRAVENOUS KIT DL | 5 | PA |
| MATULANE 50 MG CAPSULE DL | 5 | |
| MEKINIST 0.5 MG TABLET DL | 5 | PA,QL (120 per 30 days) |
| MEKINIST 2 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| MEKTOVI 15 MG TABLET DL | 5 | PA,QL (180 per 30 days) |
| <i>melphalan 2 mg tablet</i> MO | 4 | B vs D |
| <i>melphalan hcl 50 mg vial</i> MO | 1 | B vs D |
| <i>mercaptopurine 50 mg tablet</i> MO | 3 | |
| <i>mesna 1 gram/10 ml vial</i> MO | 4 | B vs D |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| MESNEX 400 MG TABLET DL | 5 | |
| mitomycin 20 mg, 40 mg, 5 mg vial MO | 4 | B vs D |
| mitoxantrone 25 mg/12.5 ml vial MO | 3 | B vs D |
| MUSTARGEN 10 MG VIAL MO | 4 | B vs D |
| MUTAMYCIN 20 MG, 40 MG, 5 MG INTRAVENOUS SOLUTION MO | 4 | B vs D |
| MVASI 25 MG/ML INTRAVENOUS SOLUTION DL | 5 | PA |
| MYLOTARG 4.5 MG (1 MG/ML INITIAL CONCENTRATION) INTRAVENOUS SOLUTION DL | 5 | PA |
| NERLYNX 40 MG TABLET DL | 5 | PA,QL (180 per 30 days) |
| NEXAVAR 200 MG TABLET DL | 5 | PA,QL (120 per 30 days) |
| nilutamide 150 mg tablet DL | 5 | QL (60 per 30 days) |
| NINLARO 2.3 MG, 3 MG, 4 MG CAPSULE DL | 5 | PA,QL (3 per 28 days) |
| NIPENT 10 MG INTRAVENOUS SOLUTION DL | 5 | B vs D |
| NUBEQA 300 MG TABLET DL | 5 | PA,QL (120 per 30 days) |
| ODOMZO 200 MG CAPSULE DL | 5 | PA,QL (30 per 30 days) |
| OGIVRI 150 MG, 420 MG INTRAVENOUS SOLUTION DL | 5 | PA |
| ONCASPAR 750 UNIT/ML INJECTION SOLUTION DL | 5 | PA |
| ONIVYDE 4.3 MG/ML INTRAVENOUS DISPERSION DL | 5 | PA |
| OPDIVO 100 MG/10 ML INTRAVENOUS SOLUTION DL | 5 | PA,QL (40 per 28 days) |
| OPDIVO 240 MG/24 ML INTRAVENOUS SOLUTION DL | 5 | PA,QL (48 per 28 days) |
| OPDIVO 40 MG/4 ML INTRAVENOUS SOLUTION DL | 5 | PA,QL (16 per 28 days) |
| oxaliplatin 100 mg, 100 mg/20 ml, 50 mg, 50 mg/10 ml (5 mg/ml) vial; oxaliplatin 50 mg/10 ml vial MO | 4 | B vs D |
| paclitaxel 100 mg/16.7 ml vial MO | 3 | B vs D |
| PANRETIN 0.1 % TOPICAL GEL DL | 5 | |
| PERJETA 420 MG/14 ML (30 MG/ML) INTRAVENOUS SOLUTION DL | 5 | PA |
| PIQRAY 200 MG/DAY (200 MG X 1) TABLET DL | 5 | PA,QL (28 per 28 days) |
| PIQRAY 250 MG/DAY (200 MG X 1-50 MG X 1) TABLET; PIQRAY 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) TABLET DL | 5 | PA,QL (56 per 28 days) |
| POLIVY 140 MG INTRAVENOUS SOLUTION DL | 5 | PA |
| POMALYST 1 MG, 2 MG, 3 MG, 4 MG CAPSULE DL | 5 | PA,QL (21 per 28 days) |
| PORTRAZZA 800 MG/50 ML (16 MG/ML) INTRAVENOUS SOLUTION DL | 5 | PA,QL (100 per 21 days) |
| POTELIGEO 4 MG/ML INTRAVENOUS SOLUTION DL | 5 | PA |
| PROLEUKIN 22 MILLION UNIT INTRAVENOUS SOLUTION DL | 5 | |
| PURIXAN 20 MG/ML ORAL SUSPENSION DL | 5 | QL (300 per 30 days) |
| REVLIMID 10 MG, 15 MG, 2.5 MG, 20 MG, 25 MG, 5 MG CAPSULE DL | 5 | PA,QL (28 per 28 days) |
| RITUXAN 10 MG/ML CONCENTRATE,INTRAVENOUS DL | 5 | PA |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| RITUXAN HYCELA 1,400 MG/11.7 ML (120 MG/ML) SUBCUTANEOUS SOLUTION DL | 5 | PA,QL (46.8 per 28 days) |
| RITUXAN HYCELA 1,600 MG/13.4 ML (120 MG/ML) SUBCUTANEOUS SOLUTION DL | 5 | PA,QL (13.4 per 28 days) |
| <i>romidepsin 10 mg kit</i> DL | 5 | PA |
| ROZLYTREK 100 MG CAPSULE DL | 5 | PA,QL (30 per 30 days) |
| ROZLYTREK 200 MG CAPSULE DL | 5 | PA,QL (90 per 30 days) |
| RUBRACA 200 MG, 250 MG, 300 MG TABLET DL | 5 | PA,QL (120 per 30 days) |
| RYDAPT 25 MG CAPSULE DL | 5 | PA,QL (224 per 28 days) |
| SOLTAMOX 10 MG/5 ML ORAL SOLUTION DL | 5 | |
| SPRYCEL 100 MG, 50 MG, 70 MG, 80 MG TABLET DL | 5 | PA,QL (60 per 30 days) |
| SPRYCEL 140 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| SPRYCEL 20 MG TABLET DL | 5 | PA,QL (90 per 30 days) |
| STIVARGA 40 MG TABLET DL | 5 | PA,QL (84 per 28 days) |
| SUTENT 12.5 MG, 25 MG, 37.5 MG, 50 MG CAPSULE DL | 5 | PA,QL (28 per 28 days) |
| SYNRIBO 3.5 MG SUBCUTANEOUS SOLUTION DL | 5 | PA,QL (28 per 28 days) |
| TABLOID 40 MG TABLET DL | 5 | |
| TAFINLAR 50 MG CAPSULE DL | 5 | PA,QL (180 per 30 days) |
| TAFINLAR 75 MG CAPSULE DL | 5 | PA,QL (120 per 30 days) |
| TAGRISSO 40 MG, 80 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| TALZENNA 0.25 MG CAPSULE DL | 5 | PA,QL (90 per 30 days) |
| TALZENNA 1 MG CAPSULE DL | 5 | PA,QL (30 per 30 days) |
| <i>tamoxifen 10 mg, 20 mg tablet</i> MO | 2 | |
| TARCEVA 100 MG, 150 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| TARCEVA 25 MG TABLET DL | 5 | PA,QL (90 per 30 days) |
| TARGRETIN 1 % TOPICAL GEL DL | 5 | PA |
| TARGRETIN 75 MG CAPSULE DL | 5 | PA,QL (300 per 30 days) |
| TASIGNA 150 MG, 200 MG, 50 MG CAPSULE DL | 5 | PA,QL (120 per 30 days) |
| TECENTRIQ 1,200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION DL | 5 | PA,QL (20 per 21 days) |
| TECENTRIQ 840 MG/14 ML (60 MG/ML) INTRAVENOUS SOLUTION DL | 5 | PA,QL (28 per 28 days) |
| TEMODAR 100 MG INTRAVENOUS SOLUTION DL | 5 | PA,QL (27 per 30 days) |
| <i>temsirolimus 25 mg vial</i> DL | 5 | PA,QL (8 per 28 days) |
| <i>teniposide 50 mg/5 ml ampule</i> MO | 4 | B vs D |
| THALOMID 100 MG, 200 MG, 50 MG CAPSULE DL | 5 | PA,QL (30 per 30 days) |
| THALOMID 150 MG CAPSULE DL | 5 | PA,QL (60 per 30 days) |
| <i>thiotepa 15 mg vial</i> MO | 1 | B vs D |
| TIBSOVO 250 MG TABLET DL | 5 | PA,QL (60 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| <i>topotecan hcl 4 mg, 4 mg/4 ml (1 mg/ml) vial; topotecan hcl 4 mg/4 ml vial</i> DL | 5 | B vs D |
| <i>toremifene citrate 60 mg tab</i> DL | 5 | QL (30 per 30 days) |
| TORISEL 30 MG/3 ML (10 MG/ML) (FIRST DILUTION) INTRAVENOUS SOLUTION DL | 5 | PA,QL (8 per 28 days) |
| TREANDA 100 MG, 25 MG INTRAVENOUS POWDER FOR SOLUTION DL | 5 | PA |
| <i>tretinoin 10 mg capsule</i> DL | 5 | |
| TRISENOX 10 MG/10 ML AMPULE MO | 4 | PA |
| TRISENOX 2 MG/ML INTRAVENOUS SOLUTION DL | 5 | PA |
| TRUXIMA 10 MG/ML CONCENTRATE, INTRAVENOUS DL | 5 | PA |
| TURALIO 200 MG CAPSULE DL | 5 | PA,QL (120 per 30 days) |
| TYKERB 250 MG TABLET DL | 5 | PA,QL (150 per 30 days) |
| UNITUXIN 3.5 MG/ML INTRAVENOUS SOLUTION DL | 5 | PA,QL (40 per 30 days) |
| VALCHLOR 0.016 % TOPICAL GEL DL | 5 | PA,QL (60 per 28 days) |
| <i>valrubicin 200 mg/5 ml vial</i> DL | 5 | PA,QL (80 per 28 days) |
| VALSTAR 40 MG/ML INTRAVESICAL SOLUTION DL | 5 | PA,QL (80 per 28 days) |
| VECTIBIX 100 MG/5 ML (20 MG/ML), 400 MG/20 ML (20 MG/ML) INTRAVENOUS SOLUTION DL | 5 | PA |
| VELCADE 3.5 MG SOLUTION FOR INJECTION DL | 5 | PA |
| VENCLEXTA 10 MG TABLET MO | 4 | PA,QL (28 per 28 days) |
| VENCLEXTA 100 MG TABLET DL | 5 | PA,QL (180 per 30 days) |
| VENCLEXTA 50 MG TABLET MO | 4 | PA,QL (14 per 28 days) |
| VENCLEXTA STARTING PACK 10 MG-50 MG-100 MG TABLETS IN A DOSE PACK DL | 5 | PA,QL (42 per 28 days) |
| VERZENIO 100 MG, 150 MG, 200 MG, 50 MG TABLET DL | 5 | PA,QL (60 per 30 days) |
| <i>vinblastine 1 mg/ml vial</i> MO | 3 | B vs D |
| <i>vincasar pfs 1 mg/ml, 2 mg/2 ml vial</i> MO | 3 | B vs D |
| <i>vincristine 1 mg/ml, 2 mg/2 ml vial</i> MO | 3 | B vs D |
| <i>vinorelbine 10 mg/ml, 50 mg/5 ml vial</i> MO | 4 | B vs D |
| VITRAKVI 100 MG CAPSULE DL | 5 | PA,QL (60 per 30 days) |
| VITRAKVI 20 MG/ML ORAL SOLUTION DL | 5 | PA,QL (300 per 30 days) |
| VITRAKVI 25 MG CAPSULE DL | 5 | PA,QL (180 per 30 days) |
| VIZIMPRO 15 MG, 30 MG, 45 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| VOTRIENT 200 MG TABLET DL | 5 | PA,QL (120 per 30 days) |
| VYXEOS 44 MG-100 MG INTRAVENOUS SOLUTION DL | 5 | PA |
| XALKORI 200 MG, 250 MG CAPSULE DL | 5 | PA,QL (60 per 30 days) |
| XOSPATA 40 MG TABLET DL | 5 | PA,QL (90 per 30 days) |
| XPOVIO 100 MG/WEEK (20 MG X 5) TABLET DL | 5 | PA,QL (20 per 28 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| XPOVIO 160 MG/WEEK (20 MG X 8) TABLET DL | 5 | PA,QL (32 per 28 days) |
| XPOVIO 60 MG/WEEK (20 MG X 3) TABLET DL | 5 | PA,QL (12 per 28 days) |
| XPOVIO 80 MG/WEEK (20 MG X 4) TABLET DL | 5 | PA,QL (16 per 28 days) |
| XTANDI 40 MG CAPSULE DL | 5 | PA,QL (120 per 30 days) |
| YERVOY 200 MG/40 ML (5 MG/ML), 50 MG/10 ML (5 MG/ML) INTRAVENOUS SOLUTION DL | 5 | PA |
| YONDELIS 1 MG INTRAVENOUS SOLUTION DL | 5 | PA |
| ZALTRAP 100 MG/4 ML (25 MG/ML), 200 MG/8 ML (25 MG/ML) INTRAVENOUS SOLUTION DL | 5 | PA,QL (40 per 28 days) |
| ZANOSAR 1 GRAM INTRAVENOUS SOLUTION MO | 4 | B vs D |
| ZEJULA 100 MG CAPSULE DL | 5 | PA,QL (90 per 30 days) |
| ZELBORAF 240 MG TABLET DL | 5 | PA,QL (240 per 30 days) |
| ZOLINZA 100 MG CAPSULE DL | 5 | PA,QL (120 per 30 days) |
| ZYDELIG 100 MG, 150 MG TABLET DL | 5 | PA,QL (60 per 30 days) |
| ZYKADIA 150 MG CAPSULE DL | 5 | PA,QL (150 per 30 days) |
| ZYKADIA 150 MG TABLET DL | 5 | PA,QL (150 per 30 days) |
| ZYTIGA 250 MG TABLET DL | 5 | PA,QL (120 per 30 days) |
| ZYTIGA 500 MG TABLET DL | 5 | PA,QL (60 per 30 days) |
| Antiparasitics | | |
| <i>albendazole 200 mg tablet</i> DL | 5 | |
| ALBENZA 200 MG TABLET DL | 5 | |
| ALINIA 100 MG/5 ML ORAL SUSPENSION DL | 5 | QL (150 per 30 days) |
| ALINIA 500 MG TABLET DL | 5 | QL (40 per 30 days) |
| <i>atovaquone 750 mg/5 ml susp</i> DL | 5 | |
| <i>atovaquone-proguanil 250-100; atovaquone-proguanil 62.5-25</i> MO | 4 | |
| BILTRICIDE 600 MG TABLET DL | 5 | |
| <i>chloroquine ph 250 mg, 500 mg tablet</i> MO | 4 | |
| COARTEM 20 MG-120 MG TABLET MO | 4 | QL (24 per 30 days) |
| DARAPRIM 25 MG TABLET DL | 5 | |
| <i>hydroxychloroquine 200 mg tab</i> MO | 1 | |
| <i>ivermectin 3 mg tablet</i> MO | 3 | |
| KRINTAFEL 150 MG TABLET MO | 3 | QL (4 per 180 days) |
| <i>lindane 1% shampoo</i> MO | 4 | |
| <i>malathion 0.5% lotion</i> MO | 4 | |
| <i>mefloquine hcl 250 mg tablet</i> MO | 2 | |
| NEBUPENT 300 MG SOLUTION FOR INHALATION MO | 4 | B vs D |
| PENTAM 300 MG SOLUTION FOR INJECTION MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| pentamidine 300 mg inhal powdr ^{MO} | 4 | B vs D |
| pentamidine 300 mg vial ^{MO} | 4 | |
| permethrin 5% cream ^{MO} | 3 | |
| praziquantel 600 mg tablet ^{MO} | 4 | |
| primaquine 26.3 mg tablet ^{MO} | 3 | |
| quinine sulfate 324 mg capsule ^{MO} | 4 | PA,QL (42 per 7 days) |
| Antiparkinson Agents | | |
| amantadine 100 mg capsule ^{MO} | 4 | |
| amantadine 100 mg tablet ^{MO} | 4 | |
| amantadine 50 mg/5 ml solution ^{MO} | 3 | |
| APOKYN 10 MG/ML SUBCUTANEOUS CARTRIDGE ^{DL} | 5 | QL (84 per 28 days) |
| benztropine 2 mg/2 ml ampule ^{MO} | 4 | |
| benztropine mes 0.5 mg, 1 mg, 2 mg tab; benztropine mes 0.5 mg, 1 mg, 2 mg tablet ^{MO} | 3 | PA |
| bromocriptine 2.5 mg tablet ^{MO} | 4 | |
| carbidopa-levo 10-100 mg, 25-100 mg, 25-250 mg odt ^{MO} | 4 | |
| carbidopa-levo er 25-100 tab; carbidopa-levo er 50-200 tab ^{MO} | 3 | |
| carbidopa-levodopa 10-100 tab; carbidopa-levodopa 25-100 tab; carbidopa-levodopa 25-250 tab ^{MO} | 2 | |
| carbidopa-levodopa 100 mg-enta; carbidopa-levodopa 125 mg-enta; carbidopa-levodopa 150 mg-enta; carbidopa-levodopa 200 mg-enta; carbidopa-levodopa 50 mg-enta; carbidopa-levodopa 75 mg-enta ^{MO} | 4 | |
| entacapone 200 mg tablet ^{MO} | 4 | QL (300 per 30 days) |
| NEUPRO 1 MG/24 HOUR, 2 MG/24 HOUR, 3 MG/24 HOUR, 4 MG/24 HOUR, 6 MG/24 HOUR, 8 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH ^{MO} | 4 | QL (30 per 30 days) |
| pramipexole 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg tablet ^{MO} | 2 | |
| rasagiline mesylate 0.5 mg, 1 mg tab ^{MO} | 4 | |
| ropinirole hcl 0.25 mg, 3 mg tablet ^{MO} | 2 | QL (180 per 30 days) |
| ropinirole hcl 0.5 mg, 1 mg, 2 mg tablet ^{MO} | 2 | QL (90 per 30 days) |
| ropinirole hcl 4 mg, 5 mg tablet ^{MO} | 2 | |
| RYTARY 23.75 MG-95 MG CAPSULE,EXTENDED RELEASE; RYTARY 48.75 MG-195 MG CAPSULE,EXTENDED RELEASE ^{MO} | 4 | ST,QL (360 per 30 days) |
| RYTARY 36.25 MG-145 MG CAPSULE,EXTENDED RELEASE ^{MO} | 4 | ST,QL (270 per 30 days) |
| RYTARY 61.25 MG-245 MG CAPSULE,EXTENDED RELEASE ^{MO} | 4 | ST,QL (300 per 30 days) |
| selegiline hcl 5 mg capsule ^{MO} | 3 | |
| selegiline hcl 5 mg tablet ^{MO} | 4 | |
| STALEVO 100 25 MG-100 MG-200 MG TABLET ^{DL} | 5 | PA |
| STALEVO 125 31.25 MG-125 MG-200 MG TABLET ^{DL} | 5 | PA |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| STALEVO 150 37.5 MG-150 MG-200 MG TABLET DL | 5 | PA |
| STALEVO 200 50 MG-200 MG-200 MG TABLET DL | 5 | PA |
| STALEVO 50 12.5 MG-50 MG-200 MG TABLET DL | 5 | PA |
| STALEVO 75 18.75 MG-75 MG-200 MG TABLET DL | 5 | PA |
| tolcapone 100 mg tablet DL | 5 | PA |
| trihexyphenidyl 2 mg, 5 mg tablet MO | 3 | PA |
| trihexyphenidyl 2 mg/5 ml elx MO | 3 | PA |
| ANTIPSYCHOTICS | | |
| ABILIFY MAINTENA 300 MG, 400 MG INTRAMUSCULAR SUSPENSION,EXTENDED RELEASE DL | 5 | QL (1 per 28 days) |
| ABILIFY MAINTENA 300 MG, 400 MG SUSPENSION,EXTENDED REL. INTRAMUSCULAR SYRINGE DL | 5 | QL (1 per 28 days) |
| aripiprazole 1 mg/ml solution MO | 4 | QL (750 per 30 days) |
| aripiprazole 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg tablet MO | 4 | QL (30 per 30 days) |
| aripiprazole odt 10 mg, 15 mg tablet MO | 4 | QL (60 per 30 days) |
| ARISTADA 1,064 MG/3.9 ML SUSPENSION, EXTEND.REL. IM SYRINGE | 5 | QL (3.9 per 56 days) |
| ARISTADA 441 MG/1.6 ML SUSPENSION, EXTEND.REL. IM SYRINGE DL | 5 | QL (1.6 per 28 days) |
| ARISTADA 662 MG/2.4 ML SUSPENSION, EXTEND.REL. IM SYRINGE DL | 5 | QL (2.4 per 28 days) |
| ARISTADA 882 MG/3.2 ML SUSPENSION, EXTEND.REL. IM SYRINGE DL | 5 | QL (3.2 per 28 days) |
| ARISTADA INITIO 675 MG/2.4 ML SUSPENSION, EXTEND.REL. IM SYRINGE DL | 5 | QL (2.4 per 42 days) |
| chlorpromazine 10 mg, 25 mg tablet MO | 4 | B vs D |
| chlorpromazine 100 mg, 200 mg, 50 mg tablet MO | 4 | |
| chlorpromazine 25 mg/ml amp MO | 4 | |
| clozapine 100 mg, 200 mg, 25 mg, 50 mg tablet MO | 3 | |
| clozapine odt 100 mg, 12.5 mg, 150 mg, 200 mg, 25 mg tablet MO | 4 | PA |
| FANAPT 1 MG, 1MG(2)-2MG(2)- 4MG(2)-6MG(2), 2 MG, 4 MG TABLET; FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK MO | 4 | PA,QL (60 per 30 days) |
| FANAPT 10 MG, 12 MG, 6 MG, 8 MG TABLET DL | 5 | PA,QL (60 per 30 days) |
| fluphenazine dec 125 mg/5 ml MO | 4 | |
| fluphenazine 1 mg, 10 mg, 2.5 mg, 5 mg tablet MO | 4 | |
| fluphenazine 2.5 mg/5 ml elix MO | 4 | |
| fluphenazine 2.5 mg/ml vial MO | 4 | |
| fluphenazine 5 mg/ml conc MO | 4 | |
| GEODON 20 MG/ML (FINAL CONCENTRATION) INTRAMUSCULAR SOLUTION MO | 4 | |
| haloperidol 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg tablet MO | 2 | |
| haloperidol dec 100 mg/ml, 50 mg/ml vial MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| <i>haloperidol lac 2 mg/ml conc</i> MO | 2 | |
| <i>haloperidol lac 5 mg/ml syring</i> MO | 2 | |
| <i>haloperidol lac 5 mg/ml vial</i> MO | 2 | |
| INVEGA SUSTENNA 117 MG/0.75 ML, 234 MG/1.5 ML INTRAMUSCULAR SYRINGE DL | 5 | QL (1.5 per 28 days) |
| INVEGA SUSTENNA 156 MG/ML INTRAMUSCULAR SYRINGE DL | 5 | QL (1 per 28 days) |
| INVEGA SUSTENNA 39 MG/0.25 ML, 78 MG/0.5 ML INTRAMUSCULAR SYRINGE MO | 4 | QL (1.5 per 28 days) |
| INVEGA TRINZA 273 MG/0.875 ML INTRAMUSCULAR SYRINGE | 5 | QL (0.87 per 90 days) |
| INVEGA TRINZA 410 MG/1.315 ML INTRAMUSCULAR SYRINGE | 5 | QL (1.31 per 90 days) |
| INVEGA TRINZA 546 MG/1.75 ML INTRAMUSCULAR SYRINGE | 5 | QL (1.75 per 90 days) |
| INVEGA TRINZA 819 MG/2.625 ML INTRAMUSCULAR SYRINGE | 5 | QL (2.62 per 90 days) |
| LATUDA 120 MG, 20 MG, 40 MG, 60 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| LATUDA 80 MG TABLET DL | 5 | PA,QL (60 per 30 days) |
| <i>loxapine 10 mg, 25 mg, 5 mg, 50 mg capsule</i> MO | 2 | |
| <i>molindone hcl 10 mg tablet</i> MO | 4 | PA,QL (240 per 30 days) |
| <i>molindone hcl 25 mg tablet</i> MO | 4 | PA,QL (270 per 30 days) |
| <i>molindone hcl 5 mg tablet</i> MO | 4 | PA,QL (360 per 30 days) |
| NUPLAZID 10 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| NUPLAZID 17 MG TABLET DL | 5 | PA,QL (60 per 30 days) |
| NUPLAZID 34 MG CAPSULE DL | 5 | PA,QL (30 per 30 days) |
| <i>olanzapine 10 mg vial</i> MO | 3 | |
| <i>olanzapine 10 mg, 2.5 mg, 5 mg, 7.5 mg tablet</i> MO | 3 | QL (30 per 30 days) |
| <i>olanzapine 15 mg, 20 mg tablet</i> MO | 3 | QL (60 per 30 days) |
| <i>olanzapine odt 10 mg, 5 mg tablet</i> MO | 4 | QL (30 per 30 days) |
| <i>olanzapine odt 15 mg, 20 mg tablet</i> MO | 4 | QL (60 per 30 days) |
| <i>paliperidone er 1.5 mg, 3 mg, 9 mg tablet</i> MO | 4 | PA,QL (30 per 30 days) |
| <i>paliperidone er 6 mg tablet</i> MO | 4 | PA,QL (60 per 30 days) |
| <i>perphenazine 16 mg, 2 mg, 4 mg, 8 mg tablet</i> MO | 4 | |
| PERSERIS 120 MG, 90 MG ABDOMINAL SUBCUTANEOUS EXTEND RELEASE SUSP SYRINGE KIT DL | 5 | QL (1 per 28 days) |
| <i>pimozide 1 mg, 2 mg tablet</i> MO | 4 | |
| <i>quetiapine er 150 mg tablet</i> MO | 4 | PA,QL (90 per 30 days) |
| <i>quetiapine er 200 mg tablet</i> MO | 4 | PA,QL (30 per 30 days) |
| <i>quetiapine er 300 mg, 400 mg tablet</i> MO | 4 | PA,QL (60 per 30 days) |
| <i>quetiapine er 50 mg tablet</i> MO | 4 | PA,QL (120 per 30 days) |
| <i>quetiapine fumarate 100 mg, 300 mg, 400 mg tab</i> MO | 2 | QL (90 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| quetiapine fumarate 200 mg, 25 mg, 50 mg tab MO | 2 | QL (120 per 30 days) |
| REXULTI 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| RISPERDAL CONSTA 12.5 MG/2 ML, 25 MG/2 ML, 37.5 MG/2 ML INTRAMUSCULAR SYRINGE MO | 4 | QL (2 per 28 days) |
| RISPERDAL CONSTA 50 MG/2 ML INTRAMUSCULAR SYRINGE DL | 5 | QL (2 per 28 days) |
| risperidone 0.25 mg, 1 mg, 2 mg, 3 mg, 4 mg odt MO | 4 | QL (60 per 30 days) |
| risperidone 0.25 mg, 1 mg, 2 mg, 3 mg, 4 mg tablet MO | 1 | QL (60 per 30 days) |
| risperidone 0.5 mg odt MO | 4 | QL (120 per 30 days) |
| risperidone 0.5 mg tablet MO | 1 | QL (120 per 30 days) |
| risperidone 1 mg/ml solution MO | 2 | |
| SAPHRIS 10 MG, 2.5 MG, 5 MG SUBLINGUAL TABLET DL | 5 | PA,QL (60 per 30 days) |
| thioridazine 10 mg, 100 mg, 25 mg, 50 mg tablet MO | 3 | |
| thiothixene 1 mg, 10 mg, 2 mg, 5 mg capsule MO | 4 | |
| trifluoperazine 1 mg, 10 mg, 2 mg, 5 mg tablet MO | 3 | |
| VERSACLOZ 50 MG/ML ORAL SUSPENSION DL | 5 | PA,QL (540 per 30 days) |
| VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK MO | 4 | PA |
| VRAYLAR 1.5 MG, 3 MG, 4.5 MG, 6 MG CAPSULE DL | 5 | PA,QL (30 per 30 days) |
| ziprasidone hcl 20 mg, 40 mg, 60 mg, 80 mg capsule MO | 4 | QL (60 per 30 days) |
| ZYPREXA RELPREVV 210 MG INTRAMUSCULAR SUSPENSION MO | 4 | QL (4 per 28 days) |
| ZYPREXA RELPREVV 300 MG INTRAMUSCULAR SUSPENSION DL | 5 | QL (2 per 28 days) |
| ZYPREXA RELPREVV 405 MG INTRAMUSCULAR SUSPENSION DL | 5 | QL (1 per 28 days) |
| Antispasticity Agents | | |
| baclofen 10 mg, 20 mg tablet MO | 2 | |
| baclofen 5 mg tablet MO | 2 | QL (90 per 30 days) |
| dantrolene sodium 100 mg, 25 mg, 50 mg cap MO | 4 | |
| dantrolene sodium 20 mg vial MO | 3 | |
| revonto 20 mg intravenous solution MO | 3 | |
| tizanidine hcl 2 mg, 4 mg tablet MO | 1 | |
| Antivirals | | |
| abacavir 20 mg/ml solution MO | 4 | QL (960 per 30 days) |
| abacavir 300 mg tablet MO | 4 | QL (60 per 30 days) |
| abacavir-lamivudine 600-300 mg MO | 4 | QL (30 per 30 days) |
| abacavir-lamivudine-zidov tab DL | 5 | QL (60 per 30 days) |
| acyclovir 200 mg capsule MO | 2 | |
| acyclovir 400 mg, 800 mg tablet MO | 2 | |
| acyclovir 5% ointment MO | 4 | PA |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| <i>acyclovir 1,000 mg/20 ml vial; acyclovir sodium 1 gm vial; acyclovir sodium 1,000 mg, 50 mg/ml, 500 mg vial</i> MO | 4 | B vs D |
| <i>adefovir dipivoxil 10 mg tab</i> DL | 5 | |
| APTIVUS 100 MG/ML ORAL SOLUTION DL | 5 | QL (285 per 28 days) |
| APTIVUS 250 MG CAPSULE DL | 5 | QL (120 per 30 days) |
| <i>atazanavir sulfate 150 mg, 200 mg cap</i> DL | 5 | QL (60 per 30 days) |
| <i>atazanavir sulfate 300 mg cap</i> DL | 5 | QL (30 per 30 days) |
| ATRIPLA 600 MG-200 MG-300 MG TABLET DL | 5 | QL (30 per 30 days) |
| BARACLUDE 0.05 MG/ML ORAL SOLUTION DL | 5 | QL (630 per 30 days) |
| BIKTARVY 50 MG-200 MG-25 MG TABLET DL | 5 | QL (30 per 30 days) |
| <i>cidofovir 375 mg/5 ml vial</i> MO | 4 | |
| CIMDUO 300 MG-300 MG TABLET DL | 5 | QL (30 per 30 days) |
| COMPLERA 200 MG-25 MG-300 MG TABLET DL | 5 | QL (30 per 30 days) |
| CRIXIVAN 200 MG CAPSULE MO | 4 | QL (450 per 30 days) |
| CRIXIVAN 400 MG CAPSULE MO | 4 | QL (270 per 30 days) |
| DELSTRIGO 100 MG-300 MG-300 MG TABLET DL | 5 | QL (30 per 30 days) |
| DESCOVY 200 MG-25 MG TABLET DL | 5 | QL (30 per 30 days) |
| <i>didanosine dr 125 mg capsule</i> MO | 4 | QL (90 per 30 days) |
| <i>didanosine dr 200 mg capsule</i> MO | 4 | QL (60 per 30 days) |
| <i>didanosine dr 250 mg, 400 mg capsule</i> MO | 4 | QL (30 per 30 days) |
| DOVATO 50 MG-300 MG TABLET DL | 5 | QL (30 per 30 days) |
| EDURANT 25 MG TABLET DL | 5 | QL (30 per 30 days) |
| <i>efavirenz 200 mg capsule</i> DL | 5 | QL (120 per 30 days) |
| <i>efavirenz 50 mg capsule</i> MO | 4 | QL (480 per 30 days) |
| <i>efavirenz 600 mg tablet</i> DL | 5 | QL (30 per 30 days) |
| EMTRIVA 10 MG/ML ORAL SOLUTION MO | 4 | QL (680 per 28 days) |
| EMTRIVA 200 MG CAPSULE MO | 4 | QL (30 per 30 days) |
| <i>entecavir 0.5 mg, 1 mg tablet</i> MO | 4 | QL (30 per 30 days) |
| EPCLUSA 400 MG-100 MG TABLET DL | 5 | PA,QL (28 per 28 days) |
| EPIVIR HBV 25 MG/5 ML (5 MG/ML) ORAL SOLUTION MO | 4 | |
| EVOTAZ 300 MG-150 MG TABLET DL | 5 | QL (30 per 30 days) |
| <i>famciclovir 125 mg, 250 mg, 500 mg tablet</i> MO | 3 | QL (90 per 30 days) |
| <i>fosamprenavir 700 mg tablet</i> DL | 5 | QL (120 per 30 days) |
| <i>foscarnet 24 mg/ml infus bttl</i> MO | 4 | B vs D |
| FUZEON 90 MG SUBCUTANEOUS SOLUTION DL | 5 | QL (60 per 30 days) |
| <i>ganciclovir 50 mg/ml, 500 mg vial; ganciclovir 500 mg/10 ml vial</i> DL | 5 | B vs D |
| GENVOYA 150 MG-150 MG-200 MG-10 MG TABLET DL | 5 | QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| HARVONI 45 MG-200 MG TABLET; HARVONI 90 MG-400 MG TABLET DL | 5 | PA,QL (28 per 28 days) |
| INTELENCE 100 MG TABLET DL | 5 | QL (120 per 30 days) |
| INTELENCE 200 MG TABLET DL | 5 | QL (60 per 30 days) |
| INTELENCE 25 MG TABLET MO | 4 | QL (120 per 30 days) |
| INTRON A 10 MILLION UNIT (1 ML), 10 MILLION UNIT/ML, 18 MILLION UNIT (1 ML), 50 MILLION UNIT (1 ML), 6 MILLION UNIT/ML INJECTION SOLUTION; INTRON A 10 MILLION UNIT (1 ML), 10 MILLION UNIT/ML, 18 MILLION UNIT (1 ML), 50 MILLION UNIT (1 ML), 6 MILLION UNIT/ML SOLUTION FOR INJECTION DL | 5 | PA |
| INVIRASE 200 MG CAPSULE DL | 5 | QL (300 per 30 days) |
| INVIRASE 500 MG TABLET DL | 5 | QL (120 per 30 days) |
| ISENTRESS 100 MG CHEWABLE TABLET DL | 5 | QL (180 per 30 days) |
| ISENTRESS 100 MG ORAL POWDER PACKET MO | 3 | QL (300 per 30 days) |
| ISENTRESS 25 MG CHEWABLE TABLET MO | 4 | QL (180 per 30 days) |
| ISENTRESS 400 MG TABLET DL | 5 | QL (120 per 30 days) |
| ISENTRESS HD 600 MG TABLET DL | 5 | QL (60 per 30 days) |
| JULUCA 50 MG-25 MG TABLET DL | 5 | QL (30 per 30 days) |
| KALETRA 100 MG-25 MG TABLET MO | 4 | QL (300 per 30 days) |
| KALETRA 200 MG-50 MG TABLET DL | 5 | QL (150 per 30 days) |
| <i>lamivudine 10 mg/ml oral soln</i> MO | 3 | |
| <i>lamivudine 150 mg tablet</i> MO | 4 | QL (60 per 30 days) |
| <i>lamivudine 300 mg tablet</i> MO | 4 | QL (30 per 30 days) |
| <i>lamivudine hbv 100 mg tablet</i> MO | 4 | QL (90 per 30 days) |
| <i>lamivudine-zidovudine tablet</i> MO | 4 | QL (60 per 30 days) |
| <i>ledipasvir-sofosbuvir 90-400mg</i> DL | 5 | PA,QL (28 per 28 days) |
| LEXIVA 50 MG/ML ORAL SUSPENSION MO | 4 | QL (1575 per 28 days) |
| <i>lopinavir-ritonavir 80-20mg/ml</i> MO | 4 | |
| MAVYRET 100 MG-40 MG TABLET DL | 5 | PA,QL (84 per 28 days) |
| <i>nevirapine 200 mg tablet</i> MO | 2 | QL (60 per 30 days) |
| <i>nevirapine 50 mg/5 ml susp</i> MO | 4 | QL (1200 per 30 days) |
| <i>nevirapine er 100 mg tablet</i> MO | 4 | QL (120 per 30 days) |
| <i>nevirapine er 400 mg tablet</i> MO | 4 | QL (30 per 30 days) |
| NORVIR 100 MG ORAL POWDER PACKET DL | 5 | QL (360 per 30 days) |
| NORVIR 100 MG TABLET MO | 4 | QL (360 per 30 days) |
| NORVIR 80 MG/ML ORAL SOLUTION MO | 4 | QL (480 per 30 days) |
| ODEFSEY 200 MG-25 MG-25 MG TABLET DL | 5 | QL (30 per 30 days) |
| <i>oseltamivir 6 mg/ml suspension</i> MO | 4 | QL (1440 per 365 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| <i>oseltamivir phos 30 mg capsule</i> MO | 3 | QL (224 per 365 days) |
| <i>oseltamivir phos 45 mg, 75 mg capsule</i> MO | 3 | QL (112 per 365 days) |
| PEGASYS 180 MCG/0.5 ML SUBCUTANEOUS SYRINGE DL | 5 | PA,QL (2 per 28 days) |
| PEGASYS 180 MCG/ML SUBCUTANEOUS SOLUTION DL | 5 | PA,QL (4 per 28 days) |
| PEGASYS PROCLICK 135 MCG/0.5; PEGASYS PROCLICK 135 MCG/0.5 ML, 180 MCG/0.5 ML SUBCUTANEOUS PEN INJECTOR DL | 5 | PA,QL (2 per 28 days) |
| PIFELTRO 100 MG TABLET DL | 5 | QL (60 per 30 days) |
| PREZCOBIX 800 MG-150 MG TABLET DL | 5 | QL (30 per 30 days) |
| PREZISTA 100 MG/ML ORAL SUSPENSION DL | 5 | QL (360 per 30 days) |
| PREZISTA 150 MG TABLET MO | 4 | QL (240 per 30 days) |
| PREZISTA 600 MG TABLET DL | 5 | QL (60 per 30 days) |
| PREZISTA 75 MG TABLET DL | 5 | QL (480 per 30 days) |
| PREZISTA 800 MG TABLET DL | 5 | QL (30 per 30 days) |
| RELENZA DISKHALER 5 MG/ACTUATION POWDER FOR INHALATION MO | 4 | QL (60 per 180 days) |
| RESCRIPTOR 100 MG TABLET MO | 4 | QL (360 per 30 days) |
| RESCRIPTOR 200 MG TABLET MO | 4 | QL (180 per 30 days) |
| RETROVIR 10 MG/ML INTRAVENOUS SOLUTION MO | 4 | |
| REYATAZ 50 MG ORAL POWDER PACKET MO | 4 | |
| RIBASPHERE RIBAPAK 200-400 MG DL | 5 | QL (112 per 28 days) |
| RIBASPHERE RIBAPAK 400-400 MG DL | 5 | QL (84 per 28 days) |
| RIBASPHERE RIBAPAK 600 MG (28)-400 MG (28) TABLETS IN A DOSE PACK; RIBASPHERE RIBAPAK 600 MG (7)-400 MG (7) TABLETS IN A DOSE PACK DL | 5 | QL (112 per 30 days) |
| RIBASPHERE RIBAPAK 600 MG (28)-600 MG (28) TABLETS IN A DOSE PACK; RIBASPHERE RIBAPAK 600 MG (7)-600 MG (7) TABLETS IN A DOSE PACK DL | 5 | QL (56 per 28 days) |
| <i>ribavirin 200 mg capsule</i> MO | 3 | QL (168 per 28 days) |
| <i>ribavirin 200 mg tablet</i> MO | 3 | QL (168 per 28 days) |
| <i>ribavirin 6 gm inhalation vial</i> DL | 5 | B vs D |
| <i>rimantadine hcl 100 mg tablet</i> MO | 4 | |
| <i>ritonavir 100 mg tablet</i> MO | 4 | QL (360 per 30 days) |
| SELZENTRY 150 MG TABLET DL | 5 | QL (240 per 30 days) |
| SELZENTRY 20 MG/ML ORAL SOLUTION DL | 5 | QL (1800 per 30 days) |
| SELZENTRY 25 MG TABLET MO | 4 | QL (240 per 30 days) |
| SELZENTRY 300 MG, 75 MG TABLET DL | 5 | QL (120 per 30 days) |
| <i>sofosbuvir-velpatasvir 400-100</i> DL | 5 | PA,QL (28 per 28 days) |
| <i>stavudine 15 mg, 20 mg capsule</i> MO | 3 | QL (120 per 30 days) |
| <i>stavudine 30 mg, 40 mg capsule</i> MO | 3 | QL (60 per 30 days) |
| STRIBILD 150 MG-150 MG-200 MG-300 MG TABLET DL | 5 | QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| SUSTIVA 200 MG CAPSULE DL | 5 | QL (120 per 30 days) |
| SUSTIVA 50 MG CAPSULE DL | 5 | QL (480 per 30 days) |
| SUSTIVA 600 MG TABLET DL | 5 | QL (30 per 30 days) |
| SYLATRON 200 MCG, 300 MCG, 600 MCG SUBCUTANEOUS KIT DL | 5 | PA,QL (4 per 28 days) |
| SYMFI 600 MG-300 MG-300 MG TABLET DL | 5 | QL (30 per 30 days) |
| SYMFI LO 400 MG-300 MG-300 MG TABLET DL | 5 | QL (30 per 30 days) |
| SYMTUZA 800 MG-150 MG-200 MG-10 MG TABLET DL | 5 | QL (30 per 30 days) |
| TEMIXYS 300 MG-300 MG TABLET DL | 5 | QL (30 per 30 days) |
| <i>tenofovir disop fum 300 mg tb</i> DL | 5 | QL (30 per 30 days) |
| TIVICAY 10 MG TABLET MO | 4 | QL (60 per 30 days) |
| TIVICAY 25 MG, 50 MG TABLET DL | 5 | QL (60 per 30 days) |
| <i>trifluridine 1% eye drops</i> MO | 3 | |
| TRIUMEQ 600 MG-50 MG-300 MG TABLET DL | 5 | QL (30 per 30 days) |
| TROGARZO 200 MG/1.33 ML (150 MG/ML) INTRAVENOUS SOLUTION DL | 5 | |
| TRUVADA 100 MG-150 MG TABLET; TRUVADA 133 MG-200 MG TABLET; TRUVADA 167 MG-250 MG TABLET; TRUVADA 200 MG-300 MG TABLET DL | 5 | QL (30 per 30 days) |
| TYBOST 150 MG TABLET MO | 4 | QL (30 per 30 days) |
| <i>valacyclovir hcl 1 gram, 500 mg tablet</i> MO | 3 | QL (90 per 30 days) |
| <i>valganciclovir 450 mg tablet</i> DL | 5 | QL (120 per 30 days) |
| <i>valganciclovir hcl 50 mg/ml</i> DL | 5 | QL (1056 per 30 days) |
| VIDEX 2 GRAM PEDIATRIC 10 MG/ML (FINAL CONC.) ORAL SOLUTION MO | 4 | QL (1200 per 30 days) |
| VIDEX 4 GM PEDIATRIC SOLN MO | 4 | QL (1200 per 30 days) |
| VIDEX EC 125 MG CAPSULE, DELAYED RELEASE MO | 4 | QL (90 per 30 days) |
| VIRACEPT 250 MG TABLET DL | 5 | QL (300 per 30 days) |
| VIRACEPT 625 MG TABLET DL | 5 | QL (120 per 30 days) |
| VIRAMUNE 50 MG/5 ML ORAL SUSPENSION DL | 5 | QL (1200 per 30 days) |
| VIREAD 150 MG, 200 MG, 250 MG, 300 MG TABLET DL | 5 | QL (30 per 30 days) |
| VIREAD 40 MG/SCOOP (40 MG/GRAM) ORAL POWDER DL | 5 | QL (240 per 30 days) |
| XOFLUZA 20 MG, 40 MG TABLET MO | 4 | QL (10 per 365 days) |
| ZERIT 1 MG/ML SOLUTION MO | 4 | QL (2400 per 30 days) |
| <i>zidovudine 100 mg capsule</i> MO | 4 | QL (180 per 30 days) |
| <i>zidovudine 300 mg tablet</i> MO | 2 | QL (60 per 30 days) |
| <i>zidovudine 50 mg/5 ml syrup</i> MO | 3 | QL (1680 per 28 days) |
| ZIRGAN 0.15 % EYE GEL MO | 4 | QL (5 per 30 days) |
| Anxiolytics | | |
| <i>alprazolam 0.25 mg, 0.5 mg, 1 mg tablet</i> DL | 2 | QL (120 per 30 days) |
| <i>alprazolam 2 mg tablet</i> DL | 2 | QL (150 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| <i>bupirone hcl 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg tablet</i> ^{MO} | 2 | |
| <i>clonazepam 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg dis tab; clonazepam 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg dis tablet; clonazepam 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg odt</i> ^{DL} | 4 | |
| <i>clonazepam 0.5 mg, 1 mg, 2 mg tablet</i> ^{DL} | 3 | |
| <i>clorazepate 15 mg, 3.75 mg, 7.5 mg tablet</i> ^{DL} | 4 | |
| <i>diazepam 10 mg tablet</i> ^{DL} | 3 | QL (120 per 30 days) |
| <i>diazepam 2 mg, 5 mg tablet</i> ^{DL} | 3 | QL (90 per 30 days) |
| <i>diazepam 5 mg/5 ml solution</i> ^{DL} | 4 | QL (1200 per 30 days) |
| <i>diazepam 5 mg/ml oral conc</i> ^{DL} | 4 | QL (240 per 30 days) |
| <i>diazepam intensol 5 mg/ml oral concentrate</i> ^{DL} | 4 | QL (240 per 30 days) |
| <i>doxepin 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg capsule</i> ^{MO} | 4 | PA |
| <i>doxepin 10 mg/ml oral conc</i> ^{MO} | 4 | PA |
| <i>hydroxyzine 10 mg/5 ml soln</i> ^{MO} | 3 | |
| <i>hydroxyzine hcl 10 mg, 25 mg, 50 mg tablet</i> ^{MO} | 3 | |
| <i>lorazepam 0.5 mg, 1 mg tablet</i> ^{DL} | 2 | QL (90 per 30 days) |
| <i>lorazepam 2 mg tablet</i> ^{DL} | 2 | QL (150 per 30 days) |
| <i>lorazepam 2 mg/ml oral concent</i> ^{DL} | 3 | QL (150 per 30 days) |
| LORAZEPAM INTENSOL 2 MG/ML ORAL CONCENTRATE ^{DL} | 3 | QL (150 per 30 days) |
| <i>oxazepam 10 mg, 15 mg, 30 mg capsule</i> ^{DL} | 4 | |
| Bipolar Agents | | |
| <i>lithium carbonate 150 mg, 300 mg, 600 mg cap</i> ^{MO} | 1 | |
| <i>lithium carbonate 300 mg tab</i> ^{MO} | 1 | |
| <i>lithium carbonate er 300 mg, 450 mg tb</i> ^{MO} | 2 | |
| <i>lithium 8 meq/5 ml solution</i> ^{MO} | 3 | |
| Blood Glucose Regulators | | |
| <i>acarbose 100 mg, 25 mg, 50 mg tablet</i> ^{MO} | 3 | |
| BYDUREON 2 MG VIAL ^{MO} | 4 | QL (4 per 28 days) |
| BYDUREON 2 MG/0.65 ML SUBCUTANEOUS PEN INJECTOR ^{MO} | 4 | QL (4 per 28 days) |
| BYDUREON BCISE 2 MG/0.85 ML SUBCUTANEOUS AUTO-INJECTOR ^{MO} | 4 | QL (3.4 per 28 days) |
| BYETTA 10 MCG/DOSE(250 MCG/ML)2.4 ML SUBCUTANEOUS PEN INJECTOR; BYETTA 5 MCG/DOSE (250 MCG/ML)1.2 ML SUBCUTANEOUS PEN INJECTOR ^{MO} | 4 | ST,QL (2.4 per 30 days) |
| FARXIGA 10 MG, 5 MG TABLET ^{MO} | 4 | QL (30 per 30 days) |
| FIASP FLEXTOUCH U-100 INSULIN 100 UNIT/ML (3 ML) SUBCUTANEOUS PEN ^{MO} | 3 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| FIASP PENFILL U-100 INSULIN 100 UNIT/ML (3 ML) SUBCUTANEOUS CARTRIDGE MO | 3 | |
| FIASP U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION MO | 3 | |
| <i>glimepiride 1 mg, 2 mg, 4 mg tablet</i> MO | 1 | |
| <i>glipizide 10 mg, 5 mg tablet</i> MO | 1 | |
| <i>glipizide er 10 mg, 2.5 mg, 5 mg tablet; glipizide xl 10 mg, 2.5 mg, 5 mg tablet</i> MO | 1 | |
| <i>glipizide-metformin 2.5-250 mg, 2.5-500 mg, 5-500 mg</i> MO | 1 | |
| GLUCAGEN HYPOKIT 1 MG INJECTION MO | 3 | |
| <i>glyburide 1.25 mg, 2.5 mg, 5 mg tablet</i> MO | 4 | |
| <i>glyburide micro 1.5 mg, 3 mg, 6 mg tab; glyburide micro 1.5 mg, 3 mg, 6 mg tablet</i> MO | 4 | |
| <i>glyburid-metformin 1.25-250 mg, 2.5-500 mg, 5-500 mg; glyburide-metformin 1.25-250 mg, 2.5-500 mg, 5-500 mg</i> MO | 4 | |
| GLYXAMBI 10 MG-5 MG TABLET; GLYXAMBI 25 MG-5 MG TABLET MO | 3 | QL (30 per 30 days) |
| HUMULIN R U-500 (CONCENTRATED) INSULIN 500 UNIT/ML SUBCUTANEOUS SOLN DL | 5 | |
| HUMULIN R U-500 (CONC) INSULIN KWIKPEN 500 UNIT/ML (3 ML) SUBCUTANEOUS DL | 5 | |
| INVOKAMET 150 MG-1,000 MG TABLET; INVOKAMET 150 MG-500 MG TABLET; INVOKAMET 50 MG-1,000 MG TABLET; INVOKAMET 50 MG-500 MG TABLET MO | 3 | QL (60 per 30 days) |
| INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE; INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE; INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE; INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE MO | 3 | QL (60 per 30 days) |
| INVOKANA 100 MG, 300 MG TABLET MO | 3 | QL (30 per 30 days) |
| JANUMET 50 MG-1,000 MG TABLET; JANUMET 50 MG-500 MG TABLET MO | 3 | QL (60 per 30 days) |
| JANUMET XR 100 MG-1,000 MG TABLET,EXTENDED RELEASE MO | 3 | QL (30 per 30 days) |
| JANUMET XR 50 MG-1,000 MG TABLET,EXTENDED RELEASE; JANUMET XR 50 MG-500 MG TABLET,EXTENDED RELEASE MO | 3 | QL (60 per 30 days) |
| JANUVIA 100 MG, 25 MG, 50 MG TABLET MO | 3 | QL (30 per 30 days) |
| JARDIANCE 10 MG, 25 MG TABLET MO | 3 | QL (30 per 30 days) |
| JENTADUETO 2.5 MG-1,000 MG TABLET; JENTADUETO 2.5 MG-500 MG TABLET; JENTADUETO 2.5 MG-850 MG TABLET MO | 3 | QL (60 per 30 days) |
| JENTADUETO XR 2.5 MG-1,000 MG TABLET, EXTENDED RELEASE MO | 3 | QL (60 per 30 days) |
| JENTADUETO XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE MO | 3 | QL (30 per 30 days) |
| KAZANO 12.5 MG-1,000 MG TABLET; KAZANO 12.5 MG-500 MG TABLET MO | 4 | QL (60 per 30 days) |
| KOMBIGLYZE XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE MO | 4 | QL (60 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| KOMBIGLYZE XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE; KOMBIGLYZE XR 5 MG-500 MG TABLET,EXTENDED RELEASE MO | 4 | QL (30 per 30 days) |
| LANTUS SOLOSTAR U-100 INSULIN 100 UNIT/ML (3 ML) SUBCUTANEOUS PEN MO | 3 | |
| LANTUS U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION MO | 3 | |
| LEVEMIR FLEXTOUCH U-100 INSULIN 100 UNIT/ML (3 ML) SUBCUTANEOUS PEN MO | 3 | |
| LEVEMIR U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION MO | 3 | |
| metformin hcl 1,000 mg, 500 mg, 850 mg tablet MO | 1 | |
| metformin hcl er 500 mg tablet MO | 1 | QL (120 per 30 days) |
| metformin hcl er 750 mg tablet MO | 1 | QL (60 per 30 days) |
| nateglinide 120 mg, 60 mg tablet MO | 3 | |
| NESINA 12.5 MG, 25 MG, 6.25 MG TABLET MO | 4 | QL (30 per 30 days) |
| NOVOLIN 70-30 FLEXPEN U-100 INSULIN 100 UNIT/ML (70-30) SUBCUTANEOUS MO | 3 | |
| NOVOLIN 70/30 U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SUSPENSION MO | 3 | |
| NOVOLIN N NPH U-100 INSULIN ISOPHANE 100 UNIT/ML SUBCUTANEOUS SUSP MO | 3 | |
| NOVOLIN R REGULAR U-100 INSULIN 100 UNIT/ML INJECTION SOLUTION MO | 3 | |
| NOVOLOG FLEXPEN U-100 INSULIN ASPART 100 UNIT/ML (3 ML) SUBCUTANEOUS MO | 3 | |
| NOVOLOG MIX 70-30 U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION MO | 3 | |
| NOVOLOG MIX 70-30 FLEXPEN U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS PEN MO | 3 | |
| NOVOLOG PENFILL U-100 INSULIN ASPART 100 UNIT/ML SUBCUTANEOUS CARTRIDG MO | 3 | |
| NOVOLOG U-100 INSULIN ASPART 100 UNIT/ML SUBCUTANEOUS SOLUTION MO | 3 | |
| ONGLYZA 2.5 MG, 5 MG TABLET MO | 4 | QL (30 per 30 days) |
| OSENI 12.5 MG-15 MG TABLET; OSENI 12.5 MG-30 MG TABLET; OSENI 12.5 MG-45 MG TABLET; OSENI 25 MG-15 MG TABLET; OSENI 25 MG-30 MG TABLET; OSENI 25 MG-45 MG TABLET MO | 4 | QL (30 per 30 days) |
| OZEMPIC 0.25 MG OR 0.5 MG (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR MO | 3 | QL (1.5 per 28 days) |
| OZEMPIC 1 MG/DOSE (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR MO | 3 | QL (3 per 28 days) |
| pioglitazone hcl 15 mg, 30 mg, 45 mg tablet MO | 1 | QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| PROGLYCEM 50 MG/ML ORAL SUSPENSION MO | 4 | |
| <i>repaglinide 0.5 mg, 1 mg, 2 mg tablet</i> MO | 3 | |
| SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS INSULIN PEN MO | 3 | ST,QL (15 per 24 days) |
| SYMLINPEN 120 2,700 MCG/2.7 ML SUBCUTANEOUS PEN INJECTOR DL | 5 | QL (10.8 per 30 days) |
| SYMLINPEN 60 1,500 MCG/1.5 ML SUBCUTANEOUS PEN INJECTOR DL | 5 | QL (10.5 per 28 days) |
| SYNJARDY 12.5 MG-1,000 MG TABLET; SYNJARDY 12.5 MG-500 MG TABLET; SYNJARDY 5 MG-1,000 MG TABLET; SYNJARDY 5 MG-500 MG TABLET MO | 3 | QL (60 per 30 days) |
| SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE; SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE MO | 3 | QL (30 per 30 days) |
| SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE; SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE MO | 3 | QL (60 per 30 days) |
| TOUJEO MAX U-300 SOLOSTAR 300 UNIT/ML (3 ML) SUBCUTANEOUS INSULIN PEN MO | 3 | |
| TOUJEO SOLOSTAR U-300 INSULIN 300 UNIT/ML (1.5 ML) SUBCUTANEOUS PEN MO | 3 | |
| TRADJENTA 5 MG TABLET MO | 3 | QL (30 per 30 days) |
| TRESIBA FLEXTOUCH U-100 INSULIN 100 UNIT/ML (3 ML) SUBCUTANEOUS PEN MO | 3 | |
| TRESIBA FLEXTOUCH U-200 INSULIN 200 UNIT/ML (3 ML) SUBCUTANEOUS PEN MO | 3 | |
| TRESIBA U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION MO | 3 | |
| TRULICITY 0.75 MG/0.5 ML, 1.5 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR MO | 3 | QL (2 per 28 days) |
| VICTOZA 2-PAK 0.6 MG/0.1 ML (18 MG/3 ML) SUBCUTANEOUS PEN INJECTOR MO | 3 | QL (9 per 30 days) |
| VICTOZA 3-PAK 0.6 MG/0.1 ML (18 MG/3 ML) SUBCUTANEOUS PEN INJECTOR MO | 3 | QL (9 per 30 days) |
| XIGDUO XR 10 MG-1,000 MG TABLET,EXTENDED RELEASE; XIGDUO XR 10 MG-500 MG TABLET,EXTENDED RELEASE; XIGDUO XR 5 MG-500 MG TABLET,EXTENDED RELEASE MO | 4 | QL (30 per 30 days) |
| XIGDUO XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE; XIGDUO XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE MO | 4 | QL (60 per 30 days) |
| XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) SUBCUTANEOUS INSULIN PEN MO | 3 | ST,QL (15 per 30 days) |
| Blood Products/Modifiers/Volume Expanders | | |
| AMICAR 1,000 MG, 500 MG TABLET DL | 5 | |
| AMICAR 250 MG/ML (25 %) ORAL SOLUTION DL | 5 | |
| <i>aminocaproic acid 0.25 gram/ml</i> DL | 5 | |
| <i>aminocaproic acid 1,000 mg, 500 mg tab</i> DL | 5 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| <i>aminocaproic acid 5 g/20 ml vial</i> MO | 4 | |
| <i>anagrelide hcl 0.5 mg, 1 mg capsule</i> MO | 4 | |
| <i>aspirin-dipyridam er 25-200 mg</i> MO | 4 | ST |
| <i>azacitidine 100 mg vial</i> DL | 5 | PA |
| BRILINTA 60 MG, 90 MG TABLET MO | 3 | QL (60 per 30 days) |
| <i>cilostazol 100 mg, 50 mg tablet</i> MO | 2 | |
| <i>clopidogrel 300 mg tablet</i> MO | 2 | |
| <i>clopidogrel 75 mg tablet</i> MO | 1 | QL (30 per 30 days) |
| COUMADIN 1 MG, 10 MG, 2 MG, 2.5 MG, 3 MG, 4 MG, 5 MG, 6 MG, 7.5 MG TABLET MO | 4 | |
| <i>dipyridamole 25 mg, 50 mg, 75 mg tablet</i> MO | 4 | |
| EFFIENT 10 MG, 5 MG TABLET MO | 4 | PA,QL (30 per 30 days) |
| ELIQUIS 2.5 MG TABLET MO | 3 | QL (60 per 30 days) |
| ELIQUIS 5 MG TABLET MO | 3 | QL (74 per 30 days) |
| ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG (74 TABLETS) IN DOSE PACK MO | 3 | QL (74 per 30 days) |
| <i>enoxaparin 100 mg/ml, 150 mg/ml syringe</i> MO | 4 | QL (28 per 28 days) |
| <i>enoxaparin 120 mg/0.8 ml, 80 mg/0.8 ml syr</i> MO | 4 | QL (22.4 per 28 days) |
| <i>enoxaparin 30 mg/0.3 ml, 60 mg/0.6 ml syr</i> MO | 4 | QL (16.8 per 28 days) |
| <i>enoxaparin 300 mg/3 ml vial</i> MO | 4 | QL (84 per 28 days) |
| <i>enoxaparin 40 mg/0.4 ml syr</i> MO | 4 | QL (11.2 per 28 days) |
| EPOGEN 10,000 UNIT/ML, 20,000 UNIT/ML INJECTION SOLUTION DL | 5 | PA,QL (14 per 30 days) |
| EPOGEN 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML INJECTION SOLUTION DL | 4 | PA,QL (14 per 30 days) |
| EPOGEN 20,000 UNIT/2 ML INJECTION SOLUTION DL | 4 | PA,QL (28 per 30 days) |
| <i>fondaparinux 10 mg/0.8 ml syr</i> DL | 5 | QL (24 per 30 days) |
| <i>fondaparinux 2.5 mg/0.5 ml syr</i> MO | 4 | QL (15 per 30 days) |
| <i>fondaparinux 5 mg/0.4 ml syr</i> DL | 5 | QL (12 per 30 days) |
| <i>fondaparinux 7.5 mg/0.6 ml syr</i> DL | 5 | QL (18 per 30 days) |
| FRAGMIN 10,000 ANTI-XA UNIT/ML SUBCUTANEOUS SYRINGE DL | 5 | QL (30 per 30 days) |
| FRAGMIN 12,500 ANTI-XA UNIT/0.5 ML SUBCUTANEOUS SYRINGE DL | 5 | QL (15 per 30 days) |
| FRAGMIN 15,000 ANTI-XA UNIT/0.6 ML SUBCUTANEOUS SYRINGE DL | 5 | QL (18 per 30 days) |
| FRAGMIN 18,000 ANTI-XA UNIT/0.72 ML SUBCUTANEOUS SYRINGE DL | 5 | QL (21.6 per 30 days) |
| FRAGMIN 2,500 ANTI-XA UNIT/0.2 ML, 5,000 ANTI-XA UNIT/0.2 ML SUBCUTANEOUS SYRINGE MO | 4 | QL (6 per 30 days) |
| FRAGMIN 25,000 ANTI-XA UNIT/ML SUBCUTANEOUS SOLUTION DL | 5 | QL (22.8 per 30 days) |
| FRAGMIN 7,500 ANTI-XA UNIT/0.3 ML SUBCUTANEOUS SYRINGE DL | 5 | QL (9 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| FULPHILA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE DL | 5 | PA,QL (1.2 per 28 days) |
| heparin 5,000 unit/ml carpuyct MO | 3 | |
| heparin sod 1,000 unit/ml, 10,000 unit/ml, 5,000 unit/ml vial; heparin sod 1,000 unit/ml, 10,000 unit/ml, 5,000 unit/ml vl MO | 3 | |
| heparin sod 20,000 unit/ml vl MO | 4 | |
| heparin sod 5,000 unit/ml syrg MO | 3 | |
| heparin 2,000 unit/2 ml vial; heparin sod 5,000 unit/ 0.5 ml MO | 3 | |
| heparin sod 5,000 unit/0.5 ml, 5,000 unit/ml; heparin sod 5,000 unit/0.5 ml, 5,000 unit/ml syrg MO | 3 | |
| gantoven 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg tablet MO | 1 | |
| MOZOBIL 24 MG/1.2 ML (20 MG/ML) SUBCUTANEOUS SOLUTION DL | 5 | PA,QL (9.6 per 30 days) |
| NEULASTA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE; NEULASTA 6 MG/0.6 ML, 6 MG/0.6ML WITH WEARABLE SUBCUTANEOUS INJECTOR DL | 5 | PA,QL (1.2 per 28 days) |
| NEUPOGEN 300 MCG/0.5 ML INJECTION SYRINGE DL | 5 | PA,QL (7 per 30 days) |
| NEUPOGEN 300 MCG/ML INJECTION SOLUTION DL | 5 | PA,QL (14 per 30 days) |
| NEUPOGEN 480 MCG/0.8 ML INJECTION SYRINGE DL | 5 | PA,QL (11.2 per 30 days) |
| NEUPOGEN 480 MCG/1.6 ML INJECTION SOLUTION DL | 5 | PA,QL (22.4 per 30 days) |
| PRADAXA 110 MG, 150 MG, 75 MG CAPSULE MO | 4 | QL (60 per 30 days) |
| prasugrel 10 mg, 5 mg tablet MO | 3 | QL (30 per 30 days) |
| PROCRIT 10,000 UNIT/ML, 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML INJECTION SOLUTION DL | 4 | PA,QL (14 per 30 days) |
| PROCRIT 20,000 UNIT/2 ML INJECTION SOLUTION DL | 4 | PA,QL (28 per 30 days) |
| PROCRIT 20,000 UNIT/ML, 40,000 UNIT/ML INJECTION SOLUTION DL | 5 | PA,QL (14 per 30 days) |
| PROMACTA 12.5 MG ORAL POWDER PACKET DL | 5 | PA,QL (360 per 30 days) |
| PROMACTA 12.5 MG, 75 MG TABLET DL | 5 | PA,QL (60 per 30 days) |
| PROMACTA 25 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| PROMACTA 50 MG TABLET DL | 5 | PA,QL (90 per 30 days) |
| RETACRIT 10,000 UNIT/ML, 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML INJECTION SOLUTION DL | 4 | PA,QL (14 per 30 days) |
| RETACRIT 40,000 UNIT/ML INJECTION SOLUTION DL | 5 | PA,QL (14 per 30 days) |
| tranexamic acid 1,000 mg/10 ml MO | 4 | PA |
| tranexamic acid 650 mg tablet MO | 3 | QL (30 per 5 days) |
| UDENYCA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE DL | 5 | PA,QL (1.2 per 28 days) |
| warfarin sodium 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg tablet MO | 1 | |
| XARELTO 10 MG, 20 MG TABLET MO | 3 | QL (30 per 30 days) |
| XARELTO 15 MG (42)-20 MG (9) TABLETS IN A STARTER PACK MO | 3 | QL (51 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| XARELTO 15 MG, 2.5 MG TABLET MO | 3 | QL (60 per 30 days) |
| ZARXIO 300 MCG/0.5 ML INJECTION SYRINGE DL | 5 | PA,QL (7 per 30 days) |
| ZARXIO 480 MCG/0.8 ML INJECTION SYRINGE DL | 5 | PA,QL (11.2 per 30 days) |
| CARDIOVASCULAR AGENTS | | |
| acebutolol 200 mg, 400 mg capsule MO | 2 | |
| acetazolamide 125 mg, 250 mg tablet MO | 4 | |
| acetazolamide er 500 mg cap MO | 3 | |
| acetazolamide sod 500 mg vial MO | 2 | |
| adenosine 12 mg/4 ml syringe MO | 1 | |
| adenosine 12 mg/4 ml vial MO | 1 | |
| afeditab cr 30 mg, 60 mg tablet MO | 3 | QL (60 per 30 days) |
| aliskiren 150 mg, 300 mg tablet MO | 3 | QL (30 per 30 days) |
| amiloride hcl 5 mg tablet MO | 3 | |
| amiloride hcl-hctz 5-50 mg tab MO | 2 | |
| amiodarone 150 mg/3 ml syringe MO | 2 | |
| amiodarone 150 mg/3 ml vial MO | 2 | |
| amiodarone hcl 100 mg, 400 mg tablet MO | 4 | |
| amiodarone hcl 200 mg tablet MO | 2 | |
| amlodipine besylate 10 mg, 2.5 mg, 5 mg tab MO | 1 | |
| amlodipine-atorvast 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg, 2.5-10 mg, 2.5-20 mg, 2.5-40 mg, 5-10 mg, 5-20 mg, 5-40 mg, 5-80 mg MO | 4 | QL (30 per 30 days) |
| amlodipine-benazepril 10-20 mg, 2.5-10 mg, 5-10 mg, 5-20 mg; amlodipine-benazepril 2.5-10 MO | 1 | QL (60 per 30 days) |
| amlodipine-benazepril 10-40 mg, 5-40 mg MO | 1 | QL (30 per 30 days) |
| amlodipine-olmesartan 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg MO | 4 | QL (30 per 30 days) |
| amlodipine-valsartan 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg MO | 2 | QL (30 per 30 days) |
| atenolol 100 mg, 25 mg, 50 mg tablet MO | 1 | |
| atenolol-chlorthalidone 100-25; atenolol-chlorthalidone 50-25 MO | 1 | |
| atorvastatin 10 mg, 20 mg, 40 mg, 80 mg tablet MO | 1 | QL (30 per 30 days) |
| benazepril hcl 10 mg, 20 mg, 40 mg, 5 mg tablet MO | 1 | |
| benazepril-hctz 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg tab MO | 2 | |
| BIDIL 20 MG-37.5 MG TABLET MO | 3 | QL (180 per 30 days) |
| bisoprolol fumarate 10 mg, 5 mg tab MO | 2 | |
| bisoprolol-hctz 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg tab; bisoprolol-hctz 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg tb MO | 1 | |
| bumetanide 0.5 mg, 1 mg, 2 mg tablet MO | 2 | |
| bumetanide 2.5 mg/10 ml vial MO | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| BYSTOLIC 10 MG TABLET MO | 3 | QL (120 per 30 days) |
| BYSTOLIC 2.5 MG, 5 MG TABLET MO | 3 | QL (30 per 30 days) |
| BYSTOLIC 20 MG TABLET MO | 3 | QL (60 per 30 days) |
| candesartan cilexetil 16 mg, 4 mg, 8 mg tab; candesartan cilexetil 16 mg, 4 mg, 8 mg tb MO | 3 | QL (60 per 30 days) |
| candesartan cilexetil 32 mg tb MO | 3 | QL (30 per 30 days) |
| candesartan-hctz 16-12.5 mg, 32-12.5 mg, 32-25 mg tab; candesartan-hctz 16-12.5 mg, 32-12.5 mg, 32-25 mg tb MO | 3 | QL (30 per 30 days) |
| captopril 100 mg, 12.5 mg, 25 mg, 50 mg tablet MO | 3 | |
| captopril-hctz 25-15 mg, 25-25 mg, 50-15 mg, 50-25 mg tablet MO | 3 | |
| cartia xt 120 mg, 180 mg, 240 mg capsule, extended release MO | 2 | QL (60 per 30 days) |
| cartia xt 300 mg capsule, extended release MO | 2 | QL (30 per 30 days) |
| carvedilol 12.5 mg, 25 mg, 3.125 mg, 6.25 mg tablet MO | 1 | |
| carvedilol er 10 mg, 20 mg, 40 mg, 80 mg capsule MO | 4 | QL (30 per 30 days) |
| chlorothiazide 250 mg, 500 mg tablet MO | 2 | |
| chlorothiazide sod 500 mg vial MO | 2 | |
| chlorthalidone 25 mg, 50 mg tablet MO | 2 | |
| cholestyramine packet; cholestyramine powder MO | 3 | |
| cholestyramine light 4 gram oral powder; cholestyramine light 4 gram powder for susp in a packet MO | 3 | |
| clonidine 0.1 mg/day patch; clonidine 0.2 mg/day patch; clonidine 0.3 mg/day patch MO | 4 | QL (4 per 28 days) |
| clonidine hcl 0.1 mg, 0.2 mg, 0.3 mg tablet MO | 1 | |
| colestipol hcl granules MO | 4 | |
| colestipol hcl granules packet MO | 4 | |
| colestipol micronized 1 gm tab MO | 3 | |
| COREG CR 10 MG, 20 MG, 40 MG, 80 MG CAPSULE, EXTENDED RELEASE MO | 4 | PA, QL (30 per 30 days) |
| CORLANOR 5 MG, 7.5 MG TABLET MO | 4 | PA, QL (60 per 30 days) |
| CORLOPAM 10 MG/ML INTRAVENOUS SOLUTION MO | 4 | |
| DEMSEER 250 MG CAPSULE DL | 5 | |
| digitek 125 mcg (0.125 mg), 250 mcg (0.25 mg) tablet MO | 2 | QL (30 per 30 days) |
| digox 125 mcg (0.125 mg), 250 mcg (0.25 mg) tablet MO | 2 | QL (30 per 30 days) |
| digoxin 125 mcg tablet; digoxin 250 mcg tablet MO | 2 | QL (30 per 30 days) |
| dilt-xr 120 mg, 180 mg, 240 mg capsule, extended release MO | 2 | QL (60 per 30 days) |
| diltiazem 100 mg add-van vial MO | 4 | |
| diltiazem 120 mg, 30 mg, 60 mg, 90 mg tablet MO | 2 | |
| diltiazem 125 mg/25 ml vial MO | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| diltiazem 12hr er 120 mg, 60 mg, 90 mg cap ^{MO} | 2 | |
| diltiazem 24h er(cd) 120 mg, 180 mg, 240 mg cp; diltiazem 24hr er 120 mg, 180 mg, 240 mg cap ^{MO} | 2 | QL (60 per 30 days) |
| diltiazem 24h er(cd) 300 mg, 360 mg, 420 mg cp; diltiazem 24hr er 300 mg, 360 mg, 420 mg cap ^{MO} | 2 | QL (30 per 30 days) |
| diltiazem 24h er(xr) 120 mg, 180 mg, 240 mg cp ^{MO} | 2 | QL (60 per 30 days) |
| DIURIL 250 MG/5 ML ORAL SUSPENSION ^{MO} | 4 | |
| dobutamine 12.5 mg/ml vial; dobutamine 250 mg/20 ml vial ^{MO} | 2 | |
| dobutamine 1 gm-d5w 250 ml; dobutamine 250 mg-d5w 250 ml; dobutamine 500 mg-d5w 250 ml ^{MO} | 2 | |
| dofetilide 125 mcg capsule ^{MO} | 4 | QL (240 per 30 days) |
| dofetilide 250 mcg capsule ^{MO} | 4 | QL (120 per 30 days) |
| dofetilide 500 mcg capsule ^{MO} | 4 | QL (60 per 30 days) |
| dopamine 160 mg/ml vial; dopamine 200 mg/5 ml vial; dopamine 400 mg/10 ml vial; dopamine 80 mg/ml vial ^{MO} | 1 | |
| dopamine 200 mg-d5w 250 ml; dopamine 400 mg-d5w 500 ml; dopamine 400 mg/250 ml-d5w bag; dopamine 800 mg/250 ml-d5w bag; dopamine 800 mg/500 ml-d5w bag ^{MO} | 1 | |
| doxazosin mesylate 1 mg, 2 mg, 4 mg, 8 mg tab ^{MO} | 2 | |
| enalapril maleate 10 mg, 2.5 mg, 20 mg, 5 mg tab; enalapril maleate 10 mg, 2.5 mg, 20 mg, 5 mg tablet ^{MO} | 1 | |
| enalapril-hctz 10-25 mg, 5-12.5 mg tab; enalapril-hctz 10-25 mg, 5-12.5 mg tablet ^{MO} | 1 | |
| enalaprilat 1.25 mg/ml vial ^{MO} | 2 | |
| ENTRESTO 24 MG-26 MG TABLET; ENTRESTO 49 MG-51 MG TABLET; ENTRESTO 97 MG-103 MG TABLET ^{MO} | 3 | PA,QL (60 per 30 days) |
| eplerenone 25 mg, 50 mg tablet ^{MO} | 4 | |
| esmolol hcl 100 mg/10 ml vial ^{MO} | 1 | |
| ethacrynate sodium 50 mg vial ^{MO} | 4 | |
| ezetimibe 10 mg tablet ^{MO} | 3 | QL (30 per 30 days) |
| ezetimibe-simvastatin 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg ^{MO} | 4 | ST,QL (30 per 30 days) |
| felodipine er 10 mg, 2.5 mg, 5 mg tablet ^{MO} | 3 | QL (30 per 30 days) |
| fenofibrate 160 mg tablet ^{MO} | 2 | QL (30 per 30 days) |
| fenofibrate 54 mg tablet ^{MO} | 2 | QL (60 per 30 days) |
| fenofibrate 130 mg, 43 mg capsule ^{MO} | 4 | ST,QL (30 per 30 days) |
| fenofibrate 134 mg, 200 mg capsule ^{MO} | 3 | QL (30 per 30 days) |
| fenofibrate 67 mg capsule ^{MO} | 3 | QL (60 per 30 days) |
| fenofibrate 145 mg tablet ^{MO} | 3 | QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| fenofibrate 48 mg tablet MO | 3 | QL (60 per 30 days) |
| fenofibric acid 105 mg, 35 mg tablet MO | 3 | QL (30 per 30 days) |
| flecainide acetate 100 mg, 150 mg, 50 mg tab MO | 3 | |
| fosinopril sodium 10 mg, 20 mg, 40 mg tab MO | 1 | |
| fosinopril-hctz 10-12.5 mg, 20-12.5 mg tab MO | 2 | |
| furosemide 10 mg/ml, 40 mg/5 ml (8 mg/ml) solution; furosemide 40 mg/5 ml soln MO | 1 | |
| furosemide 20 mg, 40 mg, 80 mg tablet MO | 1 | |
| furosemide 40 mg/4 ml syringe MO | 2 | |
| furosemide 40 mg/4 ml vial MO | 2 | |
| gemfibrozil 600 mg tablet MO | 2 | QL (60 per 30 days) |
| guanfacine 1 mg, 2 mg tablet MO | 4 | |
| hydralazine 10 mg, 100 mg, 25 mg, 50 mg tablet MO | 2 | |
| hydralazine 20 mg/ml vial MO | 4 | |
| hydrochlorothiazide 12.5 mg cp MO | 1 | |
| hydrochlorothiazide 12.5 mg, 25 mg, 50 mg tab; hydrochlorothiazide 12.5 mg, 25 mg, 50 mg tb MO | 1 | |
| ibutilide fum 1 mg/10 ml vial MO | 1 | |
| indapamide 1.25 mg, 2.5 mg tablet MO | 1 | |
| irbesartan 150 mg, 300 mg, 75 mg tablet MO | 1 | QL (30 per 30 days) |
| irbesartan-hctz 150-12.5 mg tb MO | 1 | QL (60 per 30 days) |
| irbesartan-hctz 300-12.5 mg tb MO | 1 | QL (30 per 30 days) |
| ISORDIL 40 MG TABLET MO | 4 | |
| ISORDIL TITRADOSE 5 MG TABLET MO | 4 | PA |
| isosorbide dinitr er 40 mg tab MO | 4 | |
| isosorbide dinitrate 10 mg, 20 mg, 30 mg, 5 mg tab MO | 3 | |
| isosorbide mononit 10 mg, 20 mg tab MO | 1 | |
| isosorbide mononit er 120 mg MO | 2 | |
| isosorbide mononit er 30 mg, 60 mg tb MO | 1 | |
| isradipine 2.5 mg, 5 mg capsule MO | 4 | |
| ISUPREL 0.2 MG/ML INJECTION SOLUTION MO | 4 | |
| labetalol hcl 100 mg, 200 mg, 300 mg tablet MO | 2 | |
| labetalol hcl 100 mg/20 ml vl MO | 4 | |
| lidocaine hcl 2% vial MO | 2 | |
| lidocaine 0.4% in d5w 250 ml; lidocaine 0.8% in d5w soln MO | 1 | |
| LIPOFEN 150 MG CAPSULE MO | 4 | QL (30 per 30 days) |
| LIPOFEN 50 MG CAPSULE MO | 4 | QL (60 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| lisinopril 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg tablet ^{MO} | 1 | |
| lisinopril-hctz 10-12.5 mg, 20-12.5 mg, 20-25 mg tab ^{MO} | 1 | |
| losartan potassium 100 mg, 25 mg, 50 mg tab ^{MO} | 1 | QL (60 per 30 days) |
| losartan-hctz 100-12.5 mg, 100-25 mg, 50-12.5 mg tab ^{MO} | 1 | QL (60 per 30 days) |
| lovastatin 10 mg, 20 mg, 40 mg tablet ^{MO} | 1 | QL (60 per 30 days) |
| mannitol 10% iv solution ^{MO} | 2 | |
| mannitol 20% iv solution ^{MO} | 2 | |
| mannitol 25% vial ^{MO} | 2 | |
| mannitol 5% iv solution ^{MO} | 2 | |
| methazolamide 25 mg, 50 mg tablet ^{MO} | 4 | |
| methyldopa 250 mg, 500 mg tablet ^{MO} | 3 | |
| methyldopa-hctz 250-15 mg, 250-25 mg tab ^{MO} | 4 | |
| methyldopate 250 mg/5 ml vial ^{MO} | 4 | |
| metolazone 10 mg, 2.5 mg, 5 mg tablet ^{MO} | 2 | |
| metoprolol succ er 100 mg, 200 mg, 25 mg, 50 mg tab ^{MO} | 1 | QL (60 per 30 days) |
| metoprolol-hctz 100-25 mg, 100-50 mg, 50-25 mg tab ^{MO} | 3 | |
| metoprolol 5 mg/5 ml carpject ^{MO} | 1 | |
| metoprolol tart 5 mg/5 ml vial ^{MO} | 3 | |
| metoprolol tartrate 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg tab; metoprolol tartrate 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg tb ^{MO} | 1 | |
| midodrine hcl 10 mg, 2.5 mg, 5 mg tablet ^{MO} | 3 | |
| minoxidil 10 mg, 2.5 mg tablet ^{MO} | 2 | |
| moexipril hcl 15 mg, 7.5 mg tablet ^{MO} | 2 | |
| moexipril-hctz 15-12.5 mg, 15-25 mg, 7.5-12.5 mg tab; moexipril-hctz 15-12.5 mg, 15-25 mg, 7.5-12.5 mg tablet ^{MO} | 2 | |
| MULTAQ 400 MG TABLET ^{MO} | 3 | QL (60 per 30 days) |
| nadolol 20 mg, 40 mg, 80 mg tablet ^{MO} | 3 | |
| nadolol-bendroflu 40-5 mg, 80-5 mg tab ^{MO} | 4 | |
| NEXTERONE 150 MG/100 ML (1.5 MG/ML), 360 MG/200 ML (1.8 MG/ML) INTRAVENOUS SOLUTION ^{MO} | 4 | |
| niacin er 1,000 mg, 500 mg, 750 mg tablet ^{MO} | 4 | |
| niacor 500 mg tablet ^{MO} | 2 | |
| nifedipine er 30 mg, 60 mg, 90 mg tablet ^{MO} | 3 | QL (60 per 30 days) |
| nimodipine 30 mg capsule ^{MO} | 4 | |
| nisoldipine er 17 mg, 20 mg, 34 mg, 40 mg, 8.5 mg tablet ^{MO} | 4 | QL (30 per 30 days) |
| nisoldipine er 25.5 mg, 30 mg tablet ^{MO} | 4 | QL (60 per 30 days) |
| nitroglycerin 0.1 mg/hr, 0.2 mg/hr, 0.6 mg/hr patch ^{MO} | 2 | QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| nitroglycerin 0.3 mg, 0.4 mg, 0.6 mg tablet sl MO | 3 | |
| nitroglycerin 0.4 mg/hr patch MO | 2 | QL (60 per 30 days) |
| nitroglycerin 5 mg/ml vial MO | 2 | |
| nitroglycerin lingual 0.4 mg MO | 4 | |
| ntg 0.2 mg/ml in d5w; ntg 100 mg/250 ml in d5w; ntg 200 mg/500 ml in d5w; ntg 25 mg/250 ml in d5w; ntg 50 mg/500 ml in d5w MO | 2 | |
| NITROSTAT 0.3 MG, 0.4 MG, 0.6 MG SUBLINGUAL TABLET MO | 3 | |
| norepinephrine 4 mg/4 ml vial MO | 1 | |
| NORTHERA 100 MG, 200 MG CAPSULE DL | 5 | PA,QL (90 per 30 days) |
| NORTHERA 300 MG CAPSULE DL | 5 | PA,QL (180 per 30 days) |
| olmesartan medoxomil 20 mg, 40 mg, 5 mg tab MO | 2 | QL (30 per 30 days) |
| olmsrtn-amldpn-hctz 20-5-12.5; olmsrtn-amldpn-hctz 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg; olmsrtn-amldpn-hctz 40-10-12.5; olmsrtn-amldpn-hctz 40-10-25mg; olmsrtn-amldpn-hctz 40-5-12.5 MO | 4 | QL (30 per 30 days) |
| olmesartan-hctz 20-12.5 mg, 40-12.5 mg, 40-25 mg tab MO | 3 | QL (30 per 30 days) |
| omega-3 ethyl esters 1 gm cap MO | 4 | QL (120 per 30 days) |
| OSMITROL 10 % INTRAVENOUS SOLUTION MO | 4 | |
| OSMITROL 15 % INTRAVENOUS SOLUTION MO | 4 | |
| OSMITROL 20 % INTRAVENOUS SOLUTION MO | 4 | |
| OSMITROL 5 % INTRAVENOUS SOLUTION MO | 4 | |
| PACERONE 100 MG, 400 MG TABLET MO | 4 | |
| pacerone 200 mg tablet MO | 2 | |
| pentoxifylline er 400 mg tab MO | 2 | |
| perindopril erbumine 2 mg, 4 mg, 8 mg tab MO | 2 | |
| pindolol 10 mg, 5 mg tablet MO | 3 | |
| PRALUENT PEN 150 MG/ML, 75 MG/ML SUBCUTANEOUS PEN INJECTOR DL | 5 | PA,QL (2 per 28 days) |
| pravastatin sodium 10 mg, 20 mg, 80 mg tab MO | 1 | QL (30 per 30 days) |
| pravastatin sodium 40 mg tab MO | 1 | QL (60 per 30 days) |
| prazosin 1 mg, 2 mg, 5 mg capsule MO | 2 | |
| prevalite 4 gram oral powder; prevalite 4 gram powder for susp in a packet MO | 3 | |
| procainamide 1,000 mg/10 ml vl; procainamide 100 mg/ml, 500 mg/ml vial MO | 1 | |
| propafenone hcl 150 mg, 225 mg, 300 mg tab; propafenone hcl 150 mg, 225 mg, 300 mg tablet MO | 3 | |
| propafenone hcl er 225 mg, 325 mg, 425 mg cap MO | 4 | |
| propranolol 1 mg/ml vial MO | 2 | |
| propranolol 10 mg, 20 mg, 40 mg, 60 mg, 80 mg tablet MO | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| propranolol 20 mg/5 ml soln; propranolol 40 mg/5 ml soln ^{MO} | 3 | |
| propranolol er 120 mg, 160 mg, 60 mg, 80 mg capsule ^{MO} | 4 | |
| propranolol-hctz 40-25 mg, 80-25 mg tab ^{MO} | 3 | |
| quinapril 10 mg, 20 mg, 40 mg, 5 mg tablet ^{MO} | 1 | |
| quinapril-hctz 10-12.5 mg, 20-12.5 mg, 20-25 mg tab ^{MO} | 2 | |
| quinidine gluc 80 mg/ml vial ^{MO} | 2 | |
| quinidine sulfate 200 mg, 300 mg tab ^{MO} | 2 | |
| ramipril 1.25 mg, 10 mg, 2.5 mg, 5 mg capsule ^{MO} | 1 | |
| RANEXA 1,000 MG, 500 MG TABLET,EXTENDED RELEASE ^{MO} | 3 | ST,QL (120 per 30 days) |
| ranolazine er 1,000 mg, 500 mg tablet ^{MO} | 3 | QL (120 per 30 days) |
| REPATHA PUSHTRONEX 420 MG/3.5 ML SUBCUTANEOUS WEARABLE INJECTOR ^{DL} | 5 | PA,QL (3.5 per 28 days) |
| REPATHA SURECLICK 140 MG/ML SUBCUTANEOUS PEN INJECTOR ^{DL} | 5 | PA,QL (3 per 28 days) |
| REPATHA SYRINGE 140 MG/ML SUBCUTANEOUS SYRINGE ^{DL} | 5 | PA,QL (3 per 28 days) |
| RESECTISOL 5 % TRANSURETHRAL SOLUTION ^{MO} | 4 | |
| rosuvastatin calcium 10 mg, 20 mg, 40 mg, 5 mg tab ^{MO} | 1 | QL (30 per 30 days) |
| simvastatin 10 mg, 20 mg, 40 mg, 5 mg, 80 mg tablet ^{MO} | 1 | QL (30 per 30 days) |
| sorine 120 mg, 160 mg, 240 mg, 80 mg tablet ^{MO} | 2 | |
| sotalol 120 mg, 160 mg, 240 mg, 80 mg tablet ^{MO} | 2 | |
| sotalol af 120 mg, 160 mg, 80 mg tablet ^{MO} | 2 | |
| spironolactone-hctz 25-25 tab ^{MO} | 2 | |
| spironolactone 100 mg, 25 mg, 50 mg tablet ^{MO} | 1 | |
| taztia xt 120 mg, 180 mg, 240 mg capsule,extended release ^{MO} | 2 | QL (60 per 30 days) |
| taztia xt 300 mg, 360 mg capsule,extended release ^{MO} | 2 | QL (30 per 30 days) |
| TEKTURNA 150 MG, 300 MG TABLET ^{MO} | 3 | QL (30 per 30 days) |
| TEKTURNA HCT 150 MG-12.5 MG TABLET; TEKTURNA HCT 150 MG-25 MG TABLET; TEKTURNA HCT 300 MG-12.5 MG TABLET; TEKTURNA HCT 300 MG-25 MG TABLET ^{MO} | 3 | QL (30 per 30 days) |
| telmisartan 20 mg, 40 mg tablet ^{MO} | 2 | QL (30 per 30 days) |
| telmisartan 80 mg tablet ^{MO} | 2 | QL (60 per 30 days) |
| telmisartan-amlodipine 40-10; telmisartan-amlodipine 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg; telmisartan-amlodipine 80-10 ^{MO} | 4 | QL (30 per 30 days) |
| telmisartan-hctz 40-12.5 mg, 80-25 mg tab; telmisartan-hctz 40-12.5 mg, 80-25 mg tb ^{MO} | 4 | ST,QL (30 per 30 days) |
| telmisartan-hctz 80-12.5 mg tb ^{MO} | 4 | ST,QL (60 per 30 days) |
| terazosin 1 mg, 10 mg, 2 mg, 5 mg capsule ^{MO} | 1 | |
| tiadylt er 360 mg capsule,extended release ^{MO} | 2 | QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| timolol maleate 10 mg, 20 mg, 5 mg tablet MO | 4 | |
| toremide 10 mg, 100 mg, 20 mg, 5 mg tablet MO | 2 | |
| trandolapril 1 mg, 2 mg, 4 mg tablet MO | 1 | |
| trandolapr-verapam er 1-240 mg, 2-180 mg, 2-240 mg, 4-240 mg MO | 3 | |
| triamterene-hctz 37.5-25 mg cp MO | 1 | |
| triamterene-hctz 37.5-25 mg, 75-50 mg tab; triamterene-hctz 37.5-25 mg, 75-50 mg tb MO | 1 | |
| triamterene-hctz 50-25 mg cap MO | 2 | |
| triklo 1 gram capsule MO | 4 | QL (120 per 30 days) |
| valsartan 160 mg, 320 mg, 40 mg, 80 mg tablet MO | 1 | QL (60 per 30 days) |
| valsartan-hctz 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg tab MO | 1 | QL (30 per 30 days) |
| VASCEPA 0.5 GRAM CAPSULE MO | 4 | QL (240 per 30 days) |
| VASCEPA 1 GRAM CAPSULE MO | 4 | QL (120 per 30 days) |
| verapamil 10 mg/4 ml syringe MO | 2 | |
| verapamil 120 mg, 180 mg, 240 mg, 360 mg cap pellet; verapamil er 120 mg, 180 mg, 240 mg, 360 mg capsule; verapamil sr 120 mg, 180 mg, 240 mg, 360 mg capsule MO | 3 | QL (60 per 30 days) |
| verapamil 120 mg, 40 mg, 80 mg tablet MO | 1 | |
| verapamil 5 mg/2 ml vial MO | 2 | |
| verapamil er 120 mg, 180 mg, 240 mg tablet MO | 2 | |
| verapamil er pm 100 mg, 300 mg capsule MO | 2 | QL (30 per 30 days) |
| verapamil er pm 200 mg capsule MO | 2 | QL (60 per 30 days) |
| VYNDAMAX 61 MG CAPSULE DL | 5 | PA,QL (30 per 30 days) |
| VYNDAQEL 20 MG CAPSULE DL | 5 | PA,QL (120 per 30 days) |
| VYTORIN 10 MG-10 MG TABLET MO | 4 | ST,QL (30 per 30 days) |
| VYTORIN 10 MG-20 MG TABLET MO | 4 | ST,QL (30 per 30 days) |
| VYTORIN 10 MG-40 MG TABLET MO | 4 | ST,QL (30 per 30 days) |
| VYTORIN 10 MG-80 MG TABLET MO | 4 | ST,QL (30 per 30 days) |
| WELCHOL 3.75 GRAM ORAL POWDER PACKET MO | 3 | |
| WELCHOL 625 MG TABLET MO | 3 | |
| Central Nervous System Agents | | |
| AMPYRA 10 MG TABLET,EXTENDED RELEASE DL | 5 | PA,QL (60 per 30 days) |
| atomoxetine hcl 10 mg, 18 mg, 25 mg, 40 mg capsule MO | 3 | QL (60 per 30 days) |
| atomoxetine hcl 100 mg, 60 mg, 80 mg capsule MO | 3 | QL (30 per 30 days) |
| AUSTEDO 12 MG, 9 MG TABLET DL | 5 | PA,QL (120 per 30 days) |
| AUSTEDO 6 MG TABLET DL | 5 | PA,QL (60 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| BETASERON 0.3 MG SUBCUTANEOUS KIT DL | 5 | PA,QL (15 per 30 days) |
| COPAXONE 20 MG/ML SUBCUTANEOUS SYRINGE DL | 5 | PA,QL (30 per 30 days) |
| COPAXONE 40 MG/ML SUBCUTANEOUS SYRINGE DL | 5 | PA,QL (12 per 28 days) |
| dalfampridine er 10 mg tablet MO | 4 | PA,QL (60 per 30 days) |
| dexmethylphenidate 10 mg, 2.5 mg, 5 mg tab MO | 3 | QL (60 per 30 days) |
| dextroamphetamine 10 mg tab MO | 4 | QL (180 per 30 days) |
| dextroamphetamine 5 mg tab MO | 4 | QL (150 per 30 days) |
| dextroamp-amphetam 10 mg, 12.5 mg, 15 mg, 20 mg, 5 mg, 7.5 mg tab; dextroamp-amphetamin 10 mg, 12.5 mg, 15 mg, 20 mg, 5 mg, 7.5 mg tab; dextroamp-amphetamine 10 mg, 12.5 mg, 15 mg, 20 mg, 5 mg, 7.5 mg tab MO | 3 | QL (90 per 30 days) |
| dextroamp-amphetamin 30 mg tab MO | 3 | QL (60 per 30 days) |
| FIRDAPSE 10 MG TABLET DL | 5 | PA,QL (240 per 30 days) |
| GILENYA 0.25 MG, 0.5 MG CAPSULE DL | 5 | PA,QL (30 per 30 days) |
| glatiramer 20 mg/ml syringe DL | 5 | PA,QL (30 per 30 days) |
| glatiramer 40 mg/ml syringe DL | 5 | PA,QL (12 per 28 days) |
| glatopa 20 mg/ml subcutaneous syringe DL | 5 | PA,QL (30 per 30 days) |
| glatopa 40 mg/ml subcutaneous syringe DL | 5 | PA,QL (12 per 28 days) |
| LYRICA 100 MG, 150 MG, 200 MG, 25 MG, 50 MG, 75 MG CAPSULE MO | 3 | QL (90 per 30 days) |
| LYRICA 20 MG/ML ORAL SOLUTION MO | 3 | QL (900 per 30 days) |
| LYRICA 225 MG, 300 MG CAPSULE MO | 3 | QL (60 per 30 days) |
| methylphenidate 10 mg, 20 mg, 5 mg tablet MO | 3 | QL (90 per 30 days) |
| methylphenidate 10 mg/5 ml sol MO | 4 | QL (900 per 30 days) |
| methylphenidate 5 mg/5 ml soln MO | 4 | QL (1800 per 30 days) |
| methylphenidate er 10 mg tab MO | 4 | QL (180 per 30 days) |
| methylphenidate er 20 mg tab MO | 4 | QL (90 per 30 days) |
| NUEDEXTA 20 MG-10 MG CAPSULE MO | 4 | PA,QL (60 per 30 days) |
| pregabalin 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg capsule MO | 3 | QL (90 per 30 days) |
| pregabalin 20 mg/ml solution MO | 3 | QL (900 per 30 days) |
| pregabalin 225 mg, 300 mg capsule MO | 3 | QL (60 per 30 days) |
| riluzole 50 mg tablet MO | 4 | |
| RUZURGI 10 MG TABLET DL | 5 | PA,QL (300 per 30 days) |
| SAVELLA 100 MG, 12.5 MG, 12.5 MG (5)-25 MG(8)-50 MG(42), 25 MG, 50 MG TABLET; SAVELLA 12.5 MG (5)-25 MG(8)-50MG(42) TABLETS IN A DOSE PACK MO | 3 | QL (60 per 30 days) |
| STRATTERA 10 MG, 18 MG, 25 MG, 40 MG CAPSULE MO | 4 | PA,QL (60 per 30 days) |
| STRATTERA 100 MG, 60 MG, 80 MG CAPSULE MO | 4 | PA,QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| TECFIDERA 120 MG (14)- 240 MG (46), 240 MG CAPSULE,DELAYED RELEASE; TECFIDERA 120 MG (14)-240 MG (46) CAPSULE,DELAYED RELEASE DL | 5 | PA,QL (60 per 30 days) |
| TECFIDERA 120 MG CAPSULE,DELAYED RELEASE DL | 5 | PA,QL (14 per 30 days) |
| tetrabenazine 12.5 mg tablet DL | 5 | PA,QL (240 per 30 days) |
| tetrabenazine 25 mg tablet DL | 5 | PA,QL (120 per 30 days) |
| VYVANSE 10 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG, 70 MG CAPSULE MO | 4 | PA,QL (30 per 30 days) |
| Dental & Oral Agents | | |
| cevimeline hcl 30 mg capsule MO | 4 | |
| chlorhexidine 0.12% rinse MO | 1 | |
| KEPIVANCE 6.25 MG INTRAVENOUS SOLUTION DL | 5 | |
| oralone 0.1 % dental paste MO | 3 | |
| paroex oral rinse 0.12 % mouthwash MO | 1 | |
| periogard 0.12 % mouthwash MO | 1 | |
| pilocarpine hcl 5 mg, 7.5 mg tablet MO | 4 | |
| triamcinolone 0.1% paste MO | 3 | |
| Dermatological Agents | | |
| acitretin 10 mg, 17.5 mg, 25 mg capsule DL | 5 | |
| adapalene 0.1% gel MO | 4 | |
| ammonium lactate 12% cream MO | 2 | |
| ammonium lactate 12% lotion MO | 2 | |
| amnesteem 10 mg, 20 mg capsule MO | 4 | QL (60 per 30 days) |
| amnesteem 40 mg capsule MO | 4 | QL (120 per 30 days) |
| azelaic acid 15% gel MO | 4 | ST |
| calcipotriene 0.005% cream MO | 4 | QL (120 per 30 days) |
| calcipotriene 0.005% solution MO | 4 | QL (60 per 30 days) |
| CARAC 0.5 % TOPICAL CREAM DL | 5 | PA |
| CORTISPORIN 3.5 MG/G-10,000 UNIT/G-0.5 % TOPICAL CREAM MO | 4 | |
| COSENTYX 150 MG/ML SUBCUTANEOUS SYRINGE DL | 5 | PA,QL (32 per 365 days) |
| COSENTYX 300 MG/2 SYRINGES (150 MG/ML) SUBCUTANEOUS DL | 5 | PA,QL (32 per 365 days) |
| COSENTYX PEN 150 MG/ML SUBCUTANEOUS DL | 5 | PA,QL (32 per 365 days) |
| COSENTYX PEN 300 MG/2 PENS (150 MG/ML) SUBCUTANEOUS DL | 5 | PA,QL (32 per 365 days) |
| diclofenac sodium 3% gel MO | 4 | PA |
| ELIDEL 1 % TOPICAL CREAM MO | 4 | |
| ENSTILAR 0.005 %-0.064 % TOPICAL FOAM DL | 4 | QL (120 per 30 days) |
| FINACEA 15 % TOPICAL GEL MO | 4 | ST |
| fluorouracil 0.5% cream DL | 5 | |
| fluorouracil 2% topical soln; fluorouracil 5% topical soln MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| fluorouracil 5% cream MO | 4 | |
| imiquimod 3.75% cream pump MO | 4 | QL (15 per 30 days) |
| imiquimod 5% cream packet MO | 3 | QL (12 per 30 days) |
| isotretinoin 10 mg, 20 mg, 30 mg capsule MO | 4 | QL (60 per 30 days) |
| isotretinoin 40 mg capsule MO | 4 | QL (120 per 30 days) |
| methoxsalen 10 mg capsule DL | 5 | |
| myorisan 10 mg, 20 mg, 30 mg capsule MO | 4 | QL (60 per 30 days) |
| myorisan 40 mg capsule MO | 4 | QL (120 per 30 days) |
| PICATO 0.015 % TOPICAL GEL MO | 4 | QL (3 per 30 days) |
| PICATO 0.05 % TOPICAL GEL MO | 4 | QL (2 per 30 days) |
| pimecrolimus 1% cream MO | 4 | |
| podofilox 0.5% topical soln MO | 4 | |
| RECTIV 0.4 % (W/W) OINTMENT MO | 4 | QL (30 per 30 days) |
| REGRANEX 0.01 % TOPICAL GEL DL | 5 | |
| SANTYL 250 UNIT/GRAM TOPICAL OINTMENT MO | 4 | |
| selenium sulfide 2.5% lotion MO | 2 | |
| SKYRIZI 150 MG/1.66 ML(75 MG/0.83 ML X 2) SUBCUTANEOUS SYRINGE KIT DL | 5 | PA,QL (6 per 365 days) |
| SKYRIZI 75 MG/0.83 ML SUBCUTANEOUS SYRINGE DL | 5 | PA,QL (9.96 per 365 days) |
| TACLONEX 0.005 %-0.064 % TOPICAL SUSPENSION MO | 3 | QL (420 per 30 days) |
| tacrolimus 0.03% ointment; tacrolimus 0.1% ointment MO | 4 | |
| tazarotene 0.1% cream MO | 4 | PA |
| TAZORAC 0.05 % TOPICAL CREAM MO | 4 | PA |
| TAZORAC 0.05 %, 0.1 % TOPICAL GEL MO | 4 | PA |
| TOLAK 4 % TOPICAL CREAM MO | 3 | |
| tretinoin 0.01% gel; tretinoin 0.05% gel MO | 4 | PA |
| tretinoin 0.025% cream; tretinoin 0.05% cream; tretinoin 0.1% cream MO | 4 | PA |
| tretinoin 0.025% gel MO | 3 | PA |
| UVADEX 20 MCG/ML INJECTION SOLUTION MO | 4 | B vs D |
| zenatane 10 mg, 20 mg, 30 mg capsule MO | 4 | QL (60 per 30 days) |
| zenatane 40 mg capsule MO | 4 | QL (120 per 30 days) |
| ZYCLARA 2.5 %, 3.75 % TOPICAL CREAM IN A PUMP MO | 4 | QL (15 per 30 days) |
| ZYCLARA 3.75 % TOPICAL CREAM PACKET MO | 4 | |
| Electrolytes/Minerals/Metals/Vitamins | | |
| AMINOSYN 10 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN 7 % WITH ELECTROLYTES INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN 8.5 % INTRAVENOUS SOLUTION MO | 4 | B vs D |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| AMINOSYN 8.5 % WITH ELECTROLYTES INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN II 10 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN II 15 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN II 7 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN II 8.5 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN II 8.5 % WITH ELECTROLYTES INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN M 3.5 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN-HBC 7% INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN-PF 10 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN-PF 7 % (SULFITE-FREE) INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN-RF 5.2 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AURYXIA 210 MG IRON TABLET MO | 4 | PA,QL (360 per 30 days) |
| <i>bal-care dha 27 mg-1 mg-430 mg tablet-capsule, delayed release</i> MO | 4 | |
| <i>c-nate dha 28 mg iron-1 mg-200 mg capsule</i> MO | 4 | |
| <i>calcium acetate 667 mg gelcap</i> MO | 3 | |
| <i>calcium acetate 667 mg tablet</i> MO | 3 | |
| <i>calcium chloride 10% syringe</i> MO | 1 | |
| <i>calcium chloride 10% vial</i> MO | 1 | |
| <i>calcium gluc 1,000mg/50ml-nacl</i> MO | 1 | |
| <i>calcium gluconate 10% vial</i> MO | 1 | |
| CARBAGLU 200 MG DISPERSIBLE TABLET DL | 5 | PA |
| CHEMET 100 MG CAPSULE DL | 5 | |
| CLINIMIX 5 % IN 15 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION MO | 4 | B vs D |
| CLINIMIX 5 % IN 25 % DEXTROSE SULFITE-FREE INTRAVENOUS SOLUTION MO | 4 | B vs D |
| CLINIMIX 2.75%-5% SOLUTION MO | 4 | B vs D |
| CLINIMIX 4.25%-20% SOLUTION MO | 4 | B vs D |
| CLINIMIX 4.25 % IN 25 % DEXTROSE (SULFITE-FREE) INTRAVENOUS SOLUTION MO | 4 | B vs D |
| CLINIMIX 4.25 % IN 10 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION MO | 4 | B vs D |
| CLINIMIX 4.25 % IN 5 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION MO | 4 | B vs D |
| CLINIMIX 5 % IN 20 % DEXTROSE (SULFITE-FREE) INTRAVENOUS SOLUTION MO | 4 | B vs D |
| CLINIMIX E 2.75%-10% SOLUTION MO | 4 | B vs D |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| CLINIMIX E 2.75 % IN 5 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION MO | 4 | B vs D |
| CLINIMIX E 4.25 % IN 10 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION MO | 4 | B vs D |
| CLINIMIX E 4.25%-25% SOLUTION MO | 4 | B vs D |
| CLINIMIX E 4.25 % IN 5 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION MO | 4 | B vs D |
| CLINIMIX E 5 % IN 15 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION MO | 4 | B vs D |
| CLINIMIX E 5 % IN 20 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION MO | 4 | B vs D |
| CLINIMIX E 5 % IN 25 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION MO | 4 | B vs D |
| CLINISOL SF 15 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| CLINOLIPID 20 % INTRAVENOUS EMULSION MO | 4 | B vs D |
| clovique 250 mg capsule DL | 5 | |
| complete natal dha 29 mg-1 mg-250 mg oral pack MO | 4 | |
| completenate 29 mg iron-1 mg chewable tablet MO | 4 | |
| CONCEPT DHA 35 MG-1 MG-200 MG CAPSULE MO | 4 | |
| CONCEPT OB 85 MG-1 MG CAPSULE MO | 4 | |
| CUPRIMINE 250 MG CAPSULE DL | 5 | |
| dextrose 10%-0.45% nacl iv sol MO | 2 | |
| dextrose 2.5%-0.45% nacl iv MO | 2 | |
| dextrose 5%-0.9% nacl iv soln MO | 2 | |
| dextrose 5%-0.45% nacl iv soln MO | 2 | |
| deferoxamine 2 gram, 500 mg vial MO | 4 | |
| DEPEN TITRATABS 250 MG TABLET DL | 5 | |
| dextrose 10%-0.2% nacl iv soln MO | 2 | |
| dextrose 10%-water iv solution MO | 2 | |
| dextrose 20%-water iv soln MO | 2 | |
| dextrose 25%-water syringe MO | 2 | |
| dextrose 30%-water iv soln MO | 2 | |
| dextrose 40%-water iv soln MO | 2 | |
| dextrose 5%-water iv soln MO | 2 | |
| dextrose 5%-lr iv solution MO | 2 | |
| dextrose 5%-0.2% nacl iv soln MO | 2 | |
| dextrose 5%-0.3% nacl iv soln MO | 2 | |
| dextrose 50%-water syringe MO | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| <i>dextrose 50%-water vial</i> MO | 2 | |
| <i>dextrose 70%-water iv soln</i> MO | 2 | |
| <i>dextrose 5%-electrolyte 48</i> MO | 2 | |
| EXJADE 125 MG, 250 MG, 500 MG DISPERSIBLE TABLET DL | 5 | PA |
| <i>folivane-ob 85 mg-1 mg capsule</i> MO | 4 | |
| FREAMINE HBC 6.9 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| FREAMINE III 10 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| GLYCOPHOS 1 MMOL/ML INTRAVENOUS SOLUTION MO | 1 | |
| HEPATAMINE 8% INTRAVENOUS SOLUTION MO | 4 | B vs D |
| INTRALIPID 20 %, 30 % INTRAVENOUS EMULSION MO | 4 | B vs D |
| IONOSOL-B IN D5W INTRAVENOUS SOLUTION MO | 4 | |
| IONOSOL-MB IN D5W INTRAVENOUS SOLUTION MO | 4 | |
| ISOLYTE S PH 7.4 INTRAVENOUS SOLUTION MO | 4 | |
| ISOLYTE-P IN 5 % DEXTROSE INTRAVENOUS SOLUTION MO | 4 | |
| ISOLYTE-S INTRAVENOUS SOLUTION MO | 4 | |
| JADENU 180 MG, 360 MG, 90 MG TABLET DL | 5 | PA |
| K-TAB 10 MEQ, 20 MEQ, 8 MEQ TABLET,EXTENDED RELEASE MO | 4 | |
| KABIVEN 3.31 %-9.8 %-3.9 % INTRAVENOUS EMULSION MO | 4 | B vs D |
| <i>kionex powder</i> MO | 3 | |
| KIONEX 15 GM/60 ML SUSPENSION MO | 3 | |
| KLOR-CON 10 MEQ TABLET,EXTENDED RELEASE MO | 2 | |
| KLOR-CON 8 MEQ TABLET,EXTENDED RELEASE MO | 2 | |
| <i>klor-con m10 meq tablet,extended release</i> MO | 2 | |
| KLOR-CON M15 MEQ TABLET,EXTENDED RELEASE MO | 2 | |
| <i>klor-con m20 meq tablet,extended release</i> MO | 2 | |
| <i>klor-con sprinkle 10 meq, 8 meq capsule,extended release; klor-con sprinkle er 10 meq, 8 meq cp</i> MO | 2 | |
| <i>lactated ringers injection</i> MO | 2 | |
| <i>levocarnitine 330 mg tablet</i> MO | 3 | |
| <i>levocarnitine 1 g/10 ml soln</i> MO | 4 | |
| <i>m-natal plus 27 mg iron-1 mg tablet</i> MO | 4 | |
| <i>magnesium sulfat 50% syringe</i> MO | 2 | |
| <i>magnesium sulfat 50% vial</i> MO | 2 | |
| <i>magnesium sulf 1 g/100 ml-d5w</i> MO | 2 | |
| <i>magnesium sulf 2 g/50 ml bag; magnesium sulf 4 g/100 ml bag; magnesium sulf 4 g/50 ml bag</i> MO | 2 | |
| <i>magnesium sulf 20 g/500 ml bag; magnesium sulf 40 g/1,000 ml</i> MO | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| NEPHRAMINE 5.4 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| NORMOSOL-M IN 5 % DEXTROSE INTRAVENOUS SOLUTION MO | 4 | |
| NORMOSOL-R INTRAVENOUS SOLUTION MO | 4 | |
| NORMOSOL-R IN 5 % DEXTROSE INTRAVENOUS SOLUTION MO | 4 | |
| NORMOSOL-R PH 7.4 INTRAVENOUS SOLUTION MO | 4 | |
| NUTRILIPID 20 % INTRAVENOUS EMULSION MO | 4 | B vs D |
| O-CAL PRENATAL 15 MG IRON-1,000 MCG TABLET MO | 4 | |
| <i>penicillamine 250 mg capsule</i> DL | 5 | |
| PERIKABIVEN 2.36 %-6.8 %-3.5 % INTRAVENOUS EMULSION MO | 4 | B vs D |
| PHYSIOLYTE 140 MEQ-5 MEQ-3 MEQ-98 MEQ/L IRRIGATION SOLUTION MO | 1 | |
| PHYSIOSOL IRRIGATION 140 MEQ-5 MEQ-3 MEQ-98 MEQ/L SOLUTION MO | 1 | |
| PLASMA-LYTE 148 INTRAVENOUS SOLUTION MO | 4 | |
| PLASMA-LYTE A INTRAVENOUS SOLUTION MO | 4 | |
| <i>plenamine 15 % intravenous solution</i> MO | 4 | B vs D |
| <i>pnv ob+dha combo pack</i> MO | 4 | |
| <i>potassium acet 40 meq/20 ml vl</i> MO | 1 | |
| <i>d5%-1/2ns-kcl 10 meq/l, 20 meq/l, 30 meq/l, 40 meq/l iv sol; kcl 20 meq in d5w-0.45% nacl</i> MO | 2 | |
| <i>potassium cl 10% (20 meq/15ml); potassium cl 20% (40 meq/15ml)</i> MO | 4 | |
| <i>potassium cl 40 meq/20 ml conc</i> MO | 2 | |
| <i>potassium cl er 10 meq, 20 meq tablet</i> MO | 2 | |
| <i>potassium cl er 10 meq, 20 meq, 8 meq tablet</i> MO | 2 | |
| <i>potassium cl er 10 meq, 8 meq capsule</i> MO | 2 | |
| <i>kcl 20 meq-ns 1,000 ml iv soln; kcl 40 meq-ns 1,000 ml iv soln</i> MO | 2 | |
| <i>d5w-kcl 20 meq/l, 30 meq/l, 40 meq/l iv solution; kcl 20 meq in d5w solution; kcl 40 meq in d5w solution</i> MO | 2 | |
| <i>kcl 20 meq in d5w-lact ringer; kcl 40 meq in d5w-lact ringer</i> MO | 2 | |
| <i>potassium cl 10 meq/100 ml, 10 meq/50 ml, 20 meq/100 ml, 20 meq/50 ml, 30 meq/100 ml, 40 meq/100 ml sol</i> MO | 2 | |
| <i>potassium cl 20 meq-0.45% nacl</i> MO | 2 | |
| <i>d5%-1/4ns-kcl 20 meq/l, 30 meq/l, 40 meq/l iv sol; kcl 20 meq in d5w-0.225% nacl</i> MO | 2 | |
| <i>kcl 20 meq in d5w-0.3% nacl</i> MO | 2 | |
| <i>kcl 20 meq in d5w-ns; kcl 40 meq in d5w-nacl 0.9%</i> MO | 2 | |
| <i>potassium citrate er 10 meq (1,080 mg), 15 meq, 5 meq (540 mg) tb; potassium citrate er 10 meq tb; potassium citrate er 5 meq tab</i> MO | 3 | |
| <i>pr natal 400 29 mg-1 mg-400 mg oral pack</i> MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| <i>pr natal 400 ec 29 mg-1 mg-400 mg tablet-capsule, delayed release</i> MO | 4 | |
| <i>pr natal 430 29 mg iron-1 mg-430 mg oral pack</i> MO | 4 | |
| <i>pr natal 430 ec 29 mg-1 mg-430 mg tablet-capsule, delayed release</i> MO | 4 | |
| PREMASOL 10 % INTRAVENOUS SOLUTION MO | 1 | B vs D |
| PREMASOL 6 % INTRAVENOUS SOLUTION MO | 1 | B vs D |
| PRENATA 29 MG IRON-1 MG CHEWABLE TABLET MO | 4 | |
| PRENATABS FA 29 MG-1 MG TABLET MO | 4 | |
| <i>prenatal plus (calcium carbonate) 27 mg iron-1 mg tablet</i> MO | 4 | |
| PRENATE DHA 28 MG IRON-1 MG-300 MG CAPSULE MO | 4 | |
| PRENATE ELITE 26 MG IRON-1 MG TABLET MO | 4 | |
| PRENATE ESSENTIAL 29 MG IRON-1 MG-300 MG CAPSULE MO | 4 | |
| <i>preplus 27 mg iron-1 mg tablet</i> MO | 4 | |
| PROCALAMINE 3% INTRAVENOUS SOLUTION MO | 4 | B vs D |
| PROSOL 20 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| RENAGEL 400 MG, 800 MG TABLET MO | 4 | ST |
| REVELA 0.8 GRAM ORAL POWDER PACKET MO | 3 | QL (540 per 30 days) |
| REVELA 2.4 GRAM ORAL POWDER PACKET MO | 3 | QL (180 per 30 days) |
| REVELA 800 MG TABLET MO | 3 | QL (540 per 30 days) |
| <i>ringer's iv solution</i> MO | 1 | |
| SAMSCA 15 MG, 30 MG TABLET DL | 5 | QL (60 per 30 days) |
| <i>se-natal 19 tablet</i> MO | 4 | |
| <i>se-natal 19 chewable 29 mg iron-1 mg tablet</i> MO | 4 | |
| <i>sevelamer 0.8 gm powder packet</i> MO | 3 | QL (540 per 30 days) |
| <i>sevelamer 2.4 gm powder packet</i> MO | 3 | QL (180 per 30 days) |
| <i>sevelamer carbonate 800 mg tab</i> MO | 3 | QL (540 per 30 days) |
| <i>sevelamer hcl 400 mg, 800 mg tablet</i> MO | 4 | ST |
| SMOFLIPID 20 % INTRAVENOUS EMULSION MO | 4 | B vs D |
| <i>sodium acetate 40 meq/20 ml v1</i> MO | 1 | |
| <i>sodium bicarb 8.4% abboject</i> MO | 4 | |
| <i>sodium chloride 0.9% irrig.</i> MO | 2 | |
| <i>sodium chloride 100 meq/40 ml</i> MO | 2 | |
| <i>saline 0.45% soln-excel con</i> MO | 2 | |
| <i>sodium chloride 0.45% soln</i> MO | 2 | |
| <i>sodium chloride 0.9% solution</i> MO | 2 | |
| <i>sodium chloride 0.9% vial</i> MO | 2 | |
| <i>sodium chloride 3% iv soln</i> MO | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| sodium chloride 5% iv soln MO | 2 | |
| sodium lactate 50 meq/10 ml vl MO | 1 | |
| sodium phosphate 45 mmol/15 ml MO | 1 | |
| sod polystyren sulf 15 g/60 ml MO | 3 | |
| sodium polystyrene sulf powder MO | 3 | |
| sps 15 gm/60 ml suspension MO | 3 | |
| sps 30 gm/120 ml enema; sps 50 gm/200 ml enema MO | 3 | |
| SPS (WITH SORBITOL) 15 GRAM-20 GRAM/60 ML ORAL SUSPENSION MO | 3 | |
| SPS (WITH SORBITOL) 30 GRAM-40 GRAM/120 ML ENEMA MO | 3 | |
| taron-c dha 35 mg-1 mg-200 mg capsule MO | 4 | |
| taron-prex prenatal-dha 30 mg iron-1.2 mg-55 mg-265mg capsule MO | 4 | |
| TPN ELECTROLYTES 35 MEQ-20 MEQ-5 MEQ/20 ML INTRAVENOUS SOLUTION MO | 4 | |
| TRAVASOL 10 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| trientine hcl 250 mg capsule DL | 5 | |
| trinatal rx 1 60 mg iron-1 mg tablet MO | 4 | |
| triveen-duo dha 29 mg-1 mg-400 mg oral pack MO | 4 | |
| TROPHAMINE 10 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| TROPHAMINE 6% INTRAVENOUS SOLUTION MO | 4 | B vs D |
| ultimatecare one capsule MO | 4 | |
| ultimatecare one nf capsule MO | 4 | |
| virt-c dha 35 mg-1 mg-200 mg capsule MO | 4 | |
| virt-nate dha 28 mg iron-1 mg-200 mg capsule MO | 4 | |
| GASTROINTESTINAL AGENTS | | |
| lansoprazol-amoxicil-clarithro MO | 4 | ST |
| CARAFATE 100 MG/ML ORAL SUSPENSION MO | 4 | |
| CHENODAL 250 MG TABLET DL | 5 | PA |
| cimetidine 200 mg, 300 mg, 400 mg, 800 mg tablet MO | 2 | |
| cimetidine 300 mg/5 ml soln MO | 2 | |
| constulose 10 gram/15 ml oral solution MO | 2 | |
| DEXILANT 30 MG, 60 MG CAPSULE, DELAYED RELEASE MO | 4 | QL (30 per 30 days) |
| dicyclomine 10 mg capsule MO | 2 | |
| dicyclomine 10 mg/5 ml soln MO | 3 | |
| dicyclomine 20 mg tablet MO | 2 | |
| diphenoxylat-atrop 2.5-0.025/5 MO | 4 | |
| diphenoxylate-atrop 2.5-0.025 MO | 4 | |
| enulose 10 gram/15 ml oral solution MO | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| esomeprazole mag dr 20 mg, 40 mg cap ^{MO} | 3 | QL (30 per 30 days) |
| famotidine 20 mg, 40 mg tablet ^{MO} | 2 | |
| famotidine 40 mg/4 ml vial ^{MO} | 2 | |
| famotidine 40 mg/5 ml susp ^{MO} | 4 | |
| famotidine 20 mg/2 ml vial ^{MO} | 2 | |
| famotidine 20 mg piggyback ^{MO} | 2 | |
| GATTEX 30-VIAL 5 MG SUBCUTANEOUS KIT ^{DL} | 5 | PA |
| GATTEX ONE-VIAL 5 MG SUBCUTANEOUS KIT ^{DL} | 5 | PA |
| gavilyte-c 240 gram-22.72 gram-6.72 gram-5.84 gram oral solution ^{MO} | 2 | |
| gavilyte-g 236 gram-22.74 gram-6.74 gram-5.86 gram oral solution ^{MO} | 2 | |
| gavilyte-n 420 gram oral solution ^{MO} | 2 | |
| generlac 10 gram/15 ml oral solution ^{MO} | 2 | |
| glycopyrrolate 1 mg, 2 mg tablet ^{MO} | 3 | |
| glycopyrrolate 4 mg/20 ml vial ^{MO} | 4 | |
| lactulose 10 gm/15 ml solution; lactulose 20 gm/30 ml solution ^{MO} | 2 | |
| lansoprazole dr 15 mg capsule ^{MO} | 3 | QL (60 per 30 days) |
| lansoprazole dr 30 mg capsule ^{MO} | 3 | QL (30 per 30 days) |
| LINZESS 145 MCG, 290 MCG, 72 MCG CAPSULE ^{MO} | 3 | QL (30 per 30 days) |
| loperamide 2 mg capsule ^{MO} | 2 | |
| methscopolamine brom 2.5 mg, 5 mg tab; methscopolamine brom 2.5 mg, 5 mg tb ^{MO} | 4 | |
| misoprostol 100 mcg, 200 mcg tablet ^{MO} | 3 | |
| MOVANTIK 12.5 MG, 25 MG TABLET ^{MO} | 3 | QL (30 per 30 days) |
| MYALEPT 5 MG/ML (FINAL CONCENTRATION) SUBCUTANEOUS SOLUTION ^{DL} | 5 | PA,QL (30 per 30 days) |
| nizatidine 15 mg/ml solution ^{MO} | 4 | |
| nizatidine 150 mg, 300 mg capsule ^{MO} | 2 | |
| omeppi 20 mg-1.1 gram capsule; omeppi 40 mg-1.1 gram capsule ^{MO} | 4 | ST,QL (30 per 30 days) |
| omeprazole dr 10 mg, 20 mg, 40 mg capsule ^{MO} | 1 | QL (60 per 30 days) |
| omeprazole-bicarb 20-1,100 cap; omeprazole-bicarb 40-1,100 cap ^{MO} | 4 | ST,QL (30 per 30 days) |
| omeprazole-bicarb 20-1,680 pkt; omeprazole-bicarb 40-1,680 pkt ^{MO} | 4 | ST,QL (30 per 30 days) |
| pantoprazole sod dr 20 mg, 40 mg tab ^{MO} | 1 | QL (60 per 30 days) |
| pantoprazole sodium 40 mg vial ^{MO} | 4 | |
| peg 3350 electrolyte soln; peg-3350 and electrolytes soln ^{MO} | 2 | |
| peg 3350-electrolyte solution ^{MO} | 2 | |
| polyethylene glycol 3350 powd ^{MO} | 2 | |
| PRILOSEC 10 MG, 2.5 MG ORAL SUSPENSION,DELAYED RELEASE ^{MO} | 4 | |
| PYLERA 140 MG-125 MG-125 MG CAPSULE ^{MO} | 4 | QL (144 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| <i>rabeprazole sod dr 20 mg tab</i> MO | 4 | QL (30 per 30 days) |
| <i>ranitidine 15 mg/ml syrup</i> MO | 2 | |
| <i>ranitidine 150 mg, 300 mg capsule</i> MO | 3 | |
| <i>ranitidine 150 mg, 300 mg tablet</i> MO | 2 | |
| <i>ranitidine hcl 150 mg/6 ml vl; ranitidine hcl 50 mg/2 ml vial</i> MO | 2 | |
| RELISTOR 12 MG/0.6 ML SUBCUTANEOUS SOLUTION MO | 4 | QL (36 per 30 days) |
| RELISTOR 12 MG/0.6 ML SUBCUTANEOUS SYRINGE MO | 4 | QL (36 per 28 days) |
| RELISTOR 150 MG TABLET MO | 4 | QL (90 per 30 days) |
| RELISTOR 8 MG/0.4 ML SUBCUTANEOUS SYRINGE MO | 4 | QL (12 per 30 days) |
| SEROSTIM 4 MG, 5 MG, 6 MG SUBCUTANEOUS SOLUTION DL | 5 | PA,QL (28 per 28 days) |
| <i>sucralfate 1 gm tablet</i> MO | 2 | |
| SUPREP BOWEL PREP KIT 17.5 GRAM-3.13 GRAM-1.6 GRAM ORAL SOLUTION MO | 3 | |
| <i>trilyte with flavor packets 420 gram oral solution</i> MO | 2 | |
| <i>ursodiol 250 mg tablet</i> MO | 3 | |
| <i>ursodiol 500 mg tablet</i> MO | 4 | |
| XIFAXAN 200 MG TABLET DL | 5 | PA,QL (9 per 30 days) |
| XIFAXAN 550 MG TABLET DL | 5 | PA,QL (84 per 28 days) |
| Genetic/Enzyme Disorder: Replacement, Modifiers, Treatment | | |
| ADAGEN 250 UNIT/ML VIAL DL | 5 | |
| ARALAST NP 1,000 MG, 500 MG INTRAVENOUS SOLUTION DL | 5 | PA |
| CERDELGA 84 MG CAPSULE DL | 5 | PA,QL (60 per 30 days) |
| CEREZYME 400 UNIT INTRAVENOUS SOLUTION DL | 5 | PA |
| CHOLBAM 250 MG, 50 MG CAPSULE DL | 5 | PA,QL (120 per 30 days) |
| CREON 12,000-38,000-60,000 UNIT CAPSULE,DELAYED RELEASE; CREON 24,000-76,000-120,000 UNIT CAPSULE,DELAYED RELEASE; CREON 3,000 UNIT-9,500 UNIT-15,000 UNIT CAPSULE,DELAYED RELEASE; CREON 36,000 UNIT-114,000 UNIT-180,000 UNIT CAPSULE,DELAYED RELEASE; CREON 6,000-19,000-30,000 UNIT CAPSULE,DELAYED RELEASE MO | 3 | |
| CRYSVITA 10 MG/ML, 20 MG/ML SUBCUTANEOUS SOLUTION DL | 5 | PA,QL (2 per 28 days) |
| CRYSVITA 30 MG/ML SUBCUTANEOUS SOLUTION DL | 5 | PA,QL (6 per 28 days) |
| CYSTADANE 1 GRAM/1.7 ML ORAL POWDER DL | 5 | |
| CYSTAGON 150 MG, 50 MG CAPSULE MO | 4 | |
| ELELYSO 200 UNIT INTRAVENOUS SOLUTION DL | 5 | PA,QL (70 per 30 days) |
| EXONDYS 51 50 MG/ML INTRAVENOUS SOLUTION DL | 5 | PA |
| GLASSIA 1 GRAM/50 ML (2 %) INTRAVENOUS SOLUTION DL | 5 | PA |
| KUVAN 100 MG SOLUBLE TABLET DL | 5 | PA |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| KUVAN 100 MG, 500 MG ORAL POWDER PACKET DL | 5 | PA |
| LUMIZYME 50 MG INTRAVENOUS SOLUTION DL | 5 | PA |
| NAGLAZYME 5 MG/5 ML INTRAVENOUS SOLUTION DL | 5 | PA |
| <i>nitisinone 10 mg, 2 mg, 5 mg capsule</i> DL | 5 | |
| NITYR 10 MG, 2 MG, 5 MG TABLET DL | 5 | |
| ORFADIN 10 MG, 2 MG, 20 MG, 5 MG CAPSULE DL | 5 | |
| ORFADIN 4 MG/ML ORAL SUSPENSION DL | 5 | |
| REVCovi 2.4 MG/1.5 ML (1.6 MG/ML) INTRAMUSCULAR SOLUTION DL | 5 | |
| <i>sodium phenylbutyrate powder</i> DL | 5 | |
| STRENSIQ 18 MG/0.45 ML, 28 MG/0.7 ML, 40 MG/ML SUBCUTANEOUS SOLUTION DL | 5 | PA |
| STRENSIQ 80 MG/0.8 ML SUBCUTANEOUS SOLUTION DL | 5 | PA,QL (38.4 per 28 days) |
| SUCRAID 8,500 UNIT/ML ORAL SOLUTION DL | 5 | |
| ZENPEP 10,000 UNIT-32,000 UNIT-42,000 UNIT CAPSULE,DELAYED RELEASE; ZENPEP 15,000 UNIT-47,000 UNIT-63,000 UNIT CAPSULE,DELAYED RELEASE; ZENPEP 20,000 UNIT-63,000 UNIT-84,000 UNIT CAPSULE,DELAYED RELEASE; ZENPEP 25,000 UNIT-79,000 UNIT-105,000 UNIT CAPSULE,DELAYED RELEASE; ZENPEP 3,000 UNIT-10,000 UNIT-14,000 UNIT CAPSULE,DELAYED RELEASE; ZENPEP 40,000 UNIT-126,000 UNIT-168,000 UNIT CAPSULE,DELAYED RELEASE; ZENPEP 5,000 UNIT-17,000 UNIT-24,000 UNIT CAPSULE,DELAYED RELEASE; ZENPEP DR 10,000 UNIT CAPSULE; ZENPEP DR 15,000 UNIT CAPSULE; ZENPEP DR 25,000 UNIT CAPSULE; ZENPEP DR 3,000 UNIT CAPSULE; ZENPEP DR 40,000 UNIT CAPSULE; ZENPEP DR 5,000 UNIT CAPSULE MO | 4 | |
| Genitourinary Agents | | |
| <i>alfuzosin hcl er 10 mg tablet</i> MO | 2 | QL (30 per 30 days) |
| <i>bethanechol 10 mg, 25 mg, 5 mg tablet</i> MO | 3 | |
| <i>bethanechol 50 mg tablet</i> MO | 4 | |
| <i>darifenacin er 15 mg, 7.5 mg tablet</i> MO | 4 | ST,QL (30 per 30 days) |
| <i>dutasteride 0.5 mg capsule</i> MO | 3 | QL (30 per 30 days) |
| <i>dutasteride-tamsulosin 0.5-0.4</i> MO | 4 | QL (30 per 30 days) |
| ELMIRON 100 MG CAPSULE MO | 4 | QL (90 per 30 days) |
| <i>finasteride 5 mg tablet</i> MO | 1 | QL (30 per 30 days) |
| <i>flavoxate hcl 100 mg tablet</i> MO | 3 | |
| MYRBETRIQ 25 MG, 50 MG TABLET,EXTENDED RELEASE MO | 3 | QL (30 per 30 days) |
| <i>oxybutynin 5 mg tablet</i> MO | 2 | |
| <i>oxybutynin 5 mg/5 ml syrup</i> MO | 2 | |
| <i>oxybutynin cl er 10 mg, 15 mg, 5 mg tablet</i> MO | 3 | QL (60 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| RAPAFLO 4 MG, 8 MG CAPSULE ^{MO} | 4 | PA,QL (30 per 30 days) |
| silodosin 4 mg, 8 mg capsule ^{MO} | 4 | QL (30 per 30 days) |
| tamsulosin hcl 0.4 mg capsule ^{MO} | 2 | QL (60 per 30 days) |
| THIOLA 100 MG TABLET ^{DL} | 5 | |
| tolterodine tart er 2 mg, 4 mg cap ^{MO} | 4 | QL (30 per 30 days) |
| tolterodine tartrate 1 mg, 2 mg tab ^{MO} | 4 | QL (60 per 30 days) |
| TOVIAZ 4 MG, 8 MG TABLET,EXTENDED RELEASE ^{MO} | 3 | QL (30 per 30 days) |
| Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal) | | |
| a-hydrocort 100 mg solution for injection ^{MO} | 1 | |
| ACTHAR 80 UNIT/ML INJECTION GEL ^{DL} | 5 | PA,QL (30 per 30 days) |
| ARISTOSPAN INTRA-ARTICULAR 20 MG/ML SUSPENSION FOR INJECTION ^{MO} | 4 | |
| ARISTOSPAN INTRALESIONAL 5 MG/ML SUSPENSION FOR INJECTION ^{MO} | 4 | |
| betamethasone sp-ac 30 mg/5 ml ^{MO} | 2 | |
| betamethasone dp 0.05% crm ^{MO} | 3 | |
| betamethasone dp 0.05% lot ^{MO} | 3 | |
| betamethasone dp 0.05% oint ^{MO} | 3 | |
| betamethasone va 0.1% cream ^{MO} | 2 | |
| betamethasone va 0.1% lotion ^{MO} | 2 | |
| betamethasone valer 0.1% ointm ^{MO} | 2 | |
| betamethasone dp aug 0.05% crm ^{MO} | 2 | |
| betamethasone dp aug 0.05% gel ^{MO} | 4 | |
| betamethasone dp aug 0.05% lot ^{MO} | 4 | |
| betamethasone dp aug 0.05% oin ^{MO} | 4 | |
| clobetasol 0.05% cream ^{MO} | 4 | |
| clobetasol 0.05% gel ^{MO} | 4 | |
| clobetasol 0.05% ointment ^{MO} | 4 | |
| clobetasol 0.05% solution ^{MO} | 4 | |
| clobetasol 0.05% topical lotn ^{MO} | 4 | |
| clobetasol emollient 0.05% crm ^{MO} | 4 | |
| cormax 0.05 % scalp solution ^{MO} | 4 | |
| cortisone 25 mg tablet ^{MO} | 4 | |
| decadron 0.5 mg/5 ml elixir ^{MO} | 2 | |
| desonide 0.05% cream ^{MO} | 4 | |
| desonide 0.05% ointment ^{MO} | 4 | |
| desoximetasone 0.25% cream ^{MO} | 4 | |
| desoximetasone 0.25% ointment ^{MO} | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| dexamethasone 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg tablet ^{MO} | 2 | |
| dexamethasone 0.5 mg/5 ml elx ^{MO} | 2 | |
| dexamethasone 0.5 mg/5 ml liq ^{MO} | 2 | |
| DEXAMETHASONE INTENSOL 1 MG/ML DROPS (CONCENTRATE) ^{MO} | 3 | |
| dexamethasone 10 mg/ml syring ^{MO} | 2 | |
| dexamethasone 10 mg/ml vial ^{MO} | 2 | |
| dexamethasone 10 mg/ml, 4 mg/ml vial ^{MO} | 2 | |
| dexamethasone 4 mg/ml syringe ^{MO} | 2 | |
| diflorasone 0.05% cream ^{MO} | 4 | |
| diflorasone 0.05% ointment ^{MO} | 4 | |
| fludrocortisone 0.1 mg tablet ^{MO} | 2 | |
| fluocinolone 0.01% body oil ^{MO} | 4 | |
| fluocinolone 0.01% cream; fluocinolone 0.025% cream ^{MO} | 4 | |
| fluocinolone 0.01% solution ^{MO} | 4 | |
| fluocinolone 0.025% ointment ^{MO} | 4 | |
| fluocinolone 0.01% scalp oil ^{MO} | 4 | |
| fluocinonide 0.05% cream ^{MO} | 3 | |
| fluocinonide 0.05% gel ^{MO} | 4 | |
| fluocinonide 0.05% ointment ^{MO} | 3 | |
| fluocinonide 0.05% solution ^{MO} | 4 | |
| fluocinonide-e 0.05 % topical cream ^{MO} | 4 | |
| fluocinonide-e 0.05% cream ^{MO} | 4 | |
| fluticasone prop 0.005% oint ^{MO} | 2 | |
| fluticasone prop 0.05% cream ^{MO} | 2 | |
| hydrocortisone 1% cream; hydrocortisone 2.5% cream ^{MO} | 2 | |
| hydrocortisone 1% ointment; hydrocortisone 2.5% ointment ^{MO} | 2 | |
| hydrocortisone 10 mg, 20 mg, 5 mg tablet ^{MO} | 2 | |
| hydrocortisone 2.5% cream ^{MO} | 4 | |
| hydrocortisone 2.5% lotion ^{MO} | 2 | |
| hydrocortisone val 0.2% cream ^{MO} | 4 | |
| hydrocortisone val 0.2% ointmt ^{MO} | 4 | |
| hydrocortisone 1% absorbase ^{MO} | 2 | |
| LOCOID LIPOCREAM 0.1 % TOPICAL ^{MO} | 4 | |
| MEDROL 2 MG TABLET ^{MO} | 4 | B vs D |
| methylprednisolone 16 mg, 32 mg, 4 mg, 8 mg tab; methylprednisolone 16 mg, 32 mg, 4 mg, 8 mg tablet ^{MO} | 2 | B vs D |
| methylprednisolone 4 mg dosepk ^{MO} | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| <i>methylprednisolone 40 mg/ml, 80 mg/ml v1</i> ^{MO} | 2 | |
| <i>methylprednisolone ss 1 gm v1; methylprednisolone ss 1,000 mg, 125 mg, 40 mg; methylprednisolone ss 1,000 mg, 125 mg, 40 mg v1</i> ^{MO} | 4 | |
| <i>mometasone furoate 0.1% cream</i> ^{MO} | 2 | |
| <i>mometasone furoate 0.1% oint</i> ^{MO} | 2 | |
| <i>mometasone furoate 0.1% soln</i> ^{MO} | 2 | |
| <i>prednisolone 15 mg/5 ml syrup</i> ^{MO} | 2 | |
| <i>prednisolone 15 mg/5 ml soln</i> ^{MO} | 2 | |
| <i>prednisolone 20 mg/5 ml soln</i> ^{MO} | 4 | |
| <i>prednisolone 5 mg/5 ml soln; prednisolone sod ph 25 mg/5 ml</i> ^{MO} | 3 | |
| <i>prednisone 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg tablet</i> ^{MO} | 1 | B vs D |
| <i>prednisone 10 mg, 5 mg tab dose pack</i> ^{MO} | 2 | |
| <i>prednisone 5 mg/5 ml solution</i> ^{MO} | 3 | B vs D |
| PREDNISONE INTENSOL 5 MG/ML ORAL CONCENTRATE ^{MO} | 4 | B vs D |
| <i>procto-med hc 2.5 % topical cream perineal applicator</i> ^{MO} | 4 | |
| <i>procto-pak 1 % topical cream perineal applicator</i> ^{MO} | 2 | |
| <i>proctosol hc 2.5 % topical cream perineal applicator</i> ^{MO} | 4 | |
| <i>proctozone-hc 2.5 % topical cream perineal applicator</i> ^{MO} | 4 | |
| SOLU-MEDROL 2 GRAM INTRAVENOUS SOLUTION ^{MO} | 4 | |
| SOLU-MEDROL (PF) 1,000 MG/8 ML, 125 MG/2 ML, 40 MG/ML, 500 MG/4 ML INTRAVENOUS SOLUTION; SOLU-MEDROL (PF) 1,000 MG/8 ML, 125 MG/2 ML, 40 MG/ML, 500 MG/4 ML SOLUTION FOR INJECTION ^{MO} | 4 | |
| <i>triamcinolone 0.025% cream; triamcinolone 0.1% cream; triamcinolone 0.5% cream</i> ^{MO} | 2 | |
| <i>triamcinolone 0.025% lotion; triamcinolone 0.1% lotion</i> ^{MO} | 3 | |
| <i>triamcinolone 0.025% oint; triamcinolone 0.1% ointment; triamcinolone 0.5% ointment</i> ^{MO} | 2 | |
| <i>triderm 0.1 %, 0.5 % topical cream</i> ^{MO} | 2 | |
| VERIPRED 20 20 MG/5 ML (4 MG/ML) ORAL SOLUTION ^{MO} | 4 | |
| Hormonal Agents, Stimulant/Replacement/Modifying (Pituitary) | | |
| <i>chorionic gonad 10,000 unit v1</i> ^{DL} | 5 | PA |
| <i>desmopressin 0.01% solution; desmopressin 10 mcg/0.1 ml spr</i> ^{MO} | 4 | QL (25 per 30 days) |
| <i>desmopressin ac 4 mcg/ml vial</i> ^{MO} | 4 | |
| <i>desmopressin acetate 0.1 mg tb</i> ^{MO} | 4 | QL (180 per 30 days) |
| <i>desmopressin acetate 0.2 mg tb</i> ^{MO} | 4 | |
| EGRIFTA 1 MG SUBCUTANEOUS SOLUTION ^{DL} | 5 | PA,QL (60 per 30 days) |
| EGRIFTA 2 MG VIAL ^{DL} | 5 | PA,QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| INCRELEX 10 MG/ML SUBCUTANEOUS SOLUTION DL | 5 | PA |
| OMNITROPE 10 MG/1.5 ML (6.7 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) SUBCUTANEOUS CARTRIDGE DL | 5 | PA |
| OMNITROPE 5.8 MG SUBCUTANEOUS SOLUTION DL | 5 | PA |
| STIMATE 150 MCG/SPRAY (0.1 ML) NASAL SPRAY DL | 5 | |
| ZORBTIVE 8.8 MG SUBCUTANEOUS SOLUTION DL | 5 | PA |
| Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers) | | |
| <i>afirmelle</i> 0.1 mg-20 mcg tablet MO | 4 | |
| <i>altavera</i> (28) 0.15 mg-0.03 mg tablet MO | 4 | |
| <i>alyacen</i> 1/35 (28) 1 mg-35 mcg tablet MO | 4 | |
| <i>alyacen</i> 7/7/7 (28) 0.5 mg/0.75 mg/1 mg-35 mcg tablet MO | 4 | |
| <i>amabelz</i> 0.5 mg-0.1 mg tablet; <i>amabelz</i> 1 mg-0.5 mg tablet MO | 4 | |
| <i>amethia</i> 0.15 mg-30 mcg (84)/10 mcg(7) tablets, 3 month dose pack MO | 4 | QL (91 per 90 days) |
| AMETHIA LO 0.10 MG-20 MCG (84)/10 MCG(7) TABLETS, 3 MONTH DOSE PACK MO | 4 | QL (91 per 90 days) |
| <i>amethyst</i> (28) 90 mcg-20 mcg tablet MO | 4 | |
| ANADROL-50 50 MG TABLET DL | 5 | |
| ANDROGEL 1.62 % (20.25 MG/1.25 GRAM) TRANSDERMAL GEL PACKET MO | 3 | PA,QL (37.5 per 30 days) |
| ANDROGEL 1.62 % (40.5 MG/2.5 GRAM), 20.25 MG/1.25 GRAM (1.62 %) TRANSDERMAL GEL PACKET; ANDROGEL 1.62 % (40.5 MG/2.5 GRAM), 20.25 MG/1.25 GRAM (1.62 %) TRANSDERMAL GEL PUMP MO | 3 | PA,QL (150 per 30 days) |
| <i>apri</i> 0.15 mg-0.03 mg tablet MO | 4 | |
| <i>aranelle</i> (28) 0.5 mg/1 mg/0.5 mg-35 mcg tablet MO | 4 | |
| <i>ashlyna</i> 0.15 mg-30 mcg (84)/10 mcg(7) tablets, 3 month dose pack MO | 4 | QL (91 per 90 days) |
| <i>aubra</i> 0.1 mg-20 mcg tablet MO | 4 | |
| <i>aubra eq</i> 0.1 mg-20 mcg tablet MO | 4 | |
| <i>aurovela</i> 1.5/30 (21) 1.5 mg-30 mcg tablet MO | 4 | |
| <i>aurovela</i> 1/20 (21) 1 mg-20 mcg tablet MO | 4 | |
| <i>aurovela</i> 24 fe 1 mg-20 mcg (24)/75 mg (4) tablet MO | 4 | |
| <i>aurovela fe</i> 1-20 (28) 1 mg-20 mcg (21)/75 mg (7) tablet MO | 4 | |
| <i>aurovela fe</i> 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) tablet MO | 4 | |
| <i>aviane</i> 0.1 mg-20 mcg tablet MO | 4 | |
| <i>ayuna</i> 0.15 mg-0.03 mg tablet MO | 4 | |
| <i>azurette</i> (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet MO | 4 | |
| <i>balziva</i> (28) 0.4 mg-35 mcg tablet MO | 4 | |
| <i>bekyree</i> (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet MO | 4 | |
| <i>blisovi</i> 24 fe 1 mg-20 mcg (24)/75 mg (4) tablet MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| <i>blisovi fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) tablet</i> ^{MO} | 4 | |
| <i>blisovi fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) tablet</i> ^{MO} | 4 | |
| <i>briellyn 0.4 mg-35 mcg tablet</i> ^{MO} | 4 | |
| <i>camila 0.35 mg tablet</i> ^{MO} | 4 | |
| CAMRESE 0.15 MG-30 MCG (84)/10 MCG(7) TABLETS,3 MONTH DOSE PACK ^{MO} | 4 | QL (91 per 90 days) |
| CAMRESE LO 0.10 MG-20 MCG (84)/10 MCG(7) TABLETS,3 MONTH DOSE PACK ^{MO} | 4 | QL (91 per 90 days) |
| <i>caziant (28) 0.1 mg/0.125 mg/0.15 mg-25 mcg tablet</i> ^{MO} | 4 | |
| <i>chateal (28) 0.15 mg-0.03 mg tablet</i> ^{MO} | 4 | |
| <i>chateal eq (28) 0.15 mg-0.03 mg tablet</i> ^{MO} | 4 | |
| <i>cryselle (28) 0.3 mg-30 mcg tablet</i> ^{MO} | 4 | |
| <i>cyclafem 1/35 (28) 1 mg-35 mcg tablet</i> ^{MO} | 4 | |
| <i>cyclafem 7/7/7 (28) 0.5 mg/0.75 mg/1 mg-35 mcg tablet</i> ^{MO} | 4 | |
| CYCLESSA 28 DAY TABLET ^{MO} | 4 | |
| <i>cyred 0.15 mg-0.03 mg tablet</i> ^{MO} | 4 | |
| <i>cyred eq 0.15 mg-0.03 mg tablet</i> ^{MO} | 4 | |
| <i>danazol 100 mg, 200 mg, 50 mg capsule</i> ^{MO} | 4 | |
| <i>dasetta 1/35 (28) 1 mg-35 mcg tablet</i> ^{MO} | 4 | |
| <i>dasetta 7/7/7 (28) 0.5 mg(7)/0.75 mg(7)/1 mg(7)-35 mcg tablet</i> ^{MO} | 4 | |
| <i>daysee 0.15 mg-30 mcg (84)/10 mcg(7) tablets,3 month dose pack</i> ^{MO} | 4 | QL (91 per 90 days) |
| <i>deblitane 0.35 mg tablet</i> ^{MO} | 4 | |
| <i>delyla-28 tablet</i> ^{MO} | 4 | |
| DEPO-ESTRADIOL 5 MG/ML INTRAMUSCULAR OIL ^{MO} | 3 | QL (5 per 30 days) |
| DEPO-PROVERA 400 MG/ML INTRAMUSCULAR SUSPENSION ^{MO} | 4 | |
| DEPO-SUBQ PROVERA 104 104 MG/0.65 ML SUBCUTANEOUS SYRINGE ^{MO} | 4 | QL (0.65 per 90 days) |
| <i>desogestr-eth estrad eth estra</i> ^{MO} | 4 | |
| <i>desogest-eth estra 0.15-0.03mg</i> ^{MO} | 4 | |
| <i>dotti 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr transdermal patch</i> ^{MO} | 4 | QL (8 per 28 days) |
| <i>drospirenone-ee 3-0.02 mg, 3-0.03 mg tab</i> ^{MO} | 4 | |
| DUAVEE 0.45 MG-20 MG TABLET ^{MO} | 4 | PA,QL (30 per 30 days) |
| <i>elinest 0.3 mg-30 mcg tablet</i> ^{MO} | 4 | |
| ELLA 30 MG TABLET ^{MO} | 3 | QL (1 per 30 days) |
| <i>emoquette 0.15 mg-0.03 mg tablet</i> ^{MO} | 4 | |
| ENDOMETRIN 100 MG VAGINAL INSERT ^{DL} | 5 | |
| <i>enpresse 50-30 (6)/75-40(5)/125-30(10) tablet</i> ^{MO} | 4 | |
| <i>enskyce 0.15 mg-0.03 mg tablet</i> ^{MO} | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| <i>errin 0.35 mg tablet</i> MO | 4 | |
| <i>estradiol 0.01% cream</i> MO | 3 | |
| <i>estradiol 0.025 mg patch; estradiol 0.0375 mg patch; estradiol 0.05 mg patch; estradiol 0.075 mg patch; estradiol 0.1 mg patch</i> MO | 4 | QL (8 per 28 days) |
| <i>estradiol 0.0375 mg/day patch; estradiol 0.06 mg/day patch; estradiol 0.075 mg/day patch; estradiol tds 0.025 mg/day; estradiol tds 0.05 mg/day; estradiol tds 0.1 mg/day</i> MO | 4 | QL (4 per 28 days) |
| <i>estradiol 0.5 mg, 1 mg, 10 mcg, 2 mg tablet; estradiol 0.5 mg, 1 mg, 10 mcg, 2 mg vaginal insrt</i> MO | 4 | |
| <i>estradiol valerate 20 mg/ml, 40 mg/ml vl</i> MO | 4 | |
| <i>estradiol-noreth 0.5-0.1 mg, 1-0.5 mg tab; estradiol-noreth 0.5-0.1 mg, 1-0.5 mg tb</i> MO | 3 | |
| <i>ESTRING 2 MG (7.5 MCG/24 HOUR) VAGINAL RING</i> MO | 4 | QL (1 per 90 days) |
| <i>ESTROSTEP FE-28 1-20 (5)/1-30(7)/1MG-35MCG(9) TABLET</i> MO | 4 | |
| <i>ethynodiol-eth estra 1mg-35mcg; ethynodiol-eth estra 1mg-50mcg</i> MO | 4 | |
| <i>falmina (28) 0.1 mg-20 mcg tablet</i> MO | 4 | |
| <i>fayosim 0.15 mg-20 mcg/0.15 mg-25 mcg tablets,3 month dose pack</i> MO | 4 | QL (91 per 90 days) |
| <i>FEMRING 0.05 MG/24 HR, 0.1 MG/24 HR VAGINAL</i> MO | 4 | QL (1 per 90 days) |
| <i>femynor 0.25 mg-35 mcg tablet</i> MO | 4 | |
| <i>GIANVI (28) 3 MG-0.02 MG TABLET</i> MO | 4 | |
| <i>gildagia 0.4 mg-0.035 mg tab</i> MO | 4 | |
| <i>hailey 1.5 mg-30 mcg tablet</i> MO | 4 | |
| <i>hailey 24 fe 1 mg-20 mcg (24)/75 mg (4) tablet</i> MO | 4 | |
| <i>heather 0.35 mg tablet</i> MO | 4 | |
| <i>incassia 0.35 mg tablet</i> MO | 4 | |
| <i>introvale 0.15 mg-30 mcg (91) tablets,3 month dose pack</i> MO | 4 | QL (91 per 90 days) |
| <i>isibloom 0.15 mg-0.03 mg tablet</i> MO | 4 | |
| <i>jasmiel (28) 3 mg-0.02 mg tablet</i> MO | 4 | |
| <i>jencycla 0.35 mg tablet</i> MO | 4 | |
| <i>JOLESSA 0.15 MG-30 MCG (91) TABLETS,3 MONTH DOSE PACK</i> MO | 4 | QL (91 per 90 days) |
| <i>JOLIVETTE TABLET</i> MO | 4 | |
| <i>juleber 0.15 mg-0.03 mg tablet</i> MO | 4 | |
| <i>junel 1.5/30 (21) 1.5 mg-30 mcg tablet</i> MO | 4 | |
| <i>junel 1/20 (21) 1 mg-20 mcg tablet</i> MO | 4 | |
| <i>junel fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) tablet</i> MO | 4 | |
| <i>junel fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) tablet</i> MO | 4 | |
| <i>junel fe 24 1 mg-20 mcg (24)/75 mg (4) tablet</i> MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| kalliga 0.15 mg-0.03 mg tablet MO | 4 | |
| kariva (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet MO | 4 | |
| kelnor 1-50 1 mg-50 mcg tablet MO | 4 | |
| kelnor 1/35 (28) 1 mg-35 mcg tablet MO | 4 | |
| kimidess 28 day tablet MO | 4 | |
| kurvelo (28) 0.15 mg-0.03 mg tablet MO | 4 | |
| levono-e estrad 0.10-0.02-0.01; levono-e estrad 0.15-0.03-0.01; levonorg 0.15mg-ee 20-25-30mcg MO | 4 | QL (91 per 90 days) |
| larin 1.5/30 (21) 1.5 mg-30 mcg tablet MO | 4 | |
| larin 1/20 (21) 1 mg-20 mcg tablet MO | 4 | |
| larin 24 fe 1 mg-20 mcg (24)/75 mg (4) tablet MO | 4 | |
| larin fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) tablet MO | 4 | |
| larin fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) tablet MO | 4 | |
| larissia 0.1 mg-20 mcg tablet MO | 4 | |
| LEENA 28 0.5 MG/1 MG/0.5 MG-35 MCG TABLET MO | 4 | |
| lessina 0.1 mg-20 mcg tablet MO | 4 | |
| levonest (28) 50-30 (6)/75-40(5)/125-30(10) tablet MO | 4 | |
| levonor-eth estrad triphasic MO | 4 | |
| levonor-eth estra 0.09-0.02 mg; levonor-eth estrad 0.1-0.02 mg; levonor-eth estrad 0.15-0.03 MO | 4 | |
| levonor-eth estrad 0.15-0.03 MO | 4 | QL (91 per 90 days) |
| levora-28 0.15 mg-0.03 mg tablet MO | 4 | |
| lillow (28) 0.15 mg-0.03 mg tablet MO | 4 | |
| lo-zumandimine (28) 3 mg-0.02 mg tablet MO | 4 | |
| loestrin 1.5/30 (21) 1.5 mg-30 mcg tablet MO | 4 | |
| loestrin 1/20 (21) 1 mg-20 mcg tablet MO | 4 | |
| loestrin fe 1.5/30 (28-day) 1.5 mg-30 mcg (21)/75 mg (7) tablet MO | 4 | |
| loestrin fe 1/20 (28-day) 1 mg-20 mcg (21)/75 mg (7) tablet MO | 4 | |
| lomedica 24 fe 1 mg-20 mcg tab MO | 4 | |
| loryna (28) 3 mg-0.02 mg tablet MO | 3 | |
| low-ogestrel (28) 0.3 mg-30 mcg tablet MO | 4 | |
| lutra (28) 0.1 mg-20 mcg tablet MO | 4 | |
| lyza 0.35 mg tablet MO | 4 | |
| marlissa (28) 0.15 mg-0.03 mg tablet MO | 4 | |
| medroxyprogesterone 10 mg, 2.5 mg, 5 mg tab MO | 2 | |
| medroxyprogesterone 150 mg/ml MO | 2 | QL (1 per 90 days) |
| megestrol 20 mg, 40 mg tablet MO | 3 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| megestrol 400 mg/10 ml (10 ml), 400 mg/10 ml (40 mg/ml), 625 mg/5 ml susp; megestrol acet 40 mg/ml susp; megestrol acet 400 mg/10 ml MO | 4 | |
| MENEST 0.3 MG, 0.625 MG, 1.25 MG TABLET MO | 4 | |
| METHITEST 10 MG TABLET DL | 5 | |
| methyltestosterone 10 mg cap DL | 5 | |
| MICROGESTIN 1.5/30 (21) 1.5 MG-30 MCG TABLET MO | 4 | |
| MICROGESTIN 1/20 (21) 1 MG-20 MCG TABLET MO | 4 | |
| MICROGESTIN FE 1.5/30 (28) 1.5 MG-30 MCG (21)/75 MG (7) TABLET MO | 4 | |
| MICROGESTIN FE 1/20 (28) 1 MG-20 MCG (21)/75 MG (7) TABLET MO | 4 | |
| mili 0.25 mg-35 mcg tablet MO | 4 | |
| mimvey 1 mg-0.5 mg tablet MO | 4 | |
| mircette (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet MO | 4 | |
| mono-lyyah 0.25 mg-35 mcg tablet MO | 4 | |
| MONONESSA 28 TABLET MO | 4 | |
| myzilra-28 tablet MO | 4 | |
| NATAZIA 3 MG/2 MG-2 MG/2 MG-3 MG/1 MG TABLET MO | 4 | |
| necon 0.5/35 (28) 0.5 mg-35 mcg tablet MO | 4 | |
| NECON 7-7-7-28 TABLET MO | 4 | |
| nikki (28) 3 mg-0.02 mg tablet MO | 4 | |
| NORA-BE 0.35 MG TABLET MO | 4 | |
| noret-estr-fe 0.4-0.035(21)-75 MO | 4 | |
| norethindrone 0.35 mg tablet MO | 4 | |
| norethin-ee 1.5-0.03 mg(21) tb; norethin-eth estrad 1 mg-5 mcg; norethind-eth estrad 0.5-2.5; norethind-eth estrad 1-0.02 mg MO | 4 | |
| norethindrone 5 mg tablet MO | 3 | |
| noreth-estrad-fe 1-0.02(21)-75; noreth-estrad-fe 1-0.02(24)-75 MO | 4 | |
| noreth-estrad-fe 1-0.02(24)-75 MO | 4 | |
| norg-ee 0.18-0.215-0.25/0.025; norg-ee 0.18-0.215-0.25/0.035; norg-ethin estra 0.25-0.035 mg MO | 4 | |
| norlyda 0.35 mg tablet MO | 4 | |
| norlyroc 0.35 mg tablet MO | 4 | |
| nortrel 0.5/35 (28) 0.5 mg-35 mcg tablet MO | 4 | |
| nortrel 1/35 (21) 1 mg-35 mcg tablet MO | 4 | |
| nortrel 1/35 (28) 1 mg-35 mcg tablet MO | 4 | |
| nortrel 7/7/7 (28) 0.5 mg/0.75 mg/1 mg-35 mcg tablet MO | 4 | |
| NUVARING 0.12 MG -0.015 MG/24 HR VAGINAL MO | 4 | QL (1 per 28 days) |
| OCELLA 3 MG-0.03 MG TABLET MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| ogestrel (28) 0.5 mg-50 mcg tablet MO | 4 | |
| orsythia 0.1 mg-20 mcg tablet MO | 4 | |
| ORTHO-NOVUM 7/7/7 (28) 0.5 MG/0.75 MG/1 MG-35 MCG TABLET MO | 4 | |
| oxandrolone 10 mg tablet DL | 5 | PA,QL (60 per 30 days) |
| oxandrolone 2.5 mg tablet MO | 4 | PA,QL (120 per 30 days) |
| philith 0.4 mg-35 mcg tablet MO | 4 | |
| pimtrex (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet MO | 4 | |
| pirmella 0.5/0.75/1 mg-35 mcg tablet; pirmella 1 mg-35 mcg tablet MO | 4 | |
| portia 28 0.15 mg-0.03 mg tablet MO | 4 | |
| PREMARIN 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG TABLET MO | 4 | |
| PREMARIN 0.625 MG/GRAM VAGINAL CREAM MO | 3 | |
| previfem 0.25 mg-35 mcg tablet MO | 4 | |
| progesterone 500 mg/10 ml vial MO | 3 | |
| progesterone 100 mg, 200 mg capsule MO | 3 | |
| QUARTETTE 0.15 MG-20 MCG/0.15 MG-25 MCG TABLETS,3 MONTH DOSE PACK MO | 4 | QL (91 per 90 days) |
| quasense 0.15-0.03 mg tablet MO | 4 | QL (91 per 90 days) |
| raloxifene hcl 60 mg tablet MO | 2 | QL (30 per 30 days) |
| reclipsen (28) 0.15 mg-0.03 mg tablet MO | 4 | |
| RIVELSA 0.15 MG-20 MCG/0.15 MG-25 MCG TABLETS,3 MONTH DOSE PACK MO | 4 | QL (91 per 90 days) |
| setlakin 0.15 mg-30 mcg (91) tablets,3 month dose pack MO | 4 | QL (91 per 90 days) |
| sharobel 0.35 mg tablet MO | 4 | |
| simliya (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet MO | 4 | |
| simpesse 0.15 mg-30 mcg (84)/10 mcg(7) tablets,3 month dose pack MO | 4 | QL (91 per 90 days) |
| SLYND 4 MG (28) TABLET MO | 4 | |
| sprintec (28) 0.25 mg-35 mcg tablet MO | 4 | |
| sronyx 0.1 mg-20 mcg tablet MO | 4 | |
| syeda 3 mg-0.03 mg tablet MO | 4 | |
| tarina 24 fe 1 mg-20 mcg (24)/75 mg (4) tablet MO | 4 | |
| tarina fe 1-20 eq (28) 1 mg-20 mcg (21)/75 mg (7) tablet MO | 4 | |
| tarina fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) tablet MO | 4 | |
| testosterone 1.62% (2.5 g) pkt; testosterone 1.62% gel pump MO | 3 | PA,QL (150 per 30 days) |
| testosterone 1.62%(1.25 g) pkt MO | 3 | PA,QL (37.5 per 30 days) |
| testosteron cyp 1,000 mg/10 ml; testosterone cyp 100 mg/ml, 200 mg/ml MO | 3 | QL (24 per 90 days) |
| testosterone enan 200 mg/ml MO | 3 | QL (24 per 90 days) |
| TILIA FE 1-20 (5)/1-30(7)/1MG-35MCG(9) TABLET MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| tri femynor (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet MO | 4 | |
| tri-legest fe 1-20 (5)/1-30(7)/1mg-35mcg(9) tablet MO | 4 | |
| tri-linyah (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet MO | 4 | |
| tri-lo-estarylla 0.18 mg/0.215 mg/0.25 mg-25 mcg tablet MO | 4 | |
| tri-lo-marzia 0.18 mg/0.215 mg/0.25 mg-25 mcg tablet MO | 4 | |
| tri-lo-mili 0.18/0.215/0.25 mg-25 mcg tablet MO | 4 | |
| tri-lo-sprintec 0.18 mg/0.215 mg/0.25 mg-25 mcg tablet MO | 4 | |
| tri-mili (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet MO | 4 | |
| TRI-NORINYL 28 TABLET MO | 4 | |
| tri-previfem (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet MO | 4 | |
| tri-sprintec (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet MO | 4 | |
| tri-vylibra (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet MO | 4 | |
| tri-vylibra lo 0.18/0.215/0.25 mg-25 mcg tablet MO | 4 | |
| TRINESSA TABLET MO | 4 | |
| TRINESSA LO TABLET MO | 4 | |
| trivora (28) 50-30 (6)/75-40(5)/125-30(10) tablet MO | 4 | |
| tulana 0.35 mg tablet MO | 4 | |
| VAGIFEM 10 MCG VAGINAL TABLET MO | 4 | PA |
| velivet triphasic regimen (28) 0.1 mg/0.125 mg/0.15 mg-25 mcg tablet MO | 4 | |
| vestura 3 mg-0.02 mg tablet MO | 4 | |
| vienva 0.1 mg-20 mcg tablet MO | 4 | |
| viorele (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet MO | 4 | |
| vyfemla (28) 0.4 mg-35 mcg tablet MO | 4 | |
| vylibra 0.25 mg-35 mcg tablet MO | 4 | |
| wera (28) 0.5 mg-35 mcg tablet MO | 4 | |
| wymzya fe 0.4 mg-35 mcg (21)/75 mg (7) chewable tablet MO | 4 | |
| xulane 150 mcg-35 mcg/24 hr transdermal patch MO | 4 | QL (3 per 28 days) |
| YAZ (28) 3 MG-0.02 MG TABLET MO | 4 | |
| yuvafem 10 mcg vaginal tablet MO | 4 | |
| zarah 3 mg-0.03 mg tablet MO | 4 | |
| zenchent 0.4 mg-35 mcg tablet MO | 4 | |
| zovia 1/35e (28) 1 mg-35 mcg tablet MO | 4 | |
| zovia 1-50e tablet MO | 4 | |
| zumandimine (28) 3 mg-0.03 mg tablet MO | 4 | |
| Hormonal Agents, Stimulant/Replacement/Modifying (Thyroid) | | |
| ARMOUR THYROID 120 MG, 15 MG, 180 MG, 240 MG, 30 MG, 300 MG, 60 MG, 90 MG TABLET MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| LEVO-T 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO | 3 | |
| levothyroxine 100 mcg, 100 mcg/ml, 20 mcg/ml, 200 mcg, 40 mcg/ml, 500 mcg vial; levothyroxine 100 mcg/5 ml vl; levothyroxine 200 mcg/5 ml vl; levothyroxine 500 mcg/5 ml vl MO | 4 | |
| levothyroxine 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg tablet MO | 1 | |
| LEVOXYL 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO | 3 | |
| liothyronine sod 10 mcg/ml vl MO | 3 | |
| liothyronine sod 25 mcg, 5 mcg, 50 mcg tab MO | 3 | |
| SYNTHROID 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO | 3 | |
| THYROLAR-1 12.5 MCG-50 MCG TABLET MO | 2 | |
| THYROLAR-1/2 6.25 MCG-25 MCG TABLET MO | 2 | |
| THYROLAR-1/4 3.1 MCG-12.5 MCG TABLET MO | 2 | |
| THYROLAR-2 25 MCG-100 MCG TABLET MO | 2 | |
| THYROLAR-3 37.5 MCG-150 MCG TABLET MO | 2 | |
| UNITHROID 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO | 3 | |
| Hormonal Agents, Suppressant (Adrenal) | | |
| LYSODREN 500 MG TABLET MO | 3 | |
| Hormonal Agents, Suppressant (Pituitary) | | |
| cabergoline 0.5 mg tablet MO | 4 | QL (16 per 28 days) |
| ELIGARD 7.5 MG (1 MONTH) SUBCUTANEOUS SYRINGE MO | 4 | PA |
| ELIGARD 22.5 MG (3 MONTH) SUBCUTANEOUS SYRINGE MO | 4 | PA |
| ELIGARD 30 MG (4 MONTH) SUBCUTANEOUS SYRINGE MO | 4 | PA |
| ELIGARD 45 MG (6 MONTH) SUBCUTANEOUS SYRINGE MO | 4 | PA |
| FIRMAGON 120 MG SUBCUTANEOUS SOLUTION DL | 5 | PA |
| FIRMAGON KIT WITH DILUENT SYRINGE 120 MG SUBCUTANEOUS SOLUTION DL | 5 | PA |
| FIRMAGON KIT WITH DILUENT SYRINGE 80 MG SUBCUTANEOUS SOLUTION MO | 4 | PA |
| leuprolide 2wk 14 mg/2.8 ml kt MO | 4 | B vs D |
| LUPRON DEPOT 3.75 MG INTRAMUSCULAR SYRINGE KIT MO | 4 | PA,QL (1 per 30 days) |
| LUPRON DEPOT 7.5 MG INTRAMUSCULAR SYRINGE KIT DL | 5 | PA,QL (1 per 30 days) |
| LUPRON DEPOT 11.25 MG, 22.5 MG (3 MONTH) INTRAMUSCULAR SYRINGE KIT MO | 4 | PA,QL (1 per 90 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| LUPRON DEPOT 30 MG (4 MONTH) INTRAMUSCULAR SYRINGE KIT MO | 4 | PA,QL (1 per 112 days) |
| LUPRON DEPOT (6 MONTH) 45 MG INTRAMUSCULAR SYRINGE KIT | 5 | PA,QL (1 per 168 days) |
| LUPRON DEPOT-PED 11.25 MG, 15 MG, 7.5 MG (PED) INTRAMUSCULAR KIT DL | 5 | PA,QL (1 per 28 days) |
| LUPRON DEPOT-PED 11.25 MG, 30 MG (3 MONTH) INTRAMUSCULAR SYRINGE KIT | 5 | PA,QL (1 per 90 days) |
| octreotide 1,000 mcg/ml, 100 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml vial; octreotide acet 0.05 mg/ml vial; octreotide acet 1,000 mcg/ml, 100 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml vial MO | 4 | PA |
| octreotide acet 100 mcg/ml syr; octreotide acet 50 mcg/ml syr; octreotide acet 500 mcg/ml syr MO | 4 | PA |
| SANDOSTATIN LAR DEPOT 10 MG, 20 MG, 30 MG INTRAMUSCULAR SUSP, EXTENDED RELEASE DL | 5 | PA |
| SIGNIFOR 0.3 MG/ML (1 ML), 0.6 MG/ML (1 ML), 0.9 MG/ML (1 ML) SUBCUTANEOUS SOLUTION DL | 5 | PA,QL (60 per 30 days) |
| SOMATULINE DEPOT 120 MG/0.5 ML SUBCUTANEOUS SYRINGE DL | 5 | PA,QL (0.5 per 28 days) |
| SOMATULINE DEPOT 60 MG/0.2 ML SUBCUTANEOUS SYRINGE DL | 5 | PA,QL (0.2 per 28 days) |
| SOMATULINE DEPOT 90 MG/0.3 ML SUBCUTANEOUS SYRINGE DL | 5 | PA,QL (0.3 per 28 days) |
| SOMAVERT 10 MG, 15 MG, 20 MG SUBCUTANEOUS SOLUTION DL | 5 | PA,QL (60 per 30 days) |
| SOMAVERT 25 MG, 30 MG SUBCUTANEOUS SOLUTION DL | 5 | PA,QL (30 per 30 days) |
| SYNAREL 2 MG/ML NASAL SPRAY DL | 5 | |
| TRELSTAR 11.25 MG, 22.5 MG INTRAMUSCULAR SUSPENSION | 5 | PA |
| TRELSTAR 3.75 MG INTRAMUSCULAR SUSPENSION DL | 5 | PA |
| ZOLADEX 10.8 MG SUBCUTANEOUS IMPLANT MO | 4 | PA,QL (1 per 84 days) |
| ZOLADEX 3.6 MG SUBCUTANEOUS IMPLANT MO | 4 | PA,QL (1 per 28 days) |
| Hormonal Agents, Suppressant (Thyroid) | | |
| methimazole 10 mg, 5 mg tablet MO | 2 | |
| propylthiouracil 50 mg tablet MO | 3 | |
| Immunological Agents | | |
| ACTHIB (PF) 10 MCG/0.5 ML INTRAMUSCULAR SOLUTION MO | 4 | |
| ACTIMMUNE 100 MCG (2 MILLION UNIT)/0.5 ML SUBCUTANEOUS SOLUTION DL | 5 | PA |
| ADACEL (TDAP ADOLESN/ADULT)(PF)2 LF-(2.5-5-3-5)-5 LF/0.5 ML IM SYRINGE MO | 4 | |
| ADACEL (TDAP ADOLESN/ADULT)(PF)2LF-(2.5-5-3-5MCG)-5 LF/0.5 ML IM SUSP MO | 4 | |
| ARCALYST 220 MG SUBCUTANEOUS SOLUTION DL | 5 | PA |
| ATGAM 50 MG/ML INTRAVENOUS SOLUTION MO | 4 | PA |
| azathioprine 50 mg tablet MO | 1 | B vs D |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| <i>bcg vaccine (tice strain) vial</i> ^{MO} | 4 | |
| BENLYSTA 120 MG INTRAVENOUS SOLUTION ^{DL} | 5 | PA,QL (20 per 28 days) |
| BENLYSTA 200 MG/ML SUBCUTANEOUS AUTO-INJECTOR ^{DL} | 5 | PA,QL (4 per 28 days) |
| BENLYSTA 200 MG/ML SUBCUTANEOUS SYRINGE ^{DL} | 5 | PA,QL (4 per 28 days) |
| BENLYSTA 400 MG INTRAVENOUS SOLUTION ^{DL} | 5 | PA,QL (6 per 28 days) |
| BEXSERO 50 MCG-50 MCG-50 MCG-25 MCG/0.5 ML INTRAMUSCULAR SYRINGE ^{MO} | 4 | |
| BOOSTRIX TDAP 2.5 LF UNIT-8 MCG-5 LF/0.5 ML INTRAMUSCULAR SUSPENSION ^{MO} | 4 | |
| BOOSTRIX TDAP 2.5 LF UNIT-8 MCG-5 LF/0.5 ML INTRAMUSCULAR SYRINGE ^{MO} | 4 | |
| CELLCEPT 200 MG/ML ORAL SUSPENSION ^{DL} | 5 | B vs D |
| CELLCEPT 250 MG CAPSULE ^{MO} | 4 | B vs D |
| CELLCEPT 500 MG TABLET ^{DL} | 5 | B vs D |
| CELLCEPT INTRAVENOUS 500 MG INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| <i>cyclosporine 100 mg, 25 mg capsule</i> ^{MO} | 4 | B vs D |
| <i>cyclosporine 250 mg/5 ml ampul</i> ^{MO} | 4 | B vs D |
| <i>cyclosporine modified 100 mg, 25 mg, 50 mg</i> ^{MO} | 4 | B vs D |
| <i>cyclosporine modified 100mg/ml</i> ^{MO} | 4 | B vs D |
| CYTOGAM 50 MG/ML INTRAVENOUS SOLUTION ^{DL} | 5 | PA,QL (1050 per 30 days) |
| DAPTACEL (DTAP PEDIATRIC) (PF) 15 LF UNIT-10 MCG-5 LF/0.5 ML IM SUSP ^{MO} | 4 | |
| ENBREL 25 MG (1 ML) SUBCUTANEOUS SOLUTION ^{DL} | 5 | PA,QL (8 per 28 days) |
| ENBREL 25 MG/0.5 ML (0.5 ML) SUBCUTANEOUS SYRINGE ^{DL} | 5 | PA,QL (8.16 per 28 days) |
| ENBREL 50 MG/ML (1 ML) SUBCUTANEOUS SYRINGE ^{DL} | 5 | PA,QL (7.84 per 28 days) |
| ENBREL MINI 50 MG/ML (1 ML) SUBCUTANEOUS CARTRIDGE ^{DL} | 5 | PA,QL (7.84 per 28 days) |
| ENBREL SURECLICK 50 MG/ML (1 ML) SUBCUTANEOUS PEN INJECTOR ^{DL} | 5 | PA,QL (7.84 per 28 days) |
| ENGERIX-B (PF) 20 MCG/ML INTRAMUSCULAR SUSPENSION ^{MO} | 4 | B vs D |
| ENGERIX-B (PF) 20 MCG/ML INTRAMUSCULAR SYRINGE ^{MO} | 4 | B vs D |
| ENGERIX-B PEDIATRIC (PF) 10 MCG/0.5 ML INTRAMUSCULAR SYRINGE ^{MO} | 4 | B vs D |
| FIRAZYR 30 MG/3 ML SUBCUTANEOUS SYRINGE ^{DL} | 5 | PA,QL (9 per 30 days) |
| GAMUNEX-C 1 GRAM/10 ML (10 %), 10 GRAM/100 ML (10 %), 2.5 GRAM/25 ML (10 %), 20 GRAM/200 ML (10 %), 40 GRAM/400 ML (10 %), 5 GRAM/50 ML (10 %) INJECTION SOLUTION ^{DL} | 5 | PA |
| GARDASIL 9 (PF) 0.5 ML INTRAMUSCULAR SUSPENSION ^{MO} | 4 | QL (1.5 per 365 days) |
| GARDASIL 9 (PF) 0.5 ML INTRAMUSCULAR SYRINGE ^{MO} | 4 | QL (1.5 per 365 days) |
| <i>gengraf 100 mg, 25 mg, 50 mg capsule</i> ^{MO} | 4 | B vs D |
| <i>gengraf 100 mg/ml oral solution</i> ^{MO} | 4 | B vs D |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| HAEGARDA 2,000 UNIT, 3,000 UNIT SUBCUTANEOUS SOLUTION DL | 5 | PA,QL (24 per 28 days) |
| HAVRIX (PF) 1,440 ELISA UNIT/ML, 720 ELISA UNIT/0.5 ML INTRAMUSCULAR SUSPENSION; HAVRIX 720 UNITS/0.5 ML VIAL MO | 4 | |
| HAVRIX (PF) 1,440 ELISA UNIT/ML, 720 ELISA UNIT/0.5 ML INTRAMUSCULAR SYRINGE MO | 4 | |
| HIBERIX (PF) 10 MCG/0.5 ML INTRAMUSCULAR SOLUTION MO | 4 | |
| HUMIRA 10 MG/0.2 ML SUBCUTANEOUS SYRINGE KIT DL | 5 | PA,QL (2 per 28 days) |
| HUMIRA 20 MG/0.4 ML, 40 MG/0.8 ML SUBCUTANEOUS SYRINGE KIT DL | 5 | PA,QL (6 per 28 days) |
| HUMIRA PEDIATRIC CROHN'S STARTER 40 MG/0.8 ML SUBCUTANEOUS SYRINGE KIT DL | 5 | PA,QL (6 per 28 days) |
| HUMIRA PEN 40 MG/0.8 ML SUBCUTANEOUS KIT DL | 5 | PA,QL (6 per 28 days) |
| HUMIRA PEN CROHN'S-ULC COLITIS-HID SUP STARTER 40 MG/0.8 ML SUBCUT KIT DL | 5 | PA,QL (6 per 28 days) |
| HUMIRA PEN PSORIASIS-UVEITIS-ADOL HID SUP START 40 MG/0.8 ML SUBCUT KIT DL | 5 | PA,QL (6 per 28 days) |
| HUMIRA(CF) 10 MG/0.1 ML SUBCUTANEOUS SYRINGE KIT DL | 5 | PA,QL (2 per 28 days) |
| HUMIRA(CF) 20 MG/0.2 ML, 40 MG/0.4 ML SUBCUTANEOUS SYRINGE KIT DL | 5 | PA,QL (6 per 28 days) |
| HUMIRA(CF) PEDI CROHN'S START 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML SUBCUT SYR KIT; HUMIRA(CF) PEDIATRIC CROHN'S STARTER 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML SUBCUT SYRINGE KIT DL | 5 | PA,QL (6 per 28 days) |
| HUMIRA(CF) PEN 40 MG/0.4 ML, 80 MG/0.8 ML SUBCUTANEOUS KIT DL | 5 | PA,QL (6 per 28 days) |
| HUMIRA(CF) PEN CROHN'S-ULC COLITIS-HID SUP STRT 80 MG/0.8 ML SUBCUT KIT DL | 5 | PA,QL (6 per 28 days) |
| HUMIRA(CF) PEN PS-UV-ADOL HS 80 MG/0.8 ML(1)-40 MG/0.4 ML(2)SUBCUT KIT DL | 5 | PA,QL (6 per 28 days) |
| HYPERRAB (PF) 300 UNIT/ML INTRAMUSCULAR SOLUTION DL | 5 | B vs D |
| HYPERRAB S/D (PF) 150 UNIT/ML INTRAMUSCULAR SOLUTION DL | 5 | B vs D |
| HYPERTET S/D (PF) 250 UNIT INTRAMUSCULAR SYRINGE MO | 4 | B vs D |
| <i>icatibant 30 mg/3 ml syringe</i> DL | 5 | PA,QL (9 per 30 days) |
| IMOGAM RABIES-HT (PF) 150 UNIT/ML INTRAMUSCULAR SOLUTION MO | 4 | B vs D |
| IMOVAX RABIES VACCINE (PF) 2.5 UNIT INTRAMUSCULAR SOLUTION MO | 3 | B vs D |
| INFANRIX (DTAP) (PF) 25 LF UNIT-58 MCG-10 LF/0.5ML INTRAMUSCULAR SUSP MO | 4 | |
| INFANRIX (DTAP)(PF) 25 LF UNIT-58MCG-10 LF/0.5ML INTRAMUSCULAR SYRINGE MO | 4 | |
| INFLECTRA 100 MG INTRAVENOUS SOLUTION DL | 5 | PA |
| IPOL 40 UNIT-8 UNIT-32 UNIT/0.5 ML SUSPENSION FOR INJECTION MO | 4 | |
| IXIARO (PF) 6 MCG/0.5 ML INTRAMUSCULAR SYRINGE MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| KEDRAB (PF) 150 UNIT/ML INTRAMUSCULAR SOLUTION DL | 5 | B vs D |
| KEVZARA 150 MG/1.14 ML, 200 MG/1.14 ML SUBCUTANEOUS PEN INJECTOR DL | 5 | PA,QL (2.28 per 28 days) |
| KEVZARA 150 MG/1.14 ML, 200 MG/1.14 ML SUBCUTANEOUS SYRINGE DL | 5 | PA,QL (2.28 per 28 days) |
| KINRIX (PF) 25 LF-58 MCG-10 LF/0.5 ML INTRAMUSCULAR SUSPENSION MO | 4 | |
| KINRIX (PF) 25 LF-58 MCG-10 LF/0.5 ML INTRAMUSCULAR SYRINGE MO | 4 | |
| leflunomide 10 mg, 20 mg tablet MO | 2 | QL (30 per 30 days) |
| M-M-R II (PF) 1,000-12,500 TCID50/0.5 ML SUBCUTANEOUS SOLUTION MO | 4 | |
| MENACTRA (PF) 4 MCG/0.5 ML INTRAMUSCULAR SOLUTION MO | 4 | |
| MENVEO A-C-Y-W-135-DIP (PF) 10 MCG-5 MCG/0.5 ML INTRAMUSCULAR KIT MO | 4 | |
| methotrexate 2.5 mg tablet MO | 1 | B vs D |
| methotrexate 50 mg/2 ml vial MO | 1 | |
| methotrexate 1 gm vial MO | 2 | |
| methotrexate 50 mg/2 ml vial MO | 1 | |
| mycophenolate 200 mg/ml susp MO | 4 | B vs D |
| mycophenolate 250 mg capsule MO | 3 | B vs D |
| mycophenolate 500 mg tablet MO | 3 | B vs D |
| mycophenolate 500 mg vial MO | 4 | B vs D |
| mycophenolic acid dr 180 mg, 360 mg tb MO | 4 | B vs D |
| MYFORTIC 180 MG, 360 MG TABLET,DELAYED RELEASE MO | 4 | B vs D |
| NULOJIX 250 MG INTRAVENOUS SOLUTION DL | 5 | PA,QL (20 per 30 days) |
| PEDIARIX (PF) 10 MCG-25 LF-25 MCG-10 LF/0.5 ML INTRAMUSCULAR SYRINGE MO | 4 | |
| PEDVAX HIB (PF) 7.5 MCG/0.5 ML INTRAMUSCULAR SOLUTION MO | 4 | |
| PENTACEL (PF) 15 LF UNIT-20 MCG-5 LF /0.5 ML INTRAMUSCULAR KIT MO | 4 | |
| PROGRAF 0.2 MG, 1 MG ORAL GRANULES IN PACKET MO | 4 | B vs D |
| PROGRAF 0.5 MG, 1 MG, 5 MG CAPSULE MO | 4 | B vs D |
| PROGRAF 5 MG/ML INTRAVENOUS SOLUTION MO | 4 | B vs D |
| PROQUAD (PF) 10EXP3-4.3-3-3.99TCID50/0.5ML SUBCUTANEOUS SUSPENSION MO | 4 | |
| QUADRACEL (PF) 15 LF-48 MCG-5 LF UNIT/0.5 ML INTRAMUSCULAR SUSPENSION MO | 4 | |
| RABAVERT (PF) 2.5 UNIT INTRAMUSCULAR SUSPENSION MO | 3 | B vs D |
| RAPAMUNE 0.5 MG, 1 MG, 2 MG TABLET MO | 4 | B vs D |
| RAPAMUNE 1 MG/ML ORAL SOLUTION MO | 4 | B vs D |
| RECOMBIVAX HB (PF) 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML INTRAMUSCULAR SUSPENSION MO | 4 | B vs D |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| RECOMBIVAX HB (PF) 10 MCG/ML, 5 MCG/0.5 ML INTRAMUSCULAR SYRINGE MO | 4 | B vs D |
| REMICADE 100 MG INTRAVENOUS SOLUTION DL | 5 | PA |
| RHOPHYLAC 1,500 UNIT (300 MCG)/2 ML INJECTION SYRINGE DL | 5 | |
| RIDAURA 3 MG CAPSULE DL | 5 | |
| RINVOQ ER 15 MG TABLET,EXTENDED RELEASE DL | 5 | PA,QL (30 per 30 days) |
| ROTARIX 10EXP6 CCID50/ML SUSPENSION MO | 4 | |
| ROTATEQ VACCINE 2 ML ORAL SOLUTION MO | 4 | |
| RUCONEST 2,100 UNIT INTRAVENOUS SOLUTION DL | 5 | PA,QL (8 per 28 days) |
| SANDIMMUNE 100 MG/ML ORAL SOLUTION MO | 4 | B vs D |
| SHINGRIX (PF) 50 MCG/0.5 ML INTRAMUSCULAR SUSPENSION, KIT MO | 3 | QL (2 per 365 days) |
| SIMULECT 10 MG, 20 MG INTRAVENOUS SOLUTION DL | 5 | B vs D |
| <i>sirolimus 0.5 mg, 1 mg, 2 mg tablet</i> MO | 4 | B vs D |
| <i>sirolimus 1 mg/ml solution</i> MO | 4 | B vs D |
| SYLVANT 100 MG, 400 MG INTRAVENOUS SOLUTION DL | 5 | PA |
| SYNAGIS 100 MG/ML, 50 MG/0.5 ML INTRAMUSCULAR SOLUTION DL | 5 | PA |
| <i>tacrolimus 0.5 mg, 1 mg, 5 mg capsule</i> MO | 4 | B vs D |
| <i>tdvax 2 lf unit-2 lf unit/0.5 ml intramuscular suspension</i> MO | 4 | |
| TENIVAC (PF) 5 LF UNIT-2 LF UNIT/0.5 ML INTRAMUSCULAR SUSPENSION MO | 4 | |
| TENIVAC (PF) 5 LF UNIT-2 LF UNIT/0.5 ML INTRAMUSCULAR SYRINGE MO | 4 | |
| <i>diphtheria-tetanus toxoids-ped</i> MO | 4 | |
| THYMOGLOBULIN 25 MG INTRAVENOUS SOLUTION MO | 3 | PA |
| TREXALL 10 MG, 15 MG, 5 MG, 7.5 MG TABLET MO | 4 | B vs D |
| TRUMENBA 120 MCG/0.5 ML INTRAMUSCULAR SYRINGE MO | 4 | |
| TWINRIX (PF) 720 ELISA UNIT-20 MCG/ML INTRAMUSCULAR SYRINGE MO | 4 | |
| TYPHIM VI 25 MCG/0.5 ML INTRAMUSCULAR SOLUTION MO | 4 | |
| TYPHIM VI 25 MCG/0.5 ML INTRAMUSCULAR SYRINGE MO | 4 | |
| VAQTA (PF) 25 UNIT/0.5 ML, 50 UNIT/ML INTRAMUSCULAR SUSPENSION MO | 4 | |
| VAQTA (PF) 25 UNIT/0.5 ML, 50 UNIT/ML INTRAMUSCULAR SYRINGE MO | 4 | |
| VARIVAX (PF) 1,350 UNIT/0.5 ML SUBCUTANEOUS SUSPENSION MO | 3 | |
| VARIZIG 125 UNIT VIAL DL | 5 | PA,QL (10 per 30 days) |
| VARIZIG 125 UNIT/1.2 ML INTRAMUSCULAR SOLUTION DL | 5 | PA,QL (12 per 30 days) |
| WINRHO SDF 1,500 UNIT (300 MCG)/1.3 ML, 15000 UNIT(3000 MCG)/13 ML, 2,500 UNIT (500 MCG)/2.2 ML, 5,000 UNIT(1000 MCG)/4.4 ML INJECTION SOLUTION; WINRHO SDF 15,000 UNIT (3,000 MCG)/13 ML INJECTION SOLUTION; WINRHO SDF 5,000 UNIT (1,000 MCG)/4.4 ML INJECTION SOLUTION DL | 5 | B vs D |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| XATMEP 2.5 MG/ML ORAL SOLUTION DL | 5 | PA |
| XOLAIR 150 MG SUBCUTANEOUS SOLUTION DL | 5 | PA,QL (6 per 28 days) |
| XOLAIR 150 MG/ML SUBCUTANEOUS SYRINGE DL | 5 | PA,QL (6 per 28 days) |
| XOLAIR 75 MG/0.5 ML SUBCUTANEOUS SYRINGE DL | 5 | PA,QL (3 per 28 days) |
| YF-VAX (PF) 10 EXP4.74 UNIT/0.5 ML SUBCUTANEOUS SUSPENSION MO | 4 | |
| ZORTRESS 0.25 MG, 0.75 MG TABLET MO | 4 | B vs D,QL (60 per 30 days) |
| ZORTRESS 0.5 MG TABLET MO | 4 | B vs D,QL (120 per 30 days) |
| ZORTRESS 1 MG TABLET DL | 5 | B vs D,QL (60 per 30 days) |
| ZOSTAVAX (PF) 19,400 UNIT/0.65 ML SUBCUTANEOUS SUSPENSION MO | 4 | QL (1 per 365 days) |
| Inflammatory Bowel Disease Agents | | |
| APRISO 0.375 GRAM CAPSULE,EXTENDED RELEASE MO | 3 | QL (120 per 30 days) |
| <i>balsalazide disodium 750 mg cp</i> MO | 4 | |
| <i>budesonide ec 3 mg capsule</i> MO | 4 | |
| <i>colocort 100 mg enema</i> MO | 4 | |
| <i>hydrocortisone 100 mg/60 ml</i> MO | 4 | |
| <i>mesalamine 4 gm/60 ml enema</i> MO | 4 | QL (1800 per 30 days) |
| <i>sulfasalazine 500 mg tablet; sulfasalazine dr 500 mg tab</i> MO | 1 | |
| Metabolic Bone Disease Agents | | |
| <i>alendronate sodium 10 mg, 40 mg, 5 mg tab; alendronate sodium 10 mg, 40 mg, 5 mg tablet</i> MO | 1 | QL (30 per 30 days) |
| <i>alendronate sodium 35 mg, 70 mg tab</i> MO | 1 | QL (4 per 28 days) |
| BINOSTO 70 MG EFFERVESCENT TABLET MO | 4 | QL (4 per 28 days) |
| <i>calcitonin-salmon 200 units sp</i> MO | 3 | QL (3.7 per 28 days) |
| <i>calcitriol 0.25 mcg, 0.5 mcg capsule</i> MO | 2 | |
| <i>calcitriol 1 mcg/ml ampul</i> MO | 2 | |
| <i>calcitriol 1 mcg/ml solution</i> MO | 4 | |
| <i>cinacalcet hcl 30 mg, 60 mg tablet</i> DL | 5 | QL (60 per 30 days) |
| <i>cinacalcet hcl 90 mg tablet</i> DL | 5 | QL (120 per 30 days) |
| <i>doxercalciferol 0.5 mcg, 1 mcg, 2.5 mcg cap; doxercalciferol 0.5 mcg, 1 mcg, 2.5 mcg capsule</i> MO | 4 | |
| <i>doxercalciferol 4 mcg/2 ml vl</i> MO | 4 | |
| <i>etidronate disodium 200 mg, 400 mg tab</i> MO | 4 | |
| FORTEO 20 MCG/DOSE (600 MCG/2.4 ML) SUBCUTANEOUS PEN INJECTOR MO | 4 | PA,QL (2.4 per 28 days) |
| HECTOROL 2 MCG/ML INTRAVENOUS SOLUTION MO | 3 | |
| <i>ibandronate 3 mg/3 ml syringe</i> MO | 4 | PA,QL (3 per 90 days) |
| <i>ibandronate 3 mg/3 ml vial</i> MO | 4 | PA,QL (3 per 90 days) |
| <i>ibandronate sodium 150 mg tab</i> MO | 2 | QL (1 per 28 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| MIACALCIN 200 UNIT/ML INJECTION SOLUTION MO | 4 | |
| NATPARA 100 MCG/DOSE, 25 MCG/DOSE, 50 MCG/DOSE, 75 MCG/DOSE SUBCUTANEOUS CARTRIDGE DL | 5 | PA,QL (2 per 28 days) |
| <i>pamidronate 30 mg/10 ml vial</i> MO | 1 | B vs D,QL (30 per 21 days) |
| <i>pamidronate 60 mg/10 ml vial; pamidronate 90 mg/10 ml vial</i> MO | 1 | B vs D,QL (10 per 21 days) |
| <i>paricalcitol 1 mcg, 2 mcg capsule</i> MO | 4 | QL (30 per 30 days) |
| <i>paricalcitol 10 mcg/2 ml vial; paricalcitol 5 mcg/ml vial</i> MO | 3 | QL (48 per 28 days) |
| <i>paricalcitol 2 mcg/ml vial</i> MO | 3 | QL (24 per 30 days) |
| <i>paricalcitol 4 mcg capsule</i> MO | 4 | QL (12 per 30 days) |
| PROLIA 60 MG/ML SUBCUTANEOUS SYRINGE MO | 4 | B vs D,QL (1 per 180 days) |
| <i>risedronate sod dr 35 mg tab; risedronate sodium 35 mg tab</i> MO | 4 | QL (4 per 28 days) |
| <i>risedronate sodium 150 mg tab</i> MO | 4 | QL (1 per 30 days) |
| <i>risedronate sodium 30 mg, 5 mg tab; risedronate sodium 30 mg, 5 mg tablet</i> MO | 4 | QL (30 per 30 days) |
| SENSIPAR 30 MG, 60 MG TABLET DL | 5 | QL (60 per 30 days) |
| SENSIPAR 90 MG TABLET DL | 5 | QL (120 per 30 days) |
| XGEVA 120 MG/1.7 ML (70 MG/ML) SUBCUTANEOUS SOLUTION DL | 5 | PA,QL (1.7 per 28 days) |
| <i>zoledronic acid 4 mg/100 ml</i> MO | 4 | PA,QL (300 per 21 days) |
| <i>zoledronic acid 4 mg vial</i> MO | 4 | PA |
| <i>zoledronic acid 4 mg/5 ml vial</i> MO | 4 | PA,QL (15 per 21 days) |
| <i>zoledronic acid 5 mg/100 ml</i> MO | 2 | PA,QL (100 per 365 days) |
| Miscellaneous Therapeutic Agents | | |
| 1ST TIER UNIFINE PENTIPS 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" NEEDLE MO | 1 | |
| 1ST TIER UNIFINE PENTIPS PLUS 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" NEEDLE MO | 1 | |
| <i>acetic acid 0.25% irrig soln</i> MO | 2 | |
| <i>acetylcysteine 6 gram/30 ml vl</i> MO | 4 | |
| ADVOCATE PEN NEEDLE 29 GAUGE X 1/2", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 33 GAUGE X 5/32" MO | 1 | |
| ADVOCATE SYRINGES 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16"; ADVOCATE SYRINGES 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16" MO | 1 | |
| ALCOHOL PADS MO | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| ALCOHOL PREP PADS MO | 1 | |
| ALCOHOL SWAB MO | 1 | |
| ALCOHOL WIPES MO | 1 | |
| ASSURE ID INSULIN SAFETY 0.5 ML 29 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" SYRINGE MO | 1 | |
| ASSURE ID PEN NEEDLE 30 GAUGE X 3/16", 30 GAUGE X 5/16", 31 GAUGE X 3/16" MO | 1 | |
| AUTOJECT 2 INJECTION DEVICE SUBCUTANEOUS INSULIN PEN MO | 1 | |
| AUTOPEN 1 TO 21 UNITS SUBCUTANEOUS MO | 1 | |
| AUTOPEN 2 TO 42 UNITS SUBCUTANEOUS MO | 1 | |
| BAL IN OIL 100 MG/ML INTRAMUSCULAR SOLUTION MO | 4 | |
| BAND-AID GAUZE PADS 2" X 2" BANDAGE MO | 1 | |
| BD ALCOHOL SWABS MO | 1 | |
| BD AUTOSHIELD DUO PEN NEEDLE 30 GAUGE X 3/16" MO | 1 | |
| BD ECLIPSE LUER-LOK 1 ML 30 GAUGE X 1/2" SYRINGE MO | 1 | |
| BD INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.5 ML 29 GAUGE X 1/2", 1 ML 25 GAUGE X 5/8", 1 ML 25 X 1", 1 ML 26 X 1/2", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" MO | 1 | |
| BD INSULIN SYRINGE HALF UNIT ULTRA-FINE 0.3 ML 31 GAUGE X 5/16" MO | 1 | |
| BD INSULIN SYRINGE MICRO-FINE 1 ML 28 GAUGE X 1/2" MO | 1 | |
| BD INSULIN SYRINGE SAFETY-LOK 1 ML 29 GAUGE X 1/2" MO | 1 | |
| BD INSULIN SYRINGE SLIP TIP 1 ML MO | 1 | |
| BD INSULIN SYRINGE U-500 1/2 ML 31 GAUGE X 15/64" MO | 1 | |
| BD INSULIN SYRINGE ULTRA-FINE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 31 GAUGE X 5/16; BD INSULIN SYRINGE ULTRA-FINE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 31 GAUGE X 5/16" MO | 1 | |
| BD LO-DOSE MICRO-FINE IV 1/2 ML 28 GAUGE X 1/2" SYRINGE MO | 1 | |
| BD LO-DOSE ULTRA-FINE 0.5 ML 29 GAUGE X 1/2" SYRINGE MO | 1 | |
| BD NANO 2ND GEN PEN NEEDLE 32 GAUGE X 5/32" MO | 1 | |
| BD SAFETYGLIDE INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 15/64", 1 ML 29 GAUGE X 1/2", 1 ML 31 GAUGE X 15/64" MO | 1 | |
| BD SAFETYGLIDE SYRINGE 1 ML 27 GAUGE X 5/8" MO | 1 | |
| BD ULTRA-FINE MICRO PEN NEEDLE 32 GAUGE X 1/4" MO | 1 | |
| BD ULTRA-FINE MINI PEN NEEDLE 31 GAUGE X 3/16" MO | 1 | |
| BD ULTRA-FINE NANO PEN NEEDLE 32 GAUGE X 5/32" MO | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| BD ULTRA-FINE ORIGINAL PEN NEEDLE 29 GAUGE X 1/2" MO | 1 | |
| BD ULTRA-FINE SHORT PEN NEEDLE 31 GAUGE X 5/16" MO | 1 | |
| BD VEO INSULIN SYRINGE HALF UNIT ULTRA-FINE 0.3 ML 31 GAUGE X 15/64" MO | 1 | |
| BD VEO INSULIN SYRINGE ULTRA-FINE 0.3 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 15/64", 1/2 ML 31 GAUGE X 15/64" MO | 1 | |
| BORDERED GAUZE 2" X 2" BANDAGE MO | 1 | |
| CABLIVI 11 MG INJECTION KIT DL | 5 | PA,QL (30 per 30 days) |
| <i>caffeine cit 60 mg/3 ml oral; caffeine cit 60 mg/3 ml vial</i> MO | 1 | |
| <i>calcium disodium versenate 200 mg/ml injection solution</i> MO | 1 | |
| CAREFINE PEN NEEDLE 29 GAUGE X 1/2", 30 GAUGE X 5/16", 31 GAUGE X 1/4", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/32" MO | 1 | |
| CARETOUCH ALCOHOL PREP PAD TOPICAL PADS MO | 1 | |
| CARETOUCH INSULIN SYRINGE 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 X 5/16", 1 ML 29 GAUGE X 5/16, 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16; CARETOUCH INSULIN SYRINGE 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 X 5/16", 1 ML 29 GAUGE X 5/16, 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16"; CARETOUCH INSULIN SYRINGE 1 ML 28 GAUGE X 5/16" MO | 1 | |
| CARETOUCH PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 3/16", 32 GAUGE X 5/32" MO | 1 | |
| CLICKFINE PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 5/16", 32 GAUGE X 5/32" MO | 1 | |
| COMFORT EZ INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2"; COMFORT EZ INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2" MO | 1 | |
| COMFORT EZ PEN NEEDLES 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/16", 32 GAUGE X 5/32", 33 GAUGE X 1/4", 33 GAUGE X 3/16", 33 GAUGE X 5/16", 33 GAUGE X 5/32" MO | 1 | |
| CURITY ALCOHOL SWABS MO | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| CURITY GAUZE 2" X 2" BANDAGE MO | 1 | |
| DERMACEA 2" X 2" BANDAGE MO | 1 | |
| DROPLET INSULIN SYRINGE HALF UNIT 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 15/64", 0.5 ML 31 GAUGE X 5/16", 0.5ML 30 GAUGE X 15/64"; DROPLET INSULIN SYRINGE HALF UNIT 0.5 ML 30 GAUGE X 15/64" MO | 1 | |
| DROPLET INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 15/64", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 15/64", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 5/16; DROPLET INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 15/64", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 15/64", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 5/16" MO | 1 | |
| DROPLET PEN NEEDLE 29 GAUGE X 1/2", 29 GAUGE X 3/8", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/16", 32 GAUGE X 5/32" MO | 1 | |
| DROPSAFE PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 5/16" MO | 1 | |
| EASY COMFORT ALCOHOL PAD TOPICAL PADS MO | 1 | |
| EASY COMFORT INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1 ML 32 GAUGE X 5/16", 1/2 ML 32 GAUGE X 5/16"; EASY COMFORT INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1 ML 32 GAUGE X 5/16", 1/2 ML 32 GAUGE X 5/16" MO | 1 | |
| EASY COMFORT PEN NEEDLES 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32", 33 GAUGE X 1/4", 33 GAUGE X 3/16", 33 GAUGE X 5/32" MO | 1 | |
| EASY GLIDE INSULIN SYRINGE 0.3 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 15/64", 1/2 ML 31 GAUGE X 15/64" MO | 1 | |
| EASY GLIDE PEN NEEDLE 33 GAUGE X 5/32" MO | 1 | |
| EASY TOUCH 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/32" NEEDLE MO | 1 | |
| EASY TOUCH ALCOHOL PREP PADS MO | 1 | |
| EASY TOUCH FLIPLOCK INSULIN 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16" SYRINGE; EASY TOUCH FLIPLOCK INSULIN SYRINGE 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16" MO | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| EASY TOUCH INSULIN SAFETY SYRINGE 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2" MO | 1 | |
| EASY TOUCH INSULIN SYRINGE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 27 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2"; EASY TOUCH INSULIN SYRINGE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 27 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2" MO | 1 | |
| EASY TOUCH LUER LOCK INSULIN 1 ML SYRINGE MO | 1 | |
| EASY TOUCH PEN NEEDLE 30 GAUGE X 5/16" MO | 1 | |
| EASY TOUCH SHEATHLOCK INSULIN 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16" SYRINGE; EASY TOUCH SHEATHLOCK INSULIN SYRINGE 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16" MO | 1 | |
| EASY TOUCH UNI-SLIP 1 ML SYRINGE MO | 1 | |
| <i>enlon 10 mg/ml vial</i> MO | 1 | |
| EXEL INSULIN 0.3 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2" SYRINGE; EXEL INSULIN 0.3 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2" SYRINGE MO | 1 | |
| <i>flumazenil 0.5 mg/5 ml vial</i> MO | 4 | |
| FREESTYLE PRECISION 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 SYRINGE; FREESTYLE PRECISION 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" SYRINGE MO | 1 | |
| GAUZE PADS 2"X2" MO | 1 | |
| GAUZE PAD 2" X 2" BANDAGE MO | 1 | |
| HEALTHWISE INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16; HEALTHWISE INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" MO | 1 | |
| HEALTHWISE PEN NEEDLE 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" MO | 1 | |
| HEALTHY ACCENTS UNIFINE PENTIP 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" NEEDLE MO | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| HUMAPEN LUXURA HD MO | 1 | |
| INCONTROL ALCOHOL PADS MO | 1 | |
| INCONTROL PEN NEEDLE 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" MO | 1 | |
| INSULIN SYR 0.3ML 31GX1/4(1/2) MO | 1 | |
| INSULIN SYRINGE 0.5 ML 29 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" MO | 1 | |
| INSULIN SYRINGE MICROFINE 1 ML 27 GAUGE X 5/8", 1/2 ML 28 GAUGE X 1/2" MO | 1 | |
| BD LUER-LOK SYRINGE 1 ML MO | 1 | |
| BD INSULIN SYR 1 ML 28GX1/2"; INSULIN 1 ML SYRINGE; INSULIN 1/2 ML SYRINGE; INSULIN 3/10 ML SYRINGE; INSULIN SYRIN 0.3 ML 30GX1/2"; INSULIN SYRIN 0.3 ML 31GX5/16"; INSULIN SYRIN 0.5 ML 30GX1/2"; INSULIN SYRING 0.5 ML 27GX1/2"; INSULIN SYRINGE 0.3 ML 31GX1/4; INSULIN SYRINGE 0.5 ML 31GX1/4; INSULIN SYRINGE 1 ML 27GX1/2"; INSULIN SYRINGE 1 ML 30GX1/2"; INSULIN SYRINGE 1 ML 31GX1/4"; INSULIN SYRINGE 1 ML 31GX5/16"; PREFERRED PLUS SYRINGE 0.5 ML; PREFERRED PLUS SYRINGE 1 ML; RELI-ON INSULIN 0.3 ML SYR; RELI-ON INSULIN 0.5 ML SYR; RELI-ON INSULIN 1 ML SYR; RELION INS SYR 0.3 ML 29GX1/2"; RELION INS SYR 0.3 ML 31GX6MM; RELION INS SYR 0.5 ML 31GX6MM; RELION INS SYR 1 ML 29GX1/2"; RELION INS SYR 1 ML 31GX15/64"; RELION SYRING 0.5 ML 31GX5/16"; TERUMO INS SYRINGE U100-1 ML; ULTICARE SAFETY 0.5 ML 29GX1/2; ULTICARE SYR 0.3 ML 30GX5/16"; ULTICARE SYR 0.5 ML 30GX5/16"; ULTICARE SYR 1 ML 30GX5/16"; ULTICARE SYRIN 0.5 ML 28GX1/2" MO | 1 | |
| INSUPEN 29 GAUGE X 1/2", 30 GAUGE X 5/16", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 5/16", 32 GAUGE X 5/32", 33 GAUGE X 5/32" NEEDLE MO | 1 | |
| IV PREP WIPES MEDICATED MO | 1 | |
| KORLYM 300 MG TABLET DL | 5 | PA,QL (120 per 30 days) |
| <i>lactated ringers irrigation</i> MO | 2 | |
| LITE TOUCH INSULIN PEN NEEDLES 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16" MO | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| LITE TOUCH INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE, 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 30 GAUGE X 7/16", 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE, 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 GAUGE; LITE TOUCH INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE, 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 30 GAUGE X 7/16", 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE, 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 GAUGE"; LITE TOUCH INSULIN SYRINGE 1/2 ML 29 MO | 1 | |
| LITHOSTAT 250 MG TABLET MO | 4 | |
| MAGELLAN INSULIN SAFETY SYRINGE 0.3 ML 29 X 1/2", 0.5 ML 29 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16" MO | 1 | |
| MAGELLAN SYRINGE 0.3 ML 30 X 5/16", 0.5 ML 30 GAUGE X 5/16" MO | 1 | |
| MAXI-COMFORT INSULIN SYRINGE 1 ML 28 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2" MO | 1 | |
| MAXICOMFORT II PEN NEEDLE 31 GAUGE X 1/4" MO | 1 | |
| MAXICOMFORT INSULIN SYRINGE 1 ML 27 GAUGE X 1/2", 1/2 ML 27 GAUGE X 1/2" MO | 1 | |
| MAXICOMFORT SAFETY PEN NEEDLE 29 GAUGE X 3/16", 29 GAUGE X 5/16" MO | 1 | |
| <i>methergine 0.2 mg tablet</i> MO | 4 | |
| <i>methylergonovine 0.2 mg tablet</i> MO | 4 | |
| <i>methylergonovine 0.2 mg/ml amp</i> MO | 3 | |
| MICRODOT INSULIN PEN NEEDLE 31 GAUGE X 1/4", 32 GAUGE X 5/32", 33 GAUGE X 5/32" MO | 1 | |
| MINI ULTRA-THIN II 31 GAUGE X 3/16" NEEDLE MO | 1 | |
| MONOJECT INSULIN SAFETY SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 29 GAUGE X 1/2" MO | 1 | |
| MONOJECT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 25 GAUGE X 5/8", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2"; MONOJECT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 25 GAUGE X 5/8", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2"; MONOJECT INSULIN SYRINGE 1 ML MO | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| MONOJECT SYRINGE 1/2 ML 28 GAUGE MO | 1 | |
| MONOJECT ULTRA COMFORT INSULIN 1/2 ML 28 GAUGE SYRINGE MO | 1 | |
| NOVOFINE 30G X 1/3" NEEDLES MO | 1 | |
| NOVOFINE 32 32 GAUGE X 1/4" NEEDLE MO | 1 | |
| NOVOFINE AUTOCOVER 30 GAUGE X 1/3" NEEDLE MO | 1 | |
| NOVOFINE PLUS 32 GAUGE X 1/6" NEEDLE MO | 1 | |
| NOVOPEN ECHO SUBCUTANEOUS MO | 1 | |
| NOVOTWIST 32 GAUGE X 1/5" NEEDLE MO | 1 | |
| OMNIPOD DASH INSULIN POD SUBCUTANEOUS CARTRIDGE MO | 3 | |
| OMNIPOD INSULIN MANAGEMENT MO | 3 | |
| OMNIPOD INSULIN REFILL SUBCUTANEOUS CARTRIDGE MO | 3 | |
| PEN NEEDLE 29 GAUGE X 1/2", 30 GAUGE X 5/16", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" MO | 1 | |
| COMFORT POINT PEN NDL 31GX1/3"; COMFORT POINT PEN NDL 31GX1/6"; FIFTY50 PEN 31G X 3/16" NEEDLE; FIFTY50 PEN NEEDLE 32G X 1/4"; PEN NEEDLE 12MM 29G; PEN NEEDLE 32G X 3/16"; PEN NEEDLE 32G X 5/32"; PEN NEEDLE 8MM 31G; PEN NEEDLES 6MM 31G MO | 1 | |
| PENTIPS 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" NEEDLE MO | 1 | |
| PREVENT DROPSAFE PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 5/16" MO | 1 | |
| PRIALT 100 MCG/ML, 25 MCG/ML INTRATHECAL SOLUTION DL | 5 | PA |
| PRO COMFORT ALCOHOL PADS MO | 1 | |
| PRO COMFORT INSULIN SYRINGE 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16; PRO COMFORT INSULIN SYRINGE 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" MO | 1 | |
| PRO COMFORT PEN NEEDLE 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/32" MO | 1 | |
| PRODIGY INSULIN SYRINGE 0.3 ML 31 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2" MO | 1 | |
| <i>protamine 250 mg/25 ml vial</i> MO | 1 | |
| RELION NEEDLES 31 GAUGE X 1/4" MO | 1 | |
| RELION PEN NEEDLES 32 GAUGE X 5/32" MO | 1 | |
| RENACIDIN 1980.6 MG-59.4MG-980.4MG/30ML IRRIGATION SOLUTION MO | 4 | |
| <i>ringers irrigation solution</i> MO | 1 | |
| SAFESNAP INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" MO | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| SAFETY PEN NEEDLE 31 GAUGE X 3/16" MO | 1 | |
| <i>sod phenylacet-sod benzoate vl</i> DL | 5 | |
| <i>sorbitol-mannitol irrig</i> MO | 1 | |
| SURE COMFORT ALCOHOL PREP PADS MO | 1 | |
| SURE COMFORT INSULIN SYRINGE U-100 0.5 ML 29 GAUGE X 1/2" MO | 1 | |
| SURE COMFORT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 1/4", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 1/4", 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2", 1/2 ML 31 GAUGE X 1/4"; SURE COMFORT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 1/4", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 1/4", 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2", 1/2 ML 31 GAUGE X 1/4" MO | 1 | |
| SURE COMFORT PEN NEEDLE 29 GAUGE X 1/2", 30 GAUGE X 5/16", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 5/32" MO | 1 | |
| SURE-FINE PEN NEEDLES 29 GAUGE X 1/2", 31 GAUGE X 3/16", 31 GAUGE X 5/16" MO | 1 | |
| SURE-JECT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2"; SURE-JECT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2" MO | 1 | |
| SURE-PREP ALCOHOL PREP PADS MO | 1 | |
| TECHLITE INSULIN SYRINGE HALF UNIT 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 15/64", 0.5 ML 31 GAUGE X 5/16" MO | 1 | |
| TECHLITE INSULIN SYRINGE 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 5/16; TECHLITE INSULIN SYRINGE 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 5/16" MO | 1 | |
| TECHLITE PEN NEEDLE 29 GAUGE X 1/2", 29 GAUGE X 3/8", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 5/16", 32 GAUGE X 5/32" MO | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| TERUMO INSULIN SYRINGE 0.3 ML 30 X 3/8", 0.5 ML 29 GAUGE X 1/2", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1/2 ML 27 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 X 3/8" MO | 1 | |
| THINPRO INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 X 3/8", 0.3 ML 31 X 3/8", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 31 X 3/8", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 3/8", 1 ML 31 X 3/8", 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 X 3/8" MO | 1 | |
| TOPCARE CLICKFINE 31 GAUGE X 1/4", 31 GAUGE X 5/16" NEEDLE MO | 1 | |
| TOPCARE ULTRA COMFORT 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 SYRINGE; TOPCARE ULTRA COMFORT 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" SYRINGE MO | 1 | |
| TRUE COMFORT ALCOHOL PADS MO | 1 | |
| TRUE COMFORT INSULIN SYRINGE 0.5 ML 31 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16; TRUE COMFORT INSULIN SYRINGE 0.5 ML 31 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16" MO | 1 | |
| TRUE COMFORT PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 3/16", 32 GAUGE X 5/32" MO | 1 | |
| TRUEPLUS INSULIN 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2" SYRINGE; TRUEPLUS INSULIN 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2" SYRINGE MO | 1 | |
| TRUEPLUS PEN NEEDLE 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" MO | 1 | |
| ULTICARE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 31 GAUGE X 5/16 SYRINGE; ULTICARE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 31 GAUGE X 5/16" SYRINGE MO | 1 | |
| ULTICARE INSULIN SYRINGE HALF UNIT 0.3 ML 31 GAUGE X 1/4" MO | 1 | |
| ULTICARE INSULIN SYRINGE 0.3 ML 31 GAUGE X 1/4", 1 ML 31 GAUGE X 1/4", 1/2 ML 31 GAUGE X 1/4" MO | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| ULTICARE PEN NEEDLE 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 5/32" MO | 1 | |
| ULTILET ALCOHOL SWAB MO | 1 | |
| ULTILET INSULIN SYRINGE 0.3 ML 29 GAUGE, 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16; ULTILET INSULIN SYRINGE 0.3 ML 29 GAUGE, 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16"; ULTILET INSULIN SYRINGE 1/2 ML 29 MO | 1 | |
| ULTILET PEN NEEDLE 29 GAUGE, 32 GAUGE X 5/32" MO | 1 | |
| ULTRA COMFORT INSULIN SYRINGE HALF UNIT 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16" MO | 1 | |
| ULTRA COMFORT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30, 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE, 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 30 GAUGE X 7/16", 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE, 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 GAUGE; ULTRA COMFORT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30, 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE, 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 30 GAUGE X 7/16", 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE, 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 GAUGE"; ULTRA COMFORT INSULIN SYRINGE 1/2 ML 29 MO | 1 | |
| ULTRA FLO PEN NEEDLE 31 GAUGE X 3/16" MO | 1 | |
| ULTRA THIN PEN NEEDLE 32 GAUGE X 5/32" MO | 1 | |
| ULTRA-THIN II (SHORT) INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16; ULTRA-THIN II (SHORT) INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" MO | 1 | |
| ULTRA-THIN II (SHORT) PEN NDL 31 GAUGE X 5/16" NEEDLE MO | 1 | |
| ULTRA-THIN II INSULIN PEN NEEDLES 29 GAUGE X 1/2" MO | 1 | |
| ULTRA-THIN II INS 0.3 ML 29G; ULTRA-THIN II INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.5 ML 29 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" MO | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| ULTRACARE INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16; ULTRACARE INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" MO | 1 | |
| ULTRACARE PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/32", 33 GAUGE X 5/32" MO | 1 | |
| UNIFINE PENTIPS 29 GAUGE, 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 5/32", 33 GAUGE X 5/32" NEEDLE MO | 1 | |
| UNIFINE PENTIPS MAXFLOW 30 GAUGE X 3/16" NEEDLE MO | 1 | |
| UNIFINE PENTIPS PLUS 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32", 33 GAUGE X 5/32" NEEDLE MO | 1 | |
| UNIFINE PENTIPS PLUS MAXFLOW 30 GAUGE X 3/16" NEEDLE MO | 1 | |
| V-GO 20 DEVICE MO | 3 | |
| V-GO 30 DEVICE MO | 3 | |
| V-GO 40 DEVICE MO | 3 | |
| VANISHPOINT SYRINGE 0.5 ML 30 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" MO | 1 | |
| VERIFINE PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 5/16", 32 GAUGE X 3/16", 32 GAUGE X 5/32" MO | 1 | |
| VISTOGARD 10 GRAM ORAL GRANULES IN PACKET DL | 5 | QL (20 per 365 days) |
| <i>sterile water for irrigation</i> MO | 2 | |
| WEBCOL TOPICAL PADS MO | 1 | |
| Ophthalmic Agents | | |
| <i>ak-poly-bac 500 unit-10,000 unit/gram eye ointment</i> MO | 2 | |
| AKTEN (PF) 3.5 % EYE GEL MO | 4 | |
| ALCAINE 0.5 % EYE DROPS MO | 2 | |
| ALPHAGAN P 0.1 % EYE DROPS MO | 3 | |
| <i>apraclonidine hcl 0.5% drops</i> MO | 4 | |
| <i>atropine 1% eye drops</i> MO | 2 | |
| <i>azelastine hcl 0.05% drops</i> MO | 3 | |
| <i>bacitracin-polymyxin eye oint</i> MO | 2 | |
| BEPREVE 1.5 % EYE DROPS MO | 4 | QL (5 per 25 days) |
| BETADINE OPHTHALMIC PREP 5 % SOLUTION MO | 4 | |
| <i>betaxolol hcl 0.5% eye drop</i> MO | 3 | |
| <i>brimonidine 0.2% eye drop</i> MO | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| brimonidine tartrate 0.15% drp ^{MO} | 3 | |
| carteolol hcl 1% eye drops ^{MO} | 1 | |
| COMBIGAN 0.2 %-0.5 % EYE DROPS ^{MO} | 3 | QL (5 per 25 days) |
| cromolyn 4% eye drops ^{MO} | 1 | |
| CYSTARAN 0.44 % EYE DROPS ^{DL} | 5 | PA,QL (60 per 28 days) |
| dexamethasone 0.1% eye drop ^{MO} | 2 | |
| diclofenac 0.1% eye drops ^{MO} | 2 | |
| dorzolamide hcl 2% eye drops ^{MO} | 1 | QL (10 per 30 days) |
| dorzolamide-timolol eye drops ^{MO} | 1 | QL (10 per 30 days) |
| DUREZOL 0.05 % EYE DROPS ^{MO} | 3 | |
| fluorometholone 0.1% drops ^{MO} | 3 | |
| flurbiprofen 0.03% eye drop ^{MO} | 2 | |
| ILEVRO 0.3 % EYE DROPS,SUSPENSION ^{MO} | 3 | |
| ketorolac 0.4% ophth solution; ketorolac 0.5% ophth solution ^{MO} | 2 | |
| latanoprost 0.005% eye drops ^{MO} | 1 | QL (5 per 25 days) |
| levobunolol 0.5% eye drops ^{MO} | 1 | |
| LOTEMAX 0.5 % EYE DROPS,SUSPENSION; LOTE MAX 0.5 % EYE GEL DROPS ^{MO} | 4 | |
| LOTEMAX 0.5 % EYE OINTMENT ^{MO} | 4 | |
| LOTEMAX SM 0.38 % EYE GEL DROPS ^{MO} | 4 | |
| loteprednol etabonate 0.5% drp ^{MO} | 4 | |
| LUMIGAN 0.01 % EYE DROPS ^{MO} | 3 | QL (2.5 per 25 days) |
| metipranolol 0.3% eye drops ^{MO} | 2 | |
| MIOSTAT 0.01 % INTRAOCULAR SOLUTION ^{MO} | 4 | |
| neo-polycin 3.5 mg-400 unit-10,000 unit/g eye ointment ^{MO} | 3 | |
| neo-polycin hc 3.5 mg-400-10,000 unit/g-1 % eye ointment ^{MO} | 3 | |
| neo-bacit-poly-hc eye ointment ^{MO} | 3 | |
| neomyc-bacit-polymix eye oint ^{MO} | 3 | |
| neomyc-polym-dexamet eye ointm ^{MO} | 2 | |
| neomyc-polym-dexameth eye drop ^{MO} | 2 | |
| neomyc-polym-gramicid eye drop ^{MO} | 3 | |
| neomycin-poly-hc eye drops ^{MO} | 4 | |
| olopatadine hcl 0.1% eye drops ^{MO} | 3 | ST |
| olopatadine hcl 0.2% eye drop ^{MO} | 2 | |
| PATADAY 0.2 % EYE DROPS ^{MO} | 4 | ST |
| PAZEO 0.7 % EYE DROPS ^{MO} | 3 | QL (2.5 per 25 days) |
| PHOSPHOLINE IODIDE 0.125 % EYE DROPS ^{MO} | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| <i>pilocarpine 1% eye drops; pilocarpine 2% eye drops; pilocarpine 4% eye drops</i> MO | 3 | |
| <i>polycin 500 unit-10,000 unit/gram eye ointment</i> MO | 2 | |
| <i>polymyxin b-tmp eye drops</i> MO | 1 | |
| PRED-G 0.3 %-1 % EYE DROPS,SUSPENSION MO | 4 | |
| PRED-G S.O.P. 0.3 %-0.6 % EYE OINTMENT MO | 4 | |
| <i>prednisolone ac 1% eye drop</i> MO | 3 | |
| <i>prednisolone sod 1% eye drop</i> MO | 3 | |
| <i>proparacaine 0.5% eye drops</i> MO | 2 | |
| RESTASIS 0.05 % EYE DROPS IN A DROPPERETTE MO | 3 | QL (60 per 30 days) |
| RESTASIS MULTIDOSE 0.05 % EYE DROPS MO | 3 | QL (5.5 per 25 days) |
| <i>sulf-pred 10-0.23% eye drops</i> MO | 2 | |
| <i>timolol 0.25% gfs gel-solution; timolol 0.5% gfs gel-solution</i> MO | 3 | |
| <i>timolol maleate 0.25% eye drop; timolol maleate 0.5% eye drops</i> MO | 1 | |
| <i>tobramycin-dexameth ophth susp</i> MO | 4 | |
| TRAVATAN Z 0.004 % EYE DROPS MO | 3 | QL (2.5 per 25 days) |
| <i>tropicamide 0.5% eye drops; tropicamide 1% eye drops</i> MO | 2 | |
| Otic Agents | | |
| CIPRODEX 0.3 %-0.1 % EAR DROPS,SUSPENSION MO | 4 | |
| <i>hydrocortison-acetic acid soln</i> MO | 4 | |
| <i>neomycin-polymyxin-hc ear soln</i> MO | 3 | |
| <i>neomycin-polymyxin-hc ear susp</i> MO | 3 | |
| Respiratory Tract/Pulmonary Agents | | |
| <i>acetylcysteine 10% vial; acetylcysteine 20% vial</i> MO | 4 | B vs D |
| ADCIRCA 20 MG TABLET DL | 5 | PA,QL (60 per 30 days) |
| ADEMPAS 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG TABLET DL | 5 | PA,QL (90 per 30 days) |
| ADVAIR DISKUS 100 MCG-50 MCG/DOSE POWDER FOR INHALATION; ADVAIR DISKUS 250 MCG-50 MCG/DOSE POWDER FOR INHALATION; ADVAIR DISKUS 500 MCG-50 MCG/DOSE POWDER FOR INHALATION MO | 3 | QL (60 per 30 days) |
| ADVAIR HFA 115 MCG-21 MCG/ACTUATION AEROSOL INHALER; ADVAIR HFA 230 MCG-21 MCG/ACTUATION AEROSOL INHALER; ADVAIR HFA 45 MCG-21 MCG/ACTUATION AEROSOL INHALER MO | 3 | QL (12 per 30 days) |
| <i>albuterol 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml, 5 mg/ml sol; albuterol 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml, 5 mg/ml solution; albuterol sul 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml, 5 mg/ml sol; albuterol sul 2.5 mg/3 ml soln</i> MO | 2 | B vs D |
| <i>albuterol sulf 2 mg/5 ml syrup</i> MO | 2 | |
| <i>albuterol sulfate 2 mg, 4 mg tab</i> MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| <i>albuterol sulfate er 4 mg, 8 mg tab</i> ^{MO} | 4 | |
| <i>alyq 20 mg tablet</i> ^{MO} | 4 | PA,QL (60 per 30 days) |
| <i>ambrisentan 10 mg, 5 mg tablet</i> ^{DL} | 5 | PA,QL (30 per 30 days) |
| <i>aminophylline 250 mg/10 ml, 500 mg/20 ml vl</i> ^{MO} | 2 | |
| ANORO ELLIPTA 62.5 MCG-25 MCG/ACTUATION POWDER FOR INHALATION ^{MO} | 3 | QL (60 per 30 days) |
| ARNUITY ELLIPTA 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION POWDER FOR INHALATION ^{MO} | 3 | QL (30 per 30 days) |
| <i>azelastine 0.1% (137 mcg) spry</i> ^{MO} | 3 | QL (30 per 25 days) |
| <i>azelastine 0.15% nasal spray</i> ^{MO} | 4 | QL (30 per 25 days) |
| BEVESPI AEROSPHERE 9 MCG-4.8 MCG HFA AEROSOL INHALER ^{MO} | 4 | QL (10.7 per 30 days) |
| <i>bosentan 125 mg, 62.5 mg tablet</i> ^{DL} | 5 | PA,QL (60 per 30 days) |
| BREO ELLIPTA 100 MCG-25 MCG/DOSE POWDER FOR INHALATION; BREO ELLIPTA 200 MCG-25 MCG/DOSE POWDER FOR INHALATION ^{MO} | 3 | QL (60 per 30 days) |
| BROVANA 15 MCG/2 ML SOLUTION FOR NEBULIZATION ^{MO} | 4 | PA |
| <i>budesonide 0.25 mg/2 ml, 0.5 mg/2 ml susp</i> ^{MO} | 4 | B vs D |
| CAYSTON 75 MG/ML SOLUTION FOR NEBULIZATION ^{DL} | 5 | PA,QL (84 per 28 days) |
| <i>cetirizine hcl 1 mg/ml soln</i> ^{MO} | 2 | QL (300 per 30 days) |
| <i>clemastine fum 2.68 mg tab</i> ^{MO} | 4 | |
| COMBIVENT RESPIMAT 20 MCG-100 MCG/ACTUATION SOLUTION FOR INHALATION ^{MO} | 4 | QL (4 per 20 days) |
| <i>cromolyn 100 mg/5 ml oral conc</i> ^{MO} | 4 | |
| <i>cromolyn 20 mg/2 ml neb soln</i> ^{MO} | 4 | B vs D |
| <i>cyproheptadine 2 mg/5 ml syrup</i> ^{MO} | 4 | |
| <i>cyproheptadine 4 mg tablet</i> ^{MO} | 4 | |
| DALIRESP 250 MCG TABLET ^{MO} | 3 | QL (28 per 365 days) |
| DALIRESP 500 MCG TABLET ^{MO} | 3 | QL (30 per 30 days) |
| <i>desloratadine 5 mg tablet</i> ^{MO} | 3 | QL (30 per 30 days) |
| <i>diphenhydramine 50 mg/ml vial</i> ^{MO} | 4 | |
| <i>epinephrine 0.15 mg auto-inject; epinephrine 0.3 mg auto-inject</i> ^{MO} | 3 | QL (4 per 30 days) |
| <i>epoprostenol sodium 0.5 mg, 1.5 mg vl</i> ^{DL} | 5 | PA |
| ESBRIET 267 MG CAPSULE ^{DL} | 5 | PA,QL (270 per 30 days) |
| ESBRIET 267 MG TABLET ^{DL} | 5 | PA,QL (270 per 30 days) |
| ESBRIET 801 MG TABLET ^{DL} | 5 | PA,QL (90 per 30 days) |
| FLOVENT DISKUS 100 MCG/ACTUATION, 250 MCG/ACTUATION, 50 MCG/ACTUATION POWDER FOR INHALATION ^{MO} | 3 | QL (60 per 30 days) |
| FLOVENT HFA 110 MCG/ACTUATION, 220 MCG/ACTUATION AEROSOL INHALER ^{MO} | 3 | QL (24 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| FLOVENT HFA 44 MCG/ACTUATION AEROSOL INHALER MO | 3 | QL (10.6 per 30 days) |
| flunisolide 0.025% spray MO | 3 | QL (50 per 30 days) |
| fluticasone-salmeterol 100-50; fluticasone-salmeterol 250-50; fluticasone-salmeterol 500-50 MO | 3 | QL (60 per 30 days) |
| fluticasone-salmeterol 113-14; fluticasone-salmeterol 232-14; fluticasone-salmeterol 55-14 MO | 3 | QL (1 per 30 days) |
| fluticasone prop 50 mcg spray MO | 2 | QL (16 per 30 days) |
| hydroxyzine pam 100 mg, 25 mg, 50 mg cap MO | 3 | |
| INCRUSE ELLIPTA 62.5 MCG/ACTUATION POWDER FOR INHALATION MO | 3 | QL (30 per 30 days) |
| ipratropium 0.03% spray MO | 2 | QL (30 per 30 days) |
| ipratropium 0.06% spray MO | 2 | QL (45 per 30 days) |
| ipratropium br 0.02% soln MO | 2 | B vs D |
| iprat-albut 0.5-3(2.5) mg/3 ml MO | 2 | B vs D |
| KALYDECO 150 MG TABLET DL | 5 | PA,QL (60 per 30 days) |
| KALYDECO 25 MG, 50 MG, 75 MG ORAL GRANULES IN PACKET DL | 5 | PA,QL (56 per 28 days) |
| LETAIRIS 10 MG, 5 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| levalbuterol 0.31 mg/3 ml, 0.63 mg/3 ml, 1.25 mg/0.5 ml, 1.25 mg/3 ml sol; levalbuterol conc 1.25 mg/0.5 MO | 4 | B vs D |
| levalbuterol tar hfa 45mcg inh MO | 4 | ST,QL (30 per 30 days) |
| levocetirizine 5 mg tablet MO | 1 | QL (30 per 30 days) |
| metaproterenol 10 mg, 20 mg tablet MO | 4 | |
| metaproterenol 10 mg/5 ml syr MO | 4 | |
| mometasone furoate 50 mcg spry MO | 4 | ST,QL (34 per 30 days) |
| montelukast sod 10 mg tablet MO | 1 | QL (30 per 30 days) |
| montelukast sod 4 mg granules MO | 4 | QL (30 per 30 days) |
| montelukast sod 4 mg, 5 mg tab chew MO | 2 | QL (30 per 30 days) |
| NASONEX 50 MCG/ACTUATION SPRAY MO | 4 | ST,QL (34 per 30 days) |
| OFEV 100 MG, 150 MG CAPSULE DL | 5 | PA,QL (60 per 30 days) |
| olopatadine 665 mcg nasal spry MO | 4 | ST,QL (30.5 per 30 days) |
| OPSUMIT 10 MG TABLET DL | 5 | PA,QL (30 per 30 days) |
| ORKAMBI 100 MG-125 MG ORAL GRANULES IN PACKET; ORKAMBI 150 MG-188 MG ORAL GRANULES IN PACKET DL | 5 | PA,QL (56 per 28 days) |
| ORKAMBI 100 MG-125 MG TABLET; ORKAMBI 200 MG-125 MG TABLET DL | 5 | PA,QL (112 per 28 days) |
| PERFORMIST 20 MCG/2 ML SOLUTION FOR NEBULIZATION MO | 4 | PA |
| PULMOZYME 1 MG/ML SOLUTION FOR INHALATION DL | 5 | B vs D |
| REVATIO 10 MG/ML ORAL SUSPENSION DL | 5 | PA,QL (180 per 30 days) |
| SEREVENT DISKUS 50 MCG/DOSE POWDER FOR INHALATION MO | 3 | QL (60 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| <i>sildenafil 10 mg/ml oral susp</i> ^{DL} | 5 | PA,QL (180 per 30 days) |
| <i>sildenafil 20 mg tablet</i> ^{MO} | 4 | PA,QL (90 per 30 days) |
| SPIRIVA RESPIMAT 1.25 MCG/ACTUATION, 2.5 MCG/ACTUATION SOLUTION FOR INHALATION ^{MO} | 3 | QL (4 per 28 days) |
| SPIRIVA WITH HANDIHALER 18 MCG AND INHALATION CAPSULES ^{MO} | 3 | QL (30 per 30 days) |
| STIOLTO RESPIMAT 2.5 MCG-2.5 MCG/ACTUATION SOLUTION FOR INHALATION ^{MO} | 3 | QL (4 per 28 days) |
| STRIVERDI RESPIMAT 2.5 MCG/ACTUATION SOLUTION FOR INHALATION ^{MO} | 3 | QL (4 per 30 days) |
| SYMBICORT 160 MCG-4.5 MCG/ACTUATION HFA AEROSOL INHALER; SYMBICORT 80 MCG-4.5 MCG/ACTUATION HFA AEROSOL INHALER ^{MO} | 3 | QL (10.2 per 30 days) |
| SYMJEPI 0.15 MG/0.3 ML, 0.3 MG/0.3 ML INJECTION SYRINGE; SYMJEPI 0.15 MG/0.3 ML, 0.3 MG/0.3 ML INJECTION SYRINGE (FOR 33 LB TO 66 LB PATIENTS) ^{MO} | 3 | QL (4 per 30 days) |
| <i>tadalafil 20 mg tablet</i> ^{MO} | 4 | PA,QL (60 per 30 days) |
| <i>theophylline er 100 mg, 200 mg tablet</i> ^{MO} | 3 | |
| <i>theophylline er 300 mg, 450 mg tab</i> ^{MO} | 4 | |
| <i>theophylline er 400 mg tablet</i> ^{MO} | 3 | |
| <i>theophylline er 600 mg tablet</i> ^{MO} | 4 | |
| <i>theophylline 200 mg/100 ml, 200 mg/50 ml, 400 mg/250 ml, 400 mg/500 ml, 800 mg/250 ml d5w</i> ^{MO} | 2 | |
| TOBI PODHALER 28 MG CAPSULE WITH INHALATION DEVICE; TOBI PODHALER 28 MG CAPSULES FOR INHALATION ^{DL} | 5 | PA,QL (224 per 28 days) |
| TRACLEER 125 MG, 62.5 MG TABLET ^{DL} | 5 | PA,QL (60 per 30 days) |
| TRACLEER 32 MG TABLET FOR ORAL SUSPENSION ^{DL} | 5 | PA,QL (120 per 30 days) |
| TRELEGY ELLIPTA 100 MCG-62.5 MCG-25 MCG POWDER FOR INHALATION ^{MO} | 3 | QL (60 per 30 days) |
| TUDORZA PRESSAIR 400 MCG/ACTUATION BREATH ACTIVATED ^{MO} | 4 | QL (1 per 30 days) |
| VENTAVIS 10 MCG/ML, 20 MCG/ML SOLUTION FOR NEBULIZATION ^{DL} | 5 | PA |
| VENTOLIN HFA 90 MCG/ACTUATION AEROSOL INHALER ^{MO} | 3 | QL (36 per 30 days) |
| <i>wixela inhub 100 mcg-50 mcg/dose powder for inhalation; wixela inhub 250 mcg-50 mcg/dose powder for inhalation; wixela inhub 500 mcg-50 mcg/dose powder for inhalation</i> ^{MO} | 3 | QL (60 per 30 days) |
| <i>zafirlukast 10 mg, 20 mg tablet</i> ^{MO} | 4 | QL (60 per 30 days) |
| Skeletal Muscle Relaxants | | |
| AMRIX 15 MG, 30 MG CAPSULE,EXTENDED RELEASE ^{MO} | 4 | PA,QL (21 per 30 days) |
| <i>carisoprodol 350 mg tablet</i> ^{MO} | 4 | |
| <i>chlorzoxazone 250 mg tablet</i> ^{MO} | 4 | PA |
| <i>chlorzoxazone 500 mg tablet</i> ^{MO} | 4 | |
| <i>cyclobenzaprine 10 mg, 5 mg tablet</i> ^{MO} | 4 | PA |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| <i>cyclobenzaprine 7.5 mg tablet</i> MO | 4 | PA,QL (90 per 30 days) |
| <i>cyclobenzaprine er 15 mg, 30 mg cap</i> MO | 4 | PA,QL (21 per 30 days) |
| <i>methocarbamol 500 mg, 750 mg tablet</i> MO | 4 | |
| Sleep Disorder Agents | | |
| BELSOMRA 10 MG, 15 MG, 20 MG, 5 MG TABLET MO | 3 | |
| HETLIOZ 20 MG CAPSULE DL | 5 | PA,QL (30 per 30 days) |
| <i>modafinil 100 mg, 200 mg tablet</i> MO | 4 | PA,QL (60 per 30 days) |
| <i>temazepam 15 mg, 30 mg capsule</i> DL | 4 | QL (30 per 30 days) |
| XYREM 500 MG/ML ORAL SOLUTION DL | 5 | PA,QL (540 per 30 days) |
| <i>zolpidem tartrate 10 mg tablet</i> MO | 2 | |
| <i>zolpidem tartrate 5 mg tablet</i> MO | 2 | QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

CarePlus Coverage of Additional Prescription Drugs

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| ERECTILE DYSFUNCTION | | |
| sildenafil 100 mg, 25 mg, 50 mg tablet ED,MO | 1 | QL (6 per 30 days) |

Your CarePlus plan has additional coverage of some drugs. These drugs aren't normally covered under Medicare Part D. These drugs aren't subject to the Medicare appeals process. The amount you pay when you fill a prescription for these drugs does not count toward your total drug costs (in other words, the amount you pay does not help you qualify for catastrophic coverage).

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

CarePlus Coverage of Additional Prescription Drugs Through Medicaid Program

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| CUSTOM DRUGS | | |
| <i>folic acid 1 mg tablet</i> MO | 1 | |
| <i>folic acid 5 mg/ml vial</i> MO | 1 | |

Your CarePlus plan has a contract with the Medicaid agency to provide additional coverage for select drugs. These drugs are not normally covered in a Medicare prescription drug plan.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

Index

A

- a-hydrocort... 72
- abacavir... 41
- abacavir-lamivudine... 41
- abacavir-lamivudine-zidovudine... 41
- ABELCET... 25
- ABILIFY MAINTENA... 39
- abiraterone... 28
- ABRAXANE... 28
- acamprosate... 13
- acarbose... 46
- acebutolol... 52
- acetaminophen-codeine... 10
- acetazolamide sodium... 52
- acetazolamide... 52
- acetic acid... 13, 89
- acetylcysteine... 89, 102
- acitretin... 61
- ACTHAR... 72
- ACTHIB (PF)... 83
- ACTIMMUNE... 83
- acyclovir sodium... 42
- acyclovir... 41
- ADACEL(TDAP ADOLESN/ADULT)(PF)... 83
- ADAGEN... 70
- adapalene... 61
- ADCIRCA... 102
- adefovir... 42
- ADEMPAS... 102
- adenosine... 52
- adriamycin... 28, 29
- ADVAIR DISKUS... 102
- ADVAIR HFA... 102
- ADVOCATE PEN NEEDLE... 89
- ADVOCATE SYRINGES... 89
- afeditab cr... 52
- AFINITOR DISPERZ... 29
- AFINITOR... 29
- afirmelle... 75
- AIMOVIG AUTOINJECTOR (2 PACK)... 27
- AIMOVIG AUTOINJECTOR... 27
- ak-poly-bac... 100
- AKTEN (PF)... 100
- albendazole... 37
- ALBENZA... 37
- albuterol sulfate... 102, 103
- ALCAINE... 100
- ALCOHOL PADS... 89
- ALCOHOL PREP PADS... 90
- ALCOHOL SWABS... 90
- ALCOHOL WIPES... 90
- ALECENSA... 29
- alendronate... 88
- alfuzosin... 71
- ALIMTA... 29
- ALINIA... 37
- ALIQOPA... 29
- aliskiren... 52
- allopurinol sodium... 27
- allopurinol... 27
- almotriptan malate... 27
- ALPHAGAN P... 100
- alprazolam... 45
- altavera (28)... 75
- ALUNBRIG... 29
- alyacen 1/35 (28)... 75
- alyacen 7/7/7 (28)... 75
- alyq... 103
- amabelz... 75
- amantadine hcl... 38
- AMBISOME... 25
- ambrisentan... 103
- AMETHIA LO... 75
- amethia... 75
- amethyst (28)... 75
- AMICAR... 49
- amifostine crystalline... 29

| | | |
|---|---|-------------------------------------|
| amikacin... 14 | amlodipine-valsartan... 52 | ARCALYST... 83 |
| amiloride... 52 | ammonium lactate... 61 | aripiprazole... 39 |
| amiloride-hydrochlorothiazide... 52 | amnesteem... 61 | ARISTADA INITIO... 39 |
| aminocaproic acid... 49, 50 | amoxapine... 23 | ARISTADA... 39 |
| aminophylline... 103 | amoxicil-clarithromy-lansopraz... 68 | ARISTOSPAN INTRA-ARTICULAR... 72 |
| AMINOSYN II 10 %... 63 | amoxicillin... 14 | ARISTOSPAN INTRALESIONAL... 72 |
| AMINOSYN II 15 %... 63 | amoxicillin-pot clavulanate... 14 | ARMOUR THYROID... 81 |
| AMINOSYN II 7 %... 63 | amphotericin b... 26 | ARNUITY ELLIPTA... 103 |
| AMINOSYN II 8.5 %... 63 | ampicillin sodium... 14 | ARRANON... 29 |
| AMINOSYN II 8.5 %-ELECTROLYTES... 63 | ampicillin... 14 | arsenic trioxide... 29 |
| AMINOSYN M 3.5 %... 63 | ampicillin-sulbactam... 14 | ARZERRA... 29 |
| AMINOSYN 10 %... 62 | AMPYRA... 59 | ashlyna... 75 |
| AMINOSYN 7 % WITH ELECTROLYTES... 62 | AMRIX... 105 | aspirin-dipyridamole... 50 |
| AMINOSYN 8.5 %... 62 | ANADROL-50... 75 | ASSURE ID INSULIN SAFETY... 90 |
| AMINOSYN 8.5 %-ELECTROLYTES... 63 | anagrelide... 50 | ASSURE ID PEN NEEDLE... 90 |
| AMINOSYN-HBC 7%... 63 | anastrozole... 29 | atazanavir... 42 |
| AMINOSYN-PF 10 %... 63 | ANDROGEL... 75 | atenolol... 52 |
| AMINOSYN-PF 7 % (SULFITE-FREE)... 63 | ANORO ELLIPTA... 103 | atenolol-chlorthalidone... 52 |
| AMINOSYN-RF 5.2 %... 63 | APOKYN... 38 | ATGAM... 83 |
| amiodarone... 52 | apraclonidine... 100 | atomoxetine... 59 |
| amitriptyline... 23 | aprepitant... 25 | atorvastatin... 52 |
| amlodipine... 52 | apri... 75 | atovaquone... 37 |
| amlodipine-atorvastatin... 52 | APRISO... 88 | atovaquone-proguanil... 37 |
| amlodipine-benazepril... 52 | APTIOM... 19, 20 | ATRIPLA... 42 |
| amlodipine-olmesartan... 52 | APTIVUS... 42 | atropine... 100 |
| | ARALAST NP... 70 | aubra eq... 75 |
| | aranelle (28)... 75 | aubra... 75 |

| | | |
|-----------------------------------|--------------------------------------|--------------------------------------|
| AUGMENTIN... 14 | bal-care dha... 63 | BD SAFETYGLIDE SYRINGE... 90 |
| aurovela fe 1.5/30 (28)... 75 | balsalazide... 88 | BD ULTRA-FINE MICRO PEN NEEDLE... 90 |
| aurovela fe 1-20 (28)... 75 | BALVERSA... 29 | BD ULTRA-FINE MINI PEN NEEDLE... 90 |
| aurovela 1.5/30 (21)... 75 | balziva (28)... 75 | BD ULTRA-FINE NANO PEN NEEDLE... 90 |
| aurovela 1/20 (21)... 75 | BAND-AID GAUZE PADS... 90 | BD ULTRA-FINE ORIG PEN NEEDLE... 91 |
| aurovela 24 fe... 75 | BANZEL... 20 | BD ULTRA-FINE SHORT PEN NEEDLE... 91 |
| AURYXIA... 63 | BARACLUDE... 42 | BD VEO INSULIN SYR HALF UNIT... 91 |
| AUSTEDO... 59 | BAVENCIO... 29 | BD VEO INSULIN SYRINGE UF... 91 |
| AUTOJECT 2 INJECTION DEVICE... 90 | bcg vaccine, live (pf)... 84 | bekyree (28)... 75 |
| AUTOPEN 1 TO 21 UNITS... 90 | BD ALCOHOL SWABS... 90 | BELBUCA... 10 |
| AUTOPEN 2 TO 42 UNITS... 90 | BD AUTOSHIELD DUO PEN NEEDLE... 90 | BELEODAQ... 29 |
| AVASTIN... 29 | BD ECLIPSE LUER-LOK... 90 | BELSOMRA... 106 |
| aviane... 75 | BD INSULIN SYRINGE HALF UNIT... 90 | benazepril... 52 |
| ayuna... 75 | BD INSULIN SYRINGE MICRO-FINE... 90 | benazepril-hydrochlorothiazide... 52 |
| azacitidine... 50 | BD INSULIN SYRINGE SAFETY-LOK... 90 | BENDEKA... 29 |
| azathioprine... 83 | BD INSULIN SYRINGE SLIP TIP... 90 | BENLYSTA... 84 |
| azelaic acid... 61 | BD INSULIN SYRINGE U-500... 90 | benztropine... 38 |
| azelastine... 100, 103 | BD INSULIN SYRINGE ULTRA-FINE... 90 | BEPREVE... 100 |
| azithromycin... 14 | BD INSULIN SYRINGE... 90 | BESIVANCE... 14 |
| aztreonam... 14 | BD LO-DOSE MICRO-FINE IV... 90 | BESPONSA... 29 |
| azurette (28)... 75 | BD LO-DOSE ULTRA-FINE... 90 | BETADINE OPHTHALMIC PREP... 100 |
| B | BD NANO 2ND GEN PEN NEEDLE... 90 | betamethasone acet,sod phos... 72 |
| baciiim... 14 | BD SAFETYGLIDE INSULIN SYRINGE... 90 | betamethasone dipropionate... 72 |
| bacitracin... 14 | | |
| bacitracin-polymyxin b... 100 | | |
| baclofen... 41 | | |
| BAL IN OIL... 90 | | |

| | | |
|--------------------------------------|-------------------------------------|--------------------------------------|
| betamethasone valerate... 72 | BRAFTOVI... 29 | cabergoline... 82 |
| betamethasone, augmented... 72 | BREO ELLIPTA... 103 | CABLIVI... 91 |
| BETASERON... 60 | briellyn... 76 | CABOMETYX... 29 |
| betaxolol... 100 | BRILINTA... 50 | caffeine citrate... 91 |
| bethanechol chloride... 71 | brimonidine... 100, 101 | calcipotriene... 61 |
| BETHKIS... 14 | BRIVIACT... 20 | calcitonin (salmon)... 88 |
| BEVESPI AEROSPHERE... 103 | bromocriptine... 38 | calcitriol... 88 |
| bexarotene... 29 | BROVANA... 103 | calcium acetate... 63 |
| BEXSERO... 84 | budesonide... 88, 103 | calcium chloride... 63 |
| bicalutamide... 29 | bumetanide... 52 | calcium disodium versenate... 91 |
| BICILLIN C-R... 14 | bupivacaine (pf)... 12 | calcium gluc in nacl, iso-osm... 63 |
| BICILLIN L-A... 14 | bupivacaine... 12 | calcium gluconate... 63 |
| BICNU... 29 | buprenorphine hcl... 13 | CALQUENCE... 29 |
| BIDIL... 52 | buprenorphine-naloxone... 13 | camila... 76 |
| BIKTARVY... 42 | bupropion hcl (smoking deter)... 13 | CAMRESE LO... 76 |
| BILTRICIDE... 37 | bupropion hcl... 23 | CAMRESE... 76 |
| BINOSTO... 88 | bupirone... 46 | candesartan... 53 |
| bisoprolol fumarate... 52 | busulfan... 29 | candesartan-hydrochlorothiazid... 53 |
| bisoprolol-hydrochlorothiazide... 52 | BUSULFEX... 29 | CAPASTAT... 28 |
| bleomycin... 29 | butalbital-acetaminop-caf-cod... 10 | CAPITAL WITH CODEINE... 10 |
| blisovi fe 1.5/30 (28)... 76 | BUTISOL... 20 | CAPRELSA... 29, 30 |
| blisovi fe 1/20 (28)... 76 | butorphanol tartrate... 10 | captopril... 53 |
| blisovi 24 fe... 75 | BYDUREON BCISE... 46 | captopril-hydrochlorothiazide... 53 |
| BOOSTRIX TDAP... 84 | BYDUREON... 46 | CARAC... 61 |
| BORDERED GAUZE... 91 | BYETTA... 46 | CARAFATE... 68 |
| bortezomib... 29 | BYSTOLIC... 53 | CARBAGLU... 63 |
| bosentan... 103 | | carbamazepine... 20 |
| BOSULIF... 29 | | |

C

c-nate dha... 63

| | | |
|--------------------------------------|---------------------------------------|-------------------------------------|
| carbidopa-levodopa... 38 | cefotetan in dextrose, iso-osm... 15 | CHEMET... 63 |
| carbidopa-levodopa-entacapone... 38 | cefotetan... 15 | CHENODAL... 68 |
| carboplatin... 30 | cefoxitin in dextrose, iso-osm... 15 | chloramphenicol sod succinate... 15 |
| CAREFINE PEN NEEDLE... 91 | cefoxitin... 15 | chlorhexidine gluconate... 61 |
| CARETOUCH ALCOHOL PREP PAD... 91 | cefepodoxime... 15 | chloroquine phosphate... 37 |
| CARETOUCH INSULIN SYRINGE... 91 | cefprozil... 15 | chlorothiazide sodium... 53 |
| CARETOUCH PEN NEEDLE... 91 | ceftazidime in d5w... 15 | chlorothiazide... 53 |
| carisoprodol... 105 | ceftazidime... 15 | chlorpromazine... 39 |
| carmustine... 30 | ceftriaxone in dextrose, iso-os... 15 | chlorthalidone... 53 |
| carteolol... 101 | ceftriaxone... 15 | chlorzoxazone... 105 |
| cartia xt... 53 | cefuroxime axetil... 15 | CHOLBAM... 70 |
| carvedilol phosphate... 53 | cefuroxime sodium... 15 | cholestyramine (with sugar)... 53 |
| carvedilol... 53 | celecoxib... 10 | cholestyramine light... 53 |
| caspofungin... 26 | CELLCEPT INTRAVENOUS... 84 | chorionic gonadotropin, human... 74 |
| CAYSTON... 103 | CELLCEPT... 84 | ciclodan... 26 |
| caziant (28)... 76 | CELONTIN... 20 | ciclopirox... 26 |
| cefaclor... 14 | cephalexin... 15 | cidofovir... 42 |
| cefadroxil... 14 | CERDELGA... 70 | cilostazol... 50 |
| cefazolin in dextrose (iso-os)... 15 | CEREZYME... 70 | CILOXAN... 15 |
| cefazolin... 15 | cetirizine... 103 | CIMDUO... 42 |
| cefdinir... 15 | cevimeline... 61 | cimetidine hcl... 68 |
| cefepime in dextrose 5 %... 15 | CHANTIX CONTINUING MONTH BOX... 13 | cimetidine... 68 |
| cefepime in dextrose, iso-osm... 15 | CHANTIX STARTING MONTH BOX... 13 | cinacalcet... 88 |
| cefepime... 15 | CHANTIX... 13 | CIPRODEX... 102 |
| cefixime... 15 | chateal (28)... 76 | ciprofloxacin (mixture)... 15 |
| cefotaxime... 15 | chateal eq (28)... 76 | ciprofloxacin hcl... 15 |
| | | ciprofloxacin in 5 % dextrose... 16 |

| | | |
|---|---|------------------------------------|
| ciprofloxacin lactate... 16 | CLINIMIX E 5%/D25W SULFIT FREE... 64 | clorazepate dipotassium... 46 |
| cisplatin... 30 | | clotrimazole... 26 |
| citalopram... 23 | CLINIMIX 2.75%/D5W SULFIT FREE... 63 | clotrimazole-betamethasone... 26 |
| cladribine... 30 | CLINIMIX 4.25%-D20W SULF-FREE... 63 | clovique... 64 |
| clarithromycin... 16 | CLINIMIX 4.25%-D25W SULF-FREE... 63 | clozapine... 39 |
| clemastine... 103 | | COARTEM... 37 |
| CLEOCIN... 16 | | COLCRYS... 27 |
| CLICKFINE PEN NEEDLE... 91 | CLINIMIX 4.25%/D10W SULF FREE... 63 | colestipol... 53 |
| CLINDAGEL... 16 | CLINIMIX 4.25%/D5W SULFIT FREE... 63 | colistin (colistimethate na)... 16 |
| clindamycin hcl... 16 | CLINIMIX 5%-D20W(SULFITE-FREE)... 63 | colocort... 88 |
| clindamycin in 0.9 % sod chlor... 16 | | COMBIGAN... 101 |
| clindamycin in 5 % dextrose... 16 | CLINIMIX 5%/D15W SULFITE FREE... 63 | COMBIVENT RESPIMAT... 103 |
| clindamycin palmitate hcl... 16 | CLINIMIX 5%/D25W SULFITE-FREE... 63 | COMETRIQ... 30 |
| clindamycin pediatric... 16 | CLINISOL SF 15 %... 64 | COMFORT EZ INSULIN SYRINGE... 91 |
| clindamycin phosphate... 16 | CLINOLIPID... 64 | COMFORT EZ PEN NEEDLES... 91 |
| CLINDESSE... 16 | clobazam... 20 | COMPLERA... 42 |
| CLINIMIX E 2.75%/D10W SUL FREE... 63 | clobetasol... 72 | complete natal dha... 64 |
| CLINIMIX E 2.75%/D5W SULF FREE... 64 | clobetasol-emollient... 72 | completenate... 64 |
| CLINIMIX E 4.25%/D10W SUL FREE... 64 | clofarabine... 30 | compro... 25 |
| CLINIMIX E 4.25%/D25W SUL FREE... 64 | CLOLAR... 30 | CONCEPT DHA... 64 |
| CLINIMIX E 4.25%/D5W SULF FREE... 64 | clomipramine... 23 | CONCEPT OB... 64 |
| CLINIMIX E 5%/D15W SULFIT FREE... 64 | clonazepam... 46 | constulose... 68 |
| CLINIMIX E 5%/D20W SULFIT FREE... 64 | clonidine hcl... 53 | COPAXONE... 60 |
| | clonidine... 53 | COPIKTRA... 30 |
| | clopidogrel... 50 | COREG CR... 53 |
| | | CORLANOR... 53 |
| | | CORLOPAM... 53 |
| | | cormax... 72 |

| | | |
|-----------------------------|---|--|
| cortisone... 72 | cyred eq... 76 | decadron... 72 |
| CORTISPORIN... 61 | cyred... 76 | decitabine... 30 |
| COSENTYX (2 SYRINGES)... 61 | CYSTADANE... 70 | deferoxamine... 64 |
| COSENTYX PEN (2 PENS)... 61 | CYSTAGON... 70 | DELSTRIGO... 42 |
| COSENTYX PEN... 61 | CYSTARAN... 101 | delyla (28)... 76 |
| COSENTYX... 61 | cytarabine (pf)... 30 | demeclocycline... 16 |
| COSMEGEN... 30 | cytarabine... 30 | DEMSE... 53 |
| COTELLIC... 30 | CYTOGAM... 84 | DEPEN TITRATABS... 64 |
| COUMADIN... 50 | D | DEPO-ESTRADIOL... 76 |
| CREON... 70 | dacarbazine... 30 | DEPO-PROVERA... 76 |
| CRESEMBA... 26 | dactinomycin... 30 | DEPO-SUBQ PROVERA 104... 76 |
| CRIXIVAN... 42 | dalfampridine... 60 | DERMACEA... 92 |
| cromolyn... 101, 103 | DALIRESP... 103 | DESCOVY... 42 |
| cryselle (28)... 76 | danazol... 76 | desipramine... 23 |
| CRYSVITA... 70 | dantrolene... 41 | desloratadine... 103 |
| CUPRIMINE... 64 | dapsone... 28 | desmopressin... 74 |
| CURITY ALCOHOL SWABS... 91 | DAPTACEL (DTAP PEDIATRIC) (PF)... 84 | desog-e.estradiol/e.estradiol... 76 |
| CURITY GAUZE... 92 | daptomycin... 16 | desogestrel-ethinyl estradiol... 76 |
| cyclafem 1/35 (28)... 76 | DARAPRIM... 37 | desonide... 72 |
| cyclafem 7/7/7 (28)... 76 | darifenacin... 71 | desoximetasone... 72 |
| CYCLESSA (28)... 76 | DARZALEX... 30 | desvenlafaxine succinate... 23 |
| cyclobenzaprine... 105, 106 | dasetta 1/35 (28)... 76 | DEXAMETHASONE INTENSOL... 73 |
| cyclophosphamide... 30 | dasetta 7/7/7 (28)... 76 | dexamethasone sodium phos (pf)... 73 |
| cycloserine... 28 | daunorubicin... 30 | dexamethasone sodium phosphate... 73, 101 |
| cyclosporine modified... 84 | DAURISMO... 30 | dexamethasone... 73 |
| cyclosporine... 84 | daysee... 76 | DEXILANT... 68 |
| cyproheptadine... 103 | deblitane... 76 | |
| CYRAMZA... 30 | | |

| | | |
|---|--------------------------------|--------------------------------------|
| dexmethylphenidate... 60 | DIFICID... 16 | dorzolamide-timolol... 101 |
| dexrazoxane hcl... 30 | diflorasone... 73 | dotti... 76 |
| dextroamphetamine... 60 | digitek... 53 | DOVATO... 42 |
| dextroamphetamine-amphetamine... 60 | digox... 53 | doxazosin... 54 |
| dextrose 10 % and 0.2 % nacl... 64 | digoxin... 53 | doxepin... 46 |
| dextrose 10 % in water (d10w)... 64 | dihydroergotamine... 27 | doxercalciferol... 88 |
| dextrose 20 % in water (d20w)... 64 | dilantin extended... 20 | doxorubicin... 30 |
| dextrose 25 % in water (d25w)... 64 | DILANTIN INFATABS... 20 | doxorubicin, peg-liposomal... 30 |
| dextrose 30 % in water (d30w)... 64 | dilantin... 20 | doxy-100... 16 |
| dextrose 40 % in water (d40w)... 64 | DILANTIN-125... 20 | doxycycline hyclate... 16 |
| dextrose 5 % in water (d5w)... 64 | dilt-xr... 53 | doxycycline monohydrate... 16 |
| dextrose 5 %-lactated ringers... 64 | diltiazem hcl... 53, 54 | dronabinol... 25 |
| dextrose 5%-0.2 % sod chloride... 64 | diphenhydramine hcl... 103 | droperidol... 25 |
| dextrose 5%-0.3 % sod.chloride... 64 | diphenoxylate-atropine... 68 | DROPLET INSULIN SYR HALF UNIT... 92 |
| dextrose 50 % in water (d50w)... 64, 65 | dipyridamole... 50 | DROPLET INSULIN SYRINGE... 92 |
| dextrose 70 % in water (d70w)... 65 | disulfiram... 13 | DROPLET PEN NEEDLE... 92 |
| DIASTAT ACUDIAL... 20 | DIURIL... 54 | DROPSAFE PEN NEEDLE... 92 |
| diazepam intensol... 46 | divalproex... 20 | drospirenone-ethinyl estradiol... 76 |
| diazepam... 20, 46 | dobutamine in d5w... 54 | DROXIA... 30 |
| diclofenac epolamine... 10 | dobutamine... 54 | DUAVEE... 76 |
| diclofenac sodium... 10, 61, 101 | DOCEFREZ... 30 | duloxetine... 23 |
| diclofenac-misoprostol... 10 | docetaxel... 30 | DUREZOL... 101 |
| dicloxacillin... 16 | dofetilide... 54 | dutasteride... 71 |
| dicyclomine... 68 | donepezil... 22 | dutasteride-tamsulosin... 71 |
| didanosine... 42 | dopamine in 5 % dextrose... 54 | d10 %-0.45 % sodium chloride... 64 |
| | dopamine... 54 | d2.5 %-0.45 % sodium chloride... 64 |
| | doripenem... 16 | |
| | dorzolamide... 101 | |

d5 % and 0.9 % sodium chloride... 64

d5 %-0.45 % sodium chloride... 64

E

EASY COMFORT ALCOHOL PAD... 92

EASY COMFORT INSULIN SYRINGE... 92

EASY COMFORT PEN NEEDLES... 92

EASY GLIDE INSULIN SYRINGE... 92

EASY GLIDE PEN NEEDLE... 92

EASY TOUCH ALCOHOL PREP PADS... 92

EASY TOUCH FLIPLOCK INSULIN... 92

EASY TOUCH INSULIN SAFETY SYR... 93

EASY TOUCH INSULIN SYRINGE... 93

EASY TOUCH LUER LOCK INSULIN... 93

EASY TOUCH PEN NEEDLE... 93

EASY TOUCH SHEATHLOCK INSULIN... 93

EASY TOUCH UNI-SLIP... 93

EASY TOUCH... 92

econazole... 26

EDURANT... 42

efavirenz... 42

EFFIENT... 50

EGRIFTA... 74

electrolyte-48 in d5w... 65

ELELYSO... 70

ELIDEL... 61

ELIGARD (3 MONTH)... 82

ELIGARD (4 MONTH)... 82

ELIGARD (6 MONTH)... 82

ELIGARD... 82

elinest... 76

ELIQUIS DVT-PE TREAT 30D START... 50

ELIQUIS... 50

ELITEK... 31

ELLA... 76

ELMIRON... 71

EMBEDA... 10

EMCYT... 31

EMGALITY PEN... 27

EMGALITY SYRINGE... 27

emoquette... 76

EMPLICITI... 31

EMSAM... 23

EMTRIVA... 42

enalapril maleate... 54

enalapril-hydrochlorothiazide... 54

enalaprilat... 54

ENBREL MINI... 84

ENBREL SURECLICK... 84

ENBREL... 84

endocet... 10

ENDOMETRIN... 76

ENGERIX-B (PF)... 84

ENGERIX-B PEDIATRIC (PF)... 84

enlon... 93

enoxaparin... 50

enpresse... 76

enskyce... 76

ENSTILAR... 61

entacapone... 38

entecavir... 42

ENTRESTO... 54

enulose... 68

EPCLUSA... 42

EPIDIOLEX... 20

epinephrine... 103

epirubicin... 31

epitol... 20

EPIVIR HBV... 42

eplerenone... 54

EPOGEN... 50

epoprostenol (glycine)... 103

EQUETRO... 20

ERAXIS(WATER DILUENT)... 26

ERBITUX... 31

ERGOMAR... 27

ergotamine-caffeine... 27

ERIVEDGE... 31

ERLEADA... 31

| | | |
|-------------------------------------|--|--------------------------------------|
| erlotinib... 31 | exemestane... 31 | fentanyl citrate... 10 |
| errin... 77 | EXJADE... 65 | fentanyl... 10 |
| ertapenem... 16 | EXONDYS 51... 70 | FETZIMA... 23 |
| ERWINAZE... 31 | ezetimibe... 54 | FIASP FLEXTOUCH U-100 INSULIN... 46 |
| ery pads... 16 | ezetimibe-simvastatin... 54 | FIASP PENFILL U-100 INSULIN... 47 |
| ERYTHROCIN... 16 | F | FIASP U-100 INSULIN... 47 |
| erythromycin with ethanol... 17 | falmina (28)... 77 | FINACEA... 61 |
| erythromycin... 16, 17 | famciclovir... 42 | finasteride... 71 |
| ESBRIET... 103 | famotidine (pf)... 69 | FIRAZYR... 84 |
| escitalopram oxalate... 23 | famotidine (pf)-nacl (iso-os)... 69 | FIRDAPSE... 60 |
| esmolol... 54 | famotidine... 69 | FIRMAGON KIT W DILUENT SYRINGE... 82 |
| esomeprazole magnesium... 69 | FANAPT... 39 | FIRMAGON... 82 |
| estradiol valerate... 77 | FARESTON... 31 | flavoxate... 71 |
| estradiol... 77 | FARXIGA... 46 | flecainide... 55 |
| estradiol-norethindrone acet... 77 | FARYDAK... 31 | FLECTOR... 10 |
| ESTRING... 77 | FASLODEX... 31 | FLOVENT DISKUS... 103 |
| ESTROSTEP FE-28... 77 | fayosim... 77 | FLOVENT HFA... 103, 104 |
| ethacrynate sodium... 54 | febuxostat... 27 | floxuridine... 31 |
| ethambutol... 28 | felbamate... 20 | fluconazole in dextrose(iso-o)... 26 |
| ethosuximide... 20 | felodipine... 54 | fluconazole in nacl (iso-osm)... 26 |
| ethynodiol diac-eth estradiol... 77 | FEMRING... 77 | fluconazole... 26 |
| etidronate disodium... 88 | femynor... 77 | flucytosine... 26 |
| etodolac... 10 | fenofibrate micronized... 54 | fludarabine... 31 |
| ETOPOPHOS... 31 | fenofibrate nanocrystallized... 54, 55 | fludrocortisone... 73 |
| etoposide... 31 | fenofibrate... 54 | flumazenil... 93 |
| EVOMELA... 31 | fenofibric acid... 55 | flunisolide... 104 |
| EVOTAZ... 42 | fentanyl citrate (pf)... 10 | |
| EXEL INSULIN... 93 | | |

griseofulvin ultramicrosize... 26
guanfacine... 55
guanidine... 28
gynazole-1... 26
H
HAEGARDA... 85
hailey 24 fe... 77
hailey... 77
HALAVEN... 31
haloperidol decanoate... 39
haloperidol lactate... 40
haloperidol... 39
HARVONI... 43
HAVRIX (PF)... 85
HEALTHWISE INSULIN SYRINGE...
93
HEALTHWISE PEN NEEDLE... 93
HEALTHY ACCENTS UNIFINE
PENTIP... 93
heather... 77
HECTOROL... 88
heparin (porcine)... 51
heparin, porcine (pf)... 51
HEPATAMINE 8%... 65
HERCEPTIN HYLECTA... 32
HERCEPTIN... 31
HETLIOZ... 106
HEXALEN... 32
HIBERIX (PF)... 85

HUMAPEN LUXURA HD... 94
HUMIRA PEDIATRIC CROHNS
START... 85
HUMIRA PEN CROHNS-UC-HS
START... 85
HUMIRA PEN PSOR-UEVITS-ADOL
HS... 85
HUMIRA PEN... 85
HUMIRA... 85
HUMIRA(CF) PEDI CROHNS
STARTER... 85
HUMIRA(CF) PEN CROHNS-UC-HS...
85
HUMIRA(CF) PEN PSOR-UV-ADOL
HS... 85
HUMIRA(CF) PEN... 85
HUMIRA(CF)... 85
HUMULIN R U-500 (CONC)
INSULIN... 47
HUMULIN R U-500 (CONC)
KWIKPEN... 47
hydralazine... 55
hydrochlorothiazide... 55
hydrocodone-acetaminophen... 11
hydrocodone-ibuprofen... 11
hydrocortisone valerate... 73
hydrocortisone... 73, 88
hydrocortisone-acetic acid... 102
hydrocortisone-min oil-wht pet... 73
hydromorphone (pf)... 11

hydromorphone... 11
hydroxychloroquine... 37
hydroxyurea... 32
hydroxyzine hcl... 46
hydroxyzine pamoate... 104
HYPERRAB (PF)... 85
HYPERRAB S/D (PF)... 85
HYPERTET S/D (PF)... 85
I
ibandronate... 88
IBRANCE... 32
ibu... 11
ibuprofen... 11
ibutilide fumarate... 55
icatibant... 85
ICLUSIG... 32
idarubicin... 32
IDHIFA... 32
ifosfamide... 32
ILEVRO... 101
imatinib... 32
IMBRUVICA... 32
IMFINZI... 32
imipenem-cilastatin... 17
imipramine hcl... 24
imipramine pamoate... 24
imiquimod... 62
IMLYGIC... 32

| | | |
|---|--------------------------------------|----------------------------|
| IMOGAM RABIES-HT (PF)... 85 | INVIRASE... 43 | itraconazole... 26 |
| IMOVAX RABIES VACCINE (PF)... 85 | INVOKAMET XR... 47 | IV PREP WIPES... 94 |
| incassia... 77 | INVOKAMET... 47 | ivermectin... 37 |
| INCONTROL ALCOHOL PADS... 94 | INVOKANA... 47 | IXEMPRA... 32 |
| INCONTROL PEN NEEDLE... 94 | IONOSOL-B IN D5W... 65 | IXIARO (PF)... 85 |
| INCRELEX... 75 | IONOSOL-MB IN D5W... 65 | J |
| INCRUSE ELLIPTA... 104 | IPOL... 85 | JADENU... 65 |
| indapamide... 55 | ipratropium bromide... 104 | JAKAFI... 32 |
| indomethacin... 11 | ipratropium-albuterol... 104 | jantoven... 51 |
| INFANRIX (DTAP) (PF)... 85 | irbesartan... 55 | JANUMET XR... 47 |
| INFLECTRA... 85 | irbesartan-hydrochlorothiazide... 55 | JANUMET... 47 |
| INLYTA... 32 | IRESSA... 32 | JANUVIA... 47 |
| INREBIC... 32 | irinotecan... 32 | JARDIANCE... 47 |
| INSULIN SYR/NDL U100 HALF MARK... 94 | ISENTRESS HD... 43 | jasmiel (28)... 77 |
| INSULIN SYRINGE MICROFINE... 94 | ISENTRESS... 43 | jencycla... 77 |
| INSULIN SYRINGE NEEDLELESS... 94 | isibloom... 77 | JENTADUETO XR... 47 |
| INSULIN SYRINGE... 94 | ISOLYTE S PH 7.4... 65 | JENTADUETO... 47 |
| INSULIN SYRINGE-NEEDLE U-100... 94 | ISOLYTE-P IN 5 % DEXTROSE... 65 | JEVTANA... 32 |
| INSUPEN... 94 | ISOLYTE-S... 65 | JOLESSA... 77 |
| INTELENCE... 43 | isoniazid... 28 | JOLIVETTE... 77 |
| INTRALIPID... 65 | ISORDIL TITRADOSE... 55 | juleber... 77 |
| INTRON A... 43 | ISORDIL... 55 | JULUCA... 43 |
| introvale... 77 | isosorbide dinitrate... 55 | junel fe 1.5/30 (28)... 77 |
| INVANZ... 17 | isosorbide mononitrate... 55 | junel fe 1/20 (28)... 77 |
| INVEGA SUSTENNA... 40 | isotretinoin... 62 | junel fe 24... 77 |
| INVEGA TRINZA... 40 | isradipine... 55 | junel 1.5/30 (21)... 77 |
| | ISTODAX... 32 | junel 1/20 (21)... 77 |
| | ISUPREL... 55 | K |

| | | |
|----------------------------------|--|---|
| K-TAB... 65 | KLOR-CON 10... 65 | LATUDA... 40 |
| KABIVEN... 65 | KLOR-CON 8... 65 | ledipasvir-sofosbuvir... 43 |
| KADCYLA... 32 | KOMBIGLYZE XR... 47, 48 | LEENA 28... 78 |
| KALETRA... 43 | KORLYM... 94 | leflunomide... 86 |
| kalliga... 78 | KRINTAFEL... 37 | LENVIMA... 33 |
| KALYDECO... 104 | kurvelo (28)... 78 | lessina... 78 |
| KANJINTI... 32 | KUVAN... 70, 71 | LETAIRIS... 104 |
| kariva (28)... 78 | KYPROLIS... 33 | letrozole... 33 |
| KAZANO... 47 | L | leucovorin calcium... 33 |
| KEDRAB (PF)... 86 | l norgest/e.estradiol-e.estrad... 78 | LEUKERAN... 33 |
| kelnor 1-50... 78 | labetalol... 55 | leuprolide... 82 |
| kelnor 1/35 (28)... 78 | lactated ringers... 65, 94 | levabuterol hcl... 104 |
| KEPIVANCE... 61 | lactulose... 69 | levabuterol tartrate... 104 |
| ketoconazole... 26 | lamivudine... 43 | LEVEMIR FLEXTOUCH U-100 INSULN... 48 |
| ketoprofen... 11 | lamivudine-zidovudine... 43 | LEVEMIR U-100 INSULIN... 48 |
| ketorolac... 11, 101 | lamotrigine... 21 | levetiracetam in nacl (iso-os)... 21 |
| KEVZARA... 86 | lansoprazole... 69 | levetiracetam... 21 |
| KEYTRUDA... 32 | LANTUS SOLOSTAR U-100 INSULIN... 48 | LEVO-T... 82 |
| kimidess (28)... 78 | LANTUS U-100 INSULIN... 48 | levobunolol... 101 |
| KINRIX (PF)... 86 | larin fe 1.5/30 (28)... 78 | levocarnitine (with sugar)... 65 |
| KIONEX (WITH SORBITOL)... 65 | larin fe 1/20 (28)... 78 | levocarnitine... 65 |
| kionex... 65 | larin 1.5/30 (21)... 78 | levocetirizine... 104 |
| KISQALI FEMARA CO-PACK... 32, 33 | larin 1/20 (21)... 78 | levofloxacin in d5w... 17 |
| KISQALI... 32 | larin 24 fe... 78 | levofloxacin... 17 |
| klor-con m10... 65 | larissia... 78 | levoleucovorin calcium... 33 |
| KLOR-CON M15... 65 | LARTRUVO... 33 | levonest (28)... 78 |
| klor-con m20... 65 | latanoprost... 101 | levonorg-eth estrad triphasic... 78 |
| klor-con sprinkle... 65 | | |

| | | |
|--------------------------------------|---|--|
| levonorgestrel-ethinyl estrad... 78 | LITE TOUCH INSULIN PEN NEEDLES... 94 | LUMIGAN... 101 |
| levora-28... 78 | LITE TOUCH INSULIN SYRINGE... 95 | LUMIZYME... 71 |
| levothyroxine... 82 | lithium carbonate... 46 | LUMOXITI... 33 |
| LEVOXYL... 82 | lithium citrate... 46 | LUPRON DEPOT (3 MONTH)... 82 |
| LEVULAN... 33 | LITHOSTAT... 95 | LUPRON DEPOT (4 MONTH)... 83 |
| LEXIVA... 43 | lo-zumandimine (28)... 78 | LUPRON DEPOT (6 MONTH)... 83 |
| LIBTAYO... 33 | LOCOID LIPOCREAM... 73 | LUPRON DEPOT... 82 |
| lidocaine (pf) in d7.5w... 13 | loestrin fe 1.5/30 (28-day)... 78 | LUPRON DEPOT-PED (3 MONTH)... 83 |
| lidocaine (pf)... 55 | loestrin fe 1/20 (28-day)... 78 | LUPRON DEPOT-PED... 83 |
| lidocaine hcl... 13 | loestrin 1.5/30 (21)... 78 | lutera (28)... 78 |
| lidocaine in 5 % dextrose (pf)... 55 | loestrin 1/20 (21)... 78 | LYNPARZA... 33 |
| lidocaine viscous... 13 | lomedina 24 fe... 78 | LYRICA... 60 |
| lidocaine... 12 | LONSURF... 33 | LYSODREN... 82 |
| lidocaine-epinephrine... 13 | loperamide... 69 | lyza... 78 |
| lidocaine-prilocaine... 13 | lopinavir-ritonavir... 43 | M |
| lillow (28)... 78 | LORAZEPAM INTENSOL... 46 | M-M-R II (PF)... 86 |
| lincomycin... 17 | lorazepam... 46 | m-natal plus... 65 |
| lindane... 37 | LORBRENA... 33 | mafenide acetate... 17 |
| linezolid in dextrose 5%... 17 | loryna (28)... 78 | MAGELLAN INSULIN SAFETY SYRNG... 95 |
| linezolid... 17 | losartan... 56 | MAGELLAN SYRINGE... 95 |
| linezolid-0.9% sodium chloride... 17 | losartan-hydrochlorothiazide... 56 | magnesium sulfate in d5w... 65 |
| LINZESS... 69 | LOTEMAX SM... 101 | magnesium sulfate in water... 65 |
| liothyronine... 82 | LOTEMAX... 101 | magnesium sulfate... 65 |
| lipodox 50... 33 | loteprednol etabonate... 101 | malathion... 37 |
| lipodox... 33 | lovastatin... 56 | mannitol 10 %... 56 |
| LIPOFEN... 55 | low-ogestrel (28)... 78 | mannitol 20 %... 56 |
| lisinopril... 56 | loxapine succinate... 40 | mannitol 25 %... 56 |
| lisinopril-hydrochlorothiazide... 56 | | |

| | | |
|--|---|---|
| mannitol 5 %... 56 | mercaptapurine... 33 | methylprednisolone sodium succ... 74 |
| maprotiline... 24 | meropenem... 17 | methylprednisolone... 73 |
| marlissa (28)... 78 | meropenem-0.9% sodium chloride... 17 | methyltestosterone... 79 |
| MARPLAN... 24 | mesalamine... 88 | metipranolol... 101 |
| MARQIBO... 33 | mesna... 33 | metoclopramide hcl... 25 |
| MATULANE... 33 | MESNEX... 34 | metolazone... 56 |
| MAVYRET... 43 | metaproterenol... 104 | metoprolol succinate... 56 |
| MAXI-COMFORT INSULIN SYRINGE... 95 | metformin... 48 | metoprolol ta-hydrochlorothiaz... 56 |
| MAXICOMFORT II PEN NEEDLE... 95 | methadone intensol... 11 | metoprolol tartrate... 56 |
| MAXICOMFORT INSULIN SYRINGE... 95 | methadone... 11 | metronidazole in nacl (iso-os)... 17 |
| MAXICOMFORT SAFETY PEN NEEDLE... 95 | methazolamide... 56 | metronidazole... 17 |
| meclizine... 25 | methenamine hippurate... 17 | MIACALCIN... 89 |
| MEDROL... 73 | methergine... 95 | miconazole-3... 26 |
| medroxyprogesterone... 78 | methimazole... 83 | MICRODOT INSULIN PEN NEEDLE... 95 |
| mefloquine... 37 | METHITEST... 79 | MICROGESTIN FE 1.5/30 (28)... 79 |
| megestrol... 78, 79 | methocarbamol... 106 | MICROGESTIN FE 1/20 (28)... 79 |
| MEKINIST... 33 | methotrexate sodium (pf)... 86 | MICROGESTIN 1.5/30 (21)... 79 |
| MEKTOVI... 33 | methotrexate sodium... 86 | MICROGESTIN 1/20 (21)... 79 |
| meloxicam... 11 | methoxsalen... 62 | midodrine... 56 |
| melphalan hcl... 33 | methscopolamine... 69 | migergot... 28 |
| melphalan... 33 | methyldopa... 56 | mili... 79 |
| memantine... 22, 23 | methyldopa-hydrochlorothiazide... 56 | mimvey... 79 |
| MENACTRA (PF)... 86 | methyldopate... 56 | MINI ULTRA-THIN II... 95 |
| MENEST... 79 | methylergonovine... 95 | minocycline... 17 |
| MENVEO A-C-Y-W-135-DIP (PF)... 86 | methyphenidate hcl... 60 | minoxidil... 56 |
| mepivacaine (pf)... 13 | methylprednisolone acetate... 74 | MIOSTAT... 101 |

| | | |
|--------------------------------------|--------------------------------------|--------------------------------------|
| mircette (28)... 79 | MUTAMYCIN... 34 | NATACYN... 26 |
| mirtazapine... 24 | MVASI... 34 | NATAZIA... 79 |
| misoprostol... 69 | MYALEPT... 69 | nateglinide... 48 |
| mitomycin... 34 | MYCAMINE... 26 | NATPARA... 89 |
| mitoxantrone... 34 | mycophenolate mofetil (hcl)... 86 | NAYZILAM... 21 |
| modafinil... 106 | mycophenolate mofetil... 86 | NEBUPENT... 37 |
| moexipril... 56 | mycophenolate sodium... 86 | necon 0.5/35 (28)... 79 |
| moexipril-hydrochlorothiazide... 56 | MYFORTIC... 86 | NECON 7/7/7 (28)... 79 |
| molindone... 40 | MYLOTARG... 34 | nefazodone... 24 |
| mometasone... 74, 104 | myorisan... 62 | neo-polycin hc... 101 |
| mono-linyah... 79 | MYRBETRIQ... 71 | neo-polycin... 101 |
| MONOJECT INSULIN SAFETY SYRING... 95 | myzilra... 79 | neomycin... 18 |
| | N | neomycin-bacitracin-poly-hc... 101 |
| MONOJECT INSULIN SYRINGE... 95 | nabumetone... 12 | neomycin-bacitracin-polymyxin... 101 |
| MONOJECT SYRINGE... 96 | nadolol... 56 | neomycin-polymyxin b gu... 18 |
| MONOJECT ULTRA COMFORT INSULIN... 96 | nadolol-bendroflumethiazide... 56 | neomycin-polymyxin b-dexameth... 101 |
| MONONESSA (28)... 79 | nafacillin in dextrose iso-osm... 18 | neomycin-polymyxin b-dexameth... 101 |
| montelukast... 104 | nafacillin... 18 | neomycin-polymyxin-gramicidin... 101 |
| MONUROL... 18 | naftifine... 26 | neomycin-polymyxin-hc... 101, 102 |
| morphine concentrate... 12 | NAGLAZYME... 71 | NEPHRAMINE 5.4 %... 66 |
| morphine... 11, 12 | naloxone... 13 | NERLYNX... 34 |
| MOVANTIK... 69 | naltrexone... 13 | NESINA... 48 |
| moxifloxacin... 18 | NAMZARIC... 23 | NEULASTA... 51 |
| MOZOBIL... 51 | naproxen sodium... 12 | NEUPOGEN... 51 |
| MULTAQ... 56 | naproxen... 12 | NEUPRO... 38 |
| mupirocin... 18 | naratriptan... 28 | nevirapine... 43 |
| MUSTARGEN... 34 | NARCAN... 13 | NEXAVAR... 34 |
| | NASONEX... 104 | |

NEXTERONE... 56
 niacin... 56
 niacor... 56
 NICOTROL NS... 13
 nifedipine... 56
 nikki (28)... 79
 nilutamide... 34
 nimodipine... 56
 NINLARO... 34
 NIPENT... 34
 nisoldipine... 56
 nitisinone... 71
 nitrofurantoin macrocrystal... 18
 nitrofurantoin monohyd/m-cryst... 18
 nitrofurantoin... 18
 nitroglycerin in 5 % dextrose... 57
 nitroglycerin... 56, 57
 NITROSTAT... 57
 NITYR... 71
 nizatidine... 69
 NORA-BE... 79
 norepinephrine bitartrate... 57
 noreth-ethinyl estradiol-iron... 79
 norethindrone (contraceptive)... 79
 norethindrone ac-eth estradiol... 79
 norethindrone acetate... 79
 norethindrone-e.estradiol-iron... 79
 norgestimate-ethinyl estradiol... 79
 norlyda... 79
 norlyroc... 79
 NORMOSOL-M IN 5 % DEXTROSE... 66
 NORMOSOL-R IN 5 % DEXTROSE... 66
 NORMOSOL-R PH 7.4... 66
 NORMOSOL-R... 66
 NORTHERA... 57
 nortrel 0.5/35 (28)... 79
 nortrel 1/35 (21)... 79
 nortrel 1/35 (28)... 79
 nortrel 7/7/7 (28)... 79
 nortriptyline... 24
 NORVIR... 43
 NOVOFINE AUTOCOVER... 96
 NOVOFINE PLUS... 96
 NOVOFINE 30... 96
 NOVOFINE 32... 96
 NOVOLIN N NPH U-100 INSULIN... 48
 NOVOLIN R REGULAR U-100 INSULN... 48
 NOVOLIN 70-30 FLEXPEN U-100... 48
 NOVOLIN 70/30 U-100 INSULIN... 48
 NOVOLOG FLEXPEN U-100 INSULIN... 48
 NOVOLOG MIX 70-30 U-100 INSULN... 48
 NOVOLOG MIX 70-30FLEXPEN U-100... 48
 NOVOLOG PENFILL U-100 INSULIN... 48
 NOVOLOG U-100 INSULIN ASPART... 48
 NOVOPEN ECHO... 96
 NOVOTWIST... 96
 NOXAFIL... 26
 NUBEQA... 34
 NUCYNTA... 12
 NUEDEXTA... 60
 NULOJIX... 86
 NUPLAZID... 40
 NUTRILIPID... 66
 NUVARING... 79
 nyamyc... 26
 nystatin... 27
 nystatin-triamcinolone... 27
 nystop... 27
O
 O-CAL PRENATAL... 66
 OCELLA... 79
 octreotide acetate... 83
 ODEFSEY... 43
 ODOMZO... 34
 OFEV... 104

| | | |
|---|--------------------------------------|------------------------------------|
| ofloxacin... 18 | OPSUMIT... 104 | PACERONE... 57 |
| ogestrel (28)... 80 | ORACEA... 18 | paclitaxel... 34 |
| OGIVRI... 34 | oralone... 61 | paliperidone... 40 |
| olanzapine... 40 | ORBACTIV... 18 | pamidronate... 89 |
| olanzapine-fluoxetine... 24 | ORFADIN... 71 | PANRETIN... 34 |
| olmesartan... 57 | ORKAMBI... 104 | pantoprazole... 69 |
| olmesartan-amlodipin-hcthiazyd... 57 | orsythia... 80 | paricalcitol... 89 |
| olmesartan-hydrochlorothiazide... 57 | ORTHO-NOVUM 7/7/7 (28)... 80 | paroex oral rinse... 61 |
| olopatadine... 101, 104 | oseltamivir... 43, 44 | paromomycin... 18 |
| omega-3 acid ethyl esters... 57 | OSENI... 48 | paroxetine hcl... 24 |
| omeppi... 69 | OSMITROL 10 %... 57 | PASER... 28 |
| omeprazole... 69 | OSMITROL 15 %... 57 | PATADAY... 101 |
| omeprazole-sodium bicarbonate... 69 | OSMITROL 20 %... 57 | PAXIL... 24 |
| OMNIPOD DASH INSULIN POD... 96 | OSMITROL 5 %... 57 | PAZEO... 101 |
| OMNIPOD INSULIN MANAGEMENT... 96 | oxacillin in dextrose(iso-osm)... 18 | PEDIARIX (PF)... 86 |
| OMNIPOD INSULIN REFILL... 96 | oxacillin... 18 | PEDVAX HIB (PF)... 86 |
| OMNITROPE... 75 | oxaliplatin... 34 | peg 3350-electrolytes... 69 |
| ONCASPAR... 34 | oxandrolone... 80 | peg-electrolyte soln... 69 |
| ondansetron hcl (pf)... 25 | oxaprozin... 12 | PEGANONE... 21 |
| ondansetron hcl... 25 | oxazepam... 46 | PEGASYS PROCLICK... 44 |
| ondansetron... 25 | oxcarbazepine... 21 | PEGASYS... 44 |
| ONFI... 21 | oxybutynin chloride... 71 | PEN NEEDLE... 96 |
| ONGLYZA... 48 | oxycodone... 12 | PEN NEEDLE, DIABETIC... 96 |
| ONIVYDE... 34 | oxycodone-acetaminophen... 12 | penicillamine... 66 |
| OPDIVO... 34 | oxycodone-aspirin... 12 | penicillin g pot in dextrose... 18 |
| | oxymorphone... 12 | penicillin g potassium... 18 |
| | OZEMPIC... 48 | penicillin g procaine... 18 |
| | | penicillin g sodium... 18 |

P

| | | |
|----------------------------------|--------------------------------------|--------------------------------------|
| penicillin v potassium... 18 | PIFELTRO... 44 | potassium acetate... 66 |
| PENTACEL (PF)... 86 | pilocarpine hcl... 61, 102 | potassium chlorid-d5-0.45%nacl... 66 |
| PENTAM... 37 | pimecrolimus... 62 | potassium chloride in lr-d5... 66 |
| pentamidine... 38 | pimozide... 40 | potassium chloride in water... 66 |
| pentazocine-naloxone... 12 | pimtrea (28)... 80 | potassium chloride in 0.9%nacl... 66 |
| PENTIPS... 96 | pindolol... 57 | potassium chloride in 5 % dex... 66 |
| pentoxifylline... 57 | pioglitazone... 48 | potassium chloride... 66 |
| PERFOROMIST... 104 | piperacillin-tazobactam... 18 | potassium chloride-d5-0.2%nacl... 66 |
| PERIKABIVEN... 66 | PIQRAY... 34 | potassium chloride-d5-0.3%nacl... 66 |
| perindopril erbumine... 57 | pirmella... 80 | potassium chloride-d5-0.9%nacl... 66 |
| periogard... 61 | piroxicam... 12 | potassium chloride-0.45 % nacl... 66 |
| PERJETA... 34 | PLASMA-LYTE A... 66 | potassium citrate... 66 |
| permethrin... 38 | PLASMA-LYTE 148... 66 | POTELIGEO... 34 |
| perphenazine... 40 | plenamine... 66 | pr natal 400 ec... 67 |
| perphenazine-amitriptyline... 24 | pnv ob+dha... 66 | pr natal 400... 66 |
| PERSERIS... 40 | podofilox... 62 | pr natal 430 ec... 67 |
| pfizerpen-g... 18 | POLIVY... 34 | pr natal 430... 67 |
| phenelzine... 24 | polocaine... 13 | PRADAXA... 51 |
| phenobarbital... 21 | polocaine-mpf... 13 | PRALUENT PEN... 57 |
| PHENYTEK... 21 | polycin... 102 | pramipexole... 38 |
| phenytoin sodium extended... 21 | polyethylene glycol 3350... 69 | prasugrel... 51 |
| phenytoin sodium... 21 | polymyxin b sulf-trimethoprim... 102 | pravastatin... 57 |
| phenytoin... 21 | polymyxin b sulfate... 19 | praziquantel... 38 |
| philith... 80 | POMALYST... 34 | prazosin... 57 |
| PHOSPHOLINE IODIDE... 101 | portia 28... 80 | |
| PHYSIOLYTE... 66 | PORTRAZZA... 34 | |
| PHYSIOSOL IRRIGATION... 66 | posaconazole... 27 | |
| PICATO... 62 | | |

| | | |
|--|-----------------------------------|--------------------------------------|
| PRED-G S.O.P.... 102 | primaquine... 38 | PROMACTA... 51 |
| PRED-G... 102 | primidone... 21 | promethazine... 25 |
| prednisolone acetate... 102 | primlev... 12 | propafenone... 57 |
| prednisolone sodium phosphate... 74, 102 | PRIMSOL... 19 | proparacaine... 102 |
| prednisolone... 74 | PRISTIQ... 24 | propranolol... 57, 58 |
| PREDNISONONE INTENSOL... 74 | PRO COMFORT ALCOHOL PADS... 96 | propranolol-hydrochlorothiazid... 58 |
| prednisone... 74 | PRO COMFORT INSULIN SYRINGE... 96 | propylthiouracil... 83 |
| pregabalin... 60 | PRO COMFORT PEN NEEDLE... 96 | PROQUAD (PF)... 86 |
| PREMARIN... 80 | probenecid... 27 | PROSOL 20 %... 67 |
| PREMASOL 10 %... 67 | probenecid-colchicine... 27 | protamine... 96 |
| PREMASOL 6 %... 67 | procainamide... 57 | protriptyline... 24 |
| PRENATA... 67 | PROCALAMINE 3%... 67 | PULMOZYME... 104 |
| PRENATABS FA... 67 | prochlorperazine edisylate... 25 | PURIXAN... 34 |
| prenatal plus (calcium carb)... 67 | prochlorperazine maleate... 25 | PYLERA... 69 |
| PRENATE DHA... 67 | prochlorperazine... 25 | pyrazinamide... 28 |
| PRENATE ELITE... 67 | PROCRIT... 51 | pyridostigmine bromide... 28 |
| PRENATE ESSENTIAL... 67 | procto-med hc... 74 | Q |
| preplus... 67 | procto-pak... 74 | QUADRACEL (PF)... 86 |
| prevalite... 57 | proctosol hc... 74 | QUARTETTE... 80 |
| PREVENT DROPSAFE PEN NEEDLE... 96 | proctozone-hc... 74 | quasense... 80 |
| previfem... 80 | PRODIGY INSULIN SYRINGE... 96 | quetiapine... 40, 41 |
| PREZCOBIX... 44 | progesterone micronized... 80 | quinapril... 58 |
| PREZISTA... 44 | progesterone... 80 | quinapril-hydrochlorothiazide... 58 |
| PRIALT... 96 | PROGLYCEM... 49 | quinidine gluconate... 58 |
| PRIFTIN... 28 | PROGRAF... 86 | quinidine sulfate... 58 |
| PRILOSEC... 69 | PROLEUKIN... 34 | quinine sulfate... 38 |
| | PROLIA... 89 | R |
| | | RABAVERT (PF)... 86 |

| | | |
|------------------------------|---------------------------|--------------------------------|
| rabeprazole... 70 | RESECTISOL... 58 | rivastigmine tartrate... 23 |
| raloxifene... 80 | RESTASIS MULTIDOSE... 102 | rivastigmine... 23 |
| ramipril... 58 | RESTASIS... 102 | RIVELSA... 80 |
| RANEXA... 58 | RETACRIT... 51 | rizatriptan... 28 |
| ranitidine hcl... 70 | RETROVIR... 44 | romidepsin... 35 |
| ranolazine... 58 | REVATIO... 104 | ropinirole... 38 |
| RAPAFLO... 72 | REVCOVI... 71 | ropivacaine (pf)... 13 |
| RAPAMUNE... 86 | REVLIMID... 34 | rosuvastatin... 58 |
| rasagiline... 38 | revonto... 41 | ROTARIX... 87 |
| reclipsen (28)... 80 | REXULTI... 41 | ROTATEQ VACCINE... 87 |
| RECOMBIVAX HB (PF)... 86, 87 | REYATAZ... 44 | roweepra xr... 22 |
| RECTIV... 62 | RHOPHYLAC... 87 | roweepra... 21 |
| REGONOL... 28 | RIBASPHERE RIBAPAK... 44 | ROZLYTREK... 35 |
| REGRANEX... 62 | ribavirin... 44 | RUBRACA... 35 |
| RELENZA DISKHALER... 44 | RIDAURA... 87 | RUCONEST... 87 |
| RELION NEEDLES... 96 | rifabutin... 28 | RUZURGI... 60 |
| RELION PEN NEEDLES... 96 | rifampin... 28 | RYDAPT... 35 |
| RELISTOR... 70 | RIFATER... 28 | RYTARY... 38 |
| RELPAK... 28 | riluzole... 60 | S |
| REMICADE... 87 | rimantadine... 44 | SABRIL... 22 |
| RENACIDIN... 96 | ringer's... 67, 96 | SAFESNAP INSULIN SYRINGE... 96 |
| RENAGEL... 67 | RINVOQ ER... 87 | SAFETY PEN NEEDLE... 97 |
| RENVELA... 67 | risedronate... 89 | SAMSCA... 67 |
| repaglinide... 49 | RISPERDAL CONSTA... 41 | SANCUSO... 25 |
| REPATHA PUSHTRONEX... 58 | risperidone... 41 | SANDIMMUNE... 87 |
| REPATHA SURECLICK... 58 | ritonavir... 44 | SANDOSTATIN LAR DEPOT... 83 |
| REPATHA SYRINGE... 58 | RITUXAN HYCELA... 35 | SANTYL... 62 |
| RESCRIPTOR... 44 | RITUXAN... 34 | SAPHRIS... 41 |

| | | |
|---------------------------------------|---|---|
| SAVELLA... 60 | SKYRIZI... 62 | SPIRIVA RESPIMAT... 105 |
| scopolamine base... 25 | SLYND... 80 | SPIRIVA WITH HANDIHALER... 105 |
| se-natal 19 (with docusate)... 67 | SMOFLIPID... 67 | spironolacton-hydrochlorothiaz... 58 |
| se-natal 19 chewable... 67 | sodium acetate... 67 | spironolactone... 58 |
| selegiline hcl... 38 | sodium benzoate-sod phenylacet... 97 | sprintec (28)... 80 |
| selenium sulfide... 62 | sodium bicarbonate... 67 | SPRITAM... 22 |
| SELZENTRY... 44 | sodium chloride 0.45 %... 67 | SPRYCEL... 35 |
| SENSIPAR... 89 | sodium chloride 0.9 %... 67 | SPS (WITH SORBITOL)... 68 |
| SEREVENT DISKUS... 104 | sodium chloride 3 %... 67 | sronyx... 80 |
| SEROSTIM... 70 | sodium chloride 5 %... 68 | SSD... 19 |
| sertraline... 24 | sodium chloride... 67 | STALEVO 100... 38 |
| setlakin... 80 | sodium lactate... 68 | STALEVO 125... 38 |
| sevelamer carbonate... 67 | sodium phenylbutyrate... 71 | STALEVO 150... 39 |
| sevelamer hcl... 67 | sodium phosphate... 68 | STALEVO 200... 39 |
| sharobel... 80 | sodium polystyrene (sorb free)... 68 | STALEVO 50... 39 |
| SHINGRIX (PF)... 87 | sodium polystyrene sulfonate... 68 | STALEVO 75... 39 |
| SIGNIFOR... 83 | sofosbuvir-velpatasvir... 44 | stavudine... 44 |
| sildenafil (pulm.hypertension)... 105 | SOLQUA 100/33... 49 | STIMATE... 75 |
| sildenafil... 107 | SOLTAMOX... 35 | STIOLTO RESPIMAT... 105 |
| silodosin... 72 | SOLU-MEDROL (PF)... 74 | STIVARGA... 35 |
| silver sulfadiazine... 19 | SOLU-MEDROL... 74 | STRATTERA... 60 |
| simliya (28)... 80 | SOMATULINE DEPOT... 83 | STRENSIQ... 71 |
| simpesse... 80 | SOMAVERT... 83 | streptomycin... 19 |
| SIMULECT... 87 | sorbitol-mannitol... 97 | STRIBILD... 44 |
| simvastatin... 58 | sorine... 58 | STRIVERDI RESPIMAT... 105 |
| sirolimus... 87 | sotalol af... 58 | subvenite starter (blue) kit... 22 |
| SIRTURO... 28 | sotalol... 58 | subvenite starter (green) kit... 22 |
| SIVEXTRO... 19 | | |

| | | |
|--------------------------------------|---------------------------------------|--------------------------------------|
| subvenite starter (orange) kit... 22 | SYLATRON... 45 | TARGRETIN... 35 |
| subvenite... 22 | SYLVANT... 87 | tarina fe 1-20 eq (28)... 80 |
| SUCRAID... 71 | SYMBICORT... 105 | tarina fe 1/20 (28)... 80 |
| sucralfate... 70 | SYMFI LO... 45 | tarina 24 fe... 80 |
| sulfacetamide sodium (acne)... 19 | SYMFI... 45 | taron-c dha... 68 |
| sulfacetamide sodium... 19 | SYMJEPI... 105 | taron-prex prenatal-dha... 68 |
| sulfacetamide-prednisolone... 102 | SYMLINPEN 120... 49 | TASIGNA... 35 |
| sulfadiazine... 19 | SYMLINPEN 60... 49 | tazarotene... 62 |
| sulfamethoxazole-trimethoprim... 19 | SYMPAZAN... 22 | TAZORAC... 62 |
| sulfasalazine... 88 | SYMTUZA... 45 | taztia xt... 58 |
| sulindac... 12 | SYNAGIS... 87 | tdvax... 87 |
| sumatriptan succinate... 28 | SYNAREL... 83 | TECENTRIQ... 35 |
| SUPRAX... 19 | SYNERCID... 19 | TECFIDERA... 61 |
| SUPREP BOWEL PREP KIT... 70 | SYNJARDY XR... 49 | TECHLITE INSULIN SYR HALF UNIT... 97 |
| SURE COMFORT ALCOHOL PREP PADS... 97 | SYNJARDY... 49 | TECHLITE INSULIN SYRINGE... 97 |
| SURE COMFORT INS. SYR. U-100... 97 | SYNRIBO... 35 | TECHLITE PEN NEEDLE... 97 |
| | SYNTHROID... 82 | TEFLARO... 19 |
| | T | TEGRETOL XR... 22 |
| SURE COMFORT INSULIN SYRINGE... 97 | TABLOID... 35 | TEKTURNA HCT... 58 |
| SURE COMFORT PEN NEEDLE... 97 | TACLONEX... 62 | TEKTURNA... 58 |
| SURE-FINE PEN NEEDLES... 97 | tacrolimus... 62, 87 | telmisartan... 58 |
| SURE-JECT INSULIN SYRINGE... 97 | tadalafil (pulm. hypertension)... 105 | telmisartan-amlodipine... 58 |
| SURE-PREP ALCOHOL PREP PADS... 97 | TAFINLAR... 35 | telmisartan-hydrochlorothiazid... 58 |
| SUSTIVA... 45 | TAGRISSO... 35 | temazepam... 106 |
| SUTENT... 35 | TALZENNA... 35 | TEMIXYS... 45 |
| syeda... 80 | tamoxifen... 35 | TEMODAR... 35 |
| | tamsulosin... 72 | temsirolimus... 35 |
| | TARCEVA... 35 | |

| | | |
|--------------------------------------|---------------------------------|--------------------------------|
| teniposide... 35 | TIBSOVO... 35 | TRADJENTA... 49 |
| TENIVAC (PF)... 87 | tigecycline... 19 | tramadol... 12 |
| tenofovir disoproxil fumarate... 45 | TILIA FE... 80 | tramadol-acetaminophen... 12 |
| terazosin... 58 | timolol maleate... 59, 102 | trandolapril... 59 |
| terbinafine hcl... 27 | tinidazole... 19 | trandolapril-verapamil... 59 |
| terconazole... 27 | TIVICAY... 45 | tranexamic acid... 51 |
| TERUMO INSULIN SYRINGE... 98 | tizanidine... 41 | tranylcypromine... 24 |
| testosterone cypionate... 80 | TOBI PODHALER... 105 | TRAVASOL 10 %... 68 |
| testosterone enanthate... 80 | tobramycin sulfate... 19 | TRAVATAN Z... 102 |
| testosterone... 80 | tobramycin... 19 | trazodone... 24 |
| tetanus,diphtheria tox ped(pf)... 87 | tobramycin-dexamethasone... 102 | TREANDA... 36 |
| tetrabenazine... 61 | TOBEX... 19 | TRECTOR... 28 |
| THALOMID... 35 | TOLAK... 62 | TRELEGY ELLIPTA... 105 |
| theophylline in dextrose 5 %... 105 | tolcapone... 39 | TRELSTAR... 83 |
| theophylline... 105 | tolterodine... 72 | TRESIBA FLEXTOUCH U-100... 49 |
| THINPRO INSULIN SYRINGE... 98 | TOPCARE CLICKFINE... 98 | TRESIBA FLEXTOUCH U-200... 49 |
| THIOLA... 72 | TOPCARE ULTRA COMFORT... 98 | TRESIBA U-100 INSULIN... 49 |
| thioridazine... 41 | topiramate... 22 | tretinoin (chemotherapy)... 36 |
| thiotepa... 35 | topotecan... 36 | tretinoin... 62 |
| thiothixene... 41 | toremifene... 36 | TREXALL... 87 |
| THYMOGLOBULIN... 87 | TORISEL... 36 | tri femynor... 81 |
| THYROLAR-1... 82 | toremide... 59 | tri-legest fe... 81 |
| THYROLAR-1/2... 82 | TOUJEO MAX U-300 SOLOSTAR... 49 | tri-linyah... 81 |
| THYROLAR-1/4... 82 | TOUJEO SOLOSTAR U-300 | tri-lo-estarylla... 81 |
| THYROLAR-2... 82 | INSULIN... 49 | tri-lo-marzia... 81 |
| THYROLAR-3... 82 | TOVIAZ... 72 | tri-lo-mili... 81 |
| tiadylt er... 58 | TPN ELECTROLYTES... 68 | tri-lo-sprintec... 81 |
| tiagabine... 22 | TRACLEER... 105 | tri-mili... 81 |

| | | |
|--------------------------------------|--------------------------------------|-------------------------------------|
| TRI-NORINYL (28)... 81 | TROPHAMINE 6%... 68 | ULTILET INSULIN SYRINGE... 99 |
| tri-previfem (28)... 81 | tropicamide... 102 | ULTILET PEN NEEDLE... 99 |
| tri-sprintec (28)... 81 | TRUE COMFORT ALCOHOL PADS... 98 | ultimatecare one nf... 68 |
| tri-vylibra lo... 81 | TRUE COMFORT INSULIN SYRINGE... 98 | ultimatecare one... 68 |
| tri-vylibra... 81 | TRUE COMFORT PEN NEEDLE... 98 | ULTRA CMFT INS SYR HALF UNIT... 99 |
| triamcinolone acetonide... 61, 74 | TRUEPLUS INSULIN... 98 | ULTRA COMFORT INSULIN SYRINGE... 99 |
| triamterene-hydrochlorothiazid... 59 | TRUEPLUS PEN NEEDLE... 98 | ULTRA FLO PEN NEEDLE... 99 |
| triderm... 74 | TRULICITY... 49 | ULTRA THIN PEN NEEDLE... 99 |
| trientine... 68 | TRUMENBA... 87 | ULTRA-THIN II (SHORT) INS SYR... 99 |
| trifluoperazine... 41 | TRUVADA... 45 | ULTRA-THIN II (SHORT) PEN NDL... 99 |
| trifluridine... 45 | TRUXIMA... 36 | ULTRA-THIN II INS PEN NEEDLES... 99 |
| trihexyphenidyl... 39 | TUDORZA PRESSAIR... 105 | ULTRA-THIN II INSULIN SYRINGE... 99 |
| triklo... 59 | tulana... 81 | ULTRACARE INSULIN SYRINGE... 100 |
| trilyte with flavor packets... 70 | TURALIO... 36 | ULTRACARE PEN NEEDLE... 100 |
| trimethobenzamide... 25 | TWINRIX (PF)... 87 | UNIFINE PENTIPS MAXFLOW... 100 |
| trimethoprim... 19 | TYBOST... 45 | UNIFINE PENTIPS PLUS MAXFLOW... 100 |
| trimipramine... 24 | TYKERB... 36 | UNIFINE PENTIPS PLUS... 100 |
| trinatal rx 1... 68 | TYPHIM VI... 87 | UNIFINE PENTIPS... 100 |
| TRINESSA (28)... 81 | U | UNITHROID... 82 |
| TRINESSA LO... 81 | UDENYCA... 51 | UNITUXIN... 36 |
| TRINTELLIX... 24 | ULORIC... 27 | ursodiol... 70 |
| TRISENOX... 36 | ULTICARE INSULIN SYR HALF UNIT... 98 | UVADEX... 62 |
| TRIUMEQ... 45 | ULTICARE INSULIN SYRINGE... 98 | |
| triveen-duo dha... 68 | ULTICARE PEN NEEDLE... 99 | V |
| trivora (28)... 81 | ULTICARE... 98 | |
| TROGARZO... 45 | ULTILET ALCOHOL SWAB... 99 | |
| TROPHAMINE 10 %... 68 | | |

| | | |
|---|------------------------------|--------------------------------------|
| V-GO 20... 100 | venlafaxine... 24, 25 | virt-c dha... 68 |
| V-GO 30... 100 | VENTAVIS... 105 | virt-nate dha... 68 |
| V-GO 40... 100 | VENTOLIN HFA... 105 | VISTOGARD... 100 |
| VAGIFEM... 81 | verapamil... 59 | VITRAKVI... 36 |
| valacyclovir... 45 | VERIFINE PEN NEEDLE... 100 | VIVITROL... 13 |
| VALCHLOR... 36 | VERIPRED 20... 74 | VIZIMPRO... 36 |
| valganciclovir... 45 | VERSACLOZ... 41 | voriconazole... 27 |
| valproate sodium... 22 | VERZENIO... 36 | VOTRIENT... 36 |
| valproic acid (as sodium salt)... 22 | vestura (28)... 81 | VRAYLAR... 41 |
| valproic acid... 22 | VICTOZA 2-PAK... 49 | vyfemla (28)... 81 |
| valrubicin... 36 | VICTOZA 3-PAK... 49 | vylibra... 81 |
| valsartan... 59 | VIDEX EC... 45 | VYNDAMAX... 59 |
| valsartan-hydrochlorothiazide... 59 | VIDEX 2 GRAM PEDIATRIC... 45 | VYNDAQEL... 59 |
| VALSTAR... 36 | VIDEX 4 GRAM PEDIATRIC... 45 | VYTORIN 10-10... 59 |
| vancomycin in dextrose 5 %... 19 | vienva... 81 | VYTORIN 10-20... 59 |
| vancomycin in 0.9 % sodium chl... 19 | vigabatrin... 22 | VYTORIN 10-40... 59 |
| vancomycin... 19 | vigadrone... 22 | VYTORIN 10-80... 59 |
| VANISHPOINT SYRINGE... 100 | VIGAMOX... 19 | VYVANSE... 61 |
| VAQTA (PF)... 87 | VIIBRYD... 25 | VYXEOS... 36 |
| VARIVAX (PF)... 87 | VIMPAT... 22 | W |
| VARIZIG... 87 | vinblastine... 36 | warfarin... 51 |
| VASCEPA... 59 | vincasar pfs... 36 | water for irrigation, sterile... 100 |
| VECTIBIX... 36 | vincristine... 36 | WEBCOL... 100 |
| VELCADE... 36 | vinorelbine... 36 | WELCHOL... 59 |
| velivet triphasic regimen (28)... 81 | viorele (28)... 81 | wera (28)... 81 |
| VENCLEXTA STARTING PACK... 36 | VIRACEPT... 45 | WINRHO SDF... 87 |
| VENCLEXTA... 36 | VIRAMUNE... 45 | wixela inhub... 105 |
| | VIREAD... 45 | wymzya fe... 81 |

X

XALKORI... 36
 XARELTO... 51, 52
 XATMEP... 88
 XGEVA... 89
 XIFAXAN... 70
 XIGDUO XR... 49
 XOFLUZA... 45
 XOLAIR... 88
 XOSPATA... 36
 XPOVIO... 36, 37
 XTAMPZA ER... 12
 XTANDI... 37
 xulane... 81
 XULTOPHY 100/3.6... 49
 XYREM... 106

Y

YAZ (28)... 81
 YERVOY... 37
 YF-VAX (PF)... 88
 YONDELIS... 37
 yuvafem... 81

Z

zafirlukast... 105
 ZALTRAP... 37
 ZANOSAR... 37
 zarah... 81
 ZARXIO... 52

ZEJULA... 37
 ZELBORAF... 37
 zenatane... 62
 zenchent (28)... 81
 ZENPEP... 71
 ZERBAXA... 19
 ZERIT... 45
 zidovudine... 45
 ziprasidone hcl... 41
 ZIRGAN... 45
 ZOLADEX... 83
 zoledronic ac-mannitol-0.9nacl...
 89
 zoledronic acid... 89
 zoledronic acid-mannitol-water...
 89
 ZOLINZA... 37
 zolpidem... 106
 zonisamide... 22
 ZORBTIVE... 75
 ZORTRESS... 88
 ZOSTAVAX (PF)... 88
 zovia 1/35e (28)... 81
 zovia 1/50e (28)... 81
 ZUBSOLV... 13
 ZULRESSO... 25
 zumandimine (28)... 81
 ZYCLARA... 62

ZYDELIG... 37
 ZYKADIA... 37
 ZYPREXA RELPREVV... 41
 ZYTIGA... 37
 1ST TIER UNIFINE PENTIPS PLUS...
 89
 1ST TIER UNIFINE PENTIPS... 89

Discrimination is against the law

CarePlus Health Plans, Inc. ("CarePlus") complies with applicable Federal Civil Rights laws and does not discriminate on the basis of race, color, national origin, age, disability, sex, sexual orientation, gender identity, or religion. CarePlus does not exclude people or treat them differently because of race, color, national origin, age, disability, sex, sexual orientation, gender identity, or religion. CarePlus provides:

- Free assistance and services to people with disabilities to communicate effectively with us, such as:
 - Qualified sign language interpreters
 - Video remote interpretation
 - Written information in other formats
- Free language services to people whose primary language is not English when those services are necessary to provide meaningful access, such as:
 - Qualified interpreters
 - Information written in other languages

If you need these services, call the number on the back of your Member ID Card or contact Member Services using the information below. If you believe that CarePlus has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, sex, sexual orientation, gender identity, or religion, you can file a grievance with:

CarePlus Health Plans, Inc. Attention: Member Services Department. 11430 NW 20th Street, Suite 300. Miami, FL 33172. Telephone: **1-800-794-5907; (TTY: 711)**. From October 1 - March 31, we are open 7 days a week; 8 a.m. to 8 p.m. From April 1 - September 30, we are open Monday - Friday, 8 a.m. to 8 p.m. You may always leave a voicemail after hours, Saturdays, Sundays, and holidays and we will return your call within 1 business day. Fax: **1-800-956-4288**.

You can file a grievance in person or by mail, phone or fax. If you need help filing a grievance, our Member Services Representatives are available to help you at the contact information listed above.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at: **U.S. Department of Health and Human Services.**

200 Independence Avenue, SW, Room 509F, HHH Building, Washington, D.C. 20201. **1-800-368-1019; 800-537-7697 (TDD)**
Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.

Multi-Language Interpreter Services

English: ATTENTION: If you do not speak English, language assistance services, free of charge, are available to you. Call 1-800-794-5907 (TTY: 711).

Español (Spanish): ATENCIÓN: Si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-800-794-5907 (TTY: 711).

繁體中文 (Chinese): 注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 1-800-794-5907 (TTY: 711)。

Tiếng Việt (Vietnamese): CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1-800-794-5907 (TTY: 711).

한국어 (Korean): 주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1-800-794-5907 (TTY: 711) 번으로 전화해 주십시오.

Tagalog (Tagalog – Filipino): PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 1-800-794-5907 (TTY: 711).

Русский (Russian): ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1-800-794-5907 (телетайп: 711).

Kreyòl Ayisyen (French Creole): ATANSYON: Si w pale Kreyòl Ayisyen, gen sèvis èd pou lang ki disponib gratis pou ou. Rele 1-800-794-5907 (TTY: 711).

Français (French): ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 1-800-794-5907 (ATS : 711).

Polski (Polish): UWAGA: Jeżeli mówisz po polsku, możesz skorzystać z bezpłatnej pomocy językowej. Zadzwoń pod numer 1-800-794-5907 (TTY: 711).

Português (Portuguese): ATENÇÃO: Se fala português, encontram-se disponíveis serviços linguísticos, grátis. Ligue para 1-800-794-5907 (TTY: 711).

Italiano (Italian): ATTENZIONE: In caso la lingua parlata sia l'italiano, sono disponibili servizi di assistenza linguistica gratuiti. Chiamare il numero 1-800-794-5907 (TTY: 711).

Deutsch (German): ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1-800-794-5907 (TTY: 711).

ગુજરાતી (Gujarati): સુચના: જો તમે ગુજરાતી બોલતા છો, તો નિ:શુલ્ક ભાષા સહાય સેવાઓ તમારા માટે ઉપલબ્ધ છે. ફોન કરો 1-800-794-5907 (TTY: 711).

ภาษาไทย (Thai): เรียน: ถ้าคุณพูดภาษาไทยคุณสามารถใช้บริการช่วยเหลือทางภาษาได้ฟรี โทร1-800-794-5907 (TTY: 711).

Diné Bizaad (Navajo): Díí baa akó nínízin: Díí saad bee yáníłti'go Diné Bizaad, saad bee áká'ánída'áwo'déé', t'áá jiik'eh, éí ná hóló, kojí' hódíílnih 1-800-794-5907 (TTY: 711).

العربية (Arabic):

ملحوظة: إذا كنت تتحدث اللغة العربية، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 1-800-794-5907 (رقم هاتف الصم والبكم: 711).

CarePlus

HEALTH PLANS

CarePlusHealthPlans.com

H1019-073, 090

This formulary was updated on 12/03/2019. For more recent information or other questions, please contact CarePlus Member Services, at 1-800-794-5907 or for TTY users, 711. From October 1 - March 31, we are open 7 days a week; 8 a.m. to 8 p.m. From April 1 - September 30, we are open Monday - Friday, 8 a.m. to 8 p.m. You may always leave a voice mail message after-hours, Saturdays, Sundays, and holidays and we will return your call within 1 business day, or visit www.careplushealthplans.com.

CarePlus is an HMO plan with a Medicare contract. Enrollment in CarePlus depends on contract renewal.

ATENCIÓN: Si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-800-794-5907 (TTY: 711).